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Abstract
Introduction
Motor neurone disease (MND) is a degenerative disease that adversely
affects the nervous system and muscular control. Eventually respiratory
muscles weaken, causing breathing, communication and swallowing difficulties,
and ultimately, respiratory failure and death. Improved quality of life and
potentially a short extension of life can be provided with non-invasive ventilation
(NIV), which is offered to people with MND when symptoms of respiratory
distress become evident.
It is recommended that end-of-life communication, encompassing the
benefits and burdens of symptom-relieving interventions (NIV and percutaneous
gastrostomy tube to assist with nutrition), NIV withdrawal (proposed when
continued use is considered futile) and other respiratory distress-relieving
interventions (e.g., opioids), is initiated either before respiratory symptoms
emerge or at that time. Little is known, however, about whether, when and how
this communication occurs.

Methods
This qualitative research sought to address this gap in knowledge by
determining the content and timing of end-of-life options clinicians communicate
to people with MND and their families. Nineteen clinician participants and six
families, all experienced with MND, were interviewed. Clinicians’ accounts of
their communication were compared to bereaved families’ recollections of
communication by clinicians. A framework incorporating patient-centred care
principles and evidence-based medicine was used to link clinicians’
communication to the most recent MND guideline recommendations. The data
collected were coded and categorised manually for each participant transcript
and again using NVivo 10 software. Trustworthiness was established through
independent coding of randomly selected participant interviews by one of the
candidate’s supervisors. Symbolic interactionism and interpretive description
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provided the theoretical lens and methodology, respectively, through which the
data were interpreted.

Findings
Despite the existence of comprehensive evidence-based guidelines
reflecting international consensus, this research found some clinicians were
unaware of the recommended timing and content of end-of-life communication,
some chose to depart from or adapt the recommendations and some found the
recommendations too difficult to implement. Clinicians stated they had
insufficient time to communicate and reiterate the benefits and burdens of care
options to ensure understanding. The recommendation to refer people with
MND to palliative care soon after diagnosis was reported to happen
infrequently. Clinicians stated that they felt discussion recommending early
palliative care referral was confrontational for people with MND and their
families; family participants confirmed this view.

Recommendations
Despite their ethos of patient-centred care, clinicians were concerned
that early end-of-life communication would take away any hope the person with
MND and their family may have. Consequently, many of the family participants
appeared unprepared for the consequences of NIV, not having understood the
potential of NIV withdrawal, with several turning to the Internet for answers.
Compounding confusion was the disjointed nature of the care provided to
people with MND often involving several health care providers.

This research recommends the establishment of a progressive
interactive timeline, incorporating a case manager and reducing the number of
external care providers particularly in the terminal phase of the disease.
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Glossary of Terms
A “good death”: A dignified death in which symptoms are well controlled, the
patient’s choice of end-of-life care is known and followed and emotional support
for the patient and family/significant other and clarity of communication and
explanation are provided (Steinhauser et al., 2000).
Advance care planning: A care plan put together by an individual, often in
discussion with family and doctors. The plan directs a person’s medical care for
a time when poor health and verbal communication may be adversely affected.
Advance care plan: A request for end-of-life care, whilst not a legal document
(less formal than an advance health directive), clinicians are required to follow if
known to exist.
Advance health directive: A legal document that ideally clearly stipulates a
person’s end-of-life care preferences and acceptable interventions.
Caregiver: Those employed through organisations to provide professional
personal care and assistance to patients with MND and their families. This may
also include a member of the family who is employed by the person diagnosed
with MND and their significant other, or it could be a person volunteering their
time to attend to the patient and assist the family. In a hospital situation, a
caregiver would be a personal care assistant, or assistant to the nurses.
Clinician: Health professional involved with people with MND at the stage of
respiratory decline and/or involved with the terminal stage of the disease
process when the withdrawal of the NIV is considered. The type of clinician may
differ depending on the region where the patient with MND resides. In more
rural areas, initial discussions and subsequent palliation may occur with general
practitioners, whereas in larger urban locations, respiratory physicians,
neurologists, palliative care specialists, palliative care nurses, neurology nurses
and allied health professionals may all be involved as part of a multidisciplinary
team.
Content of NIV communication: The information provided to the person with
MND and their family regarding NIV use: benefits, burdens, limitations, process
of initiation and withdrawal, the relatively temporary symptom control due to the
xix

aggressive nature of the disease at the stage of respiratory distress, and
medication use as alternative and/or in addition to NIV. Inclusion of NIV
withdrawal and end-of-life choices is recommended (National Institute for Health
and Care Excellence, 2016).
Diagnosis: The identification of a health issue by examining the signs and
symptoms (The Oxford English Dictionary, 2013).
Dyspnoea: Difficulty in breathing or breathlessness (Mosby, 2002).
Effective communication: When the person with MND and family have
received explicit communication from a healthcare professional regarding NIV,
PEG and end-of-life choices, and the patient and family have understood the
benefits, burdens and limitations of NIV, the temporary nature of its effect, and
know what to expect in the process of initiation and withdrawal of NIV (National
Institute for Health and Care Excellence, 2016).
Epidemiology: The study of the distribution, incidence and prevalence of
health-related events or diseases and the application of this information to the
recognition and improvement of health outcomes (Mosby, 2012)
Hospice care: All care required for a dying person, often delivered within a
specific hospice unit during the terminal phase of life (Connolly, Galvin, &
Hardiman, 2015). Hospice care may also be delivered at a dying person’s
home, aged care facility or within a palliative care unit.
Hyperreflexia: Over extended and increased reflexes (Mosby, 2002).
Inspiration: The action of the diaphragm contracting and pulling down which
draws air into the lungs (Mosby, 2002).
Motor neurone disease (MND): A progressive, degenerative disease affecting
motor neurones (Oliver, Borasio, & Walsh, 2006). MND is used to describe the
disease entity in Australia, the United Kingdom and other Commonwealth
countries. Amyotrophic lateral sclerosis (ALS) is the most common form of
MND. ALS (Lerum, Solbrække, Holmøy, & Frich, 2015) is used interchangeably
with MND in the global literature but is a favoured description of MND in the
United States, where MND is also referred to as Lou Gehrig’s disease after the
famous U.S. baseball player (Oliver et al., 2006).
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Multidisciplinary team/care: A team of multidisciplinary health professionals
(MDT) generally including physiotherapists, social workers, dieticians, specialist
palliative care doctors and nurses, occupational therapists and, often for people
with MND, respiratory specialists and neurologists. Multidisciplinary teams may
vary with availability of health professionals, and patients may only be able to
access a few of the specialists relevant to their disease. Ideally, MDT
professionals work as a team within an organisation and can meet to discuss
preferred treatment and management of a patient.
Non-invasive ventilation: Used in people with MND for symptoms of
respiratory distress, often commenced to alleviate nocturnal respiratory
symptoms with increasing dependency as the disease progresses. Generally,
bilevel positive airway pressure (BiPap) is offered. This is a method of noninvasive ventilation that delivers inspiratory and expiratory pressures at a
variable rate via a face or nasal mask to help a patient breath. Regular
respiratory functional testing, including the sniff nasal inspiratory pressure
(SNIP) test, is used as a screening tool for the deterioration of the respiratory
muscles and this may be used by clinicians to offer or increase the use of NIV
(NICE, 2010). Eventually the respiratory muscles are unable to respond to NIV
and its use becomes futile. NIV is withdrawn at this stage and death occurs.
Occupational therapist: A health professional who assists and enables people
with their daily life activities. This may include provision of equipment such as
walking frames, patient specific chairs, ramps and handrails.
Opioids: A broad term used to describe both natural (opiates e.g., morphine)
and synthetic medications (opioids e.g., oxycodone) which act on the brain’s
opioid receptors to relieve pain (Doyle, Hanks, Cherny, & Calman, 2005).
Palliative care: The World Health Organisation (WHO) describes palliative care
as: “… an approach that improves quality of life of patients and their families
facing the problem associated with life-threatening illness, through the
prevention of suffering by early identification and impeccable assessment and
treatment of pain and other problems, physical, psychological and spiritual”
(World Health Organization, 1998).
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Palliative care management for people with MND: A specific system of care
structured around the priorities and needs of the patient and their significant
others, incorporating a multi-disciplinary approach where possible, and where
the benefits, burdens and limitations of all options have been considered (Motor
Neurone Disease Australia, 2012).
Paresis: A partial paralysis caused by nerve damage which may affect any
muscles of the body (Mosby, 2002).
Patient: A person receiving treatment for a particular ailment or disease, or a
client using a healthcare service (Mosby, 2002).
Percutaneous endoscopic gastrostomy tube: A permanent feeding tube
inserted into the stomach in an attempt to maintain nutrition and hydration when
swallowing food becomes difficult. In Australia, two types of gastrostomy tubes
are commonly used, differing only in their method of insertion: percutaneous
endoscopic gastronomy (PEG), inserted via the stomach wall and radiologically
inserted gastronomy (RIG).
Process of communication about NIV: How, when and where discussions
about NIV take place and who is involved in the communication, as this is
defined above.
Prognosis: The Oxford Dictionary defines prognosis as “An opinion, based on
medical experience, of the likely course of a medical condition” and an opinion
which could outline the outcome of the disease (The Oxford English Dictionary,
2013). An explanation of the course and outcome of a disease, in this case
MND, is not necessarily a prediction of time.
Respiratory failure: Inadequate gas exchange in the lungs due to the nerves
which activate muscles (in particular the diaphragm) involved with intake and
expulsion of air in the lungs becoming too weak to function adequately. This
may result in generalised fatigue, headaches and, ultimately, death.
Significant others: Family and friends who are significantly and emotionally
involved with the person with MND.
Successful communication about NIV: The patient and family have had the
content of communication regarding NIV explained effectively and have
understood the benefits, burdens and limitations of NIV, the temporary nature of
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its effect and know what to expect in the process of initiation and withdrawal of
NIV.
Terminal care and end-of-life care: The dignified management of a patient
who has reached the stage of disease progression where prognosis is one of
imminent decline and death (Doyle et al., 2005).
The literature: For this thesis, this includes information written in English, peer
reviewed prior to publication from January 2000 to July 2016 and published
either as an electronic or hardcopy journal article or guidelines in a reputable
journal or website.
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A qualitative study into the communication surrounding the initiation and withdrawal of noninvasive ventilation (NIV) in people with motor neurone disease

Chapter 1:
Introduction

Motor neurone disease (MND), of which amyotrophic lateral sclerosis
(ALS) is the most usual form, is a degenerative disease affecting the nervous
system which in turn adversely affects muscular control (Borasio, Voltz, & Miller,
2001; Gent, 2012; Oliver et al., 2006). The disease is most commonly
diagnosed after the age of 40 years and is usually slowly progressive over 3-5
years, with an average life expectancy of approximately three years. The
average length of survival from MND symptom onset is approximately 20-48
months although there is considerable variability within the disease. Most
studies report a survival rate of 10 years or more in approximately 5-10% of
people with MND (Chiò et al., 2013; Motor Neurone Disease Australia
(MNDAust), 2014).

1.1.

Epidemiology
The most recent published estimate of the global incidence of MND is 1.5

– 2 per 100,000 per year (Doyle et al., 2005), with an approximate lifetime risk
of developing the disease of 1 in 800 (Phukan & Hardiman, 2009). A more
recent systematic review of European literature suggests an incidence rate of
2.08 per 100,000 (Chiò et al., 2013). In a population-based study by Alonso,
Logroscino, Jick and Hernán (2009), which utilised data from the General
Practice Research Database (UK), the incidence was found to be higher in men
than women with a lifetime risk of 2.7 per 1000 in men and 2.1 per 1000 in
women, and the peak age at diagnosis to be 75-79 years (Alonso, Logroscino,
Jick, & Hernán, 2009).
In 2013, 787 persons died from MND in Australia compared to 592 in
2001 (AIHW, 2015). According to current MNDAust statistics, two people are
diagnosed with MND and two people die from MND daily (MNDAust, 2013).
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Approximately 1,900 people have MND throughout Australia, and the MNDA
estimates a further 14 people per person with MND live with the consequences
of caring for a family member with MND (MNDAust, 2013). Therefore,
approximately 26,600 people live with or have lives affected by a person living
with MND at any time. In Western Australia, the Motor Neurone Disease
Association of Western Australia (MNDAWA) reported that it assists
approximately 145 people with MND and their families at any time, including
approximately six months grief support (Department of Health, 2008 [WA
Health]).

Despite ongoing research, the cause of the disease is unknown, and it
remains incurable. However, autosomal dominant genetic defects that appear in
over half of the 5-10% of familial cases diagnosed with mutations in the SOD1,
TDP-43, FUS and C90RF72 genes have been closely linked to the disease
(Gent, 2012; Oliver et al., 2006; Oliver & Faull, 2013). In addition to the
suggestion that autoimmunity and viral infections are involved in the causation
of MND, more recently a bacterial toxin, beta-N-methylamino-l-alanine (BMAA),
has been found to create a faulty protein within cells, causing protein clumping
and ultimately cell death (Dunlop, Cox, Banack, & Rodgers, 2013; Oliver et al.,
2006). Dunlop et al. (2013) suggest that motor neurones appear to be
susceptible to BMAA, and that the effect may be linked to neurodegenerative
diseases such as MND.

1.2. Clinical Presentation and Disease Trajectory
The clinical presentation in MND is muscle weakness, which may involve
all muscles (general paralysis), or partial paralysis corresponding to a single
muscle group, with possible hyperreflexia (over-responsive reflexes) and
neurone degeneration affecting both the upper and lower neurological pathways
(Gent, 2012; Huether & McCance, 2014). The progressive neurological
degeneration causes muscles to weaken, leading to communication and
swallowing difficulties, potential aspiration and choking, respiratory distress and
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ultimately, respiratory failure and death (ProGas Study Group, 2015; Skelton,
2005). The main cause of death from MND is respiratory failure (inadequate
gaseous exchange in the lungs) caused by respiratory muscle weakness and
often complicated by respiratory infection (Gruis & Lechtzin, 2012; Oliver et al.,
2006). These infections may be caused or complicated by dysphagia (the
inability to swallow effectively) resulting in involuntary aspiration of oral
secretions, food or hydrating fluids.

Given the devastating implications of the disease certainty of diagnosis is
sought. The current lack of a single diagnostic test means there may be a
protracted period of symptoms, often up to a year, with exhaustive testing to
eliminate alternative diseases prior to confirming a diagnosis (Andersen et al.,
2012; Oliver et al., 2006).

1.3. Symptom Management
Unlike cancer there is no cure for MND, so interventions to improve
symptom management are recommended to ensure optimum levels of comfort
prior to the stage when the deteriorating patient can no longer benefit from such
interventions (National Institute for Health and Care Excellence [NICE], 2016;
NICE, 2010; Palliative Care Expert Group, 2010). These symptom-modifying
treatments include non-invasive ventilation (NIV) for respiration assistance,
gastrostomy tube placements (for nutrition and hydration when the ability to
swallow is adversely affected) and medications to reduce pain, respiratory
distress, secretions and anxiety.
1.3.1. NIV
The onset of declining respiratory function, reflected in symptoms such
as headaches on waking or dyspnoea (difficulty in breathing), is a distressing
and at times frightening experience for a person, and can severely diminish
their quality of life (Rafiq, Proctor, McDermott, & Shaw, 2012). At this stage, NIV
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to support a person’s failing respiratory effort is generally offered by respiratory
physicians.

Respiratory failure cannot be prevented or reversed; however, improved
quality of life and potentially a short extension of life can be provided by
palliating the symptoms with NIV (Bourke et al., 2006; Rafiq et al., 2012). NIV
delivers positive airway pressure to assist breathing and is administered via
either a face mask covering the nose and mouth or by a nasal appliance. In
MND, the positive pressure is usually delivered with a changeable inspiration
and expiration pressure, known as a bi-level positive airways pressure (Rafiq et
al., 2012). NIV is normally offered to people with MND via a device called a Bilevel Positive Pressure Airway Device often referred to by the registered trade
name BiPap (Phillips Respironics, Inc., Murrysville, PA). These machines are
programmed to assist inspiration (helping the diaphragm to contract and pull
downwards) by delivering a precise airway pressure and can be set for either
spontaneous or timed inspiration, depending on the strength and ability of a
person with MND to breathe (Gruis & Lechtzin, 2012). NIV is thought to facilitate
some resting of the respiratory muscles and improve comfort and quality of life
by easing symptoms related to respiratory function, thereby potentially
improving survival (Faull, Rowe-Haynes, & Oliver, 2014; Rafiq et al., 2012).

A Cochrane systematic review (Radunovic, Annane, Rafiq, & Mustfa,
2013) provides evidence that NIV prolongs the life expectancy of people with
MND who do not have severe bulbar (lower cranial nerve involvement)
involvement. The reason for improved survival in people with MND using NIV is
not fully understood. However, it has been suggested that by resting and
reducing the workload of the respiratory muscles, oxygen intake and absorption
are improved; thus, NIV may contribute to a small increase in life expectancy
(Rafiq et al., 2012). There is widespread agreement that NIV increases
potential life expectancy due to improvement of symptoms associated with
respiratory insufficiency, as stated in both the NICE (this organisation has
formally be known as the National Institute for Health and Clinical Excellence
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but will be referred to by its current name in this thesis) clinical guidelines
(2010) and the more recent NICE MND Assessment and Management
Guidelines (NICE, 2016), but not by improving the underlying disease
progression (Doyle et al., 2005; Hardiman, 2011). Assuming no bulbar
involvement, for which the research indicates no survival improvement with NIV,
a median survival improvement of 205 days has been suggested (Bourke et al.,
2012). Bourke et al. (2012) note that the timing of commencement of NIV may
influence the length of survival, but the optimal timing of NIV initiation remains
uncertain. As Bourke et al. show, early introduction of NIV may also be linked to
poor adherence to NIV.

Approximately 20% of people with MND in Western Australia, who are
physically suitable for and able to use NIV, will choose to use it in the latter
stage of their disease (Baxter et al., 2013). Research has shown that almost all
people diagnosed with MND will develop respiratory problems. Regardless of
whether NIV is used or not, respiratory complications are the most common
cause of death and one of the most accurate prognostic indicators (Miller et al.,
2009; Rafiq et al., 2012). A small proportion of people with MND (five per cent)
present with respiratory failure on diagnosis, whilst 30% present with bulbar
dysfunction. NIV may be contraindicated in this instance due to disturbed
swallow and gag reflexes resulting in increased secretions and risk of aspiration
(Hardiman, Van Den Berg, & Kiernan, 2011).

The progressive weakness of the muscles of the neck region involved
with swallowing and upper respiratory airway function (bulbar muscles), can
adversely affect the symptomatic advantages of NIV due to an increased
inability to clear secretions and risk of aspiration (D. Oliver et al., 2006). Whilst
the majority of people with MND will experience respiratory symptoms and be
offered NIV management, many do not accept nor tolerate NIV (Hardiman,
2011). The tightly fitting mask has the potential to cause areas of pressure
discomfort often resulting in sores. Hardiman (2011) reports that some people
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find the mask claustrophobic and may trial the nasal appliance or decline further
use.

A proportion of people who tolerate NIV in hospital do not continue to
use it at home due to a decline in the manual dexterity necessary to adjust the
mask for comfort, increased secretions which may cause aspiration difficulties
or a person’s general deteriorating functional level (Hardiman, 2011). An
increase in symptoms and declining dexterity may be countered by increased
caregiver support. However, this extra care may not necessarily be available,
nor is it always part of a person’s care preferences as it increases the
responsibilities and burdens of the caregiver.

Declining respiratory function becomes increasingly burdensome for
people with MND and their caregivers and is often used as an indicator of
nearing the terminal phase of the disease (Eng, 2006; Hardiman, 2011).
Importantly, the time at which NIV commencement is indicated is generally
acknowledged to be an opportunity to discuss patient preferences in end-of-life
options including the use of medications, and the benefits and burdens of NIV
including withdrawal (MNDAust, 2014; NICE 2010, 2016).

Some people living with MND may elect not to commence NIV at the
time of respiratory distress, deciding instead to have well medicated symptom
control and perhaps a shorter life (NICE, 2016). Comfort-giving and symptomrelieving palliating medications may be chosen because the person with MND
does not wish to prolong their inevitable suffering, or perhaps because the
person does not want to become an increasing burden on their family (Ando et
al., 2014; Faull, Phelps, Regen, Rowe-Haynes, et al., 2014). Increased
dependency on NIV is inevitable with disease progression as the respiratory
muscles continue to weaken (Faull, Phelps, Regen, Oliver, et al., 2014). NIV is
withdrawn when the respiratory muscles fail completely and prolonging its use
becomes futile, or at the patient’s clear request. Death then typically occurs
within minutes or hours of ceasing NIV (NICE, 2016). The withdrawal of NIV can
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be an extremely traumatic and ethically challenging experience for both families
and attending clinicians (Baxter et al., 2013; Phelps, Regen, Oliver, McDermott,
& Faull, 2015). Families and some clinicians may have the perception that
withdrawing NIV is a form of euthanasia, despite the futility of using NIV further
and the terminal stage of the disease (Baxter et al., 2013; Faull, Rowe-Haynes,
et al., 2014).
1.3.2. Swallowing and nutrition
People with MND may experience swallowing difficulties resulting in poor
nutrition and weight loss in addition to respiratory weakness. The insertion of a
percutaneous endoscopic gastrostomy (PEG) tube prior to the commencement
of NIV is recommended, as later PEG insertion may increase respiratory
complications (NICE, 2016). Further risks of late gastrostomy placement include
potential insertion difficulties, which are associated with a higher incidence of
mortality, and difficulty maintaining nutrition and hydration. However, as
insertion of a PEG offers little or no life extension, and may cause possible
discomfort, some people with MND reject the idea (Andersen et al., 2012;
ProGas Study Group, 2015). Discussion of gastrostomy tube insertion and its
implications early in the course of MND is recommended particularly if
swallowing is affected (NICE, 2016). Despite the use of interventions, the
disease progresses relentlessly toward the terminal stage.
1.3.3 Choices during disease progression
Figure 1.1 represents the course of MND in relation to the options of NIV
initiation or refusal and the timing of suggested PEG insertion and outlines the
progression of the disease to palliation. The flow chart is based on statistics
obtained from the Motor Neurone Disease Association of Western Australia
(MNDAWA, 2008) and does not necessarily reflect the percentages in other
parts of Australia or the world. The intervention points for the communication
recommendations (Figure 1.1) are based on recommendations from the NICE
MND Assessment and Management Guidelines (‘the NICE Guidelines’) (NICE,
2016), which are discussed further in Chapter 2. The incidence of PEG tube
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insertion is added to present a more complete picture of the progression of
MND as the respiratory muscles start to fail, and as an indication of
recommended communication points. Within each stage of the disease
progressive an outline of the recommended communication, according to the
NICE (2016) Assessment and Management Guidelines, is included. The red
arrows indicate advancement to the terminal stage and end-of-life.
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Respiratory muscles fail:

MND diagnosed:

NIV offered.

A small number of people with MND present
with primary respiratory problems.

Communication recommended on:

Communication recommended on:

End-of-life issues, potential of NIV
withdrawal and PEG tubes.

Palliative care, NIV (including benefits and
burdens), PEG and advance care planning.

People continuing on NIV:
Those who are able, continue on
NIV but continue to decline as
disease progresses.
Communication recommended on:
The potential for withdrawal of NIV
as the disease continues to
progress.

NIV unsuitable:
For MND with bulbar symptoms.
Communication recommended on:
PEG tubes and end-of-life choices.

NIV suitable:

NIV refused or unable to be
tolerated:

In WA approx. 20% of those able will
eventually use NIV and approx.

Of those commenced on NIV,
30% will not tolerate it.

20% will accept PEG tubes.

Communication recommended
on:

Communication recommended on:
End-of-life choices and advance care
planning.

Palliating symptom
management, end-of-lifechoices
and advance care planning.

Palliation:
Palliating medications offered for pain,
secretion control, anxiety and depression.

Death:
People with MND die from co-morbidities such as aspiration infection
whilst on NIV, stop NIV due to discomfort/incompatability or
withdrawal of NIV by choice.

Figure 1.1. Disease Progression and Non-invasive Ventilation Flow Chart
(Flow chart created by the candidate with information from the Motor Neurone Disease Association of Western Australia, 2015)
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1.4. Communication Experiences of People Living with MND
Research into the experiences of people with MND and their families
frequently suggests that clinician communication is generally inadequate,
particularly when delivering the diagnosis (Aoun, Connors, Priddis, Breen, &
Colyer, 2012; Belkora, 2003; Faull, Rowe-Haynes, et al., 2014). For people with
MND, deteriorating health and increasing symptoms mean that treatment
decisions involving potential life-sustaining technologies are often faced early in
the person’s clinical care. Thus, accurate information about the benefits and
burdens as well as the life extension limitations of such treatments needs to be
communicated early and revisited as the disease progresses (NICE, 2016).

A potential complication lies in how MND is perceived and characterised
by clinicians. The variants of MND and the sometimes unpredictable timing of
progression of the disease can mean that the point at which a person is
perceived as having a chronic and terminal disease becomes difficult to predict.
Whilst MND cannot be understood to be other than a terminal disease, it does
have an indefinite illness course with a small prospect of technology extending
life for some people, but not halting the disease progression. The point at which
chronic illness becomes defined as terminal may confuse the timing of support
required by the person with MND and their caregivers (Lerum et al., 2015). A
further challenge for clinicians is the consideration of when to involve palliative
care services. These may be restricted by the capacity of local amenities to
support the necessary technology, the preparedness of caregivers for palliative
care team involvement and the quality of life the patient desires. Given the
relentless progression of MND and the common misunderstanding that
“palliative” means “no hope”, there is uncertainty among clinicians as to when to
introduce the support of the palliative care team to the patient and family. The
World Health Organisation (WHO) states that early palliative care reduces
unnecessary hospital admissions and that health professionals’ lack of palliative
care training and knowledge poses a real barrier to admission to a specialist
palliative care service (WHO, 2015b).
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Anecdotally, multiple health professionals and several different service
organisations may be involved with the person with MND from diagnosis, which
has the potential to cause confusion and lead to conflicting messages. The
often unpredictable nature of the disease and the changeable requirements of
people with MND requires easily accessible support to maintain the person at
home, less disruption for patient and family, and to prevent lengthy and costly
admissions to acute hospitals. The most recent WA HEALTH data available on
this topic is from 2008, when an average length of stay at a tertiary hospital for
a person with MND was between two and four weeks at an approximate cost of
between AUD10,000-AUD25,000 (Department of Health, 2008). Consequently,
the report recommended early involvement of palliative care specialists and
other members of a multidisciplinary team (MDT) in order to maintain people
with MND within their home environment and to closely monitor their changing
requirements those of their caregivers (Department of Health, 2008).

1.5. Death from MND
Patient preferences in relation to choices for end-of-life care require
sensitive, explicit discussion and clear documentation by clinicians to reflect and
achieve patient wishes (Smith & O'Neill, 2008). Hogden, Greenfield, Nugus and
Kiernan (2013) found that the caregiver is as occupied and affected by the
complex decisions surrounding patient care as the patient, and acknowledge
that communication between patient, caregiver and clinical team is vital to
achieve optimum patient care (patient-centred care). While there are guidelines
regarding general end-of-life care containing recommendations specific to
people with MND, these guidelines are mostly general in nature, broadly
concerned with “what should be done”, and do not specifically define, describe,
or detail the implementation steps for recommended best practice (National
Health and Medical Research Council [NHMRC], 2012).
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As death occurs soon after the removal of NIV and opiates are used to
ease the distress associated with extreme difficulty breathing, families and
significant others may feel confused and concerned if they have not understood
the information provided to them or expected the events leading up to the end of
life. Therefore, clear, unambiguous communication addressing the link between
initiation and withdrawal of NIV and the end of life is critical for people with MND
and their families. In order to make a fully informed decision about NIV,
discussion and a shared understanding of all salient considerations prior to the
onset of respiratory distress and loss of verbal communication is vital. This
communication must include the limitations of NIV on disease prognosis.

Death can cause distress and fear for the patient and their family. Ideally,
therefore, caregivers facilitate an early understanding for the patient and their
family that, whilst death is inevitable, a “good death” is possible. Over the past
40-50 years end-of-life research has led to an agreement on what constitutes
good end-of-life care and, through a series of exploratory studies, a consensus
between clinicians, patients and caregivers has emerged on the definition of a
good death (Steinhauser et al., 2000). Early studies show a remarkable degree
of agreement concerning what components of clinical, psychological, financial,
and social support are deemed important to patients and families at the end of
life. Complexities arise around differences in ethnicity, gender, religion,
spirituality and culture (Meffert, Becker, Körner, & Stößel, 2015). In 1969 KublerRoss published a book “On Death and Dying”, which identified patient choices
and personal decisions relating to terminal care including place of end-of-life
care and treatment. Kubler-Ross suggested that the dying and aged tend to be
isolated, as they are reminders of the inevitability of life, but she argued more
resources should be made available to ensure a more caring end of life at home
which might ensure a good death (Kubler-Ross, 1969).

In 2000, Steinhauser et al. conducted a study into what constitutes a
good death by collecting descriptions of areas of importance from patients and
families experiencing end-of-life care. Six factors were identified: symptom
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management, clear communication for decision-making, preparation for death,
attention to family and close friends, reciprocity of care and concern for the
wellbeing of others and recognition of the patient as an individual rather than a
disease entity (Steinhauser et al., 2000; Steinhauser, Voils, Bosworth, & Tulsky,
2015). In the later study by Steinhauser, Voils, Bosworth and Tulsky (2015) a
more comprehensive form of end-of-life care, including understanding and
supporting the choices of care made by the patient and family, is identified as
contributing to a good death.
Understanding a person’s end-of-life choices is particularly important
when their ability to clearly verbalise or communicate their wishes has been
adversely affected. The clinician/patient interaction is especially relevant in
MND when clear communication is often extremely difficult due to the person’s
disease progression. Consequently, to achieve a good death, clinicians need to
engage in clear, honest and comprehensive communication in order to develop
a shared understanding of the goals of care for the patient and their family.
Therefore, clinicians must not only be compassionate but clinically informed
and, ideally, experienced if they are to conduct such conversations effectively
(McConigley et al., 2012; NICE, 2016). Determining when a person with MND
and their family are ready to accept and receive such honest communication,
however, adds further complexity.

1.6. Hospice Care and Specialised Palliative Care
Palliative care management for people with MND is focused on the
symptoms, support and needs of the patient and their family. Ideally, this
management would integrate an MDT approach where the benefits, burdens
and limitations of all options would be discussed between all health
professionals, the patient and their family (MNDAust, 2012). The integration of a
centralised, rather than a delegated community-based system, MDT
incorporating palliative care has been found to reduce hospital admissions and
have a positive effect on the survival of people with MND (Rooney et al., 2015).
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Specialist palliative care has become more accessible throughout Australia over
the last 30 years and should be central to discussions concerning end-of-life
communication. The following section describes the development and
significance of hospice and specialised palliative care in Australia. The role of
specialist palliative care in the delivery of treatment options and the importance
of unambiguous communication is discussed. This historical overview of
hospice and palliative care provides contextual background to the current study.
The history and significance of the concept of “hospice” care dates back
to the 12th century, when religious orders offered a place of rest to those
severely ill or dying (Palliative Care South Australia, 2015). The idea of a
medical specialty focused on caring for the dying was developed after the
Second World War by Dame Cicely Saunders, who established St Christopher’s
Hospice for the terminally ill in London. She presented her idea in a lecture in
1963 at Yale University in the United States and her thinking laid the
foundations for end-of-life care as an area of expertise, a medical speciality and
the development of modern hospices. Dame Saunders recognised the many
facets, depths and causes of pain and the need for psychosocial and
psychological support for the patient and their family. In 1975, the term
“palliative care” was introduced in Canada by the physician, surgeon and
academic Balfour Mount, who was concerned the term hospice evoked places
of impoverishment and hardship (Palliative Care South Australia, 2015).

In 1990, each state and territory in Australia formed the Australian
Hospice and Palliative Care Association which was renamed Palliative Care
Australia in 1998 (Palliative Care South Australia, 2015). Palliative Care
Australia has provided recommendations for the standardisation of palliative
care within Australia as well as assisting with end-of-life research and the
development of quality standards. Historically, palliative and hospice care
focused on cancer patients and most research focused on efficacy, service
provision and cost (Palliative Care South Australia, 2015). More recently
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palliative care has come to be considered relevant to and appropriate for all
people with a life-limiting, progressive disease (e.g., heart and lung disease,
other neuro-degenerative diseases) (National Palliative Care Strategy, 2010).

Hospice care and palliative care are terms often used interchangeably.
However, palliative care may be considered a specific system of patient care
ideally introduced when a life-limiting disease is diagnosed, whereas hospice
care could reasonably describe palliating care at the terminal stage of a disease
(Connolly et al., 2015). Both community- and hospital-based specialist palliative
care focus on the quality of a person’s end-of-life, their physical and emotional
suffering and the appropriateness of ongoing treatments (Palliative Care
Australia, 2005; Palliative Care Expert Group, 2010).

Hospice and palliative care in Australia are provided in various settings:
acute, specialist, aged care facilities, medical/generalist and community.
Funding for these services comes from a complex mix of state and federal
monies plus donations and bequests (Community Affairs References
Committee & Siewert, 2012). The cost of providing a community palliative care
service is less than that provided in an acute care setting and is often the
preferred place of treatment and death (Hodgson, 2010). Hospice and palliative
care, whether as a community service or in an aged care setting, has been
shown to decrease health care costs by reducing admissions, inappropriate
diagnoses, re-admissions and length of hospital stay (Allen, O’Connor,
Chapman, & Francis, 2008; Hodgson, 2010). Community-based palliative care
improves care and symptom control in a preferred place of care and adds to
provider clinician satisfaction (Hodgson, 2010; Palliative Care Australia, 2005).

The main components of palliative care services include symptom
control, the management of disease and spiritual and psychological support for
patients and their families in order to allow a good death and choice in where to
die (Palliative Care Australia, 2005). Implicit within this description is the support
and care of a patient’s family and significant others.
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Early palliative care team involvement assists the development of trusted
relationships between clinicians, patients and families by establishing good
communication, understanding patient preferences and optimising care. Ideally
early trusted relationships facilitate discussion and documentation of end-of-life
treatment choices, known in the literature as advance health directives (AHD)
(WA Health, 2011). Generally, there has been some attempt at a cure prior to
the offer of such care but MND does not come with hope of cure, and it is,
therefore, argued that palliation should commence at diagnosis (Aoun et al.,
2012; Connolly et al., 2015; Motor Neurone Disease Association, 2012; Motor
Neurone Disease Australia, 2010). In order to monitor disease progression and
optimise the quality of life for people with MND and their family members, a care
plan incorporating palliative care from the time of diagnosis is recommended to
improve communication and support (Connolly et al., 2015; MNDA, 2012;
MNDAustr, 2014). However, barriers to this approach exist, for both clinicians
and people with MND.

Consideration if the broader approach to patient (and family) care within
the healthcare system is relevant because it impacts service users’ and carers’
(and clinicians’) readiness to accept or propose palliative care. One popular
approach to the timing and content of end-of-life communication is through the
framework of a patient-centred model of care This is discussed in the following
section.

1.7. Patient-Centered Care
A patient-centred model of care is incorporated into current medical
teaching, but there is some ambiguity around how it is defined (Bertakis & Azari,
2011). Patient-centred care is generally understood to encapsulate a holistic
approach within which the patient is an integral decision maker in care choices.
The term was first introduced in the United Kingdom. It emphasised the
importance of an individual’s involvement in their own medical care and
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required explicit clarification for the patient of their disease prognosis and
ongoing care (Balint, 1969). In 1995 patient-centered care was explored as a
model of care more from the doctor’s perspective (Schofield, 1995). Patientcentred care incorporates the idea of enhancing the doctor-patient relationship
through a sharing of health issues whilst understanding the individual within
their social and familial context. Incorporated within this model are health
promotion and prevention, plus consideration of the doctor’s time and resource
restrictions.

A systematic review undertaken more recently identified a failure to
define patient-centred care within articles which either incorporated the term in
the title or within the abstract (Scholl, Zill, Härter, & Dirmaier, 2014). From the
articles that did offer a definition, Scholl et al. (2014) were able to categorise 15
dimensions to patient-centred care. Clinical communication was identified by
Scholl et al. as an important element of patient-centred care. However,
characteristics of the clinician, coordination and continuity of care and the
psychosocial perspective are all aspects of the patient-centred care model
(Scholl et al., 2014).

In Australia, the definition of patient-centred care includes understanding
the patient within their social/familial context as well as being responsive to the
preferences and principles of the individual. Incorporating informative
communication, emotional and physical support and respect is the definitive
holistic approach to patient-centered care in Australia (Australian Commission
on Safety and Quality in Health Care, 2011). One of the recommendations from
the Australian Commission into the delivery of care, is that research funding and
its distribution acknowledge the importance of patient-centered care (Australian
Commission on Safety and Quality in Health Care, 2011).

Similarly, the definition of patient-centred care in the United Kingdom
encourages consulting with a patient to ascertain their preferences and
incorporating shared control and management of their health issues (Farrell,
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2004). In the United States, an analysis into the determinants of patient
centered-care found the more educated and healthier patients cared for by their
family physician were more likely to have participated in patient-centered care
(Bertakis & Azari, 2011). Bertakis and Azari (2011) suggest that patients with
more serious illnesses are more encumbered by their medical needs and have
less time to partake in patient-centered communication. Berkaki and Azari,
however, found no correlation between increased patient satisfaction and
patient-centred care.

Patient-centred care stresses clarity in communication between clinicians
and those they are treating. The communication, whilst being informative,
should uphold the dignity of the person affected by the health issue. The WHO
promotes people-centred health by educating and supporting patients and their
families to make informed decisions based on their health requirements,
expectations and, importantly, preserving dignity (WHO, 2015a). However, this
ideal health care model can only be delivered with correct training of care
providers and a setting conducive to sensitive and dignified communication
(Pringle, Johnston, & Buchanan, 2015).

The following section explains the development of evidence-based
guidelines and identifies the inclusion of patient-centred care within these
guidelines. The interpretation of how recommended evidence-based, patientcentred communication is delivered and understood is central to the research
reported in this thesis.

1.8. Evidence-Based Guidelines
Following the initial work by Steinhauser et al. (2000) in defining a good
death, researchers began to investigate what the best clinical practices were to
achieve elements identified as important to patients and families at the end of
life. Clinical guidelines have appeared, based primarily on clinical and expert
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opinion, first for cancer patients and more recently for non-cancer and chronic
illness end-of-life care (Steinhauser et al., 2000; Thomas & Free, 2006).
Evidence-based clinical guidelines provide up-to-date information and
direct best clinical practice and recommendations for care in a particular field.
Within the Australian clinical setting, NHMRC guidelines provide direction for
clinical care and inform clinical decisions on a variety of disease areas
(NHMRC, 2016). The NHMRC guidelines, as well as guidelines in other
developed countries, are based on a thorough review of research evidence and
current clinical consensus. Multidisciplinary panels incorporate experts within
their field, educational institutions, consumer groups and professional bodies all
of whom contribute to inform best practice.

In the United Kingdom the NICE, an independent public organisation,
provides evidence-based recommendations to improve and guide health and
social outcomes. The development of the guidelines is based on accepted
international standards of research and assessment, undertaken by clinical
experts, NICE committee members and stakeholders (NICE, 2014). The
American College of Physicians’ development of clinical guidelines includes
systematic reviews of the research evidence plus committee support in much
the same way as the NICE and NHMRC guidelines (Qaseem, Snow, Owens, &
Shekelle, 2010). The NHMRC and NICE clinical guidelines are commonly
updated every 5-10 years (NHMRC, 2016; NICE, 2014). In the United States
the clinical practice guidelines are withdrawn or considered invalid if not updated
within five years after publication (Qaseem et al., 2010).

However, there are shortcomings with evidence-based guidelines, not
least their implementation into practice (Greenhalgh, Howick, & Maskrey, 2014).
As an example, Greenhalgh, Howick and Maskrey (2014) state that despite the
lack of evidence for arthroscopy in all but those who medically need it,
arthroscopies continue at an extremely high rate in a much broader population.
A further disadvantage is that the sheer volume of evidence may have become
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too great and time consuming to be absorbed by already busy clinicians. In
addition, clinicians often fear that clinical expertise founded on the accumulation
of years of medical practise could be overshadowed by the fear of litigation if
specific evidence-based pathways are not followed (Glasziou, Moynihan,
Richards, & Godlee, 2013). Nonetheless, clinical guidelines provide a way to
consider the issues in providing effective care.

In MND this includes communicating symptom control options such as
NIV initiation and possible removal and end-of-life options (Andersen et al.,
2012; NICE, 2016). The recommendations for timing, content and delivery of
communication within the most recent MND guidelines (NICE, 2016) incorporate
patient-centred care in their ethos. The combination of patient-centred care,
evidence-based care and a good death is represented in the most recent MND
recommendations and guidelines and provide the framework for data analysis
for the current study.

1.9. Rationale for the Research
Over the past 10 years throughout Australia there has been a rise in the
number of deaths from MND, although the cause of the increase is not known
(Motor Neurone Disease Australia, 2013). Global statistical data on MND/ALS is
not uniformly collected and the statistics within this thesis are sourced primarily
from Australian and United Kingdom publications.

In MND, early discussion of end-of-life symptom relieving choices has
been found to be particularly pertinent, as from diagnosis the person with MND
and their family need to understand there is no cure and that the progression of
disease can be rapid and unpredictable. Respiratory failure is the most
debilitating and critical symptom in MND and is the most common cause of
death. Non-invasive ventilation (NIV) is offered for respiratory symptom relief in
people with MND but has its limitations. Therefore, communicating symptom
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control alternatives and their limitations is recommended to occur soon after
diagnosis and certainly by the onset of respiratory symptoms.

Current palliative care guidelines recommend that MDT including clinical
specialists, physiotherapists, dietitians and social workers are involved with
people with a life limiting illness to ensure that all aspects of patient care are
covered (Bede et al., 2011; Rooney et al., 2015). A systematic review by Oishi
and Murtagh (2014), however, highlighted uncertainty about responsibility for
coordinated end-of-life care in non-cancer patients. Oishi and Murtagh found
that some of the clinician roles and responsibilities were unclear both to the
patients and caregivers and in some cases to the clinicians themselves (Oishi &
Murtagh, 2014). Arguably, this uncertainty may affect the nature of the timing
and content of any discussions relating to symptom control options such as
PEG and NIV.

Established patient-centred, evidence-based medicine and palliative care
clinical guidelines have all recommended that communication for people with
MND surrounding the initiation of NIV should occur early and include
discussions relating to gastrostomy tube insertion into the stomach (NICE,
2016). It is important to understand that the impact of these interventions on
people with MND and their caregivers can be significant, and the quality of life
gain may be small (ProGas Study Group, 2015). It is suggested by others that
these discussions should clearly inform people with MND and their
families/caregivers of their options, so they can make informed choices and
share these with all involved. This will in turn minimise the influence of the
healthcare professionals’ personal attitude toward initiation and potential later
discontinuation of treatment (Motor Neurone Disease Australia, 2014; Ruffell et
al., 2013). Unambiguous discussions about preferences relating to nutrition and
hydration via gastrostomy insertion are recommended to occur well in advance
of respiratory symptoms, but there is uncertainty in relation to the actual content
and timing of these discussions within the literature (Connolly et al., 2015;
Oliver, Campbell, Sykes, Tallon, & Edwards, 2011). Further, it is not clear
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whether intervention to maintain hydration and nutrition is discussed as a lifeprolonging measure despite the minimal evidence (Connolly et al., 2015), nor
whether the benefits and burdens of PEG insertion are included in the content
of effective communication. It is acknowledged that predicting the exact course
of an individual’s disease can be difficult; the call to avoid ambiguity, therefore,
refers only to the content of communication relating to symptom control options,
AHD and end-of-life choices delivered by health professionals.

Despite the existence of specific MND guidelines recommending early
and explicit communication about end-of-life care choices, there is a perception
among health care professionals that for some people with MND and their
families, symptom control and end-of-life options are neither well
communicated, understood, nor documented (Baxter et al., 2013; Faull, Phelps,
Regen, Oliver, et al., 2014). Unclear communication has the potential to lead to
confusion and emotional uncertainty for families and their health care
professionals, and to result in insufficient information to make and document
informed care choices. Of concern, and explored within this research, is the
perceived difficulty in communicating and comprehending vital information to
people with MND and their families, which acts as a barrier to informed
symptom control and end-of-life choices. The research reported in this thesis
investigated overall accountability for communicating information to people with
MND and their families to uncover how this may have affected the clarity of their
understanding. It is these issues of communication surrounding respiratory
failure and symptom control (especially NIV) in people with MND that are the
focus of this study.

More specifically, the objective of this research is to determine whether
patient-centred care, evidence-based medicine and guideline recommendations
relating to symptom control in respiratory failure and end-of-life choices were
being adequately practised by clinicians working with people and families
affected by MND. Of particular interest is the timing and content of
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communication, how effectively and comprehensively clinicians felt they
delivered the required information and consequently how they perceived people
with MND and their families understood the intended meaning of these
communications. In addition, the study examines whether clinicians involved
with people with MND were concerned that, as clinicians, they may not fully
understand their patients’ wishes for palliation and end-of-life choices.

The first part of this chapter has explained the background to the current
study. Next, the focus of the research will be presented, followed by an overview
of the subsequent chapters.

1.10. The Research Focus
The focus of the research presented in this thesis is clinical
communication about respiratory failure and symptom control at the end of life
in people with MND. Specifically, the research questions generated, and data
collection conducted for this thesis were designed to explore what information
clinicians communicate regarding NIV and end-of-life issues and what the
experience and understanding of that information was for the MND caregiver
after the death of the patient. The research sought to ascertain whether MND
communication content explaining treatment options conforms to the available
recommended guidelines (National Institute for Care and Health Excellence,
2016; National Institute for Health and Clinical Excellence, 2010). The aims of
the research reported in this thesis are described below:
1. To describe clinician communication surrounding NIV including end-oflife choices.
2. To understand how clinicians check the level of understanding among
patients and family members of the benefits, burdens and potential of
NIV withdrawal prior to NIV commencement.
3. To understand the impact of clinician communication about the benefits,
burdens and limitations of NIV on family members’ choices in relation to
NIV introduction.
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4. To understand what timing, content and style of communication most
effectively helps the families of people with MND to make decisions
about NIV initiation and withdrawal.
5. To compare the content, process and outcomes of NIV communication
as described by clinicians and families of people with MND within this
study against the currently available recommendations relating to
commencement and withdrawal of NIV and related end-of-life care
options.
The following questions were answered where possible by the literature
review and formed the foundation for the questions asked of the participants.

1.10.1. Research questions
1. In considering the available literature and guidelines, what are the
most salient components of best practice relating to the
communication about NIV in MND prior to NIV initiation and
withdrawal?
2. What is the evidence that the best practice communication content
(benefits and burdens of NIV, continued disease progression,
explanation and offer of a PEG, end-of-life discussions and
understanding the potential for NIV withdrawal prior to the
commencement of NIV) is incorporated into the actual communication
by clinicians to people with MND and families at the time of offering
NIV?
3. What do MND families/significant others recall about the
communication (benefits and burdens, continued disease
progression, PEG insertion, potential NIV withdrawal and end-of-life
discussions) provided by clinicians at the time of respiratory failure
and the offer of NIV?
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4. To what degree do MND families/significant others feel that the NIV
communication provided by the clinicians at the time of the offer of
NIV prepared them for and helped them to understand the
implications of potential NIV withdrawal resulting in the death of their
family member?
5. What if any unmet needs for information, support, palliative care, or
other services do the clinicians and the families/significant others (or
patients themselves) with experience of MND identify?
6. Following the literature review and clinician and family/significant
other interviews regarding NIV communication, what
recommendations can be identified that would improve end-of-life
communication and process for people with MND, families and
clinicians?
Communication content surrounding the initiation of NIV and
encompassing the potential of NIV withdrawal is sparsely covered in the
literature and is an area where further research has been recommended (NICE,
2010). The most recent NICE MND Assessment and Management Guidelines
(NICE, 2016) recommend including discussions relating to “advantages and
disadvantages” of NIV when discussing its initiation. The guidelines recommend
that those diagnosed with MND have adequate information relating to what NIV
can offer, that it can be stopped at any time and that the discussions occur
sensitively and at an appropriate time (NICE, 2016).

This research examines the content of communication between clinicians
and people diagnosed with MND and their families which, if based on the
evidence-based clinical guidelines, should incorporate symptom control and
end-of-life issues. The study identifies two distinct participant groups: those that
provide the communication (the clinicians) and those that receive the
communication (the people with MND and their families). The research
questioned the clinicians involved as to when they imparted the relevant
information and whether they felt they had done so with enough clarity to allow
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the person with MND and their family to make informed choices. In particular,
clinicians’ views about understandings held by people with MND and their family
members around the possibility of NIV withdrawal followed by death when NIV
was deemed to be of no further benefit were explored. Whether and how the
implications of commencing NIV were understood by the bereaved families of a
family member with MND were also investigated. In addition, the research
explored whether the families/significant others involved with the person with
MND felt able to ask all the questions they wanted to ask, whether they felt
adequately informed and whether all the participants could offer suggestions to
improve communication between clinicians and people with MND and their
families.

This study provides a much-needed contribution to the literature on the
experiences of caregivers and families who have had a family member die from
MND and had experience with, or refusal of, NIV as a palliation measure.
Family and clinician experiences with the withdrawal of NIV are included. The
study offers valuable insights into clinicians’ experiences of communicating with
each other within an MDT, and with people with MND and their families. The
thesis explores perceived barriers to clear communication both between
clinicians as well as between clinicians and people with MND and their families.
The variation of care available to rural and metropolitan people living with MND
is also highlighted and discussed.

1.11. The Structure of the Thesis
Much of the existing literature on MND and end-of-life contains terms that
may be unfamiliar to those outside the clinical/practice domain concerned with
supporting and caring for those with a life-limiting condition. Definitions are,
therefore, provided within the glossary of terms (page XIX) to help the reader
navigate the remainder of this thesis.
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The thesis comprises six chapters. In Chapter 1 the context and broad
rationale for the study have been indicated, and the research focus, aims and
questions have been presented.

Chapter 2 contains a comprehensive review of relevant literature on the
topic of clinical communication relative to MND. This review identifies the
precise gap in knowledge that the research questions in this thesis have been
designed to address. A fully replicable literature search and selection strategy is
also detailed.

The study methodology and methods are the subject of Chapter 3. The
compatibility of interpretive description (methodology) and symbolic
interactionism (theoretical framework) are introduced. First, the purpose, aims
and significance of this investigation are restated. Next, a discussion of possible
approaches to this study and justification for the one chosen is provided. The
steps followed to conduct the research are then presented. In this chapter, the
involvement of a stakeholder advisory group formed to confirm and refine the
research questions and participant interview questions is reported, as are the
ethical considerations and measures used for trustworthiness.
Chapter 4 reports the findings of the study, which include clinicians’
reasons for not always following recommendations, and barriers to
communication between clinicians and families/caregivers of people with MND
from the perspective of both cohorts. Illustrative clinician and family participant
quotations from interview transcripts are included where relevant.
Misunderstandings around definitions of some words used in communicating, as
reported by many of the participants, are discussed.

Chapter 5 includes the discussion of the study findings. The theoretical
perspective that guided this study is also considered. This chapter also
compares existing knowledge about MND communication to the new
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information this study reveals, and incorporates any relevant literature published
since the completion of the literature review (Chapter 2 and Appendix A).

In conclusion, Chapter 6 brings the research and the thesis to a close
with recommendations for further research and suggestions for clinical practice.
Limitations identified within this study are also discussed. Chapter 6 concludes
with a reflective account of the candidate’s experience of conducting this study
(within the Epilogue). Lessons learned are identified for use in future research
endeavours.
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A qualitative study into the communication surrounding the initiation and withdrawal of noninvasive ventilation (NIV) in people with motor neurone disease

Chapter 2:
Literature Review
2.1. Section 1: Chapter Overview
In this chapter, the argument for the current study is further developed.
Chapter 1 provided the context for this research and a broad overview of the
current study. This chapter is presented in five sections, beginning with an
overview of the context of end-of-life communication in cases of MND and
identifying the need for a focused review of the literature on communication
between healthcare professionals and those with MND and their family
members in Section 1. Section 2 provides a summary of the steps taken in a
systematic (black) literature search, retrieval and selection process, conducted
to answer the question “What is known about communication between
caregivers and families about NIV in MND prior to NIV initiation and
withdrawal?”. Section 3 reports and discusses the results of this process in the
form of narrative critical review. The report of an environmental scan conducted
in which clinical guidelines pertinent to the phenomenon of interest were
retrieved and summarised is provided in Section 4. This is followed by a
statement about what is and is not known and discussed in relation to the
introduction, use and withdrawal of NIV in MND. The need for a study to
address current knowledge gap is then summarised, and the research
questions are listed in Section 5.
2.1.1. Epistemological and ontological position
To understand the nature and effect of communication in relation to endof-life treatment choices delivered by clinicians to people with MND and their
families, both the study reported in this thesis and the review of literature are
positioned within a relativist ontology and a subjective epistemological position.
These two decisions reflect an understanding that delivery of vocal
communication depends upon the clarity and specificity of the language of the
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individual delivering it, and that how the “receiving” individual understands the
delivered communication depends on a range of influencing individual factors
(Raskin, 2008).
2.1.2. The context of end-of-life communication in MND
The importance of clear communication in which the benefits, burdens
and limitations of NIV are explained to people with MND and their families has
been recommended by many in the field of MND care (Baxter et al., 2013;
NICE, 2010, 2016). Explicit communication enables people with MND to make
informed treatment choices. Studies show the use of NIV in people with MND
with good bulbar function can prolong a person’s life by 7-18 months (Bourke et
al., 2006; Jenkins, Hiollinger, & McDermott, 2014; Radunovic et al., 2013).
Nevertheless, with or without the use of NIV, complications can arise for people
with MND such as an inability to clear oropharyngeal secretions (respiratory
secretions which can become copious or viscous in MND) leading to chest
infections, or increased difficulty breathing, which in turn commonly lead to
death by respiratory failure (Rafiq et al., 2012). Additional considerations, such
as clarifying and documenting the patients’ and families’ wishes for end-of-life
treatments, such as incorporating AHDs into advance care planning, are
recommended for clear direction to clinicians. Patient comfort, caregiver support
and the value the individual places on a potentially longer life in relation to the
possible trade-off of poorer quality of life are recommended as essential
components of conversations. This communication must be undertaken when
proposing potentially life extending technologies such as NIV (Lerum,
Solbrække, & Frich, 2016; NICE, 2016). Thus, the inclusion of end-of-life issues
and documented patient wishes in communication surrounding NIV is vital for
ensuring a clear and shared understanding between all concerned.
Recent end-of-life and clinical palliative care literature suggests that NIV
is being increasingly employed as a palliating intervention for dyspnoea, not
only in MND, but also in other progressive respiratory diseases such as lung
cancer and emphysema (Gifford, 2014). NIV can also be used as a palliating
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measure in illnesses with a long trajectory such as chronic obstructive
pulmonary disease (COPD) (Gale, Jawad, Dave, & Turner, 2015). Although NIV
has been recommended for palliating respiratory symptom relief in MND, it is
unclear whether clinicians who specialise in all progressive respiratory
conditions are communicating clear and precise information about its initiation
and potential withdrawal to patients and their caregivers. Understanding what
this communication involves, at what stage the discussions occur, how well the
necessary information is being delivered and comprehended by people with
MND and their families is, therefore, becoming increasingly relevant to other
diseases (Gifford, 2014; Quill & Quill, 2014). The benefits of relieving respiratory
failure associated with MND and the burdens of wearing an NIV mask
(associated feelings of claustrophobia and discomfort) appear similar in people
with MND and those with chronic respiratory disease. People with MND and
those with COPD experience increased dependence on both NIV and caregiver
support (Ando et al., 2014; Gale et al., 2015).
2.1.3. The timing of palliative care involvement and triggers for NIV
and end-of-life discussions.
The WHO recommends a palliative approach at the end of life, to ensure
quality of care for all life-limiting illnesses (Sawatzky et al., 2016). The WHO
(1998) describes palliative care as:
…an approach that improves quality of life of patients and their families
facing the problem associated with life-threatening illness, through the
prevention of suffering by early identification and impeccable assessment
and treatment of pain and other problems, physical, psychological and
spiritual.
The WHO definition does not specify an individual’s anticipated life
duration for referral to a specialist palliative care organisation. In MND, not
knowing the best time for referral of those living with the disease to specialist
palliative care can make the transfer difficult (Dharmadasa, Matamala, &
Kiernan, 2016).
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Whilst MND is generally associated with a life expectancy of
approximately 2-5 years, some people live with the disease for more than 10
years, which potentially changes the prognostic category to chronic (rather than
terminal) disease (Lerum et al., 2015). The MND recommendations referenced
within this study discuss referral to specialist palliative care at diagnosis.
However, consideration of a palliative care approach which incorporates a GP
and organised community care as opposed to early incorporation of a specialist
palliative care service may be appropriate. This may be particularly relevant
when considering life-limiting chronic diseases, which in the instance of MND
may describe the course of some variants of the disease (Burgess, Braunack
Mayer, Crawford, & Beilby, 2013). Burgess, Braunack, Crawford and Beilby
(2013) suggest a referral to specialist palliative care is based on patient needs
as well as their symptoms rather than diagnosis alone.
The Standards for Providing Palliative Care in Australia (Palliative Care
Australia, 2005), which are generally accepted in principle throughout the world,
include acknowledging the unique holistic requirements of the patient and their
family. Ongoing assessment and communication are particularly important.
According to these standards, palliative care should be available to all but is
difficult for those with a life-limiting disease irrespective of diagnosis., based on
clinical need. The availability of coordinated assisted care to lessen the
caregiver burden, provide comfort and meet individual requirements for end-oflife care should be considered (Palliative Care Australia, 2005). In MND there is
no potential of a cure but a prolonged physical and mental decline. The timing
of referral to palliative care for people with MND has been addressed in the
general palliative care literature and current recommendations, although there is
confusion as to the optimal timing (Dharmadasa et al., 2016). Whether
specialist palliative care is introduced from diagnosis or when MND symptoms
worsen and symptom management technology (such as NIV) is needed is
dependent on when the patient and family are judged ready to receive such
information. Leaving referral too late can lead to hospital admissions and crisis
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situations, should clear information not have been forthcoming (Connolly et al.,
2015).
Opinions about when specialist palliative and end-of-life care are
introduced abound with little consensus, due in part due to the wide variation in
the trajectory of diseases (e.g., cancer versus non-cancer). However, most
experts agree that palliative care should be started soon after diagnosis and
thus, end-of-life communication needs to start early (NICE, 2016; Oliver et al.,
2006). A study in the United Kingdom investigated whether the Preferred
Priorities for Care document developed as a communication tool by the End of
Life Care Strategy (Lancashire and South Cumbria Cancer Network, 2007) had
any impact on the actual end-of-life care offered to people with MND. This plan
was developed as a patient-held advance care planning tool principally to assist
patients to make their preferred place of death clear. However, this document
was not found to improve patient end-of-life care and many health care
professionals seemed unaware of its existence (Preston, Fineberg, Callagher, &
Mitchell, 2011). Another study examined clinical support tools. The Lothian
National Health Service in the United Kingdom developed what it called the
‘Supportive and Palliative Care Indicator Tool’, which suggests general and
clinical indicators to identify those in need of immediate palliative care (Boyd &
Murray, 2010). This indicator tool does not recommend commencement of
palliative care when the neurological diagnosis is given. It suggests that
palliative care services should become involved when symptom deterioration
such as breathlessness, swallowing difficulties or communication issues occur.
Other researchers have investigated the timing of discussions between
clinicians and patients. In an article that suggests early open and honest
communication of end-of-life issues in ALS, Connolly, Galvin and Hardiman
(2015) examined published scientific literature to identify end-of-life issues
pertaining to the management of MND. They suggested that early symptom
control communication may enable patients and families time for informed
discussion and to plan and prepare, and that these discussions may prevent
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unwanted symptom control interventions such as NIV, gastrostomy tubes and
the potential of invasive ventilation. Other studies tend to support these
conclusions (Dharmadasa et al., 2016). Thus, honest communication
surrounding end-of-life options for care is recommended from initiation of
symptom control interventions (NIV/PEG), particularly if such discussions have
not previously occurred, and especially as MND has an unpredictable disease
course.
The introduction of palliative care soon after (or at) diagnosis is
discussed by Connolly et al., (2015) and is encouraged for alleviating
symptoms, improving communication, providing support to patients and families
and enhancing quality of life in a terminal disease. Some health professionals
may lack experience and confidence to manage the complex and sensitive
discussions associated with ongoing care in a relatively rare disease such as
MND, and some may perceive a sense of hopelessness should end-of-life care
be discussed too soon (MNDA, 2012). As the disease progresses and
symptoms of respiratory distress develop, the person with MND should be
referred by their primary health care provider to a respiratory physician or
neurologist for detailed specialist management and discussions regarding
appropriate forms of psychological support, ventilation options, palliating
alternatives and guidance by an MDT (NICE, 2016).
An MNDAust submission made to the Australian Senate Committee
inquiry into palliative care in Australia advised that access to MND specific
information for patients and their families is required to maintain a palliative care
approach and to support clear communication about end-of-life issues
(MNDAust, 2012). The submission also recommended referral to palliative care
services as soon as possible after diagnosis to optimise quality of life and
professional support to inform and assist with advance care planning. MNDAust
recommends that a palliative care approach to MND is initiated on diagnosis,
with discussions incorporating end-of-life decisions commencing when the
person with MND is ready (MNDAust, 2010). Although the MNDA agrees that
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the timing of such discussions is uncertain and ought to be individualised,
triggers for commencing such discussions are suggested, with one
indicator/prompt being dyspnoea (difficulty with breathing) and offering NIV
(NICE, 2010).
A survey amongst the members of the European ALS Study Group on
standards of palliative care found discrepancies in care offered amongst
palliative care providers, such as the timing of the introduction of palliative care
and MDTs, and the availability and maintenance of NIV (Borasio, Shaw,
Ludolph, Sales Luis, & Silani, 2001). Discussions relating to terminal care were
reported to occur at the request of the patient or when the patient was close to
death, highlighting the possibility that the patient and family may have worried
over symptoms such as choking in respiratory failure for the duration of the
illness. The authors recommended development of a set of common standards
for the management of ALS (Borasio, Shaw, et al., 2001).
The European Federation of Neurological Societies (EFNS) have
recently revised guidelines for the care of people with ALS and made
recommendations for further research such as studies into the quality of life
relating to NIV and PEG use (Andersen et al., 2012). Recommendations for
care within the guidelines include input from a palliative care team early after
diagnosis, initiation of end-of-life discussions when an individual is ready and at
the time of provision of potentially life-sustaining interventions. Respiratory
distress symptoms ought to prompt end-of-life discussions and trigger the
AHDs. More recently, a paper presented at the 24th Meeting of the EFNS
(European Federation of Neurological Societies and European Association of
Palliative Care, 2015) reiterated the need for communication regarding end-oflife issues prior to any impairment of communication abilities. A review of the
current international palliative care guidelines indicates that clear
communication between medical specialties and people with MND is required
(NICE, 2016). The recommendations include the need for international palliative
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care MND/ALS guidelines incorporating respiratory failure options (Bede et al.,
2011; NICE, 2016).
Finally, the NICE clinical guidelines (2010) for the use of non-invasive
ventilation in the management of MND recommend that respiratory physicians
should be part of the MDT and this is reiterated in the NICE (2016) MND
Assessment and Management Guideline. Eng (2006) suggests a general
acknowledgement amongst clinicians specialising in MND that involvement of a
palliative care service at the stage of respiratory decline, if not before, is
important. Hardiman (2011) and Borasio, Voltz and Miller (2001) agree a
palliative care approach should commence from the onset of symptoms and
initial diagnosis of MND, and recommend discussions involving the patient,
significant others and the medical team to optimise appropriate ongoing care,
understanding and support. Borasio et al. (2001) also suggest discussion and
information for families and people with MND about the terminal stage should
commence, at the latest, with the onset of symptoms of dyspnoea.
Whilst there is agreement in the literature for early palliative care
involvement and the potential usefulness for AHDs (Borasio, Voltz, et al., 2001;
Hardiman, Bede, Oliver, & Obrannagain, 2011), the optimal time for
involvement of the specialist palliative care team from the perspective of the
patient or family remains unclear. The concept of improved communication
surrounding the implementation of NIV and ongoing disease progression is
acknowledged as an area requiring further research (NICE, 2010).
In summary, people with MND can present with different palliative care
issues compared to cancer patients. Clear communication surrounding the
introduction of palliative care and symptom control delivered at a pace directed
by the person with MND and their family is an important element in quality endof-life care and is explored within this thesis.
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2.1.4. Patient and family perspectives on end-of-life communication
The literature published over the past 16 years has been reviewed for
this chapter. It identifies clear communication as a priority of end-of-life patients
and their families. Understanding the disease process is essential for them to
make appropriate and timely symptom control and end-of-life decisions. People
with MND and their caregivers can be assisted to make clear decisions relating
to their ongoing care if they know the facts of their disease and if the support is
available to ensure their wishes are upheld. In a retrospective study of 42
people with MND, Anderson, Kuru, Munroe, and Sirdofsky (2007) agree that
end-of-life discussions should commence from the time of the person’s MND
diagnosis and continue over the duration of the disease especially as patient
preferences often change over time. Anderson et al. found that people with
MND are generally agreeable to participate in end-of-life discussions particularly
relating to invasive measures soon after diagnosis, but also found that this does
not necessarily occur. Despite guidelines for clinicians recommending honest
discussions relating to interventions for symptom control prior to the need for
those interventions (Motor Neurone Disease Australia, 2014; National Institute
for Health and Clinical Excellence, 2010c), one study has identified that these
discussions may be experienced as “pressure” by some people with MND
(Greenaway et al., 2015).
In a systematic review to find the most important aspects of end-of-life
care identified by patients and their families in an inpatient setting within
Australian hospitals, Virdun, Luckett, Davidson and Phillips (2015) identified
clear communication and the ability to contribute to decision-making as priorities
in end-of-life care. From the patient’s perspective, multiple studies have
suggested that most would welcome more honest and up-front discussions
concerning prognosis, benefits and burdens of various treatment options and
their effect on patient and family quality of life (Astrow et al., 2008; Virdun,
Luckett, Davidson, & Phillips, 2015). Several studies show that people with
MND would like the opportunity to discuss their treatment options and would like
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as much information as is available, believing that doctors should initiate such
conversations (Anderson, Kuru, Munroe, & Sirdofsky, 2007; Blackhall, 2012).
A comparative study of decision-making in patients with advanced
cancer (n= 60 patients) and MND/ALS (n= 32 patients), found communicating
end-of-life issues was significantly less well discussed in the advanced cancer
patients than in MND/ALS patients (Astrow et al., 2008). Astrow et al. (2008)
suggests this may be due to the variable prognosis in cancer, with periods of
remission and the potential of a cure. Astrow et al. propose that as people with
MND have fewer treatment options and a more predictable prognostic pathway
than cancer patients, the discussions relating to the end of life occur earlier
during the disease. Astrow et al. (2008) reports a lack of evidence on whether a
patient’s diagnosis influences end-of-life discussions. Reflecting the 1999
American Academy of Neurology standards which recommend discussions well
in advance of the terminal stage, Astrow et al. (2008) encourage further
research into the relationship between diagnosis and the impact of end-of-life
communication. This is supported by others in the field of MND research (Miller
et al., 2009; Miller et al., 1999).
Communication regarding ongoing support and potential complications
are acknowledged as vital for all concerned, and advance care planning should
be continually revisited along the disease continuum (Anderson et al., 2007;
Oliver & Faull, 2013). Hardiman (2011) and Doyle et al. (2005) stress the
importance of keeping people with MND informed about their disease
progression and reassuring them that appropriate care and medications will be
available to ensure a comfortable death. When NIV is suggested by the clinician
either for a trial or for ongoing use, it is recommended that the benefits and
limitations of NIV are fully discussed with the patient and significant others
(NICE, 2016).
2.1.5. Content of end-of-life communication in MND
A U.K. telephone audit of specialist palliative care doctors caring for
people with MND in the United Kingdom (Oliver et al., 2011) found the majority
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of palliative care specialists interviewed were only involved at the terminal stage
of the patient’s care, by which stage, discussions relating to interventions which
may have an influence on patient symptoms and quality of life should have
occurred. However, this audit found wide variation in the understanding of
specialist roles and low levels of referrals to palliative care specialists by other
doctors, resulting in some patients not being offered interventions to improve
their quality of life (Oliver et al., 2011). Nearly 16 years ago a report by the
Quality Standards Subcommittee of the American Academy of Neurology (Miller
et al.,1999) recommended communicating patient information on respiratory
care in MND/ALS to ensure appropriate decision-making. The committee
recommended that such communication occur well in advance of declining
respiratory function to enable patient understanding and avoid inappropriate
emergency care (Miller et al., 2009; Miller et al., 1999). Using a combination of
focus groups and interviews with clinicians having some experience with
palliative care, McConigley et al. (2014) explored the complex communication
requirements provided to people with MND and their families. Acknowledging
the often disjointed care for people with MND in Australia and the unpredictable
speed at which MND can progress, The results from this study showed the
need for improved clinician communication, and education for clinicians
providing care (McConigley et al., 2012; McConigley et al., 2014).

The EFNS recommends that the diagnosis and prognosis of MND/ALS
could be communicated to patients and families, and that this as a skill a
clinician needs to develop. The EFNS recommends allowing adequate time for
a clinician who knows the patient and who has ascertained the patient’s level of
knowledge to provide information. The recommendations also suggest providing
written information, or a support organisation website relating to MND, with the
choices of symptom control and reassurance of ongoing support. The EFNS
highlights the importance of effective communication between patients,
caregivers and all members of the MDTs, yet patients and families are not
always satisfied with the communication they receive (Andersen et al., 2012).
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An American study completed in 2004 found age and level of education
had a significant influence on whether a patient wished to actively participate in
their healthcare decisions; those who were older and more highly educated
expressed a greater desire to participate (Levinson, Kao, Kuby, & Thisted,
2005). Clinician perceptions of patient preferred end-of-life care preferences
and the extent of honest communication can be unrepresentative, as indicated
by recent research from Taiwan (Huang et al., 2015). Huang et al. (2015)
collected data from 314 terminally ill patients (diseases unspecified) and 177
physicians involved with their end-of-life care via a questionnaire. Their
questions pertained to honesty with patients about prognosis and treatment
preferences. Whereas most of the study patients preferred to be well informed
(94.3%), only 80% of the physicians believed that their patients wanted this.
The research indicated a discrepancy between 90% of the patients preferring
supportive care only at the terminal stage, compared to 15.8% of the physicians
who felt this was their patient’s preference, and 33% who thought active
treatment was their patient’s preferred option.

Similarly, a German study found the majority of terminally ill patients
wanted and expected clear communication from their health providers about
their treatment despite the authors acknowledging that death and dying are not
widely discussed in German society (Meffert et al., 2015). Blackhall (2012), in a
review of palliative care and ALS/MND literature, suggests, as many palliative
care experts do, that usual care and specialist physicians who have not had
much exposure to palliative care education or training may avoid end-of-life
discussions with those with MND. Blackhall (2012) suggests this may be
because they fear it could lead to a sense of hopelessness, and often wait until
the patient initiates the subject. This hesitation to discuss end-of-life issues by
clinicians and their belief that such discussions should be initiated by the patient
is singled out as a particular problem in end-of-life care medicine by Lemoignan
and Ells (2010), who recommended further research into this phenomenon.
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2.1.6. Recommended communication and frontotemporal dementia
The most recent guidelines relating to MND assessment and
management, published in February 2016, recommend information about
prognosis and management of symptoms is provided at diagnosis and delivered
by a highly trained and experienced specialist such as a neurologist (NICE,
2016). Health professionals are urged to ask patients how much information
they wish to have explained at diagnosis and whether they wish their families to
be involved. In relation to PEG insertion, which is recommended prior to the
introduction of NIV, it is suggested that advice and support is offered either at
the time of diagnosis or when any concerns about swallowing or weight loss
emerge. The NICE (2016) recommendations also suggest that prior to any
decision on PEG insertion, assessment should be made of the patient’s ability
to give consent and whether frontotemporal dementia (FTD) has been
diagnosed.
Oliver et al. (2011) have argued that the impact of cognitive changes on
communication, decision-making, and understanding should be recognised by
health professionals to avoid inappropriately implementing symptom control
systems such as NIV and gastrostomy tubes. Frontotemporal dementia
(behavioural or language disorder) has more recently been recognised as an
overlapping disease component of MND, with clinical implications for patient
management (Phukan, 2007; Phukan et al., 2012). Phukan et al. (2012)
suggest 14% of people diagnosed with MND/ALS may present with dementia at
diagnosis, with more than 40% of patients experiencing cognitive changes but
without evidence of dementia. Cognitive changes, which can be subtle, have
potential implications for the capability of a patient to either understand or have
the ability to communicate adequately with clinicians, particularly in relation to
treatment options (Phukan et al., 2012). The process and ability to assess for
the presence of cognitive changes in people with MND was considered by the
candidate to be a substantial area of research so was not included in this study.
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How FTD impacts on families was touched upon by the clinician participants
and considered by some of the family participants in this study. This is
discussed further in Chapter 4.
2.2. Caregiver and Patient End-of-Life Concerns

2.2.1. NIV communication from initiation to withdrawal
incorporating advance health directives and multidisciplinary
teams.
There is little in the general MND literature covering what specific
information should be discussed surrounding initiation, non-initiation or
withdrawal of NIV, although several studies suggest detailed communication
should occur (Faull, Rowe-Haynes, et al., 2014; Lemoignan & Ells, 2010; NICE,
2010; Oliver & Faull, 2013; Preston et al., 2011).
The NICE (2016) Assessment and Management Guidelines for MND
recommend that the person with MND, their family, the respiratory
service/physician and those incorporated into the MDT, should draw up a
detailed plan which includes regular opportunities to discuss withdrawing NIV
(NICE, 2016). Anderson et al. (2007) suggest that signs of respiratory distress
should prompt discussion and documentation of patient preferred treatment
alternatives including options for the terminal phase.
The American Academy of Neurology (2012) recommend that all people
diagnosed with ALS/MND should have documented discussions relating to NIV
options with their clinician annually, and any reasons for not having such
discussions should also be clearly documented (American Academy of
Neurology, 2012). Information relating to NIV commencement remains
unchanged from the NICE (2010) guidelines. It is suggested that discussions
about NIV be “appropriate to the stage of a person’s illness” and delivered in a
sensitive manner (NICE 2016: Recommendation1.14.2, page 23). The latest
version of these guidelines recommends the patient should be reassured that
NIV can be stopped at any time and given many opportunities to discuss the
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option of withdrawal. It is not made clear, though, who should initiate these
discussions or the content of the discussions (NICE, 2016).
Preston, Fineberg, Callagher and Mitchell (2011) interviewed 11
bereaved family members/MND caregivers and found that despite patient
preferences of care being documented and read by family members, there was
an apparent lack of awareness among health professionals of the care priorities
for people with MND. Early effective communication was acknowledged to
enable advance care planning, offering peace of mind to people with MND and
their family members. However, the content of the communication between
clinicians and people with MND to enable treatment choice was not reported
(Preston et al., 2011).
Oliver and Faull (2013) recommend ongoing discussion with the patient
and family from the commencement of NIV, offering support and covering all
aspects of care including emergency care and advance health care planning.
Oliver and Faull note the lack of published literature regarding the deterioration
of patients using NIV and associated communication. For example, the
understanding of deteriorating symptoms and medications required to relieve
them, the possible medication side effects of increased sedation, and the
implications of NIV withdrawal are rarely addressed. This lack of evidence
inevitably makes conversation about these issues with patients and significant
others difficult (Oliver & Faull, 2013). However, despite considerable agreement
on the need for discussions to include withdrawal of NIV as part of usual care
provision and some suggested trigger points in the patient’s disease trajectory
for honest end-of-life discussions, in practice, it remains unclear as to who has
or should have these discussions, their content, the impact these discussions
have on the patient, significant others and clinicians at the terminal stage of the
disease, or when patients and families feel these discussions should occur.
2.2.2. Triggers for communication
Based on a consensus of expert clinical opinion, triggers for initiating
clinician and patient discussions relating to MND end-of-life discussions are
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recommended in the NICE (2010) NIV guidelines and re-iterated by Mitsumoto
and Rabkin (2007), Rafiq et al. (2012) and NICE (2016) MND Assessment and
Management Guidelines. These triggers include, for example, pain requiring
high dosages of analgesia, dyspnoea or symptoms of hypoventilation when NIV
would be offered, or when the patient or family requests information relating to
end-of-life care (Mitsumoto & Rabkin, 2007; NICE, 2010; Rafiq et al., 2012).
Another discussion in the MND literature is whether NIV initiation/respiratory
failure would be an appropriate time for explicit end-of-life discussions,
however, the input of the person living with MND or the views of their families
has been minimal (Baxter et al., 2013; Eng, 2006; National Institute for Health
and Clinical Excellence, 2010, 2016).
2.2.3. Communicating the benefits and burdens of NIV
Experiences with NIV for people with MND appear to be as varied as the
communication that surrounds the intervention. Lemoignan and Ells (2010)
interviewed nine people with MND, all of whom were suffering adverse
respiratory symptoms, regarding their decisions to use NIV. Those interviewed
felt they had a poor understanding of how respiratory failure, NIV technology,
and their own disease progression could affect their quality of life. Fear relating
to the possibility of choking, or fear of being a burden to their family members
were found to be factors in a patient’s decision-making process relating to NIV
in the study by Lemoignan and Ells (2010). Their study concluded that the
consideration of when to discuss NIV and provide information should be guided
by the person with MND and significant others, suggesting further research
regarding decisions surrounding NIV is necessary.
In another study, nine people with MND with respiratory distress were
offered NIV but declined for reasons of loss of self-control and a perception that
NIV was not of value to them (Ando et al., 2014). Ando et al. (2014) concluded
that the prolonging of life was less important to these patients than their “sense
of self” and the preservation of control and dignity (p. 341). Some participants in
the study had negative experiences using NIV with discomfort and anxiety
44

relating to the mask and forced air, and some had poor experiences with health
services and technological support. Some of the participants in the study by
Ando et al. seemed to doubt their breathlessness was really a part of the
disease or felt that they could control the symptom without the burden of NIV.
Greenaway et al. (2015), in their study involving 21 people with MND diagnosed
for longer than six months, suggested that timely communication to ensure
adequate information is received to enable an informed choice relating to NIV
and gastrostomy feeding tubes is an individualised, changing process often
influenced by relationships with healthcare providers and previous medical
experiences.
Recognising the difficulty healthcare professionals have when trying to
assess the amount and depth of information to provide to a person when
offering NIV, Greenaway et al. (2015) imply that concise information which
includes the benefits and burdens may alleviate some patient and caregiver
fears and assist the decision-making process. However, the study also
recognises that clinicians move toward interventions may be perceived by
people with MND as being pressured into an option. Greenway et al. suggest
that individualised and patient-centered symptom control alternatives may be
preferred to strict adherence to guidelines as the patient decision-making
process for interventions can be influenced by complex relationships with family
and clinicians. Whilst the participants in the study identified an apparent “lack of
accuracy of information” (p.1008) to enable a decision for or against NIV/PEG
from the clinicians, the actual content of the communication verbalised by the
clinicians surrounding the offering of interventions was not reported.
Communication about treatment options at all points in the disease
trajectory is influenced by a myriad of complex factors, including the distinctive
individual characteristics of the participants in the conversation, the content of
the information provided, what was heard and understood by those present, and
the discussion and individual decision-making mechanisms resulting from the
information. Such complexity requires that discussions regarding the benefits,
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burdens and limitations of NIV be specific and provide clarity for the patient and
their significant others. There is a great deal of ambiguity in the literature
regarding how and when clinicians should discuss significant end-of-life
decision-making issues with patients and their significant others. In addition, the
literature suggests that the benefits and burdens of various end-of-life treatment
options including the use of palliating comfort and symptom-relieving treatment
alternatives should be discussed and patient decisions relating to end-of-life
care understood and documented (Faull, Phelps, Regen, Rowe-Haynes, et al.,
2014; National Institute for Health and Clinical Excellence, 2010, 2016; Oliver &
Aoun, 2013).
Because of the progressive neurological deterioration and subsequent
decrease in independence of the person with MND, the reliance on caregivers
increases. This dependence includes the adjustment of the NIV mask, attention
to potential pressure ulcers particularly where the mask fits over the nose and
being able to remove the mask when necessary. Caregiver burden and stress
have been highlighted in recent MND literature, with a focus on a need for
improved contact with palliative care services for both patient and caregiver,
and an acknowledgement of complex decisions regarding symptom control and
quality of life (Aoun et al., 2013; Hogden, Greenfield, Nugus, & Kiernan, 2013;
Phukan & Hardiman, 2009). In an extensive review of the literature over 10
years (January 2000-April 2011), Aoun et al. (2013) identified respiratory
distress as a difficult symptom for caregivers to cope with, particularly in the
terminal stage of MND. Their review also emphasised the importance of clear
communication for patients and caregivers by health care providers, and the
need for improved access to palliative care (Aoun et al., 2013). However, the
potential of NIV, its benefits, burdens, limitations and eventual withdrawal, or
how discussion affected caregivers, were not clarified in the review by Aoun and
colleagues.
Reasons for not initiating or discontinuing NIV may include the desire to
not prolong patient suffering or discomfort relating to its use, which may become
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more pronounced as the patient becomes increasingly immobile and
incapacitated. The stage at which the respiratory muscles start to weaken and
palliation by medications and/or initiation of NIV is chosen, may be considered
to mark the commencement of the terminal stage of life (Eng, 2006). This
highlights the need to discuss all potential outcomes of NIV including the end of
life and the eventual need for end-of-life care, at the commencement of NIV.
This will ensure the clinicians are confident that caregivers/family understand
what happens when NIV is removed or if the MND patient dies of co-morbidities
whilst remaining on NIV (some people die of co-morbidities such as pneumonia
prior to withdrawal of NIV). Thus, there is a gap between recommended
discussions relating to MND and NIV use in guidelines and the reality of what
some family members and people with MND hear, remember or understand.
2.2.4. The impact of poor health communication on patients and
families
Uncertainty related to the diagnosis or prognosis of MND combined with
poor communication and understanding of technical treatment details and
information can cause severe stress and strain on the patients and their
families/significant others (Belkora, 2003; Jarvis, 2014). This uncertainty and
confusion may lead those diagnosed with the disease to attempt to collect as
much information as possible and seek out several doctors and other resources
to find answers and inform decisions. This information-seeking has the potential
to result in competing and potentially conflicting care providers with their distinct
views of the case, perhaps adding to confusion (Belkora, 2003; Borasio, Voltz,
et al., 2001). In addition, Belkora (2003) discusses the possibility for patients
and families to be overwhelmed when a diagnosis of a life-limiting disease is
communicated, and who may, therefore, leave decision-making to those with
clinical expertise. Decision-making is both an emotional and cognitive process,
and clinicians could adopt a decision dialogue process to assist people with
their choice of management and care (Belkora, 2003; Jarvis, 2014). Further
research into the content of communication between patient,
caregiver/significant other and clinical team may provide insight.
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The MND literature does not appear to incorporate or reflect the
viewpoint of the person with MND, nor their significant others, regarding when
and how communication explaining NIV initiation and potential withdrawal is
imparted. Foley, Timonen and Hardiman (2014) identified a lack of research
surrounding patient understanding of health services and studied how people
with MND engage with healthcare professionals. In their study of 34 people with
MND, each person was interviewed once, and each had involvement with
medical and support care. However, only eight of these participants had
accepted either NIV or PEG. The study found that interviewees believed NIV
and PEG were interventions to sustain life and not palliating interventions to
alleviate suffering (Foley, Timonen, & Hardiman, 2014). This poses a question
as to whether people with MND and clinicians may have varying views on
“suffering”; people with MND tend to perceive NIV as assisting symptoms of
respiratory distress and potentially extending their suffering, but clinicians
perceive NIV as relieving their suffering by assisting their symptoms.
In a study by Lerum et al. (2016), 25 MND caregivers were interviewed to
explore their experiences of caring for a person with MND. The aim of the study
was to understand the difficulties and priorities of care. Lerum et al. found
caregivers’ attitudes to seeking clarity of MND information was mixed. Some
participants found a sense of control through clarity of information, whilst others
found it spoilt the present moment which they treasured. Others used
knowledge to challenge the diagnosis (Lerum et al., 2016).
Martin et al. (2014) followed 78 people with MND and 50 MND caregivers
regarding circumstances which influenced and enabled decision-making relating
to options of symptom control. Martin et al. explored the complexity around
whether to accept interventions such as NIV and gastrostomy in people with
ALS/MND. It appeared that decisions were related to variables such as the
health status of the patient; those who were more unwell were more likely to
decide to use an intervention. People with MND and their caregivers with more
years of education and a higher IQ, according to Martin et al., were more
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capable of seeking information and more likely to decide to use an intervention.
The study also found employment status, disease management in the early
stages of illness and caregivers with a well-balanced and strong psychological
approach to the care of their family member influenced some of the decisions
made by the person with MND. It is recommended, therefore, that healthcare
professionals assess the coping ability of the caregivers and consider this along
with other decision-making factors, when advising patients about treatment
choices (Martin et al., 2014). However, the research by Martin et al. did not
include research into specific communication used to deliver the treatment
choices nor who should deliver the information.
In summary, the amount of information both the person with MND and
the family wish to hear from clinicians, and when they wish to hear it, is unclear
from the literature. Avoidance of difficult discussions by clinicians relating to
disease deterioration and progression and particularly the withdrawal of NIV
complicates this issue and is discussed by Faull, Rowe-Haynes and Oliver
(2014). Their research suggests that the prognostic conversations are
overwhelming and are laden with grief and loss, and so are avoided by patients,
significant others and clinicians alike (Faull, Rowe-Haynes, et al., 2014).
2.3. Unresolved Issues Relating to End-of-life Communication

2.3.1. Controversies and clinician/patient difficulties with NIV
withdrawal and end-of-life discussions
There is minimal evidence in the literature indicating whether or how
people with MND evaluate their quality of life or gauge their quality of death. A
lack of communication that encourages effective discussion between patients,
families and health care professionals surrounding the terminal stage and death
of a person with MND is a significant finding of a secondary data analysis
combined study conducted in Australia and England (Ray, Brown, & Street,
2014). Despite the use of advance care planning, Ray et al. (2014) highlight the
difficulties in initiating conversations about ongoing care requirements and state
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that the development of strategies for clear communication between patient,
clinicians and families is vital to ensure patient preferences of care.
A small study of eight MND caregivers identified possible conflicts of
interest between patients and caregivers when prioritising work, family and the
needs of the person with MND (Hogden et al., 2013). The complexity of
changing care requirements for people with MND, communicating with and
involving the caregiver plus gauging caregiver level of involvement can present
barriers to optimal care and challenges for clinicians (Hogden et al., 2013).
Furthermore, a correlation has been found between respiratory function in
people with MND and their caregivers’ level of distress, affecting the person
with MND (Pagnini et al., 2012). Pagnini et al. (2012) suggest the perceived
level of social support and caregiver psychological well-being may influence the
respiratory symptoms of a patient with MND. Conversely, Pagnini et al. (2012)
also suggest that well managed caregiver depression and anxiety may
positively affect a patient’s respiratory symptoms.
Whilst there is research which extends the knowledge and understanding
of clinicians’ difficulties with the withdrawal and ongoing use of NIV as well as
literature acknowledging the emotional burden of caregivers, there is little work
on the actual communication surrounding the initiation of NIV, noninitiation/refusal or withdrawal of NIV, and the patient and caregiver
understanding of the benefits, burdens and limitations of commencing on NIV.
The gap in understanding the end-of-life expectations of the person with MND in
relation to their treatment alternatives, and the recommendation that patients
should be provided with all their palliative care options, is a finding in an
investigation into depression and quality of life in people with MND/ALS (Kübler,
Winter, Ludolph, Hautzinger, & Birbaumer, 2005).
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2.3.2. Ethical issues
A complex ethical situation arises when the person with MND severely
deteriorates and NIV is no longer able to provide a level of support that is
effective and positively contributes to the person’s quality of life (Faull, RoweHaynes, et al., 2014; Phelps et al., 2015). Faull, Rowe-Haynes et al. (2014) and
Phelps, Regan, Oliver, McDermott and Faull (2015) discuss the emotionally
challenging aspects and practical implications of the experience of doctors who
work in palliative care relating to the withdrawal of NIV in people with MND.
They recommend detailed guidelines and conclude that the complex issues
affecting the doctors may be difficult to solve. The loss of the ability to
communicate with people with MND as their disease progresses is suggested in
the literature as a trigger for NIV withdrawal by doctors, and while the wishes of
the patient are considered essential, they are not always known (Faull, Phelps,
Regen, Oliver, et al., 2014; Faull, Rowe-Haynes, et al., 2014). There is minimal
literature relating to patient and family understandings of the limitations of NIV
and its potential withdrawal, although fears of choking and symptom control
have been discussed (Neudert, Oliver, Wasner, & Borasio, 2001).
As a consequence of disease progression, the patient may end up in
what has been labelled as locked in syndrome. This is more common with
tracheostomy and invasive positive ventilation but acknowledged to occur with
NIV when used constantly, or where the inability to move occurs and clear
verbal communication becomes impossible but the brain remains intact and
active (Back, 2001; Borasio, Voltz, et al., 2001; Oliver et al., 2006). An ethical
dilemma occurs at this point as to the appropriateness of prolonging life with the
continued use of NIV or the possibility of an emergency procedure of
tracheostomy to maintain respiration with positive ventilation, if the
consequences of these choices have not been clearly explained to the patient
and their significant others (Faull, Phelps, Regen, Oliver, et al., 2014).
Discussions to ensure full comprehension of the consequences of
various treatment choices including a patient’s choice to decline potentially life51

prolonging interventions such as NIV, and the patient’s and family’s decisions
for treatment or refusal, should be documented in their medical record early in
the disease process (Back, 2001; Oliver et al., 2006; Rafiq et al., 2012). Clear
communication from clinicians to those with MND relating to end-of-life issues,
which may not only influence their treatment options but help prepare them for a
potentially unpredictable disease course, have been found in several studies to
be welcomed by most people with MND (Anderson et al., 2007). In a study of 42
people with MND, Anderson et al. (2007) found that end-of-life discussions
relating to invasive mechanical ventilation via tracheostomy treatment options
were poorly covered by clinicians despite the patient wanting open and honest
conversation. Whilst NIV is not as medically invasive as mechanical ventilation,
it has burdens, so it is reasonable to suppose that honest and explicit
communication is important to clarify the patient’s preferences for treatment.
2.3.3. Patient autonomy: NIV withdrawal
On the first page of the Motor Neurone Disease Australia Patients’ Rights
document (MNDAust, 2008) the right of each patient to choose “to accept,
refuse or discontinue treatment within the legal framework of each state or
territory” is emphasised. In a study by Baxter et al. (2013), healthcare
professionals associated with people with MND using NIV in the terminal stage
found caregivers/families experienced some confusion about when to withdraw
NIV and the impact. Health professionals interviewed within the study
expressed concern that families/significant others had a perception of killing the
patient on withdrawal of NIV. Misunderstanding relating to management of
people with MND and NIV was found in this study to result in some patients
receiving emergency resuscitation attempts at the end of life. Whilst indicating
that NIV has a generally positive effect on the end of life for people with MND
using it, Baxter et al. highlighted the importance of end-of-life directives and
making the wishes of the patient known.
Some research literature supports people with MND, who wish to discuss
end-of-life issues, receiving information to enable them to make informed
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choices (Faull, Phelps, Regen, Rowe-Haynes, et al., 2014). The literature
identifies potentially stressful and controversial issues that may arise with the
cessation and withdrawal of NIV (Baxter et al., 2013; Faull, Phelps, Regen,
Rowe-Haynes, et al., 2014; Faull, Rowe-Haynes, et al., 2014; NICE, 2010). For
example, Baxter et al. (2013) identify the impact of the withdrawal of NIV on the
clinician’s psychological state, regardless of how symptoms are managed and
whether death is instantaneous. Faull et al. (2014) identify the communication
and emotional difficulties clinicians encounter with NIV withdrawal, particularly
NIV withdrawal at the request of the patient. In a recent retrospective study from
England, the ethical and legal issues arising from patient requested NIV
withdrawal were explored (Phelps et al., 2015). The study highlighted both the
challenge for clinicians to provide honest and clear communication, and the
difficulties for clinicians in having to deal with the emotional responses from
both patients and families confused by the NIV withdrawal decision process.
Patient and/or caregiver confusion and anguish has the potential to affect
end-of-life patient care should healthcare providers be uncomfortable with the
concept of NIV withdrawal (Phelps et al., 2015). If seen as an assisted death by
the clinician, or if they are unable to communicate the expected outcome
clearly, end-of-life care may be adversely affected (Phelps et al., 2015; Ruffell
et al., 2013). The literature suggests the opportunity to discuss end-of-life
decisions and potential issues is taken at the initiation of NIV and should be
reiterated throughout its use (Baxter et al., 2013; NICE, 2010, 2016).
Within the NICE (2016) MND Assessment and Management Guidelines is
a new recommendation to ask people with MND how much information they
wish to receive about the disease and whether they wish this information to be
shared with their families/caregivers (National Institute for Health and Care
Excellence, 2016). Ensuring and acknowledging patient care and comfort is a
priority as is understanding that clinicians require high level communication
skills to establish the trust required for patients to make informed decisions.
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Further research which may assist this situation was a recommendation of the
NICE MND Assessment and Management Guidelines (2016).
By highlighting the need to support all those involved with NIV withdrawal
and to eliminate emotional challenges for both clinicians and families, Faull,
Rowe-Haynes et al. (2014) recommend detailed discussions which include the
timing, how withdrawal happens, and symptom management thereafter. The
responsibility of who is to be involved (family, clinicians) with the NIV withdrawal
should be included within these discussions and patient, family and clinicians
should have a documented plan of end-of-life care. The suggestion by Faull,
Rowe-Haynes et al. that an ethical statement incorporating the clinical aspects
and outcome is included within these detailed discussions, and incorporated
within MND guidelines for NIV withdrawal, is proposed to help alleviate the
ethical and potentially legal dilemma associated with NIV withdrawal for clinician
and family. The recent NICE MND Assessment and Management Guidelines
(2016) recommend that the healthcare professional commencing NIV can
ensure there is legal and emotional support available for other health
professionals who may be involved with the withdrawal of NIV. The guidelines
also recommend that prior to the decision to withdraw NIV, the patient and
family should have support and clear legal and ethical information from
clinicians experienced with NIV withdrawal. However, whilst this may assist the
clinicians ethically, it may not assist the family members, or the clinicians
emotionally with the consequences of NIV withdrawal (Faull, Rowe Haynes et
al., 2014).
This overview has identified some gaps in the literature on the topic of
communication surrounding the initiation and withdrawal of NIV in MND and
forms the background to the research reported in this thesis. In the next section,
the methodology used to undertake a sharply focused review of clinicians’ NIVrelated communication practice is detailed. The review was conducted with
reference to the process outlined in the Australian Journal of Nursing’s
“Systematic Reviews, Step by Step” series of articles (Aromataris & Pearson,
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2014; Aromataris & Riitano, 2014; Munn, Moola, Riitano, & Lisy, 2014; Porritt,
Gomersall, & Lockwood, 2014; Robertson-Malt, 2014; Stern, Jordan, &
McArthur, 2014). The question asked of the literature was formulated using the
Population (P), phenomenon of Interest (I), Context (Co), or “PICo” design
(Forrest & Miller, 2001), and provided the basis for a systematic search and
selection of quality scientific literature that justifies the current study. The report
of the review follows the PRISMA checklist (Moher, Tetzlaff, Liberati, & Altman,
2010), modified for reviews of qualitative literature (see Appendix S).
2.4. Section 2: The Research Question and Systematic Literature Search
Strategy

2.4.1. Step 1: Developing the question to be answered by the
literature review
As stated previously, the question for this review of the literature was
developed using the adapted PICo design in which the population, interest and
context of scientific studies sought are denoted (Forrest & Miller, 2001; Moher
et al., 2010).The question developed for this review was: “What is known about
communication (I) between caregivers and families (P) about NIV in MND prior
to NIV initiation and withdrawal (Co)?”.

2.4.2. Step 2: Type of studies included
Information for this focused review was collected from qualitative studies
in which data were collected via questionnaires, face-to-face interviews, focus
groups and telephone interviews.
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2.4.3. Step 3: Developing the logic grid
The logic grid classifies the search terms or synonyms used for the
literature search. The search terms were identified from and related to the PICo
question.
Table 2. 1 Logic grid and search words

Population

Phenomenon of

Context

Interest
caregiver*

communication

NIV

clinician*

discussion

non-invasive

nurse*

decision

doctor*

choice

initiation

physician*

mnd

withdrawal

famil*

als

relative*

motor neurone

partner*

ventilation

disease
amyotrophic lateral
sclerosis
end of life
palliative

2.4.4. Step 4: Defining the search strategy
Boolean operators (AND,OR) were applied between keywords and
categories. Within Medline and CINAHL MeSH terms were used in the context
of alternate words with similar meaning.
SEARCH 1: caregiver* OR clinician* OR nurse* OR doctor* OR
physician* AND famil* OR relative* OR partner* OR loved one* AND
communication* OR discussion* OR decision* OR choice* AND mnd OR
als OR motor neurone disease OR amyotrophic lateral sclerosis AND
end of life OR palliative AND NIV OR non-invasive ventilation AND
initiation AND/OR withdrawal
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SEARCH 2: caregiver* OR clinician* OR nurse* OR doctor* OR
physician* AND famil* OR relative* OR partner* OR loved one* AND
communication* OR discussion* OR decision* OR choice* AND mnd OR
als OR motor neurone disease OR amyotrophic lateral sclerosis AND
end of life OR palliative AND NIV OR non-invasive ventilation
SEARCH 3: communication* OR discussion* OR decision* OR
choice* AND mnd OR als OR motor neurone disease OR amyotrophic
lateral sclerosis AND end of life OR palliative AND NIV OR non-invasive
ventilation
SEARCH 4: mnd OR als OR motor neurone disease OR amyotrophic
lateral sclerosis AND end of life OR palliative AND NIV OR non-invasive
ventilation.
SEARCH 5: mnd OR als OR motor neurone disease OR amyotrophic
lateral sclerosis AND NIV OR non-invasive ventilation
2.4.5. Step 5: Parameters applied to the search
The following limits were applied to the literature search:


Adult age of participants



Years of publication: 1990-2016



Peer reviewed journal articles



English language

The search inclusion and exclusion criteria are defined more explicitly in
Table 2.2. The criteria by which the included full articles were evaluated is
shown within Table 2.3.
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Table 2. 2 Inclusion and exclusion criteria for the initial literature search

Inclusion Criteria

Exclusion Criteria

Peer reviewed journal articles

Non-reputable or non-peer reviewed
articles

Articles written in English

Articles not written in English

Literature with concise titles and
abstracts relevant to the research

Literature with ambiguous or vague titles
and/or abstracts

Method considered rigorous and
well defined with sufficient
participant numbers

Method poorly described with few
participants

Discussion and conclusion well
defined and argued

Discussion and conclusion considered to be
written to fit the initial objective/hypothesis
and not the results as found

Articles able to generally clarify
research thesis topic; found via
search keywords

Articles considered too general after
reading abstract and articles where
necessary

Specific to literature review chapter:
Articles able to help identify and
clarify research questions

Articles with some relevance to MND but
not sufficiently specific to clarify research
questions

Where ‘communication’ related to
communication between clinicians,
people and families relating to MND
disease management and end-oflife care

Where communication related to items to
assist people with MND to communicate
such as whiteboards, electronic devices
and the research surrounding such
innovations

Literature which related directly to
the search question

Literature which was considered minimally
relevant to the search questions

2.4.6. Step 6: Deciding the databases to search
MEDLINE, CINAHL, ProQuest Research Library, and the Cochrane
Library of systematic reviews were searched for relevant published research
journal articles. Initially article titles were reviewed for relevance, and those that
did not resonate with the review question were discarded. The abstracts of the
remaining articles were read again and those that did not reflect the review
question were rejected. Finally, the full content of the remaining articles was
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reviewed, and only those that would likely enable the review question to be
answered were retained for quality appraisal (n=18). A hand search of the
reference lists of the articles did not identify any new abstracts for review. The
final number of articles retained for quality appraisal that met the inclusion
criteria was n=8.
2.4.7. Step 7: Example of full electronic search strategy
The following is an example of the five-phase search protocol used for
the systematic review. The Medline database search is used to illustrate and
identify several peer reviewed research journal articles. The results of each
search are shown in bold at the end of each search string:
SEARCH 1: caregiver* OR clinician* OR nurse* OR doctor* OR physician*
AND famil* OR relative* OR partner* OR loved one* AND communication* OR
discussion* OR decision* OR choice* AND mnd OR als OR motor neurone
disease OR amyotrophic lateral sclerosis AND end of life OR palliative AND
NIV OR non-invasive ventilation AND initiation AND/OR withdrawal: (0)

SEARCH 2: caregiver* OR clinician* OR nurse* OR doctor* OR physician*
AND famil* OR relative* OR partner* OR loved one* AND communication* OR
discussion* OR decision* OR choice* AND mnd OR als OR motor neurone
disease OR amyotrophic lateral sclerosis AND end of life OR palliative AND
NIV OR non-invasive ventilation (Total= 6 – 1 excluded as duplicate from
CINAHL, 4 excluded as irrelevant by title; 1 kept for abstract/full article
review)

SEARCH 3: communication* OR discussion* OR decision* OR choice* AND
mnd OR als OR motor neurone disease OR amyotrophic lateral sclerosis AND
end of life OR palliative AND NIV OR non-invasive ventilation (Total= 6 – 5
excluded as duplicates from CINAHL; excluded 25 either repetitive within
the search or by title = 1 included for abstract/article review:)

SEARCH 4: mnd OR als OR motor neurone disease OR amyotrophic lateral
sclerosis AND end of life OR palliative AND NIV OR non-invasive ventilation.
59

(Total 52- 36 excluded from systematic review but 6 retained for further
review guidelines and policy statements and retained for environmental
review; 16 retained for abstract review)

SEARCH 5: mnd OR als OR motor neurone disease OR amyotrophic
lateral sclerosis AND NIV OR non-invasive ventilation (Total= 232duplicate or rejected on title 224; 6 retained for abstract review, 2
retained for scoping review and as part of the environmental scan).
2.4.8. Step 8: Study selection
The research literature retained for quality appraisal as a result of
following the steps reported above could be categorised as qualitative, and as
such was assessed using the Standards for Reporting Qualitative Research
(SRQR) (O'Brien, el al, 2014). The COREQ checklist (Tong, Sainsbury &Craig,
2007) and criteria for reporting qualitative research has been completed
(Appendix T).
The candidate and one supervisor assessed the literature proposed for
inclusion in this review: first by title relevance and then by abstract significance
to the search question and, by extension, the candidate’s research. Lastly the
full articles were read by both the candidate and the supervisor and then
appraised for quality using the SRQR checklist. The quality appraisal process
resulted in three of the 18 retained articles being discarded.

The quality appraisal results are summarised in Table 2.2. The quality of
the papers is described more fully later in this chapter and in Table 2.3. In
summary, the journal articles identified in red in Tables 2.3 and 2.4 were
disqualified from the quality review as they did not comply with the research
criteria.
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Table 2. 3 Alignment of the 21 standards for reporting Qualitative research (SRQR)
Study

S1
and
S2

1

S3
and
S4

×
×

2

×
o

×
×

3

o

×

×
6

×
×

×
7
×

×

×

×
10

×
×

×
11

×

×

o

o
14
o
15
×
16
×

o

o

o

o

o
×

×

o

×
×

×
×

×
o

×

×

×

×

×

×

××

×

×

×

×

×

×

×o

×

×

×

×

×

×

××

×

×
×

o

×

×

×

×

×

×

××

×

×

×
×

×

×

o

o

×

×

×

×

×

×

××

×

×

×

×
×

o

×

o

×
×

×

×

×
×

×

o

×

×

o

×

×

×

×

×

×

××

×

×

×

×
×

o

×
×

×

×

×

×

×

o

×

×

×
×

×

××

×

×

×

o

o

×

×

××

×

×

×

×

×

×

×

o

×

×

×

o

o
×

×

×

×

×

×

o

×

×

×
×

×

××

×

×

×

o

×
×

×

×

×

×

×

o

×

×

×
×

×

××

×

×

×

o

o

×

×

×

××

×

×

×

×

×

×

13

o

×

×

×

o

×

×

×

×

×

×

××

×

×

×

×

×

×

12

×

×

o

×

o

o

o

×

×

×

×

××

×

×

×

×

×

×

×

×

o

×

×

o

S20
and
S21

×

×

××

×

×

×

×

×

×

×

o

×

×

o

o

o

S18
and
S19

×

×o

×

×

×

×

×

×

9

×

×

×

o

o

×

S16
and
S17

×o

×

×

×

×

×

×

8

o

o

o

×

S13,
S14 and
S15

×

×

×

×

×

o

×

o

S11
and
S12

×

×

×

×

×

o

o

×

S9
and
S10

×

×

×

×

5

o

×

o

S7
and
S8

×

×

×

4

S5
and
S6

×
×

×
×

o
o
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17

x
o

18

×
×

×
×

×
×

×

×
×

×
×

××
o

×
×

×
o

×
o

Key to table: S= Standard; x= complies with standard; o= non-compliance with standard
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Table 2. 4 Research journal articles retained or discarded for review at quality appraisal stage
Concise Title

Specific
research
purpose

Methods

Results/finding

Discussion/limitations

Funding/Conflicts

1) End-of-life
decision making in
42 patients with
ALS (Anderson et
al.2007)

Purpose stated:
Timing of
discussion of EOL
issues: (qualitative
study)

Retrospective chart
review of people with
ALS from diagnosis
and then each 3-4
month. Ethics
approval

Data collected from
June 1999September
2004.40/42 patients
had EOL discussions
at first visit

Retrospective analysis.
Limitations: All
discussions by one
clinician therefore personal
bias may have been
present

No conflicts of interest

2) Withdrawal of
ventilation at a
patient’s requests in
MND: a
retrospective
exploration of the
ethical and legal
aspects that have
arisen for doctors in
the UK (Phelps et
al.2014)
3) Physiological as
well as illness
factors influencing
acceptance of NIV
and gastrostomy in
ALS (Martin et
al.2014)

Purpose clearly
stated: To explore
and identify legal
and ethical issues
of ventilator
withdrawal:
(qualitative study)

Retrospective
thematic analysis. 24
clinicians interviewed;
5 by phone,19 face to
face. Email
recruitment to doctors
and via MND clinical
study groups. Stated
ethics approval

Data taped and
transcribed/coded.
Saturation after 15
interviews. Ethical
challenges for HCP
when withdrawal of
NIV requested by a
patient.

Previous studies identified
and integrated.
Suggestions for scope of
application discussed. No
limitations identified.

One of the authors on NICE 2015
NIV/MND guidelines.
Funding identified MNDA grant
and LOROS (hospice UK)

Purpose stated:
Identify factors
relating to NIV
and gastrostomy
acceptance in
people with ALS:
(qualitative
study)

A prospective study;
78 people with ALS
and 50 caregivers. A
descriptive analysis of
baseline information.
Ethics approval.
Written consent from
participants

Main finding, those
with fewer years of
education and lower
IQ may be more
passive in their
decisions regarding
gastrostomy and NIV,
rather than only
influenced by
symptoms and illness
variables.

Study identified potential
limitations: interpretation of
findings; no follow up data
on those refusing NIV.
NICE 2010 guidelines
published mid study and
may have influenced
results. Previous studies
identified and incorporated
into study.

No conflicts of interest. The
research was supported by
multiple associations/
organisations
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Concise Title

Specific
research
purpose

Methods

Results/finding

Discussion/limitations

Funding/Conflicts

4) Decision making
about gastrostomy
and NIV in ALS
(Martin et al. 2016)
Qualitative Health
Research 26(10),
1366-1381.

Purpose clearly
stated:
Participants were
subset of larger
study.
Interviewing
participants
occurred at point
when they
accepted or
declined
gastrostomy/NIV
(qualitative study)
Purpose clearly
stated:
Involvement,
attitudes and
knowledge of
specialist
palliative care
consultants with
NIV and
gastrostomy
discussions. Are
the guidelines
known and/or
applied?

Thematic analysis
used to investigate
symptom relieving
options in ALS. Ethics
approval obtained.
Written consent from
20 HCP (varied)
participants who were
selected
representatives of
people with ALS.

Transcribed
interviews with Nvivo
9 used to code and
organize data.
Findings suggest
themes relating to
decisions, and
previous work
integrated into
results.

Limitation of study:
potential bias in the
patient’s selection of the
HCP who represented
them at interview. Few
interviews conducted with
patient’s who refused NIV
mainly because they died
before they could nominate
a HCP to represent them

Declared funding conflict by
authors: grants and salaried
support from trusts and
organisations. Views expressed
by authors not necessarily Dept of
Health UK

Studies undertaken to
use two different
methods:62 records
analysed regarding
symptom control in
MND (previous study)
then telephone audit
(structured
questionnaire) of
palliative care
consultants who had
cared for the patients
in previous study:
referred for ethics
approval but deemed
unnecessary as
considered an audit.

Previous work
integrated into
findings. Study shows
clear differences in
timing of discussions
of NIV/PEG by
palliative care
consultants and
timing of involvement
of consultants. The
findings support other
research previously
published that
clinicians are not
always aware of
guidelines.

No limitations identified by
the authors.

No conflicts of interest identified
by the authors

5) Decision-making
for gastrostomy and
ventilatory support
for people with
MND across UK
hospices (Oliver et
al.2011). Journal of
Palliative Care
27(3), 198-201.
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Concise Title

Specific
research
purpose

Methods

Results/finding

Discussion/limitations

Funding/Conflicts

6) ALS and assisted
ventilation: How
patients decide
(Lemoignan, J.,
Ells, C. 2008)
Palliative and
Supportive Care 8,
207-213.

Purpose of study
clearly stated: to
better understand
the experience of
decision-making
in people with
ALS

Qualitative
phenomenology
methodology: 10
semi-structured
interviews with people
with ALS and their
caregivers. Ethics
approval granted and
consent from each
participant.

Timing of ventilation
discussions and relevant
information/evidence/
QOL to be given at
time to suit individual and
caregiver. Limitations
include that the interviewer
knew the participants
already. Some aspects of
the interviewer’s clinical
role may have influenced
the findings. Small sample
size.

No declared funding or conflict of
interest

7) Why don’t they
accept NIV? Insight
into the
interpersonal
perspectives of
patients with MND
(Ando et al.2014)
British Journal of
Health Psychology
20(2), 341-359.

Purpose of study
stated: To
understand why
people with MND
decline or stop
using NIV

Qualitative research:
From a cohort of 35
people with MND who
were offered NIV, 9
participated in study.
Semi-structured
interviews and
phenomenological
analysis. Participants
given information
sheet and consent.
Ethics approval
granted

Interviews with
patients or caregivers
using open-ended
questions, were taped
and transcribed. Six
main themes
identified and were
verified by the
participants: meaning
of intervention, the
importance of
context, fears, values,
information and
adaptation and
acceptance
Themes identified (4);
preservation of self,
negative perceptions
of NIV, negative
perceptions of health
care services and not
needing NIV.

Authors identify that their
interpretation of data may
not be the only
interpretation. Limitations
identified: restricted verbal
communication in some
patients, almost all the data
collected from patients who
had decline or withdrawn
from NIV at an early stage.

No declared conflicts of interest
identified
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Concise Title

Specific
research
purpose

Methods

Results/finding

Discussion/limitations

Funding/Conflicts

8) Advance care
planning in MND: a
qualitative study of
caregiver
perspectives
(Murray et al.2016)
Palliative Medicine
50(5), 471-478.

Purpose of the
study clearly
stated: caregiver
perspectives on
the accessibility
and impact of
advance care
planning in MND

Four themes
emerged: readiness
for death,
empowerment,
connections and
clarifying decisions
and choices.

Purpose of study
stated: patient and
carer perspectives
of obstacles with
NIV in MND

Limitation identified: Selfselection bias are possible
due to voluntary response
to invitations to participate.
Recall may have affected
participants in retrospective
study. Researcher
subjectivity stated as
possible during qualitative
analysis.
Limitation identified by
authors: sample was
weighed towards older
males and patients with
limb-onset disease and
tolerance may be a
consideration.

No conflicts of interest
identified.

9) The initiation of
NIV for patients with
MND: patient and
carer perspectives
of obstacles and
outcomes (Baxter et
al. 2012)

Structured interviews
with 18 caregivers of
deceased people with
MND. A qualitative,
cross-sectional study
analysed by narrative
synthesis approach.
Ethics approval from
hospital undertaking
study.
Interviews with 20
patients and 17
caregivers in the first
month following
introduction of NIV. A
qualitative study
undertaken until
saturation of data.

10) The use of NIV
at the end of life in
patients with MND:
a qualitative
exploration of family
carer and health
professionals
experiences (Baxter
et al. 2013)
Palliative Medicine
27(6), 516-523.

Purpose of study
clearly identified:

Study consistent with other
studies advising early endof-life discussion/ initiated
at commencement of NIV
Limitation: a relatively
small study of carers and
HCP in one small area of
UK. Reported information
from successful NIV users
rather than those who
discontinued or decided
not to use.

No conflicts of interest
identified. Funding under
grant: ref: PB-PG-1207-15122.

to describe
carer and health
professional
experience of
end-of-life care
in people with
MND using NIV

A qualitative
longitudinal study
incorporating in depth
face to face
interviews with
patients and carers.
Data collected
between 5/2010 and
4/2012, until
saturation of data.
Interviews audiorecorded and
transcribed verbatim.

Study identified
themes for
acceptance of NIV
and the potential
barriers which may be
anticipated by
clinicians to assist
patients make
decisions.
Study reports on 10
patients followed
through to their
terminal stage. Total
of 24 participant
interviews: HCP
nominated by carers,
plus carers relating to
the 10 NIV users,
were analysed. Study
confirmed importance
of end-of-life
discussions.

Authors report no conflict of
interest.
Research funded by research
programs; views expressed are
authors not Dept of Health.
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Concise Title

Specific
research
purpose

Methods

Results/finding

Discussion/limitations

Funding/Conflicts

11) The impact on
the family carer of
MND and
intervention with
NIV (Baxter et al.
2013) Journal of
Palliative Medicine
16(12), 1602-1609

Purpose of the
study clearly
identified: to
explore carer
burden of person
with MND using
NIV and how/if
NIV impacted on
family/carer

Carer Strain Index
used to assess level
of carer strain.20
patients recruited;15
carers completed.
Little evidence found
of increased carer
burden with NIV as
disease progressed.

Authors report and advise
caution when interpreting
very small sample for a
quantitative study.
Previous studies referred
to. This study supports
previous research in
advising support for carers
should start early although
inundation of services soon
after diagnosis was also
reported.

No conflicts of interest identified.
Funding provided under Research
for Patient Benefit, UK.

12) Healthcare
professionals’ views
on the provision of
gastrostomy and
NIV to ALS patients
in England, Wales
and Northan Ireland
(Ruffell, N et al.
2013) Journal of
Palliative Care
29(4), 225-231.

Purpose of the
research clearly
stated: study
aimed to quantify
HCP views on the
provision of
gastrostomy and
ventilatory support
for people with
MND.

A mixed methods
approach using
questionnaires and
qualitative interviews.
Quantitative data
analyzed using SPSS
19.0. Qualitative data
analyzed using
thematic analysis.
Ethics approval
granted. All
participants had
information sheets
and signed consent.
An online survey of
177 (1298 clinicians
invited to participate)
HCP’s in the UK
following email
invitation to
participate.
Questionnaire piloted
by the clinic that
helped to develop it
and wording changed
as necessary. Ethics
approval granted.

Demographic data
collected and
tabulated. Statistical
data imported into
SPSS 20.0 clearly
described. Differing
views between
medical and allied
health professional
regarding the timing
of initial discussions
around NIV and
gastrostomy.
Implications of NIV
withdrawal included

Limitations as identified by
the authors: Because the
collection method was
anonymous, unable to
follow up on nonresponders. Low response
rate could be due to lack of
experience with MND.
Practical consideration
given to time constraints of
clinicians; results may have
been influenced by recent
changes to NICE NIV
guidelines. Too many
limitations to be included in
quality appraisal

Authors acknowledge funding
from MNDA UK and other funding
grants. No conflict of interest
identified.
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Concise Title

Specific
research
purpose

Methods

Results/finding

Discussion/limitations

Funding/Conflicts

13) Accepting or
declining NIV or
gastronomy in ALS:
patients’
perspectives
(Greenaway et
al.2015) Journal of
Neurology 264(4),
1002-1013.

Purpose of study
identified: to
identify factors
associated with
decision making in
patients accepting
or declining NIV
and gastrostomy
in ALS

Three main themes
identified: Personal
experiences related
to patient centric
factors; external
influence of HCP and
family; the concept of
time and the effect on
decision making

Limitations as identified by
authors: study findings may
generalize from a clinic
population. Patients with
communication difficulties
were represented by their
care givers so views may
not have been exact.

Authors state no conflict of
interest

14) Staying just one
step ahead:
providing care for
patients with MND.
(McConigley et al.
2013) BMJ
Supportive &
Palliative Care 4(1),
38-42.

Unclear title:
Purpose of study
clear in abstract;
to determine the
experience of and
need for, HCP
education to
enable care for
people with MND
particularly at end
stage

32 participants
recruited via ALS
register as part of
larger prospective
study. Semistructured interviews
and analyzed by
inductive thematic
approach. Ethics
approval granted
Descriptive qualitative
design as part of a
larger study. 250
HCP attending MND
conference (2008)
sent invitation and
interviews and focus
groups conducted;
audiotaped interviews
were transcribed
verbatim and data
managed using Nvivo
8. Data collected until
saturation achieved.
Ethics approval
identified.

Key theme identified:
plan and prepare for
disease changes.
HCP had to be able
to predict changes in
an unpredictable
disease.
Acknowledgement
that HCP care for
patients can be
fragmented and that
communication vital
to enable informed
care choices.

Limitations identified: Small
number of participants
within focus groups held
within a conference with
competing sessions.

No competing interests. Research
funded by NHMRC (425565)
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Concise Title

Specific
research
purpose

Methods

Results/finding

Discussion/limitations

Funding/Conflicts

15) Identifying who
will benefit from NIV
in ALS/MND in a
clinical cohort
(Berlowitz et al.
2016) Journal of
Neurology,
Neurosurgery and
Psychiatry 87(3),
280-286
16) Standards of
palliative care for
patients with ALS:
results of a
European study
(Borasio et al. 2001)
Amyotrophic Lateral
Sclerosis and Other
Motor Neuron
Disorders 2, 159164.

Purpose of the
study included
within background
section in
abstract.

Retrospective
analysis of a
prospectively
collected cohort of
people with
ALS/MND. A
quantitative study.
Ethics approval
identified.

NIV was found to
increase life by 13
months compared to
other symptom
control methods.

Study did not capture
information on prolonged
survival on QOL in people
with MND on NIV.

Research funded by two grants;
authors state funders had no role
in study design, analysis or
results.

Study purpose
identified as an
investigation of
care for people
with ALS between
and within
countries.

A questionnaire was
mailed to 110
members of
European ALS group.
73 were completed
and returned, from 18
countries. Questions
focused diagnosis,
treatment, PEG,
respiratory support,
community services
and terminal care.
Ethics approval
not reported.

This study
acknowledged NIV
can increase survival
but was not widely
available in all
areas/countries.
Study suggested
many patients with
tracheostomies had
them fitted in an
emergency: validates
need for early and
improved
communication.

The results found a high
level of care for people with
ALS however was focused
on information from
specialist centers. Paucity
of published controlled
studies was identified (pre2001). Areas not covered
by study include pain and
psychological issues.
Questionnaire only
validated by experts.

No conflict of interest identified.
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Concise Title

Specific
research
purpose

Methods

17) Withdrawing
non-invasive
ventilation in a
patient with motor
neurone disease.
(Jenks A. 2014)
European Journal of
Palliative Care
21(3), 119-121

A case study of a
patient with MND

Appraisal
discontinued as not
specifically relevant to
search question

18) Issues for
palliative medicine
doctors surrounding
the withdrawal of
non-invasive
ventilation at the
request of a patient
with motor neurone
disease: a scoping
study. Faull,
Haynes, Oliver D
(2014) BMJ
Supportive &
Palliative Care 4(1),
43-49

Purpose of study
clearly described:
to identify
challenges that
palliative doctors
encounter in
relation to NIV
withdrawal in
people (at
patient’s request)
with MND.

Primary research: An
electronic
questionnaire sent via
email to palliative
care specialists (993)
within UK and Ireland
after pilot trialled with
registrars in palliative
medicine.
Mixed methods:
thematic analysis of
free text. Ethics
approval sought but
not required as study
‘service evaluation’

Results/finding

Discussion/limitations

Funding/Conflicts

134 (4 discarded as
not from doctors)
respondents of which
76 had experience
with NIV withdrawal in
MND; Practical,
ethical and emotional
challenges
acknowledged but
advance care
planning may help.
Better understanding
required to inform
future guidance for
doctors.

Limitations not clearly
identified by authors
although mention made
that survey very superficial
exploration of this difficult
area. As only palliative
care doctors surveyed,
others involved with care of
people with MND (nurses,
allied health, respiratory
specialists) could add
further insight. Those that
responded may be those
with most challenging
experiences in study area

One of the authors of this study
was a member of the NICE (2010)
guideline committee on NIV.
Research funded from LOROS
and the Wisdom Hospice
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2.5. Section 3: Search Results
Initial database (SEARCH 1-5: n=968) and manual journal reference list
searches (n=16) identified a total of 984 possible relevant articles (n=984).
However, articles were excluded using the selection criteria, leaving a total of
18 articles retained from the initial search review for full article review, after
which a further two were discarded. The number of articles retained for
inclusion in the final review was eight. The literature review illustration below
(Figure 2.1), adapted from the PRISMA Flow Diagram (Moher et al., 2010)
summarises the method used for this literature search and its results.
Articles were excluded at various stages due to the following reasons:
the irrelevance of their titles to the key word search and the search question,
non-English language, duplication of title or article, lack of specificity to MND
and ALS and/or only mentioned in the context of many diseases with nonspecific aspects of palliative care, single case studies or an ill-defined
methodology. Some articles had been superseded by the same author with
updated research and were excluded. Many articles were editorials, and only
the most relevant according to the selection criteria were selected for the
environmental literature review. The candidate acknowledges there may have
been some relevant journal articles missed due to the quantity found within the
initial search and since some articles were disregarded if their title appeared too
vague.

Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n = 968)

Additional records identified
through other sources (reference
lists) (n = 16)

Eligibility

Screening

Records after duplicates removed
(n =84)

Records screened by
abstract (n = 52)

Full-text articles assessed
for eligibility
(n =18)

Records excluded
(n = 34)

Full-text articles
excluded as not
sufficiently relevant
(n = 10)

Included

Studies included in
qualitative synthesis
(n = 8)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 0)

Figure 2. 1 Literature Search and Retrieval Process (Moher et al., 2010)
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2.6. Overview of Retained Articles

The literature generated through the systematic searches and selection
process outlined above identified knowledge gaps within the topics relevant to
this thesis. Several of the journal articles (n=15) included within the systematic
review reflected more than one theme. The themes identified within the eight
research articles retained for this review include:
1. The communication and moral challenges doctors face when
discussing the possibility of NIV withdrawal with people with MND
and their families
2. The role of healthcare professionals and influence of families on
people with MND making symptom management (NIV) decisions
3. The importance of well-timed, effective and individualised
communication by health care professionals to people with MND
and their families.

Theme 1: The communication and moral challenges doctors face
when discussing the possibility of NIV withdrawal with people with
MND and their families.
The withdrawal of NIV is not well documented within the literature. Within
the systematic search, only one article was found which explored the potential
dilemmas doctors face when asked to withdraw NIV from a person with MND. In
the United Kingdom, a retrospective qualitative analysis of 24 doctors with
experience of ventilatory withdrawal from people with MND were interviewed
(Phelps et al., 2015). The doctors experience of withdrawal of NIV (n=16)
undertaken at a patient’s request was explored. Whilst this research was
predominantly exploring the complexity of legal and ethical issues arising for the
doctors requested to withdraw NIV, individual perspectives and emotional
issues relating to the families concerned were not explored. However, Phelps et
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al. (2015) acknowledged that the influence of such complex emotional issues
for doctors might have an impact on families of and people with MND.

Theme 2: The role of healthcare professionals and influence of
families on people with MND making symptom management (NIV)
decisions.
The decision by people with MND as to whether to use symptom
relieving measures such as NIV and gastrostomy may be influenced by
a healthcare professional’s own perspectives (Martin et al., 2016). In
the study by Martin et al. (2016) health care professionals were
nominated by people with MND to represent their decision to use (or
not) NIV and gastrostomy. Whilst quality of life was related to the
practicality of the intervention, the pressures involved with making
multiple decisions because of clinical need was expressed. The
healthcare professionals found the timing of discussions relating to NIV
and PEG difficult, with some stating early discussions were vital. All
acknowledged that such discussions depended on the emotional and
social factors relating to the individual with MND. The study by Martin et
al. (2016) is limited by the small number of NIV related interviews, and
by possible bias in the selection of the healthcare professionals who
took part.
Decision-making for NIV and gastrostomy in MND and how these
decisions may be influenced by healthcare professionals, is further
explored by Oliver, Campbell, Sykes, Tallon and Edwards (2011). Their
study focused on the involvement of 22 palliative care consultants who
took part in a telephone audit. Only a small group of consultants (n=5)
was involved with early discussions with people with MND and involved
an MDT approach to discussion. The other 17 consultants were either
involved at the terminal stage of the disease or reported that the
consultant was rarely involved with a patient’s decision-making. The
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consultants with a special interest in MND or within a specialist MND
unit were more likely to involve an MDT and acknowledge the need to
develop a rapport with the person with MND. The study by Oliver et al.
(2011) suggested that the guidelines for these symptom control
measures may not be considered (or known) by healthcare
professionals involved with the care of people with MND.

Theme 3: The importance of well-timed, effective and individualised
communication by health care professionals to people with MND and
their families.

In two articles by Baxter et al. (2012, 2013), family and carer experiences
of the initiation and use of NIV in people with MND are explored. In the first
qualitative study, 20 people with MND using NIV and 17 carers were
interviewed within one month of the commencement of NIV. The aim of the
study was to investigate personal attitudes and initial concerns around using
NIV. Some of the perceived barriers to NIV, as voiced by people with MND in
the study, included the sensation of air being blown over the face, fear of the
machine itself, sleep difficulties due to machine noise and dryness of mouth,
lips and nose. Most people with MND within the study stated the need for
perseverance with NIV. The study concluded the importance of pre-empting
potential difficulties of NIV, the need for accessible advice plus the importance
of discussing NIV in detail with people affected with MND and their families.
However, this study did not discuss the content of the communication delivered
by the health care professionals to the study participants prior to the initiation of
NIV.
In the second qualitative study by Baxter et al. (2013) the difficult issues
associated with potential NIV withdrawal in people with MND were explored.
Interviews were conducted with nine bereaved family carers and 15 healthcare
professionals, in relation to 10 people with MND using NIV at the end of their
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lives. The often unexpectedly rapid deterioration of the person with MND led in
two instances to resuscitation attempts by emergency departments. This
reiterates the need for clear direction in end-of-life care planning. Rapid
deterioration within the terminal phase was described as a surprise by some of
the health professionals within the study by Baxter et al. (2013) who reiterated
the NICE (2016) guideline recommending that communication of end-of-life
issues should be ongoing once NIV is initiated.
Identifying factors which influence decisions relating to accepting or
declining NIV and gastrostomy was studied through face to face interviews with
21 people with MND by Greenaway et al. (2015). Within a thematic analysis
three themes were identified; patient-centred issues such as fear, control and
need; the role of and information provided by health care professionals; and the
concept of time. Greenaway et al. found that some health care professionals
directed their patients towards some interventions stressing the consequences
of late decisions. In some instances, this was perceived as being pressured into
a decision by the person with MND and their family. A lack of knowledge about
MND and the disease process among health professionals was also found
which caused some participants to feel under supported. Acknowledging the
complex communication dilemma for health professionals was highlighted by
Greenaway et al. Offering clarity relating to quality of life and the intervention
itself, before and after commencement, may assist people with MND make their
decisions.
The need for health professionals who have the appropriate experience
and education to assist and care for people with MND is explored in a study of
31 health professionals involved with MND and palliative care (McConigley et
al., 2014). Communication within the care team as well as a rapport between
health care professional and the person and family coping with MND was
highlighted by McConigley et al. (2014) and other studies (Faull, Rowe-Haynes,
et al., 2014; Oliver et al., 2011). The introduction of palliative care to the person
with MND and their families was admitted as being met with resistance at times,
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particularly by those families unwilling to acknowledge the terminal stage of the
disease. Skilled and accurate communication was found to be essential to
navigate the complexity, unpredictability and possible speed of change of the
disease.
Members of a professional body specifically involved with palliative care
and with experience of people with MND were asked to complete an electronic
questionnaire relating to NIV withdrawal (Faull, Rowe-Haynes, et al., 2014). The
research corresponded with the study by Phelps et al. (2015) in highlighting the
emotional and ethical challenges doctors face when asked to withdraw NIV. Of
more importance to the candidate’s study, is the research by Faull et al. (2014)
which found communication regarding the benefits and challenges of NIV
should be (but not always are) incorporated earlier in the disease rather than
when deemed necessary. Discussions relating to AHDs may assist patient care
relating to NIV withdrawal but can be overwhelming and, therefore, avoided by
families and health professionals alike.
2.6.1. Summary of retained articles
It is not clear whether or how frequently non-initiation of NIV is discussed,
when referral to a multidisciplinary palliative care team is offered, whether this
option is practically available (for example in rural Australia), and what level of
comprehension of the prognosis and options the patient and their family have.
Furthermore, when do clinicians routinely discuss the emotional, psychological
and physical impacts of NIV? Is the possibility of withdrawal of NIV and
subsequent imminent death discussed as the present guidelines recommend?
Whether the amount of extra life that NIV therapy typically offers is discussed,
but if the relentless disease progression, despite the NIV, is explained are there
also questions as yet unanswered? Finally, whether clinicians routinely
introduce the idea of not initiating NIV to avoid prolonged suffering and offer
alternatives such as medication for symptom control is unknown.
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2.7 Section 4: Environmental and Targeted Scans
More generally relevant literature sourced from the environmental scan
was included in the background to the research literature. Google scholar
produced 9,990 results for the initial search which was reduced (n=292) after
eliminating irrelevant titles, repeat articles within the same search, and
duplicates. The remaining abstracts considered broadly relevant were read
(n=50). Any peer reviewed articles considered generally relevant which could
enlighten the research question and identified gaps within the literature were
included within the background of the literature review (n= 32). These articles
are listed and described in Appendix A.
2.7.1. Environmental scan
As NIV is relevant to MND-related respiratory failure as well as several
other chronic diseases, an environmental scan of contextual literature about the
issue in relation to both MND and a variety of other healthcare conditions was
conducted. This helped to determine what care is recommended in relation to
end-of-life communication concerning NIV in people with a life-limiting health
conditions including MND. The scan resulted in a review of the contextualising
grey literature that proved essential to the candidates overall understanding of
the topic of interest and further confirmed the need for the current study (MartinMisener et al., 2012).
2.7.2. Targeted scan
The targeted search was aimed at data bases where published
recommendations for care could be found. The databases accessed included
NICE, NHMRC, WHO and the Motor Neurone Association databases for the
United Kingdom and Australia. Of particular interest for this research was the
unanswered question of how the present MND NIV Assessment and
Management Guidelines, previously the Use of Non-invasive Ventilation in the
Management of Motor Neurone Disease (NICE, 2010), in relation to the benefits
and burdens of NIV and end-of-life communication are being reflected in
practice (NICE, 2016). The NICE Assessment and Management Guidelines
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(2016) were published toward the end of the research process for this study.
The targeted search identified several MND recommendations including the
European consensus on palliative care in neurological disease (European
Federation of Neurological Societies and European Association of Palliative
Care, 2015) and a guide to ALS patient care for primary care physicians
(Amyotrophic Lateral Sclerosis Society of Canada, 2010). However, the NICE
guidelines (initially version 2010 and later 2016) were found to be the most
comprehensive and agreed with other MND management guidelines found
(Amyotrophic Lateral Sclerosis Society of Canada, 2010; Andersen et al.,
2012).
The following focus areas were identified in the documents retrieved:
1. General palliative care/MND specific palliative care research,
including patient-centered care, evidence-based medicine, clinical
guidelines and recommendations regarding best practice in end-of-life
care and a good death, and ethical issues/communication
surrounding NIV and end-of-life
2. The timing of palliative care service involvement in the illness
trajectory of the person with MND and triggers for NIV and end-of-life
communication for people with MND and their families
3. Content of communication in NIV and end-of-life discussions for
people with MND and their families
4. Factors influencing decisions, for example, MND related dementia
and the barriers to essential communication
5. Caregiver and patient concerns at the end of life and during MND and
the identification of various issues in the delivery of end-of-life care
that are still unresolved in the literature and clinical practice
6. Clinician concerns with communicating NIV benefits and burdens and
end-of-life concerns
7. The impact of insufficient NIV/end-of-life communication in people
with MND.
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As each of these focus areas is considered, what remains unknown
about each is also explored. This informs the development of a research
question to address that gap. As these focus areas are inextricably linked, they
are discussed together within the summary of evidence.
2.7.3. The development of clinical guidelines and recommendations
regarding best practice in end-of-life care
Clinical guidelines incorporate expert clinical opinion and research on
“how patients actually die” to determine optimum standards for palliative care.
For example, the WHO Policy Statement (WHO, 2015b), the NICE quality
standards for end of life care (NICE, 2011), the Gold Standards Framework for
palliative care (Thomas & Free, 2006) and guidelines from Palliative Care
Australia (The National End of Life Framework Forum Planning Group, 2010) all
agree that the following elements are vital to good end-of-life care:
communication, co-ordination of care, symptom control, continuity of care,
caregiver support and adequate practical physical and psychological care in the
terminal phase. Although there is consensus across a wide variety of clinical
specialties and disease categories on what kinds of care should be provided to
those facing the end of life, implementing these guidelines for patients across
the continuum of care has proven difficult.
2.7.4. MND specific palliative care guidelines
The few end-of-life recommendations identified specifically for people
with MND tend to mirror those guidelines identified for general end-of-life
patients. However, the literature points to some special circumstances that
people with MND and their significant others face, specifically around the
initiation, non-initiation, or withdrawal of NIV (National Institute for Health and
Clinical Excellence, 2010, 2016). For example, the earlier The Use of NonInvasive Ventilation in The Management of Motor Neurone Disease Guidelines
(NICE, 2010) provided evidence-based recommendations regarding treatment
and care of people with MND.
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The guidelines recommended that the choices of symptom-relieving
measures which may be beneficial to patients, including NIV, be honestly
communicated to people with MND at a time appropriate to the individual’s
capacity to emotionally comprehend the information. The later NICE (2016)
Management and Assessment Guidelines, which supersede the NICE (2010)
MND NIV guidelines, recommend being “sensitive about the timing of
discussion” (p.14; section1.7.1) particularly relating to any cognitive or
communication issues, without providing further detail to assist clinicians in
interpreting and applying these recommendations. In addition, these
recommendations suggest that when considering the process of initiation, noninitiation or withdrawal of NIV, patients and significant others should be
reassured that all comfort measures and medication will be provided to prevent
distress from symptoms. While this aspect of care is widely discussed in the
literature (Borasio, Voltz, et al., 2001; NICE, 2010, 2016; Oliver et al., 2006),
insufficient detail about the content of such discussions to guide clinicians was
identified.
People with MND have been found to feel more demoralised and
hopeless than cancer patients, with increased dependency on social support
and prolonged and ever worsening, physical incapacity (Clarke, McLeod, Smith,
Trauer, & Kissane, 2005).
Tables 2.5 and 2.6 summarise and compare general palliative care
guidelines with motor neurone specific recommendations found within a
targeted literature search. The two tables highlight the recommendation in all
the guidelines relating to palliative care, that clear communication is one of the
most important components of good end-of-life care. This enabling
communication style allows patients to make informed treatment choices
relating to their end-of-life care. The most pertinent take-away message from
this comparison is the uncertainty about when palliative care should commence
in MND, whereas it is understood to be relevant for cancer patients as their
condition becomes unresponsive to curative treatment. There is notable
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similarity between the recommendations in general palliative care and MND
relating to optimum symptom control and the availability of end-of-life
information. In MND, communication surrounding NIV and end-of-life care is
recommended to occur prior to the initiation of NIV and to be documented within
an AHD (NICE, 2016). Within the general palliative care guidelines
individualised care plans are recommended, although AHDs are encouraged by
the clinicians to clarify the patient’s end-of-life care wishes.
Table 2. 5 MND Specific Palliative Care Recommendations

MND Palliative
Guidelines
European Federation of
Neurological Societies (EFNS)
guidelines on the clinical
management of amyotrophic
lateral sclerosis (MALS) - revised
report of an EFNS task force
(2014).

National Institute for Health and
Clinical Excellence (2010) Motor
Neurone Disease. The use of
non-invasive ventilation in the
management of motor neurone
disease.
Updated and superseded
NICE (2016) MND Assessment
and management.
Motor Neurone Disease Australia
Quality Measures (Motor
Neurone Disease Australia,
2010).

Palliative Care Recommendations
Percutaneous endoscopic gastrostomy tubes should be placed
before respiratory insufficiency develops.
Non-invasive positive-pressure ventilation also improves survival
and quality of life.
Maintaining the patient's ability to communicate is essential.
During the entire course of the disease, every effort should be
made to maintain patient autonomy.
Advance directives for end-of-life care should be discussed early
with the patient and caregivers, respecting the patient's social and
cultural background (Andersen et al., 2012).
Multidisciplinary team to provide and coordinate ongoing
management.
Information and support for patient and families.
Discussions use withdrawal of NIV, alternative palliating strategies
and disease progression.
Discuss end-of-life decisions with patient, and if possible, families
Early palliative care involvement (NICE, 2010, 2016).

Multidisciplinary approach.
Delivery of MND specific end-of-life communication to patient and
families when appropriate.
Maintain quality of life and symptom relief; promote palliative care.
End of life planning / advance heath directives.
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Table 2. 6. General Palliative Care Recommendations and Policy Statements

General Palliative
Guidelines/Policy
World Health
Organisation (World
Health Organization,
1998) Definition of
Palliative Care

Palliative Care Recommendations










Therapeutic Guidelines;
Palliative Care
(Palliative Care Expert
Group, 2010)








National Institute for Care 
and Health Excellence

(2011) Quality standard 
for end of life care for

adults
Department of Health

(UK) (2010) End of life

strategy; quality markers 





Palliative Care Australia
(4th Ed) (2005) Standards
for providing quality

palliative care for all
Australians





Thomas, K, & Free, A.

(2006). Guidelines in
Practice, 9(6).

www.goldstandardsframe
work.nhs.uk



Provides relief from pain and other distressing symptoms.
Affirms life and regards dying as a normal process.
Intends neither to hasten nor postpone death.
Integrates the psychological and spiritual aspects of patient care.
Offers a support system to help patients live as actively as possible until
death.
Offers a support system to help the family cope during the patient’s
illness and in their own bereavement;
Uses a team approach to address the needs of patients and their
families, including bereavement counselling, if indicated.
Will enhance quality of life and may also positively influence the course
of illness.
Is applicable early in the course of illness, in conjunction with other
therapies that are intended to prolong life, such as chemotherapy or
radiation therapy, and includes those investigations needed to better
understand and manage distressing clinical complications (World Health
Organization, 1998).
Provides relief from distressing symptoms.
Neither hastens or postpones death.
Includes all aspects of culturally sensitive support and care for patient,
families and caregivers.
Avoids futile interventions.
Acknowledges death as a normal process.
Uses a multidisciplinary team to maximise requirements of
patients/families/caregivers.
Local availability of end-of-life information.
Symptom relief; information relating to care options.
Sensitive and clear communication.
Advice freely available to patients and caregivers including support
groups.
Action plan for delivery of high-quality care.
Ensure people approaching end-of-life offered care plan.
Ensure effective identification of those nearing end-of-life.
Ensure patients preferences and choices are documented and
expressed when they wish.
Ensure that the needs of caregivers are addressed.
Ensure 24 hr coordinated care for patients.
Care planning based on individual and on respect for patient, caregiver
and family.
Sensitive communication skills used by providers to ensure holistic
needs of the family.
Ongoing assessment and care planning.
Co-ordinate care with good communication.
End-of-life issues discussed honestly with patient and family.
Primary caregiver given information and support.
Access to palliative care.
To improve the quality of care for people near the end of life, in line with
their preferences; assess patient physical and psychological needs.
To develop the generalist workforce, leading to better collaboration and
coordination of care; anticipate patient requirements.
To improve cost effectiveness by decreasing hospitalisation.
Clear communication between patients, families and clinicians.
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2.8. Section 5: Summary of Evidence
The lack of clarity in the current literature regarding the content and
process of communication between clinicians, people with MND and their
significant others, as well as the level of comprehension of this information by
the patient and the family at the time of discussing NIV, forms the basis of the
research reported in this thesis. Most guidelines and recommendations are
based upon expert specialist clinical opinion rather than scientific research.
Further research regarding the withdrawal of NIV in people with MND and
specific practice guidelines may need to be developed to ensure optimum
patient care and understanding, and this remains the case as little has emerged
since this recommendation was made by Eng (2006) and endorsed by the Motor
Neurone Disease NIV Guidelines (NICE, 2010). Subsequent endorsement in the
Motor Neurone Disease Assessment and Management Guidelines (NICE, 2016)
is based on much of the same expert clinical opinion.
The procedure and communication surrounding NIV withdrawal is
included as a recommendation for further research in the NICE (2010) clinical
guidelines into the use of NIV. The importance of clear communication delivered
in a sensitive manner, is emphasised in the NICE (2016) Motor Neurone
Disease Management and Assessment Guidelines, with recommendations on
delivering concise information when the person with MND is ready to accept it.
Moreover, the Mechanical Ventilation for Amyotrophic Lateral Sclerosis/Motor
Neurone Disease Cochrane review (Radunovic et al., 2013) suggests that
further research is required in order to understand the personal factors
surrounding the use of NIV.
The influences on clinicians in initiating, conducting, ensuring patient and
family comprehension of MND respiratory symptom control and focusing on NIV
are extremely diverse. They include the factors that influence when to have the
conversation as well as what the patient and/or family is ready to hear about in
terms of the benefits, burdens, limitations and potential impacts of disease
progression and symptom control. The identification of which clinician is
84

responsible for ensuring that the patient and family are told the appropriate
information relating to end-of-life care, symptom control and quality of life issues
and their level of understanding of this information also appears uncertain at
this point. While it is clear that there are accepted trigger points in illness
trajectories at which honest discussion should occur - the proposal to initiate
NIV is one - it is also evident that these discussions are often delayed as health
professionals perceive a lack of readiness to engage in such discussions on the
part of the patient or family and they may be unwilling to acknowledge that
when the patient’s condition deteriorates these discussions are necessary
(Mitsumoto & Rabkin, 2007).
In addition, whilst MDTs are seen as important for effective symptom
control and support for the person with MND, the timing of the introduction of
multidisciplinary palliative care also remains uncertain and unpredictable (Bede
et al., 2011). Early palliative care is generally accepted as preferred practice
(Andersen et al., 2012; MNDAust, 2014); however, there are barriers to this
occurring, including ineffective communication within the MDT and between the
MDT, MND patient and their family. Some identified communication barriers to
an early palliative care referral include health professionals’ reluctance to confer
a lack of hope of recovery on the person with MND and lack of appreciation of
the potential for rapidly changing patient needs, support and symptom
management (Boersma, Miyasaki, Kutner, & Kluger, 2014).
The availability of a group of specialists to form an MDT within the same
health facility, inclusive of a palliative care specialist, who have the capacity to
meet and communicate as an interconnected team including the person with
MND and their family may prove difficult. This MDT is more likely to occur in
larger hospitals and cities. The absence of this in rural areas may prove to be a
barrier to aspects of necessary care and overall responsibility for the person
with MND and their family members. Palliative care MDTs, the variability in the
quality of the palliative care available and the inconsistency of palliative care
provision in urban versus rural areas may all create barriers to the move to
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palliation for people with MND. These have been explored within the
parameters of this research and are discussed later in the thesis.
The potential for timely, effective and explicit discussions relating to
AHDs, symptom control and end-of-life preferences are vital prior to the time
when speech becomes adversely affected and while clear communication
remains possible. Whilst these discussions are generally considered to be the
domain of the palliative care specialist, aspects relating to end-of-life care for
people with MND are considered appropriate for discussion shortly after
diagnosis so that the patient and their family can make choices prior to any
deterioration of symptoms. Particularly in rural areas, the person with MND may
not have local access to a palliative care specialist or MDT or may not be
referred by their GP. These difficult discussions become the responsibility of the
GP or are delayed until the patient’s disease progresses sufficiently that
palliative care become involved. There is a possibility for assumed responsibility
for the end-of-life discussions, and this aspect is also explored within this
research and identified within the discussion chapter. Palliative care, according
to international guidelines, should be offered to all patients when identified with
an incurable, life-limiting disease in order to alleviate adverse symptoms and
promote quality of remaining life (NICE, 2011; WHO, 2015b). It follows that
people with MND and other neurological diseases, as well as those with chronic
diseases such as renal or heart failure, should not only have equal access to
palliative care but their care should reflect evidence-based treatment pathways
and recommendations, much as cancer patients’ care is informed by evidencebased guidelines (National Institute for Care and Health Excellence, 2011;
Palliative Care Australia, 2005).
However, as MND is a rare neurological disease, many clinicians are
relatively inexperienced with the symptom control issues, the delivery of difficult
prognostic information and with optimal timing for referral to palliative care
specialist teams. Palliative care guidelines relative to those with cancer include
recommendations that value and encourage partnerships within health care
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organisations and the formation of a framework according to which care is
delivered wherever the cancer patient wishes to die (National Institute of Clinical
Excellence, 2004; Palliative Care Expert Group, 2010). Recommended end-oflife communication for cancer, chronic disease and neurological patients all
include well-coordinated patient-centered care and symptom control,
psychosocial support for patient and families and the provision of generally
detailed information about disease trajectory (NICE, 2013; Palliative Care
Australia, 2005).
The 2016 NICE guidelines recommend early referral of people with MND
to palliative care and an MDT (Anderson et al., 2007). The guidelines
encourage early discussion with the person with MND and their family about
end-of-life issues and the complications surrounding the initiation and
withdrawal of NIV. The description of points to include within conversations,
previously described as honest communication (National Institute for Health and
Clinical Excellence, 2010), is now more prescriptive; it is now considered
necessary to ensure the person with MND understands what NIV is and what it
can achieve. While the recommendations have become more precise, the inpractice content of clinician communication between people with MND and their
families about NIV and end-of-life choices is still not known. It is this gap that
the research reported in this thesis seeks to address.
2.8.1. Research questions resulting from the literature review
The research questions were formulated from the gaps evident in the
black and grey literature reviewed and are summarised as follows (Table 2.7).
The first question has been answered by the literature reviewed in this chapter.
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Table 2. 7 The Research Questions
1. In considering the available literature and guidelines, what are the most salient
components of best practice relating to the communication about NIV in MND prior to
NIV initiation and withdrawal?
2. What is the evidence that the best practice communication content (benefits and
burdens of NIV, continued disease progression, explanation and offer of a PEG, endof-life discussions and understanding the potential for NIV withdrawal prior to the
commencement of NIV) is incorporated into the actual communication by clinicians to
people with MND and their families at the time of offering NIV?
3. What do MND families/significant others recall about the communication
(benefits and burdens, continued disease progression, PEG insertion, potential NIV
withdrawal and end-of-life discussions) provided by clinicians at the time of respiratory
failure and the offer of NIV?
4. To what degree do MND families/significant others feel that the NIV
communication provided by the clinicians at the time of the offer of NIV prepared them
for and helped them to understand the implications of potential NIV withdrawal resulting
in the death of their family member?
5. What if any unmet needs for information, support, palliative care, or other
services do the clinicians and the families/significant others (or patients themselves)
with experience of MND identify?
6. Following the literature review and clinician and family/significant other interviews
regarding NIV communication, what recommendations can be identified that would
improve end-of-life communication and process for people with MND, families and
clinicians?
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2.9. Theoretical Framework: Domains of Influences on the Phenomenon of
Interest
The impact of MND on family members has been described in the
literature as potentially devastating. The lack of any possible cure for MND
restricts the communication to the patient and family to issues of adequate
symptom control, comfort and caregiver support. The communication
surrounding NIV initiation and its potential removal resulting in death, deciding if
and when to remove NIV and whether or not to have a PEG inserted prior to
weakening of the swallowing reflex and respiratory muscles, are all highly
emotional issues. In the context of a disease whose course can be so diverse
and individualistic, trying to remove all ambiguity from these complex
discussions is difficult. There are many interacting factors that influence the
effectiveness of the communication surrounding NIV, and these are
summarised in the Domains of Influence matrix provided in Figure 2.2.
It is necessary to consider the complexity of the communication
recommended to occur at various trigger points by the clinicians, the link
between commencing NIV and its potential withdrawal and death, and the way
in which communication may be interpreted by those who hear it. The Domains
of Influence framework derived from the existing literature and developed by the
candidate, is used to present and contextualise the discussion of findings of this
study in Chapters 4 and 5.

89

Timing of End-of-life
communication influenced by:
The expectation from
patient/family/clinician that each
other will raise the issue (1)
Uncertainty about timing (2)
Communication from clinicians
influenced by:

Understanding by clinicians
influenced by:

Experience with end-of-life
communication (5)

Interpretation of recommendations
for communication: NIV/end-of-life
(6)

Awareness /adherence to
recommended guidelines (5)

Timimg of NIV/end-of-life
communication (1)
Their concept of suffering (3)

Communication from
families influenced by:
Understanding by

Health literacy (4)

families influenced by:

Previous experience
with death of a family
member (4)

Families recollection
of communication (7)
Understanding of
end-of-life issues (7)

Communication
ability/experience (7)
Their concept of
suffering(3)

NIV and end-of-life Communication Concerns:
When does the communication about NIV by clinicians to
people with MND and their families occur?
What is the content of the communication relating to NIV
communicated by the clinicians?
What do the families /significant others of the person with
MND recall about the communication?
How did this communication help to prepare them for the
potential for NIV dependance, withdrawal and death?
What are the unmet needs identified for families and
clinicians involved with people with MND?
= Outcomes and recommendations from research identifying
limitations and possibilities for further research

Figure 2. 2 Domains of influences.
References: (1) (Anderson et al., 2007); (2) (Andersen et al., 2012); (3) (Foley et al., 2014); (4)
(Martin et al., 2014); (5) (McConigley et al., 2014); (6) (National Institute for Health and Care
Excellence, 2016); (7) (Phelps et al., 2015)
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2.10. Chapter Summary
As respiratory failure is the most common cause of death in people with
MND, alleviating respiratory distress either with technology or medications is
important. The clarity of communication which surrounds initiation of NIV and
the end-of-life care choices of the person with MND is, therefore, vital.
Extensive review of the literature to fully understand the implications of what the
guidelines recommend is imparted to people with MND and their families has
been undertaken and the gaps in knowledge about this phenomenon identified.
A tabulated description of the most relevant peer-reviewed journal articles is
provided in Appendix A.
Whilst there is extensive literature and numerous guidelines concerning
general end-of-life care, and specific recommendations guiding the use and
recommended communication surrounding NIV in people with MND, there is a
paucity of research examining whether and how the communication
recommendations specific to NIV in MND are applied in practice. The existing
literature does not elucidate the actual content of discussions between
clinicians, people with MND and their significant others regarding the initiation,
non-initiation or withdrawal of NIV; the benefits, burdens, and limitations of NIV;
alternatives to NIV; nor their impact on the quality of life of the patient and
family. Moreover, it is not apparent from the literature whether these discussions
are reiterated at any time during the disease progression and with whom they
occur, nor how much the patient and family comprehend the realities regarding
NIV. The lack of specific research into content and detail of communication
surrounding the experiences of people with MND, their families and their
clinicians points to the need for further research (NICE, 2010; Oliver & Faull,
2013).
This chapter has provided the foundations of this thesis and has
presented the five research questions to be answered, relating to the
communication surrounding initiation and withdrawal of NIV in people with
MND. Investigation of the literature to find how well caregivers and families of
people with MND understand the benefits, burdens and limitations of NIV prior
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to commencement; how this impacts their end-of-life decisions and subsequent
experience of their family member’s death; and how clinicians communicated
has exposed knowledge gaps and answered the first research question.
Literature concerning PEG tubes and, more broadly, on hydration and nutrition
has also been included in this literature review. The inclusion of communication
surrounding PEG tube insertion was considered relevant as PEG tubes are
generally considered for symptom control at approximately the same time as
NIV, have related clinical benefits and limitations and are recommended to be
incorporated into communication surrounding end-of-life issues. In the following
chapter, the research methodology and methods used in this study are defined,
an explanation as to why the approach taken was chosen is provided, and the
study processes and considerations are detailed.
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A qualitative study into the communication surrounding the initiation and withdrawal of noninvasive ventilation (NIV) in people with motor neurone disease

Chapter 3:
Method and Methodology
3.1. Chapter Overview
In Chapter 2 the need for this study, its purpose and aims and the
specific research questions to be asked of the data, which were informed by the
gap in available evidence, were presented. Although the published literature
touches on many aspects of MND, NIV and end-of-life care, little evidence was
found that enabled comparison of the present guideline recommendations
relating to the timing and content of a clinician’s delivery of NIV communication
with actual patient and caregiver understanding and recollections of
communication. The complexities of communicating respiratory failure symptom
relief and end-of-life choices for people with MND are, therefore, the focus of
the research questions asked in the current study.

Whilst clarity of communication in any context is difficult to verify and
measure, for this research the most recent published guidelines and
recommendations for communicating respiratory failure symptom relief and endof-life choices to people with MND were used as an indicator of what these
conversations should feature. Therefore, this study investigated what
information clinicians report they communicate, when and how they assess
patient and family understanding of the information presented to them, how its
presentation compares to guideline recommendations, and what was
understood by the recipients of this communication, that is, family members of
people with MND. This information, along with insights from an expert advisory
panel, or stakeholder advisory group (SAG), described below, helped inform the
approach to data collection in the current research.

To answer the questions and aims posed for this study, clinicians
working with people with MND and members of families of those with MND
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were asked in-depth questions about communication relative to NIV and related
end-of-life care issues. Their responses were then analysed qualitatively and
made sense of in the context of the literature on this topic. It is these research
processes and outcomes that are reported in this chapter and the two that
follow.

This chapter comprises two sections. The first section is concerned with
the philosophical, methodological and theoretical approach underpinning the
current study, and the second section reports the methods and processes
followed in the conduct of this research.

Section 1 (Methodology) begins with an overview of the four predominant
research paradigms within which contemporary health researchers work, and
the ontological and epistemological tenets of each. The broad approach to the
conduct of research by scientists working within each paradigm is then
described. Those employed for the current study are then identified as
naturalistic-interpretivism and the qualitative approach, and the rationale for
their selection is provided.

Several specific methodologies that reflect the qualitative approach are
then visited, and the one selected for the current study – interpretive descriptive
(ID) methodology - is presented and defended. Examples of theoretical lenses
through which health researchers make sense and meaning of the data they
collect are then provided. This section concludes with a statement about the
theoretical framework that was chosen to underpin the current study – symbolic
interactionism (SI) - and the reasons for its selection.

In Section 2 (Methods) the fully replicable steps taken in the current
study are detailed. This section includes information about sampling and
recruitment processes, data collection, analysis and sense-making processes
and measures taken to ensure the study is ethical and trustworthy.
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3.1.1. Research questions and aims
As a reminder to the reader, the research questions and aims pursued in
this study were as follows (the first question has already been answered
in Chapter 2):

1. In considering the available literature and guidelines, what are the
most salient components of best practice relating to the
communication about NIV in MND prior to NIV initiation and
withdrawal?
2. What is the evidence that the best practice communication content
(benefits and burdens of NIV, continued disease progression,
explanation and offer of a PEG, end-of-life discussions and
understanding the potential for NIV withdrawal prior to the
commencement of NIV) is incorporated into the actual communication
by clinicians to people with MND and families at the time of offering
NIV?
3. What do MND families/significant others recall about the
communication (benefits and burdens, continued disease
progression, PEG insertion, potential NIV withdrawal and end-of-life
discussions) provided by clinicians at the time of respiratory failure
and the offer of NIV?
4. To what degree do MND families/significant others feel that the NIV
communication provided by the clinicians at the time of the offer of
NIV prepared them for and helped them to understand the
implications of potential NIV withdrawal resulting in the death of their
family member?
5. What if any unmet needs for information, support, palliative care, or
other services do the clinicians and the families/significant others (or
patients themselves) with experience of MND identify?
6. Following the literature review and clinician and family/significant
other interviews regarding NIV communication, what
recommendations can be identified that would improve end-of-life
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communication and process for people with MND, families and
clinicians?
The study aims to be answered by the research questions are as follows:

1. To describe clinician communication surrounding NIV including endof-life choices
2. To understand how clinicians check the level of patient and family
members’ understanding of NIV benefits and burdens and the
potential of NIV withdrawal prior to NIV commencement
3. To understand the impact of clinician communication about the
benefits, burdens and limitations of NIV on family members’ choices
in relation to NIV introduction
4. To understand what timing, content and style of communication most
effectively helps the families of people with MND to make decisions
about NIV initiation and withdrawal
5. To compare the content, process and outcomes of NIV
communication as described by clinicians and families of people with
MND within this study against the currently available
recommendations relating to commencement and withdrawal of NIV
and related end-of-life options for care.

3.2. Stakeholder Advisory Group (SAG)
Once the research questions were derived from the identified gaps in the
literature, the questions for the semi-structured interviews were developed.
These were informed by a small SAG of leading MND clinicians convened for
this purpose. The SAG provided valuable insights into the experience and care
of those with MND and of end-of-life clinical practices in a range of contexts and
settings. This yielded information that was extremely useful when considering
the possible reach of the study findings and recommendations both within and
outside Australia.
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Approval to convene the SAG as a process step in the current study was
obtained from both the Wisdom Hospice in Rochester, Kent, United Kingdom
(Appendix R) and Edith Cowan University Human Research Ethics Committee
(Human Research Ethics Committee, Approval number 12099: Appendix B).
Two aspects of clinician expertise were explored in the SAG conversations. The
first aspect concerned explanations about NIV and how it was offered to and
initiated for people with MND. The second aspect was about care, symptom
control and ongoing communication relating to the end-of-life wishes of the
person with MND and their family. Based on the information gleaned in these
conversations, the nature and order of the clinician participant questions was
refined to ensure relevance to the research aims and to reflect participants’
likely thought processes; this included the omission of two questions originally
proposed that were found to be repetitive.

3.3. Significance of the Study
The literature suggests that for some families, end-of-life treatment options
and the availability of palliating medication alternatives are not well
communicated or comprehended, leading to an end-of-life decision-making
crisis and potentially creating emotional indecision and confusion for families,
significant others and the clinicians involved (MNDAust, 2012; NICE, 2010;
NICE, 2016). The overall objective of this thesis is to determine to what extent
the communication between health professionals and people diagnosed with
Motor Neurone Disease (MND) incorporates symptom control and end-of-life
choices. The significance of such a study is to ascertain whether recommended
patient-centred best care communication is occurring and whether those
involved with delivering and receiving the recommended communication
consider this to be the best timing and most useful communication regarding
end-of-life choices for people with MND. Importantly the communication
experiences of those affected by a diagnosis of MND have been explored and
compared to the clinician experiences. This study is significant as it identifies
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areas for communication improvement and consequently the end-of-life care for
those living with MND.
The findings of this study are presented in Chapter 4 (Results)

3.4. Section 1: Methodology

3.4.1. Positivism versus interpretivism
Health research is most commonly situated within one of two scientific
paradigms depending on the philosophical stance of the researcher and on the
research problem. Those who subscribe to the positivist worldview assert that
there is one truth, and that research should measure and statistically “make
sense of” data about phenomena of interest to reach that truth. Researchers
working in this paradigm almost exclusively use quantitative methods to deduce
“what is going on”, having first developed a hypothesis about the topic of focus.
In contrast, the naturalistic-interpretive worldview takes the position that truth
consists of multiple realities that arise through individuals’ constructs of it as a
result of their experiences and interactions, and that the aim of research
conducted within this paradigm is to explore and understand personal
experiences and the meaning of social or individual situations to reach those
truths (Burns & Grove, 2007; Streubert & Carpenter, 2011). Researchers who
take a naturalistic-interpretive stance most usually subscribe to inductive
qualitative methodologies in which no prior assumption is made about “what is”
in relation to the topic of interest, but rather the understanding of the
phenomenon of interest emerges from the data itself.

An inductive, learning-by-understanding technique was used for this
study to analyse ideas and experiences as they emerged from clinician and
bereaved caregiver answers. To ascertain the most effective method to capture
the required information, several approaches were considered. As MND is a
relatively rare disease some difficulty was anticipated in collecting enough data
to enable research questions to be answered through quantitative means.
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Therefore, a qualitative method was considered the most appropriate approach;
although quantitative participant data may be limited the depth of qualitative
interviews would likely be informative and personal (Wertz, 2011).

The study reflects the lived experience of the participants and relies on
information collected from in-depth semi-structured interviews with clinicians
and bereaved families of people with MND. Additional information, generously
given by an individual diagnosed with MND who asked to be part of the
research, offers valuable insight into the MND experience. This supplementary
information provided a deeper understanding of the topic not anticipated in the
original design of the research protocol. The research process for this study has
four main steps with further steps within in each of these. The theoretical
rationale (naturalistic-interpretive / qualitative), initially described within the
Chapter 2, is expanded on further in this chapter.

Given the likelihood of an insufficient quantitative sample size and having
considered the gap in knowledge and the research questions posed to address
that gap, it was determined that a quantitative approach would be inappropriate
for exploring the complexities of the communication that takes place around the
emotionally-laden topic of end-of-life care options. Rather, the phenomenon
under investigation demanded a naturalistic-interpretive / qualitative approach
to enable the candidate to fully explore participants’ experiences and views.
However, some quantifiable demographic data was collected to help
demonstrate the representativeness of the sample, and this is presented within
Chapter 4 (Tables 4.1, 4.2 and 4.3).
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3.5. Overview of Predominant Theoretical Perspectives for Health
Research and Their Epistemological Tenets

In selecting the most appropriate approach for this study, the following
criteria were considered: of most importance, the methodology should enable
the inquiry to achieve the most useful outcomes; it should also identify the
techniques of the research; and the theoretical or conceptual perspectives
should provide rational context and enlighten the methodology and
epistemology, or the theory of knowledge. Several methodological options are
available to the naturalistic-interpretive researcher (Crotty, 1998). Among others
these include phenomenology, grounded theory, ethnomethodology (Crotty,
1998), and ID (Thorne, Reimer Kirkham, & MacDonald-Emes, 1997). The key
features of the four qualitative perspectives considered for this study and their
benefits and disadvantages in relation to it are outlined in Table 3.1.
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Table 3. 1. Four possible qualitative research methodologies for a study
investigating end-of-life care decision-making in relation to MND

Perspectives

Advantage

Phenomenological
Methodology

Based on the lived
experiences as
expressed by
participants.

Grounded Theory
Methodology

How social norms
are investigated
which when
developed
generally build a
theory from
specific gathered
data.
Behaviour of a
group may be
changed by their
social constructs.

Ethnomethodology
Methodology

Interpretive
Description
Methodology

Knowledge gained
through the
research can
result in immediate
change in practice.
As a methodology,
works in
conjunction with
SI.

Disadvantages

Selected/Rejected

1) Includes imagination,
emotion, thought,
sensory perception but
not specifically
communication.
2) May be unaware of an
experience if experienced
by the semi-conscious.
1) Data gathered with
intention of building a
theory which was not
necessarily the intention
of this research.
2) Questions tend to
be unstructured.

Rejected:
Personal experiences
considered too imprecise for
this research.

1) Very specifically
studying a group who
perhaps may not even
think about their
behaviour as it is
influenced by their social
norms.
1) Involves critical
analysis and
understanding of current
clinical recommendations
and guidelines
(theoretical knowledge).
2) Results must be
practical to enable
change.

Rejected:
Too specific to social groups
and cultures.

Rejected:
Specific questions were
required to be asked of
participants and intent was
not to seek a theory.

Selected:
Provides information by
understanding and therefore
informing, by seeking
personal experiences.

3.5.1. Phenomenology
Phenomenology is a philosophical method which studies the lived
experience of individuals and how they interpret their experiences, originating
from the work of Edmund Husserl (1889-1938) and variously developed
creating a broad method for qualitative research (Streubert & Carpenter, 2011).
Much of Husserl’s work was incorporated into lectures and research
manuscripts rather than books. His ideas in developing phenomenology have
been further incorporated into more recent literature, for example by the
philosopher Martin Heidegger (Fieser & Dowden, n.d.). Phenomenology
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describes an experience of an individual’s life which, when used as a method of
research, gathers those experiences to describe and understand a particular
occurrence (Streubert & Carpenter, 2011). The theory is based on the concept
that events and objects in life create an individual’s sense of reality as they
occur and as perceived by the individual (Edgar & Sedgwick, 2008).
Phenomenology emphasises an individual’s singular view of the world
and does not attempt to reach a consensus view about phenomena of interest
Streubert & Carpenter, 2011). It was rejected for this reason. One of the key
imperatives of this study was to discover information that could be used by all
stakeholders in end-of-life care decision-making; it was, therefore, important to
use an approach that would enable a consensus about what is going on to be
reached. Phenomenology may be useful as a methodological option if MND
was being explored to see whether the person with the disease thought that
they may defined by the label of MND when perhaps they perceived the disease
as only a small part of who they were. In this situation, phenomenology could be
used to explore the individual’s feelings and mechanisms for coping with MND.
3.5.2. Grounded theory
Grounded theory is an approach developed in the 1960s by Anselm
Strauss and Barney Glaser with a view to developing a theory by collecting data
from interviews, observation and evidence relevant to the study. Grounded
theory involves purposely selecting a group with similar lived experiences which
may provide the researcher with contextual understanding of an event or
circumstance (Schreiber & Stern, 2001). Historically, grounded theory
developed from two schools of thought, one emerging from Chicago University
and the other from Iowa University. As a student of Chicago University, Blumer
(1969) described and developed social interaction theory, the philosophical
underpinning of grounded theory. The concept of an individual taking meaning
from oneself as well as through interactions with others, became the foundation
of SI (De Chesnay & Banner, 2015). Using grounded theory as a research
framework, the research questions are open-ended rather than specific,
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allowing for the research to broaden and change direction depending on the
data gathered (Maltby, Williams, McGarry, & Day, 2014). For this research,
which requires specific information, a grounded theory methodological
framework was considered too broad and ill-defined.
3.5.3. Ethnomethodology
Ethnomethodology, which was founded by Harold Garkinkel in the
1960s, is a methodological perspective derived from a collective of people or a
social group who have unique or specific practices or ways of life (Maltby et al.,
2014). In the context of MND this method could be used if the study focused on
one particular group, and to study the group as a whole would enlighten all
others who may be diagnosed with MND. Using ethnomethodology would not
be suitable for this research, however, as I wanted to illuminate the
phenomenon of interest from a range of sources.
3.5.4. Interpretive description
To understand the phenomena of interest, namely, the end-of
life/symptom control communication between clinicians and people with MND
and their families, an inductive analytic approach was selected. Interpretive
description was developed principally as a process for obtaining knowledge
within the context of clinical events to elicit change (Thorne et al., 1997).
Originally designed as an alternate research method to understand the
subjective individual experience for clinical nursing research, ID has been
developed over the past 20 years. Interpretive description starts with an
analysis of current clinical knowledge and understanding. By purposeful
sampling and capturing subjective insights by interviewing participants, themes
develop which can inform clinical norms.

Interpretive description incorporates aspects from grounded theory and
ethnomethodology in its approach to purposive data collection; however, it
rejects the sometimes restrictive development of a theory (Thorne, Reimer
Kirkham, & O'Flynn-Magee, 2004). How people act, interact and communicate
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in their lives is the foundation of this research wherein what the individual
considers to be true is uppermost; ID throws light on a collection of expressed
truths to inform a practical change. For these reasons, ID was selected as the
most appropriate methodology for the current study.

3.5.5. Theoretical perspective
The social interaction of interest in this study is the communication
between the clinician and the person with MND and their family, and the
interpretation of meaning ascribed to this communication as remembered by
participants. By understanding and appreciating the meaning of events and
participants’ interpretations of the communication engaged in, this study
attempts to identify the factors that influenced the choices of symptom control
and end-of-life care made by the person with MND. Symbolic interactionism
was selected as the most appropriate theoretical perspective for this study. By
listening and questioning people with experience of MND, understanding and
meaning were created through an interpretive process.

Communication can be confusing and misinterpreted if not clearly
delivered or left open to supposition. The understanding of words and the
nuances of interactive verbal and non-verbal delivery can lead to
communication problems and this in turn can change the meaning an individual
may give to a situation. The theory of SI involves the interaction of the meaning
individuals attribute to a situation or person, the language used to comprehend,
and the thought which allows interpretation of meaning and language.

The methodology selected for this study, ID, and SI are highly compatible
for the conduct of qualitative research studies that could effectively inform
nursing practice. In fact, the underlying assumptions of ID are considered
symbolic interactionist, and SI is considered an important part of ID’s theoretical
heritage (Oliver, 2012).
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3.6. Understanding the History of Symbolic Interactionism
The origin of SI is attributed to George Herbert Mead (1863-1931)
despite the further development of the perspective by Mead’s student, Herbert
Blumer. Symbolic interactionism focuses on the meaning and interpretation
ascribed to communication and social and interpersonal interaction (Oliver,
2012). The basic principle of SI is that how an individual perceives the world
and acts is based on their individual interpretation of the meaning of the
influences on their actions (Blumer, 1969).

Since the inception of SI, there have been several variations emanating
from different universities, including from philosophical leaders such as John
Dewey and Charles Cooley from Chicago University. The University of Iowa
developed their own variant of SI largely founded on the thoughts of Manford
Kuhn and Carl Couch (De Chesnay & Banner, 2015). Kuhn differed from the
Chicago school of thought, believing that there were some basic meanings for
an individual which remained constant despite external influences (De Chesnay
& Banner, 2015).

Mead was influenced by the work of Charles Darwin and the theory of
evolution, sharing his belief that human behaviour is a constant adaptation to
the environment (Mead & Morris, 1934). Mead considered that social interaction
influenced the way in which humans learnt or were influenced to react (Mead &
Morris, 1934). Within this social construct, Mead differentiated between mind as
an essentially social process and the brain as a human organ.
Cooley was a sociologist who developed the concept of the “looking
glass self”: how an individual perceives themselves is based on how a person
believes others sees them (Cooley, 1998). The individual appears to others in a
way that reflects how that individual believes they are seen, which in turn
involves a perceived judgement based on appearance, and an imagining of how
others feel about the individual. According to Cooley, this concept can lead to
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behavioural change based upon the perception of others toward an individual
(Cooley, 1998).

John Dewey, also from Chicago University, suggested that the way an
individual respond to a situation relates to learned responses within a social
order (Dewey, 1922). Dewey maintained that personal awareness of a social
situation by attributing certain characteristics is a habit (trait) of social
classification resulting in a personal judgement (Dewey, 1922). Dewey
described mind as intrinsically involved with the environment in its ability to
adapt behaviour. In particular, language and communication were identified by
Dewey as responses to environmental factors (Dewey, 1922). The perception of
instinct as a cause of social behaviour was rejected by Dewey who thought
spontaneity affected old habits and that consequently thought deliberation could
change a person’s behaviour (Dewey, 1922).

The development of SI at Chicago University throughout the 20th century
continued to be based on the concept of reality as constructed by social
interaction (Blumer, 1969). Following the teachings of Blumer, Straus
commenced development of a research method based on the concepts of SI.
Straus transferred to the University of California where he and Barney Glaser
developed grounded theory in the 1960s (De Chesnay & Banner, 2015).
Grounded theory is the structured collection and analysis of data which has the
potential to lead to the development of a theory (Ezzy, 2013). Grounded theory
investigates social normalities which when the data has been gathered and
analysed enables a theory to be developed.

The intellectual theories, particularly emanating from the Chicago school
of SI, have informed the choice of theoretical perspective used for this study.
The exploration of communication between those involved with MND, the
interpretation of this communication as heard and recalled, and the meaning
assumed by the individuals all fit within the scope of SI. The meanings
participants constructed, particularly from verbal communication, and to a lesser
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extent, non-verbal communication, is presented throughout this thesis. This
study has drawn on the SI concept of meanings influenced by situations and
communication, and how individuals’ interpretations influence their life choices.
3.6.1. Limitations and examples of SI and ID in research
When SI was considered for this study, any reported limitations or
criticisms of the approach were explored to ensure its appropriate use. The
approach has been criticised as insufficient to address the influences of social
structure, historical events, culture and power (Dennis & Martin, 2005; Meltzer,
1975). Symbolic interactionism has also been accused of not considering the
influence of human emotions or the influences of organisations, both factors
which have the potential to change human life (Meltzer, 1975). However,
Dennis and Martin (2005) counter-argue that SI does explain the phenomena of
power, citing studies in the areas of education and deviance where the
consequences of power are enforced within social processes. Roles and
behaviours can be influenced by circumstances and an individual can be
defined by behaving in a way that is consistent with that circumstantial situation
(Cast, 2003). Cast (2003) suggests that an individual may be able to influence
the behaviours of people by accepting the influences of others. Cast gives an
example of intravenous cannulation (IVC) and how children may be influenced
by parents and health care providers who describe the impending situation. This
has the potential of influencing the situational behaviour the child has ascribed
to the meaning of the procedure. Cast used SI as a theoretical perspective to
study and understand the communication between health care provider and
parents throughout IVC procedure in children. On balance, SI was confirmed to
be appropriate for the current study

Interpretive description was similarly considered and was confirmed to be
suitable on the basis of its application in other nursing research. In a study
exploring the moral experience of health professionals in humanitarian work, the
strengths and challenges of using ID as a qualitative method are discussed
(Hunt, 2009). Using ID in his doctoral research, Hunt (2009) found coherent
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structure to enable his research development and others have effectively
employed this methodology in the exploration of nursing topics (Kimber,
Georgiades, Jack, Couturier, & Wahoush, 2015; Nkulu Kalengayi, Hurtig, Ahlm,
& Ahlberg, 2012; Thorne, Con, McGuinness, McPherson, & Harris, 2004;
Williams & Haverkamp, 2015).

The broader interpretation of a situation and how it influences action was
addressed by Blumer in his discussion of the importance of organisation on
human society (Blumer, 1969). Blumer appeared to acknowledge aspects of a
broad environmental influence and how aspects of it may influence human
behaviour. An example in this research is the influence of the commonly held
understanding of palliative care being a place of death and how this
environmental aspect influences human behaviour. The compatibility between
ID (framework) and SI (theoretical perspective) is used in the candidate’s
research to understand and make meaning of the subjective participant insights
and to potentiate change (Oliver, 2012). The following section incorporates and
discusses SI within the research design, and how SI is used to understand the
communication which influences end-of-life choices made by or for people with
MND.
3.6.2. Theoretical perspective of SI within the research design
Initially using a perspective based on SI as a study of social interaction,
concepts and behaviour, a construction for explaining and understanding each
person’s decision-making process, and subsequent course of action relating to
the initiation and withdrawal of NIV in people with MND was developed (Blumer,
1969; Stryker, 2002). For example, studying individual participant interpretation
of communication surrounding NIV initiation, its benefits, burdens and
limitations, and how this communication related to the experience of relief from
respiratory failure and subsequent death in a person with MND, has provided
participant shared agreement or non-agreement of what constitutes useful
communication. Studying the content of communication and understanding
among the participants at the time when the person with MND was offered and
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either accepted or refused NIV, had NIV withdrawn or died of co-morbidities,
has informed several aspects of this research. These include whether
communication between participants resulted in similar memories and
understandings of any discussions relating to commencement and withdrawal of
NIV, and how their individual interpretation influenced their decisions.

Building upon the perspective of SI, and based on the literature review, a
more prescriptive framework was developed to understand the complexities and
ambiguities of NIV end-of-life communication. This enabled further refinement of
the research questions, design, and analysis plan for this study. During data
collection, the researcher found that while the theoretical perspective of SI
provided a working guide, the interacting variables created the potential for
verbal communication imprecision and misinterpretation. For example, a
number of factors interacted to complicate communication: the complexity of the
language used and the education level of participants, the capacity of the
patient and family to question the clinicians, finding and interpreting information
from the Internet by some and participants’ financial and social situations. The
additional and often undisclosed or undiagnosed cognitive changes which can
present in MND added further challenges for the person with MND, their
families and clinicians in ensuring that what was said and heard was
understood. Therefore, the theoretical perspective is grounded in an
understanding of the unique experiences and individual interpretation of each
participant.
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3.7. Section 1: Summary
The first section of this chapter focused on the importance of selecting a
methodology and theoretical framework. Various theoretical stances and
methodological approaches have been examined and their advantages,
disadvantages and relevance for this research identified. A subjective
epistemology and SI were selected for this study as the theoretical perspectives
and ID was selected as the framework for informing change. The development
of a framework representing the influences on the phenomenon of interest was
presented as the basis for the research questions. The research questions, in
turn, were designed to enable the accumulation of participant perspectives
which would inform change, broaden how communication may be delivered and
influence the care choices of people with MND and their families. The following
section of this chapter outlines how this qualitative study was designed.

3.8. Section 2: Methods
The research process is diagrammatically shown in Figure 3.1 which
identifies the order of steps taken in the study once the first draft of the research
questions had been developed.
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Literature review; identify the
knowledge gap and develop
research questions
Apply Research Ethics
approval

Stakeholder Advisory
Group
Slight amendment to
clinician questions; no
change to family
participant questions

Clinician participants recruited via
invitation through place of work

Family participants recruited via
invitation through the MNDA
(Australia) newsletter

Reliability: Recorded
interviews
transcribed verbatim
by professional
transcriber

Clinical participants: collect data
using semi-structured questions in
the setting of their choice
(generally their office at place of
work)

Clinician participants: Data
analyses using Nvivo10 and
researcher coding of themes

Validity: transcripts returned
to participants for veracity of
content

Family participants: collect data
using semi-structured questions in
the setting of their choice (generally
their home)

Family participants: Data
analyses using Nvivo10 and
researcher coding of themes

Analysis
Relate themes to original research
questions and short summary of
results to clinician participants

Relate themes to original
research questions and short
summary of results to family
participants

Ensure reliability, validity, and transferability of
research data: Discussion with limitations of research
identified. Conclusion: recommendations and
suggestions for further research

Figure 3. 1. The Research Process
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3.8.1. Setting
The research was initially confined to interviews within Western Australia.
However, due to insufficient participant numbers, the research was broadened
to include New South Wales. In respect of the sensitive nature of the research,
the clinician interviews all took place within the clinician participants’ workplace
in a suitably private room, or via a telephone/Skype recorded interview. All
family participants could determine a suitable venue of their choice and were
encouraged to bring a support person along if they felt this was appropriate
given the nature of the conversations. Only one of the participants had a
support person present, and as this was another family member who had been
involved with the care of the person with MND, they requested to be interviewed
jointly. The family and caregiver interviews all took place in their respective
homes, as chosen by each participant.
3.8.2. Qualitative data collection and analysis
A generic approach to qualitative data collection was employed for this
study. Qualitative data collection is used for various lines of inquiry which allows
the respondent the freedom to provide more than just a quantitative answer. For
example, conducting open-ended and/or semi open-ended interviews allows the
respondent to give detailed information in answering questions. This can add
meaning or context to experiences and a deeper understanding of the way
aspects of life work. These are important to inform and instruct process change
that becomes transparent and accessible to the interviewer. The process of
inquiry for qualitative research may be from interviews, observation or material
collection such as questionnaires or analysis of official records. For this study,
data were collected from semi-structured interviews with two types of
participant. Data were analysed to ensure rigor, reliability and minimisation of
researcher bias to enable others to replicate the research (Munn et al., 2014).
3.8.3. Semi-structured interviews
The interviews conducted for this study were intended to answer the
research questions shown in Table 3.2. It was anticipated that by using a
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personal semi-structured interview method, the researcher would be able to
obtain in-depth responses. Semi-structured interviews have a flexible structure
which, despite pre-organised questions, allow for detailed and personal
answers and accounts (Streubert & Carpenter, 2011). Semi-structured
interviewing requires that the researcher builds a trusting relationship with the
participant, so the participant feels listened to and able to describe their
experiences with the assurance of complete confidentiality.
The ability to observe the participants’ reactions and emotions when
describing their recollections enabled the researcher to ensure the willingness
and appropriateness of the participant continuing with the research questions.
The observation of the participants and any degree of distress dictated whether
the interview should pause or terminate, had the participant appeared
emotionally distressed. Individuals were invited to rest or cease the interview
and seek support through their place of work, or through the MNDAWA or MND
NSW emotional support staff who kindly agreed to support this research. The
researcher explained to the participants at the commencement of the interview
that they may elect not to answer any of the questions they found distressing. It
was also explained that they could choose to continue with the interview and
seek support from MNDAWA or MND NSW or they could choose to continue
with the research without seeking further support.
3.8.4. Development of the interview schedule
When considering the aims of this research, and after extensive
exploration of the literature, the research questions (Table 3.2) were formulated
and the most searching and pertinent participant questions constructed with the
assistance of a SAG (Appendices D and E). The decision to interview
participants was chosen in preference to a format of questionnaires. The
candidate felt a more personal approach may elicit more insightful information,
particularly as the subject matter was deeply personal and may cause some
emotional distress (Streubert & Carpenter, 2011). The candidate was
concerned that questionnaires may restrict the participant responses and whilst
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a larger number of participants could have responded, the information may not
have been as broad and informative. The candidate also felt that questionnaires
may be given less in-depth thought by the participants and any clarification of
questions or tangential thoughts would be less easy to obtain (Streubert &
Carpenter, 2011).

3.9. Sample Selection: Participants

3.9.1. Clinician participant identification and recruitment
Purposeful sampling was used to identify and obtain the most pertinent
group of participants. This method of sampling ensures that the participants
targeted are representative of the information required for the research (Patton,
2015). In this case, clinicians involved with the effects of adverse respiratory
symptoms in people with MND, clinicians who are involved with the initiation of
NIV, those involved with end-of-life care for people with MND, and bereaved
family/caregivers involved with people with MND were identified as best
positioned to provide information about the topic of interest. By targeting and
selecting participants with MND experience and with extensive knowledge of
the research topic, optimal insight throughout the study was ensured. Purposive
sampling and snowball sampling (information discussed and communicated to
others not previously in the study, enabling relevant and interested others to
participate) were used as a means of directing the research to the most relevant
clinicians.
3.9.2. Clinician participants: inclusion criteria
Two participant groups were identified within the clinician participant
cohort: those who were responsible for the conversation regarding initiation and
use of NIV (respiratory physicians, or neurologists) and those who interacted
with people living with MND in the terminal phase of care and were involved
with withdrawal of NIV. Community neurological and/or palliative care nurses
and allied health workers who provided ongoing support for the person with
MND and their families were included as communicators of ongoing care. All
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clinicians, whether at initiation or withdrawal of NIV in MND, were asked the
same set of questions to ascertain any areas of assumed knowledge, or
communication supposed to have occurred. The interview protocol included
questions being asked in the same order for each participant, although because
of the open-ended questions at the beginning of each interview, some parts of
the questions were answered at that time and were not asked again. Protocol
also demanded the consent of the participant for the interview to be recorded
(Appendix F).
3.9.3. Clinician participants: recruitment of interview subjects
Clinician participants were identified through their association with MND
in palliative care services, hospitals, specialist centres (neurologists, respiratory
physicians and specialist nurses) and invited by email, letter or face-to-face to
partake in the research. Any interested clinical participant was emailed or sent
the Clinician Respondent Information Sheet (Appendix G) explaining the project
and an Informed Consent Form containing further information regarding
participants’ involvement (Appendix F). All participants were provided with a
written letter explaining the purpose of the research, how the research was to
be undertaken and how long each interview was anticipated to take. Prior to the
interview commencing, participants were also provided with a written consent
form which they were asked to read and sign. Confidentiality was assured
through the process of de-identification of each interviewee and allocation of a
code (for example P1). Only the researcher had access to the link between the
identity of the participant and their code. Some of the participant quotes have
been used in the thesis to capture sentences or statements to lend meaning to
themes that have resulted from the research.
3.9.4. Family participants: recruitment of interview subjects
Bereaved families and caregivers involved with a person with MND were
targeted through advertising in MNDAust newsletters (Appendix G) and word of
mouth among the interviewees. A web-based invitation to participate was
posted on the MNDA WA website and incorporated into their monthly newsletter
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(Appendix H). The invitation was advertised twice and included details of the
research project and the expected timeframe, methods of responding to the
researcher if interested in participating and an assurance that participants’
privacy would be protected. As participant numbers were low in Western
Australia, an application was made to the ECU Human Research Ethics
Committee to extend the research via both MND NSW and interested doctors to
disseminate details of the research to bereaved caregivers. Once an interested
caregiver participant contacted the candidate, a letter/email with a Family
Respondent Information Sheet explaining the project (Appendix J) and Informed
Consent Form (Appendix F) containing further information regarding
participants’ involvement was sent to the participant. Entry into the study only
occurred after verbal and written informed consent had been confirmed. The
initial research design did not incorporate people with MND as it was thought
that the candidate’s questions relating to end-of-life decisions may cause
distress. However, a person with MND who was using NIV who wished to
explain and discuss his experiences contacted the candidate and asked to be
included. An amended ethics application and subsequent approval from the
Edith Cowan University Human Research Ethics Committee (ECUHREC) was
obtained (Appendix C). Therefore, one interview was conducted with a person
with MND. These data were used to illuminate and contextualise the two
primary data sets.

A convenient appointment date and time was subsequently organised by
the candidate in response to each potential participant’s initial responding email,
with further communication with the participant via their preferred method of
email or telephone. It was anticipated this invitation would be discussed
between family members and significant others with experience with MND and
NIV who might have wished to participate and share their communication
experience producing a snowball effect. This approach produced one further
family member participant. Within this cohort, there were six respondents and
one person with MND wishing to assist the research.
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3.9.5. Clinician participants profile: initiation of NIV
The first cohort of interview participants were respiratory clinicians,
respiratory nurses and social workers responsible for the conversations
regarding use of NIV and palliative care options, specifically at the time of
commencing NIV when respiratory muscles of the person with MND weaken
causing breathing difficulties (e.g., when NIV is offered to alleviate distressing
symptoms). A gastroenterologist was incorporated into the study and asked the
same set of questions as all the clinicians regarding communication surrounding
gastrostomy tube placement and how this communication related to NIV
commencement. Clinicians from the first group were asked what specific
information they communicated to people with MND about the benefits,
limitations and potential withdrawal of NIV; PEG insertion; when they discussed
the involvement of palliative care and end-of-life choices; and how they made
sure that the information they had given the person with MND and their families,
had been understood. Eight respondents were interviewed in this cohort.

3.9.6. Clinician participants profile: withdrawal of NIV
Clinicians from the second group - palliative care specialists, allied health
(generally as part of an MDT) and nurses involved with palliative care or
neurological nursing - were asked to recall episodes of care for people with
MND where NIV was withdrawn during the terminal phase of the disease. Of
specific interest in relation to this group were their observations and feelings
surrounding the withdrawal of ventilation support in people with MND and how
this affected the caregivers and families. They were asked to reflect on their
perception of the preparedness of families and significant others in relation to
understanding the outcome of withdrawing NIV, even if not directly involved with
the withdrawal. The clinician participants were also asked to reflect on their
feelings the preparation and communication from an MDT had on their capacity
to provide holistic support to the families and significant others at the time of
withdrawal. Any difficulty in people with MND accessing an MDT or palliative
care specialist was noted. Within this cohort of participants there were 11
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respondents interviewed. Two of the first cohort, those responsible for the
initiation of NIV, were also in a team of clinicians responsible for the removal of
NIV; however, only one of the palliative care clinicians had referred a person
with MND for NIV prior to the terminal phase.
3.9.7. Family/caregiver participants profile
Families and significant others, who have lived with a person with a
diagnosis of MND, were asked to recall their experience(s) of the conversations
which may (or may not) have occurred prior to the commencement (or refusal)
of NIV and communication relating to placement of gastrostomy tubes for their
family member diagnosed with MND. They were encouraged to reflect on how
these conversations may (or may not) have prepared them for the outcome
associated with the choice to initiate or not to initiate NIV, the limitations of NIV
as explained to them, end-of-life discussions as they occurred and withdrawal of
NIV at the terminal phase of care. Six bereaved family participants were
interviewed, in one instance a brother and sister interviewed together (F1 and
F2).

3.10. Data Collection: Clinician and Family Participants
Data was obtained using individual semi-structured interviews from the
three groups of respondents outlined above, each of whom were asked to
consider two points in time along the disease trajectory: the first point was when
the respiratory muscles of the person with MND weakened and breathing
became difficult and NIV is offered and the second point was when NIV is
withdrawn. As discussed in Chapter 1, communication relating to PEG
placement and the commencement of NIV are closely linked and are
recommended to occur prior to respiratory distress (NICE, 2016). Therefore,
questions relating to PEG insertion and use were incorporated within the semistructured questions.
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The long, in-depth interviews were recorded with the consent of each
participant and transcribed verbatim by an appointed professional transcriber
(transcription confidentiality agreement: Appendix Q) who identified the
participants by codes known only to the researcher. Statistical analysis and
demographic data were collected and collated: clinician roles, MND years of
experience, whether working within an MDT and familiarity with the most recent
NICE (2016) MND Assessment and Management Guidelines. Four of the
interviews (three clinicians and one family participant) were conducted via
recorded audio/visual SKYPE interviews. There were no interruptions or
disturbances during these interviews and they were all transcribed verbatim.
Both telephone and the face-to-face individual interviews lasted for between 6090 minutes. The interviews were terminated when the participant indicated they
had nothing further to add. A thank you email was sent to each participant
within 24 hours.

In considering the methodology, research questions (Table 3.2.) and
participant semi-structured questions, the research method was developed to
obtain the most accurate and dependable information.
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Table 3. 2. Research Questions and Strategy

Research Question

Strategy and Method

1. In considering the available literature and
guidelines, what are the most salient components of
best practice relating to the communication about NIV
in MND prior to NIV initiation and withdrawal?
2. What is the evidence that the best practice
communication content (benefits and burdens of NIV,
continued disease progression, explanation and offer
of a PEG, end-of-life discussions and understanding
potential NIV withdrawal prior to commencement of
NIV) is incorporated into the reported communication
by clinicians to people with MND and their families at
the time of offering NIV?

Extensive search of published literature through
databases, guidelines and recommendations,
reference lists in published articles and
conference material. Answered in Chapter 2.
Search of Australian and International MND
guidelines relating to MND and symptom control
particularly relating to end-of-life care.

3. What do MND families/significant others recall
about the communication (benefits and burdens,
continued disease progression, PEG insertion,
potential NIV withdrawal and end-of-life discussions)
provided by clinicians at the time of respiratory failure
and the offer of NIV?

Semi-structured interviews including ‘their story’
with families to understand the communication
as heard and understood at the time of
respiratory decline particularly relating to endof-life

Semi-structured interviews with clinicians a) to
understand what, how and when recommended
information is being communicated at the time
of respiratory failure and how clinicians assess
patient understanding of communication and b)
what the clinicians involved at the end-of-life
experience with patient and family
comprehension of prior recommended
communication

Included within this research was a person with
MND describing his experience with
communication
4. To what degree do MND families/significant others
feel that the NIV communication provided by the
clinicians at the time of the offer of NIV prepared them
for and helped them to understand the implications of
potential NIV withdrawal resulting in the death of their
family member?
5. What, if any, unmet needs for information, support,
palliative care, or other services do the clinicians and
the families/significant others (or patients themselves)
with experience of MND identify?
6. Following the literature review and clinician and
family/significant other interviews regarding NIV
communication, what recommendations can be
identified that would improve end-of-life
communication and process for the patients, families
and clinicians involved with the end-of-life care for
people with MND?

Semi-structured interviews with the bereaved
families and caregivers at least 3 months post
death of a person with MND

Suggestions made in answer to an open
question asking participants of their
experiences and recommendations

Reviewing the data and comprehensive
analysing and coding of the interviews to
identify and clarify any recommendations
verbalised by participants. This area of the
study has identified limitations of the research
and areas which may be considered for further
research
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3.10.1. Bracketing and reflexivity
An ability to reflect and be self-aware has assisted the candidate to
minimise researcher bias. By understanding the social, educational, cultural and
personal influences in her own life, a generally more empathetic stance has
been taken on interviewing techniques and analysing data (Patton, 2015).
Personal perspectives and preconceived ideas, where they existed, were put
aside, and the data collected was analysed without prejudice. The researcher
made every attempt to exclude researcher bias by using the method of
“bracketing” (Patton, 2015). This involves a process by which constant reflection
(reflexivity) by the researcher and discussion with university supervisors,
reduces and tries to eliminate any researcher preconceptions. The credibility of
the candidate’s research is inextricably linked to the researcher’s ability to justify
and analyse the evidence without bias.

3.11. Data Handling and Management

3.11.1. Data storage
The digital recordings obtained during the interview phase of this
research were transcribed from the digital recorder and onto the researcher’s
password protected computer which remained locked in the candidate’s home
office. The recorded interview data were erased once transcribed onto the
candidate’s password protected computer. As per NHMRC guidelines, all hard
copy data collected for this project and records of any work associated with this
research have been kept securely locked in a designated area in the student’s
home or at Edith Cowan University retained on the candidate’s password
protected computer. At the completion of the research transcripts and analysis
data will be kept for five years (as per NHMRC (2012) requirements) on an
Edith Cowan University password protected computer which is located inside a
locked office that is in turn located in a swipe card protected area.
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3.12. Data Analysis
Descriptive demographic information was collected for analysis, including
clinicians’ specialisation and experience, whether part of an MDT and the
number of NIV withdrawals and MND deaths the clinicians had been involved
with. The gender and age of the person with MND as stated by the family
participant, and whether the person with MND was seen by an MDT is included
in information for this research. The tabulated data are presented in Table 4.1 in
the discussion chapter of this thesis as an overview of participant demographics
and distribution of specialised services.

Data analysis commenced following the first participant interview, with
relevant and emergent themes noted. The NVivo10 software package was used
to assist this process. All the interviews were de-identified, coded and
transcribed verbatim. The quantifiable raw data were tabulated and are
contained within the results in Chapter 4 (Tables 4.1 and 4.2).
3.12.1. Stage 1 analysis: coding
The first phase of analysis included the identification of codes, or
phrases in the interview transcripts that related to the research questions.
These were colour coded on the printed verbatim transcripts, examples of which
are provided in Table 3.3. and contained within the appendices of this thesis
(Appendix M). These phrases were then extracted and alike codes were
grouped (Stage 2). Several exemplar codes are used to illustrate the findings in
Chapter 4.
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Table 3. 3. Example of first level analysis

Raw data
1) So his wife wanted a definite sign of
when she would stop the PEG fees, if he was
no longer able to communicate. I haven’t
seen the Advance Health Directive, but she
did say there was a special sign that they
would have.

Level 1 codes
1)Hydration and nutrition; discussions
about disease progression and timing of
gastrostomy

2) No. I think there’s very little work done
around AHDs, because there is just not
enough knowledge, experience or time.
3) They really do need to think about
withdrawal of NIV, which I don’t know is
discussed with clients in detail, or if it is
they’re not processing that information. I’m
not involved in any of those discussions, so I
really don’t know what has been said. But
when I have asked if that has been
discussed, people have said, “No.”

2) Advance health directives

3) NIV withdrawal; is this discussed at
the time of commencement of NIV
prognosis and limitations of treatment
included in ongoing honest discussions
timing of end of life discussions.

3.12.2. Stage 2 analysis: sub-categorising
The second phase of analysis involved grouping of alike codes into subcategories. The points at which no new sub-categories were emerging from
participant interview codes was when initial saturation of the data was assumed,
and no further interviews took place once each sub-category was sufficiently
“thick” (representative of the sample). Table 3.4. provides an example of the
sub-categorising second stage of analysis, and additional examples are
provided in Appendices K and L.
Table 3. 4. Example of second level analysis

Codes
1) NIV initiation; is end of life care
discussed at this time
2) NIV benefits, burdens and limitations
discussed including increased dependency
3) NIV withdrawal; is this discussed at
the time of commencement of NIV

Sub-category
1) Family satisfaction with end-of-life
care
2) Other clinicians involved
1) Patient and family understanding
2) Experience of refusal of NIV
1) W ithdrawal experience
2) Tracheostomy as emergency
procedure by ED
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A list of all the sub-categories and categories that emerged from this stage are
provided in Table 3.5. below.

Table 3. 5. Categories and sub-categories included in data analysis

1) Advance health directives
2) Hydration and nutrition; discussions about disease progression and timing of gastrostomy:
hydration
how is this described
3) Multidisciplinary team:
responsibility for overall care
interdisciplinary communication
4) NIV benefits, burdens and limitations discussed including increased dependency
patient and family understanding (NIV): Guideline recommendation (NICE, 2016)
experience of refusal of NIV
5) NIV initiation; is end of life care discussed at this time: Guideline recommendation (NICE,
2016)
other clinicians involved
family satisfaction with end-of-life care
6) NIV withdrawal; is this discussed at the time of commencement of NIV: Guideline
recommendation (NICE, 2016)
prognosis and limitations of treatment included in ongoing honest discussions
timing of end of life discussions
withdrawal experience
tracheostomy as emergency procedure by ED
7) Prognosis and limitations of treatment included in ongoing honest discussions
introduction to palliative care (Symbolic Interactionism: influence and understanding)
ethical dilemma
8) Understanding and obtaining the MND diagnosis family perspective
symptoms of frontotemporal changes
age at diagnosis
9) Timing of end of life discussions
barriers to clear communication
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3.12.3. Stage 3 analysis: categorising
Once all sub-categories were developed and saturated (no new
information found from the interviews), those that resonated with or reflected
with others were collapsed into major categories. Table 3.5 provides the list of
the final major categories and their component sub-categories.

3.13. Trustworthiness

3.13.1. Trustworthiness of the research candidate
The candidate conducting the interviews is an experienced registered
nurse working in palliative care, where sensitive communication and
interviewing of both patients and families is a vital skill. The candidate
understood and had the ability to separate the two roles involved with palliative
care nursing and research interviewing: to be empathetic, reflective and
understanding of the participants’ experiences whilst remaining supportive and
respectful in the researcher role. The researcher had read extensively on
sensitive interviewing techniques and followed appropriate guidelines on
interviewing (Patton, 2015). Of concern, was the potential for participants,
particularly the clinician participants, to supply information thought to be useful
to the researcher’s background as a palliative care nurse. Whilst this may
impede complete data accuracy and transferability, the researcher also
recognised that understanding clinical terminology and a familiarity of clinical
issues may have enabled greater engagement with the participants. To ensure
that data collection and analysis was conducted as objectively as possible and
reflected the research questions, the candidate and her supervisory team had
regular discussions regarding interpretation of the data. To verify the
candidate’s results, independent analysis of a selection of interview transcripts
was conducted by one of her supervisors. Comparing the findings of both the
candidate and the supervisor found the themes to be compatible.
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3.13.2. Research credibility
Guba and Lincoln (1994) suggested four criteria, which if adhered to,
should confirm the rigor of research: credibility, dependability, confirmability and
transferability. The trustworthiness, or credibility, of the research was aided by
clarity of the questions asked of the participants, which were designed to
encourage the participants to describe the conversations surrounding the
initiation, use and ultimate removal of NIV in patients with MND (Streubert &
Carpenter, 2011). The professionally transcribed interviews (Appendix Q) were
returned to the participants to ensure validation and approval for use in the data
analysis and to establish trustworthiness and credibility of the researched
information (Polit, Beck, & Hungler, 2001; Pope & Mays, 2006; Streubert &
Carpenter, 2011). Analysis of a sample of the interviews was undertaken by one
of the candidate’s supervisors post analysis by the researcher, in order to verify
credibility of the results. Data and supporting documentation allow for an audit
trail ensuring dependability of the research. The audit trail includes interview
transcripts, analysis of data, notes relating to the process and any difficulties
encountered with the method, personal notes and all copies of drafts relating to
the final work presented (Guba & Lincoln, 1994; Polit et al., 2001; Pope & Mays,
2006). Confirmability was conferred on the study by an independent reviewer’s
verification of the data analysis decisions and research audit trail. Further
confirmability will be assured by other researchers substantiating the findings as
a result of their own research in the future. Finally, the transferability of the
outcomes of the research is proven through the resonance of the findings with
clinicians from a range of practice contexts through several member-checking
opportunities. These included sharing the finding that communication between
healthcare providers and people with MND can be poor and potentially affect an
individual’s decision for end-of-life care. The finding in this research that families
find multiple healthcare providers to be confusing and to affect their
communication and decisions has been discussed by the candidate in her work
setting with agreement from palliative care patients and families alike.
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3.14. Ethical Considerations

3.14.1. Ethics approvals and considerations
The Human Research Ethics Committee at Edith Cowan University
(ECUHREC) (Number 12099: Appendix B) approved commencement of
participant interviews in June 2015. Subsequently, ethics approvals were
sought from Silver Chain Hospice Nursing (Appendix N), St John of God
Hospital Bunbury and Murdoch, WA (Appendix O) and the Neurological Council
of WA (Appendix P) and granted in mid-2015. Ethics approval from ECUHREC
was further obtained to include data from people with MND who volunteered to
participate after two people diagnosed with MND responded to the
advertisement in the MNDAWA newsletter targeted at bereaved family
members. The participants wished to tell their stories to assist others with MND,
and ethics approval was subsequently granted to allow their experiences to be
heard (Appendix C). Only one of the people with MND was ultimately
interviewed. The second potential MND participant was considered too unwell
and emotionally fragile to participate without the possibility of causing the
participant further adversity. As a means of increasing participant involvement,
subsequent ethics approval was sought and granted from ECU to include
clinicians from New South Wales via snowball effect, word of mouth and email
information between clinicians. All amendments to the original ethics application
to ECU are included in Appendix C.
3.14.2. Ethical considerations: bereaved caregivers
Recalling conversations surrounding the initiation and withdrawal of NIV
may prompt mixed memories for the caregivers, with feelings of sadness, anger
and loss. Consideration was given to the potential for feelings of profound
sadness and grief during the interviews with the bereaved families/significant
others. The candidate was particularly aware of any possible emotional ill
effects the one person with MND who chose to be interviewed for this study
may have suffered. The style of interview differed from the other participants.
The interviewee told his story and was periodically prompted rather than using
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the schedule of semi-structured questions. The interview was conducted at a
pace which suited the participant and finished when indicated by the participant.

The candidate ensured that the person with MND and bereaved family
participants were all clients of the MNDAWA and had access to pastoral and
psychological support as part of the service this organisation provides. While
funding for this service provision is limited until six months after the death of the
person diagnosed with MND, the Association agreed to provide this service to
any bereaved caregiver participants from this research that may be outside the
technically funded bereavement period. All bereaved caregiver participants and
the one person with MND were provided with written information about the
support offered by MNDAWA and support from the more generic support
counselling service offered by Lifeline at the conclusion of the interview. This
was to provide support to those who may have felt inclined to ask for emotional
assistance well after the interview.

The ethical considerations for researching patient-focused palliative care
include its acceptability for patients and families at the end of life, since
participation in research may create further intrusion and distress at such a
difficult time. For people with MND, this ethical predicament may be
compounded by cognitive changes and difficulty with communication particularly
towards the end of life. For the bereaved families, timing of the interviews was
considered and a precedent in published research was sought. In a study which
specifically investigated interviewing bereaved families of MND and cancer
patients, the timing of interviews after the death of their family member was
found to be an individual and crucial factor (Bentley & O'Connor, 2015). Bentley
and O’Connor (2015) found that offering choice in timing of the research
interviews post death of a family member enabled appropriate arrangement to
be made for each individual family and led to their willingness to participate
(Bentley & O'Connor, 2015). Therefore, when considering timing and the need
to be respectful of the grieving process, the bereaved participant interviews for
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this thesis were conducted when the bereaved families contacted the
researcher, but all more than three months post death of their family member.
3.14.3. Ethical considerations: clinician participants
Clinician participants involved with the decline of the respiratory muscles
and the initiation of NIV (respiratory clinicians and allied health), and those
providing end-of-life care to people with MND (palliative care specialists, allied
health practitioners and nurses) were interviewed regarding the content and
timing of the communication surrounding the initiation of NIV in people with
MND and any experience of NIV withdrawal. Whilst this difficult conversation
may include end-of-life and withdrawal of NIV issues, the research questions
specifically related to the clinicians normal practice protocol. Therefore, a low
level of discomfort was anticipated and found in this group. The group of
clinicians specifically responsible for end-of-life and palliative care was
interviewed regarding their experiences relating to MND and the withdrawal of
NIV, including the subsequent death of the patient and the preparedness of the
family/significant other for the outcome. The interviewing of this group of
clinicians was anticipated to elicit varied feelings associated with sadness,
frustration and loss, some of which were captured within the interviews but none
of which caused distress to the participants. All clinician participants were
reminded of their Employer Assistance Programs (free counselling programs
offered by health services) through which participants are offered support and
an opportunity to debrief. All participants were offered written information on
Lifeline, a counselling support service which they were encouraged to access at
their convenience.
3.14.4. Consent
Permission was sought from participants to undertake recorded
interviews and discussions, with consideration to a participant’s state of health
and mind throughout the research. It was emphasised at the commencement of
the research that participants can decide to withdraw from the project at any
time they chose, and that participants’ wellbeing took precedence over the
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research. The participants were supplied with information regarding the
structure and purpose of the research (Appendix J), information on free
counsellor support and examples of the potential questions that may be
included at the recorded interviews (where requested) enabling the participants
to make an informed decision as to whether to participate in the research. The
candidate ensured all participants had signed consent prior to the
commencement of the interview (Appendix F).

Whilst it may be supposed that some unanticipated information may be
forthcoming within the interviews, the participants were reassured they were
under no obligation to proceed with the interview and may stop the discussion
at any time. In this situation, the researcher would re-confirm consent from the
participant as an ongoing process to ensure the willingness of the participant to
participate, particularly if considered to be in a vulnerable condition or situation
(Oliver & Faull, 2013). As the research was obtained from families and
significant others some time post death of a family member with MND, the
information obtained for the research was reliant on the memories and
experiences of the family members, caregivers and clinical team prepared to
participate in the study.

3.15. Section 2 Summary
In Section 2 of this chapter, the method used to recruit the participants
for this research has been explained. The researcher aimed for sufficient
participant representation through an indirect approach to ensure that those
participants who became involved did so completely voluntarily. Therefore, an
advertising and/or word of mouth approach was directed electronically via
websites, newsletters or general information email toward the desired
participant groups. As MND is a rare disease the sample population is limited,
however, the small number of bereaved caregiver participants volunteering for
this research is felt to be usefully representative. Another possible limitation to
the study sampling (further identified and discussed in Chapter 6) may be those
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without electronic information access or those not supported through the
Neurological Nurses (Neurological Council of WA) who snowballed the invitation
to participate in the research through their network of nurses.

The research method of an extensive literature review and in-depth
qualitative interviews has started to address the gap in understanding the
communication which is recommended to occur at the initiation of NIV. This has
been achieved by comparing the findings of this research with the present MND
assessment and treatment recommendations concerning when and what should
be included in clinician communication. The clinician interview information has
been compared with the understandings and recollections of bereaved families
regarding the information given to them relating to their family member when
symptom control measures were discussed, implemented, refused or
withdrawn.

3.16. Chapter Summary
Clear communication is required for people with MND and their families
so they can make informed end-of-life decisions. This chapter has outlined the
method by which this research has undertaken credible and reproducible inquiry
into the communication surrounding NIV by interviewing selected participant
groups involved with MND.

The complexity of the communication recommended (NICE, 2016) to
occur at various trigger points along the MND trajectory by the clinicians, the
link between commencing NIV and its potential withdrawal and death, and the
way in which such communication may be interpreted by those who hear it are
all necessary to consider. The emotional and ethical considerations necessary
to conduct research into the end-of-life options, particularly when considering
removal of NIV, have also been discussed. The theoretical perspective of SI
and the Domains of Influence framework derived from the existing literature on
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the topic of interest are used to present and contextualise the findings of this
thesis in Chapter 4 and discussed more fully in Chapter 5.
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Chapter 4:
Findings
4.1. Chapter Overview
In this chapter, the results from 26 participant interviews is presented in
relationship to the research questions and the NICE MND Assessment and
Management Guidelines (NICE, 2016). Seven major themes emerged from
analysis of the data. These are identified in Section 4.4 of this chapter,
expanded upon throughout the chapter and discussed in Chapter 5.

Quotations from participants are included where relevant to illustrate the
results, and the context of the quotes is explained within the narrative. The
substantial amount of information gathered from the in-depth participant
interviews not only sheds light upon the research questions but provides insight
into a range of associated issues. At times information not directly relating to the
research questions is included where it helps to clarify and broaden the
understanding of end-of-life and NIV communication in MND.

The communication difficulties and factors encountered in relation to the
research questions are discussed under specific headings derived from the
themes identified. The significance of the influences on the participant data
analysis and outcomes identified are further considered in the Chapter 5. This
chapter commences by presenting the background to participants and their
involvement.
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4.2. Background to the Family Participants
The seven family participants (n=7) included a brother and sister
interviewed together (F1, F2), in accordance with their preference. At times the
brother and sister had different recollections on specific issues and different
viewpoints, making the interview particularly useful in providing depth and
perspective. Four other family participants (F3, F4, F5, F6) who had
experienced the death of a family member with MND were interviewed. The
seventh participant (P1) was diagnosed with MND and actively sought
participation. While people with MND were not the target of this study, P1
thought his experiences should be heard to assist others diagnosed with the
disease, and ethics approval was subsequently granted (Appendix C). As P1
was the only person interviewed with MND, his comments have been included
with the bereaved family participants. All the family participants were from
Western Australia (n=7). They were asked a range of questions (Appendix E)
with attention directed toward their understanding of symptom control, end-oflife choices and their involvement with palliative care.

Table 4.1 describes family participants in terms of their level of health
knowledge, use of the Internet for health information, their rural/remote
classification, the primary clinical responsibility for overall care and whether
their care was provided as part of a structured MDT. Health literacy was not the
focus of this study and, therefore, was not formally assessed. However, the
participants themselves acknowledged use of the Internet where they had
access to it, and if they were conversant with health and health systems.
Emphasis was placed on creating a good rapport with participants to help
discuss and understand their experiences.
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Table 4. 1. Family Participant Demographics
Family
Health
Participants knowledge and/or
health information
from internet
F 1/2
No

Regional,
rural
or remote
Regional/rural

Primary
Part of
clinical
structured
responsibility
MDT
for overall care
Unclear: GP
No
and
neurologist
Neurologist in
Yes
association
with GP
GP
No

F3

Yes

Regional

F4

No

Rural

F5

Yes

Remote

GP

No

F6

Yes

Rural

GP

No

P1

No

Regional

Neurologist

Intermittently

Note: General Practitioner (GP), Multidisciplinary team (MDT)

4.3. Background to the Clinical Participants
The clinicians involved in this study were from two cohorts of specialties:
those involved with respiratory decline and symptom intervention (NIV/PEG)
and those involved with palliation and end-of-life care. The two clinician
participant groups were further subdivided into doctors, nurses and allied health
providers. The medical participants included four palliative care specialists, one
rehabilitation specialist, three respiratory specialists and a gastroenterologist.
The nurse participants included four MND/neurological specialist nurses, three
palliative care nurses and a respiratory clinical nurse specialist. The two allied
health participants were a social worker and a respiratory physiotherapist, both
of whom worked with people with MND within an organised MND specific MDT.
At the time of interview, the participants worked in Western Australia (n=8), New
South Wales (n=9) and the United Kingdom (n=2). Table 4.2 shows a summary
of participants, their de-identifying codes and professions. Also included are the
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clinicians’ years of experience working with people with MND and the
percentage of their work involving people with MND. Table 4.1 also shows
whether the clinicians worked in regional, rural or remote areas and whether
they were involved with NIV withdrawal and end-of-life discussions.

There are similarities and differences between clinical specialties
regarding views about when and who should have the discussions about the
initiation and withdrawal of NIV and end-of-life choices. Both clinician cohorts in
this study had experience with the withdrawal of NIV.
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Table 4. 2. Clinician Participant Demographics

Clinician

Specialty

Years (y) of MND
experience
and workload

Involved with
NIV withdrawal
discussions

Regional,
rural or
remote

Palliative Care
Consultant

10+ y
Varies

Yes

C1

Regional and
rural

Palliative Care
Specialist

10 y
Varies

Yes

Regional

C2

17 y
Varies
12 y
Varies

Yes

Regional

C4

Palliative Care
Specialist
Respiratory Specialist

Sometimes

Regional and
rural

C5

Respiratory Specialist

6y
75%

Yes

Regional and
rural

C6

Neurological Nurse

4.5 y
Intermittent
8y
Intermittent

C3

No
Indirectly; when
patient requires
information
Yes

C7

Neurological Nurse

C8

Palliative Care Nurse

C9

Palliative Care Nurse

C10

Palliative Care Nurse

C11

Respiratory Specialist

16 y
Intermittent
14 y
Intermittent
5y
Intermittent
10 y

C12

Physiotherapist

5% of annual work

Yes

C13

Social Worker

Sometimes

C14

MND Clinical Nurse
Specialist

approx. 30 MND pts
ongoing
14 y
Ongoing
Sees 2-4 people with MND
monthly

No

MND Clinical Nurse
Consultant

15 y
Ongoing

Yes

Respiratory Clinical
Nurse Consultant

22 y
Varies

Yes

Rehabilitation MND
Specialist

16 y
approx. 30 MND/year

No

Palliative Care
Consultant

11 y
approx. 30 MND/year

Yes

C15

C16

C17

C18

C19

Gastroenterologist

Regional and
rural
Regional and
rural
Regional

Yes

Regional

Yes

Regional and
rural
Regional and
rural
Regional

Yes

Regional
Yes
Regional

Regional

Regional

Regional

Regional

Regional
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4.4. Themes Identified from the Findings
Seven major themes emerged from analysis of the categories identified
from participant interviews (Chapter 3). Together these were found to
characterise communication between clinicians and people with MND and their
family members/caregivers and are summarised in Table 4.3 below.
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Table 4. 3. Themes and Key Findings
Major Themes Identified

Key Findings

1) Experience of clinicians with end-of-life
communication and NIV withdrawal (4.5 below)

1) Reluctance to communicate end-of-life choices
by the clinicians involved with symptom control
prior to palliative care involvement.
2) Clinicians with longer experience in their field
may be less likely to be fully cognizant with the
most recent recommendations and guidelines.

2)Timing and content of communication about the
benefits and burdens of NIV, PEGs and end-of-life
choices (4.6 below)

1) Many clinicians found the recommended timing
of end-of-life communication unrealistic.
2) Confusion with understanding the benefits
burdens of PEGS and NIV by people with MND
and their families.
3) Palliative care clinicians reported patients often
had end-of-life choices communication too late
and not prior to their involvement.

3)Time allocated for communicating and
discussing end-of-life choices (4.7 below)

1) Respiratory clinicians state they have
insufficient allocated time to communicate end-oflife whilst having to discuss how NIV works and
how to use the device.
2) Respiratory clinicians state because many of
their clients are from the country and they may
only meet them once, they must prioritise the
mechanics of NIV above emotional issues.
3) Time required to recognise FTD in people with
MND and the implications for end-of-life choices.

4) Early referral to palliative care and family
understanding of palliative care (4.8 below)

1) Clinicians reluctant to refer soon after MND
diagnosed.
2) Families overwhelmed by the concept of
palliative care.

5) Communication within a multi-disciplinary team
(4.9 below)

1) Frequent poor communication and differing
opinions between members of MDT. This was
found to be worse where a group of health care
professionals made up a MDT from different areas
and organisations.
2) AHD poorly discussed and documented, and
not re-visited when NIV or PEGS became part of a
person with MNDs symptom control.

6) Patient and family communication and
understanding (4.10 below)

1) People with MND and their families were underprepared for the burdens of NIV, often feeling they
had little choice as to whether to use it or not.
2) Potential withdrawal prior to commencement of
NIV was poorly communicated if at all.

7) Communication barriers from clinician and
family perspective (4.11 below and listed in Table
4.5)

1) Clinicians report patient denial, not wanting to
take away hope and lack of adequate time to have
clear end-of-life communication; clinicians often
wait until asked for information.
2) Family members suggested lack of health
literacy may prevent confidence to ask for
information.
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4.5. Experience of Clinicians with End-of-Life Communication and NIV
Withdrawal
One of the influences on the willingness and capacity to have end-of-life
communication with people with MND identified from the literature review was
years of clinician experience (Blackhall., 2011). All the clinician participants
interviewed had many years of experience with communication surrounding
end-of-life decisions (4.5-22 years), with 12 of the 19 clinicians having had 10
years or more.
Anecdotally, experience with communicating end-of-life choices to
palliative care patients generally enhances a clinician’s ability to sensitively
discuss options of care. Clinical experience in palliative care and respiratory
medicine of the participant clinicians was, therefore, anticipated to facilitate the
difficult discussions (relating to the end of life and the potential withdrawal of
NIV) soon after diagnosis. In relation to MND, however, the experience of
having prior involvement with withdrawal of NIV, an important aspect of MND,
did not always appear to make such communication any easier for the
clinicians. Despite their years of experience, the respiratory clinicians
interviewed expressed the difficulty they encountered in having end-of-life
discussions when offering NIV to ease symptom control; framed by three
participants as giving NIV with one hand and discussing NIV withdrawal and the
end of life with the other (C4, C11, and C12). As C12 said:
C12 (physiotherapist): You’re offering them something that potentially may
treat their symptoms, but then at the same time saying, “Oh, by the way, you
know, let’s also talk about, you know, end of life as well.”

The experiences of clinicians in communicating end-of-life choices and
the potential withdrawal of NIV were relatively limited. The point was also made
by C2 (palliative care doctor) that as MND is such a rare disease, while the
clinician may feel comfortable with withdrawing NIV and having discussions
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associated with withdrawal, the nurses may be lacking in experience and
confidence to do so. This possibility was confirmed by C10 (nurse), who felt the
experience necessary to explain to the patient that NIV could be removed and
that death could follow was beyond her experience. The nurse said she felt
confident to reiterate communication relating to NIV removal only if a specialist
doctor had initiated the conversation. She did, however, feel confident to talk
generally about end-of-life as did the other nurse participants. The palliative
care and neurological nurses interviewed agreed that they felt confident and
able to discuss end-of-life issues and the possibility of NIV withdrawal if the
person with MND had some prior knowledge of the possibility of NIV withdrawal
(C6, C7, C8, C9, C10, C14, C16 and C17). All the nurses stated that they
discussed end-of-life choices despite the difficulties, preferring an approach of
gentle honesty. This is exemplified by the following quote from C8:
C8 (palliative care nurse): But it’s got to be about making sure that things are
said, even if they’re unpalatable. And, you know, there are ways – we’ve all
heard some very, you know, inappropriate ways of breaking bad news and
certainly just being right out there and unemotional, but gentle, is the only way
to go. People will respect that you’ve been honest with them, you know. They
might hate you, but that’s okay, they need to hate someone. Someone has got
to be hated.

All the clinicians were asked if they had been involved with the process
of NIV withdrawal in a person with MND and all except four (C15, C18, C6, and
C7) had been present at least once. Therefore, the experience of being present
at NIV withdrawal, and how the experience had affected the clinicians was
considered potentially relevant to future communication skills surrounding early
end-of-life discussions. Although some clinicians described well controlled and
positive experiences with NIV withdrawal, the experience was not always like
that. Despite the best protocols and recommendations, clinicians reported
difficulty with giving good information when certainty is lacking. Emotionally and
clinically, being able to decide the exact protocol and timing for NIV withdrawal,
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to assess their family dynamics and, most importantly, to maintain comfort until
death, was described by C11:
C11 (respiratory specialist): Bloody awful, because – the when, how,
pharmacotherapy, you know. What do you do? Do you necessarily withdraw
NIV or do you let people die on NIV? … I suspect it’s enormously difficult from
the family’s point of view unless the conversations leading up to it have been
really good and really clear.

C14 also described the difficulties experienced with the emotional
communication involved with NIV withdrawal:
C14 (MND clinical nurse specialist): It’s a conversation that we dread, I think,
to remove it, because the breathing is so essential to stay alive. And there’s no
good or there’s no best timing for it. It really depends on the relationship and the
time that – how much the patient trusts you to talk about it; how much the family
trust you, what you’re telling them actually makes sense, not killing her – killing
your mum. It’s – I think it’s more difficult than talking about stopping the PEG. I
certainly feel that.

This negative clinician experience, which might influence communicating
the potential of withdrawal of NIV in other people with MND, was reiterated by
C8 who, despite not being personally affected, stated that others involved had
been:

C8 (palliative care nurse): A number of staff were really confronted. A number
of staff said they didn’t want to be involved, and so then we set it up for 24
hours later.
A very specific element of clinicians’ experiences of dealing with the emotional
impact of communicating NIV withdrawal was noted by a palliative care
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consultant. C1 highlighted the confusion amongst families and clinicians as to
whether NIV withdrawal is euthanasia:

C1 (palliative care consultant): We had one example in a general hospital
where we had to spend a lot of time with the whole nursing staff, and also the
support afterwards – partly the family, who actually coped quite well, but also
the professionals - and having a debriefing after the instant so that
professionals could say how they were feeling, particularly those who perhaps
had contacted defence organisations or professional organisations and been
given misinformation.
In this research, the years of participants clinical experience did not
appear to make the early (recommended) discussions of NIV withdrawal any
easier or more likely. To the contrary, negative experiences of NIV withdrawal
and knowing the potential difficulties involved both emotionally and ethically
could lead to hesitancy in communicating the information. This research was
unable to ascertain the level of experience or education clinicians require to
enable them to initiate difficult end-of-life communication.

4.6. Timing and Content of Communication about the Benefits and
Burdens of NIV, PEGs and End-of-Life Choices

Clinicians in this study frequently assumed that communication about
NIV withdrawal and the end of life had occurred with the person with MND and
their families prior to their own involvement. The responsibility for the role of
communicating difficult end-of-life choices appeared unclear to the clinicians
and this task was sometimes left to the palliative care clinicians involved late in
the disease process. Whilst some of the clinicians (C7, C8, C14, C16, C19, C1,
and C2) were largely aware of the existence of the NICE MND Management
and Assessment Guidelines published in 2016 and their content regarding MND
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communication and end-of-life choices, the timing of these recommended
discussions was reported to be difficult. Most of the clinician participants felt that
in practice the recommended timing of end-of-life communication was not
always realistic.

Clinicians who initiated NIV stated that they try to commence end-of-life
discussions and the possibility of NIV withdrawal early on (C4, C11 and C12)
but are often faced with hesitancy or denial from the person with MND or their
family, who do not wish to discuss it:
C4 (respiratory specialist): I mean, you’re talking about end-of-life issues,
which many health practitioners are uncomfortable talking about. And then I
would think 20 to 40 to 50 per cent of patients will tend to say, “Well, we don’t
want to talk about that. We’ll think about it when the time comes.” So even
though you may have the best intentions of trying to have all this out in the open
and discussed and documented, it’s not always the case that the patients wish
to discuss it.

The four respiratory clinicians (C11, C12, C4 and C5) said they tried to
ascertain what other specialists had already said to the person with MND, and
two said they would initiate end-of-life discussions if they had not already been
broached (C11, C12). One palliative care consultant considered discussing NIV
withdrawal at the stage at which it was offered to be a logical and important for
transparency. He maintained that this ensured informed consent for
commencing and that clear information about the potential to withdraw NIV was
provided at the same time (C19):

C19 (palliative care consultant): I guess the pros is a very transparent
discussion, isn’t it, that you’re actually, at the time of putting the – sorry, of
starting the machine, the NIV, you’re also talking about the possibility of
withdrawal. I can see the merit of that. I guess on the other hand – I’m just
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thinking of the emotional dimension of that, and I guess that may – I’d have to
think of the sensitivity of that conversation at that time.
C19 also stated that the emotional dimension and sensitivity of that
communication would have to be considered on an individual (person with
MND) basis. C19 was unaware of the guideline recommendation to discuss the
potential withdrawal of NIV prior to the initiation of NIV until interviewed by the
candidate, despite being broadly aware of the MND guidelines.
However, the preservation of hope can underlie a family’s wish to not
discuss the end of life. The following is an account of how one healthcare
professional dealt with the issue:

F3 (family): And then when [person with MND] was, you know, eventually
diagnosed, we – by that stage we’d been reading up on best practice and, you
know, we knew all about the multi-disciplinary team approach, etcetera,
etcetera, etcetera. And [the health care professional’s] response was, “Oh,
you’re not going to need that for a long, long time. And don’t talk to MNDAWA.
They’re way too negative and I’ll see you in a year.”
The nurses interviewed for this study suggested that prior to their
involvement, doctors should initiate communication about the potential of NIV
withdrawal and end-of-life issues. The nurses assumed, but were uncertain, that
this was the case (C6, C7, C10, C14, C16 and C17). This further highlights the
communication issues between groups of healthcare professionals and
between healthcare organisations which is discussed in Section 4.9.

Clinicians found the timing of communication about the end of life and
NIV withdrawal challenging. There was confusion about which healthcare
professional was responsible for the communication and concern that patients
might not be prepared for the conversations. Most of the specialist clinicians
tried to ascertain how much the person with MND and their family knew about
145

the course of the disease and gauged their communication content on the
response.
4.6.1. Communicating the benefits and burdens of NIV
The respiratory clinicians in this study indicated that communicating the
benefits and burdens does not necessarily occur when initiating NIV. There are
several reasons given: too much information all at once, insufficient time,
fatigue of the person with MND and the priority given to necessary technical
aspects of NIV (C4, C11, and C12):

C11 (respiratory specialist): You know, how to set up the mask, how to set up
the machine, how to plug it in, what to do if it leaks, what to do if they get rain
out, what to do if they get this, that and something else. And sometimes a lot of
the attention can be focused on the sort of practicality of the machine, and the
sort of softer, more difficult conversations often get a little bit left to the side.

C12 (physiotherapist): We were going to start them on non-invasive ventilation
and that’s a really difficult time because trying to explain where and what NIV
can and can’t do, but also the other longer-term implications. It’s a little bit hard
to talk about deterioration and death and dying when it’s the first time you’ve
ever seen a patient. You’re throwing a machine at them, potentially – or at least
trying to get them started on it because you’ve probably got two days before
they go back to the country.

Some of the burdens mentioned by the respiratory specialists and
neurological and MND nurses involved with the support of country people with
MND were the practicalities of obtaining an NIV machine, battery backup and
emergency planning for that eventuality (C6, C7 and C11). The practicalities of
NIV may become overwhelming for the families if not adequately explained and
if emergency backup plans have not been formulated. The family participants
F1 and F2 supported the importance of contingency planning:
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F1 (family): And then if something went wrong with the machine, Dad would
ring me. I’d go to their place and then I’d try and work it out and if I couldn’t I’d
ring [the hospital], and often they couldn’t really answer my questions. So, the
technical back-up of that was really difficult. If it didn’t work I ended up finding a
chemist around here that dealt with BiPAP machines and stuff like that, so we
could get new parts … Finding the filters was something I had to research, so
finding replacement filters. And if something – it wasn’t really discussed if it
broke down or anything like that.

C6 discussed the issue that some people with MND had a backup plan of
going to a hospital with their NIV in the event of a power cut and that this was a
huge worry for the families. The initial cost of the machine appeared to depend
on whether the person with MND had health insurance cover, which clinic they
were linked with, and where they happened to live (C6, C11). The point was
made by C11 and C12 that as referral to them was often late in the disease they
had to condense vital information regarding the use of NIV to fit within the brief
time available before the person returned to the country.

One of the clinicians (C14) mentioned hospital admission would be
necessary should withdrawal of NIV be considered, which, as reported by C6,
could be very upsetting for the person who wished to die at home:
C6 (neurological nurse): The lady that couldn’t tolerate NIV, when she was
going on it, was very clear that she wanted to die at home, and it was explained
to her by the doctor that that would not happen if she was on NIV and had it
withdrawn; it would have to be done in hospital, which was very upsetting. It
didn’t eventuate, but I know that caused a lot of stress for the family.

Increased dependency on family support and caregiver strain was
mentioned as a burden of commencing NIV (C5, C11 and C2) and its long-term
use, as the person with MND is less able to adjust the mask or take it off:
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C11 (respiratory specialist): And I upfront say that, you know, “As this disease
progresses, that more and more the burden of actually putting it on and actually
making it go falls more and more on the carer as people lose the dexterity in
their upper limbs.” And that, you know, that’s something that they need to know
about upfront.

The possible benefit of improving survival with the use of NIV was
questioned by some of the clinicians who made the point that there was only
one study published (at the time of the interview) (Rafiq, Proctor, McDermott, &
Shaw, 2012). However, as added by one of the respiratory specialists:

C11 (respiratory specialist): it depends a bit on how savvy the patient is and
how good they are at understanding the idea of a survival benefit, because I
think that there probably is. But I won’t use that to push people into having NIV.

Therefore, some clinicians did not say anything about increased survival (C12,
C18), however, some respiratory clinicians did discuss improved survival as a
benefit of using NIV with their patients (C11, C14, C5):
C11 (respiratory specialist): If they’re saying, you know, “No, I don’t want it,”
I will, you know, make some sort of allusion to the idea that there might be a
survival benefit and if they want to chase it, I’ll talk about how there probably is,
but, you know, for some people surviving longer with a progressive neurological
disease may not be a benefit, in fact, and may be more of a burden.

All the clinician participants interviewed stated that they communicated
that NIV would not stop the progression of the disease, and that the person with
MND would become more dependent on it. The community nurses reiterated
dependency and disease progression, and all the bereaved family participants
and the person with MND agreed they were fully informed about this and
understood the continuation of disease progression despite the use of NIV.
However, a few of the family participants recall being told of the practical
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burdens of NIV: issues of skin tears, particularly on the bridge of the nose;
feelings of claustrophobia from the mask; and increased dependency on
caregivers to adjust or remove the mask as muscle movement becomes more
difficult (F1, F2, F5, P1). This may have been due to professional caregivers’
views of NIV, as a comment from one of the clinicians suggests:
C18 (rehabilitation specialist): But, you know, I’m actually in favour of it [NIV],
so I don’t tend to talk too negatively about it.

As previously stated, the respiratory specialist participants in this study,
whilst acknowledging the guideline recommendation of communicating the
benefits and burdens of NIV and potential of NIV withdrawal prior to NIV
commencement, had difficulty discussing those sensitive issues in practice:
C17 (respiratory nurse consultant): I mean, you can’t give the patients – if
you told them every problem that might occur in the next four years they’d go,
“I’m not using that.” Do you know what I mean?
Some of the clinicians involved at the time of respiratory failure and
distress were honest in their admission that the “lack of hope” end-of-life
discussions relating to possible withdrawal of NIV meant that these discussions
were left to the palliative care service to address later (C18, C4). Some
clinicians, whilst accepting that palliative care should be involved from the time
of diagnosis, did not acknowledge NIV as palliative care symptom control nor
explain it in such a way to the person with MND (C18, C16, C17, and C14).
Virtually all the clinicians involved with initiation of NIV felt that as NIV may
relieve much respiratory distress and had the potential to prolong life, it should
be encouraged (C5, C4). However, C11 made the point that the potential to
increase life with NIV was not always a good thing, as a longer life may equate
to longer suffering. There was some uncertainty from clinicians relating to NIV
use, who generally confirmed its usefulness but admitted it did not suit everyone
(C19, C11, C4 and C12):
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C4 (respiratory specialist): … and, you know, we talk about length of life
versus of quality of life. We say that – I’ve no doubt in certain circumstances
non-invasive ventilation can extend the life of some people with motor neuron
disease, but that has to be balanced against quality of life.

Prolonging life and hope were considered important to the clinicians and
influenced their decisions to discuss NIV withdrawal potential and end-of-life
choices. However, prolonging life (and possible suffering) was not always a
priority of the person with MND and their family (F1, F2, and F6). None of the
bereaved family participants said that the potential of prolonging life in the
context of possible suffering was alluded to or discussed. However, thinking
retrospectively, some of the bereaved family participants said that their family
member did suffer as a consequence of their lack of understanding that the NIV
could be withdrawn, as stated by F1 and F2:
F2 (family): Just get this thing [NIV] off. I just – maybe she was thinking, “I just
want to go. I’ve had enough.”

F1 (family): I think now, I would have opted for that option [NIV withdrawal]
because Mum was so uncomfortable and so suffering that I would have opted to
say, “Let’s, you know, ditch that, and let’s, you know” – and I think now Dad
would have taken that option. But from what we knew, and what we – while we
were going through it, I don’t think we would have done any different to what we
did do. But do you know what I mean, hindsight’s a wonderful thing . . .
I regret – and you can use that as a quote if you want – but I regret the last
three nights that mum had at home. It was awful for her, for dad, for me. It was
just – still burned in my memory, and it’s hard to sort of go away.’

The difficulties with NIV and the discomfort of a mask caused ongoing suffering
for some people with MND, as illustrated by F1 describing her family member
coping with the NIV mask towards the end of her life:
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F1 (family): … putting it [NIV] on, pulling it off, and putting it on, and she was
trying to stand up and sit down, and she was just all over the place. And I just
said to her, “Look” – I was in tears, and I just said, “I can’t do this again. We
need somebody that knows what to do for you to have you [referring to the
hospice].”

Some of the respiratory clinicians stated that they provided the person
with MND information regarding withdrawal at the time of offering the NIV (C5),
however, this doesn’t seem to have occurred for F1 and F2’s family. All the
respiratory clinicians stated they tried to gauge whether the person was ready to
engage with end-of-life discussions and intended to provide withdrawal
information if appropriate, time allowed and the person with MND was not too
fatigued (C11, C12, and C4).

In summary, this research has found that the family participants did not
understand the benefits and burdens of symptom control and any potential lifeextension in relation to possible prolonged suffering. Most of the clinician
participants stated that they try to discuss the benefits and burdens of symptom
control measures, but that generally the benefits, rather than the burdens, of
symptom control are more the focus of discussions.
4.6.2. Communication at end-of-life trigger points
Patient deterioration or implementation of symptom control measures
such as NIV or PEGs are also times when end-of-life discussions are
recommended to occur (NICE, 2016). Clinician participants of both cohorts
(palliative care and respiratory) were asked when they commenced end-of-life
communication and whether there were any trigger points used as openings for
such discussions.

The respiratory clinicians varied in their responses. C5 involved the
palliative care specialist at the initiation of NIV and stated that whilst some
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discussion was presumed to have occurred prior to the respiratory specialist
involvement, it was certainly reiterated by C5 at that time:

C5 (respiratory specialist): End-of-life information is provided on the first
outpatient visit. We do discuss this in great detail during the subsequent clinic
visits … through the regular reviews we do make them fully aware of the
prognosis and the limitations of treatment and the likely outcome of treatment
strategies.

Respiratory clinicians C11, C12, and C4 and the social worker, C13, stated that
they tried to ascertain how much the person with MND understood about their
disease whenever they met them and were guided by the person as to how
much information they wanted rather than waiting for recommended trigger
points and proceeding regardless of the patient’s preference:
C11 (respiratory specialist): Okay, you know, if you’re going to have – I kind
of – as a respiratory physician it depends a little bit on who the neurologist that
I’m working with is and how much they’ve done already.

C12 (physiotherapist): I guess the patient that we hate to see the most if
sometimes we get outside referrals from – not from the MND clinic ****, but
they’re being sent to us by another respiratory physician or elsewhere, and
these patients are extremely end-stage there. It’s the first time we’ve ever seen
them.

The respiratory clinicians all stated how difficult it was to have discussions
about the end of life when initiating symptom relief with NIV, suggesting that
those discussions may not always occur as recommended (C12):
C12 (physiotherapist): That’s a really difficult conversation because it’s – one
of the things we’ve found is that non-invasive ventilation is sometimes used as –
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almost as the end point. So, people will offer it, but then not talk about the
limitations of that therapy … you’re offering them something that potentially may
treat their symptoms, but then at the same time saying, “Oh, by the way, you
know, let’s also talk about, you know, end of life as well.”
The gastroenterologist (C15) interviewed stated that he was generally not
involved with discussions relating to end-of-life:

C15 (gastroenterologist): If I get a sense that prognosis has yet to be
discussed, or they don’t know, then I often don’t go down that path unless it’s
necessary for my care, only because I think the person – the team that I guess
is going to be most responsible in coordinating this person’s care should be
having that discussion rather than an external specialist they may only see
once.
The community palliative care nurses all said they commenced end-of-life
discussions at admission to their service (C8, C9 and C10) whilst the
neurological nurses (C6, C7) who were involved earlier in the disease process,
said they were open to end-of-life discussions as soon as they were involved
and particularly when they recognised deterioration within the person with MND.
The two MND specialist nurses (C14 and C16) both said that they commenced
symptom control and end-of-life discussions soon after diagnosis. C4 and C16
felt able to discuss NIV and PEGs as a positive method of controlling
symptoms, and explained end-of-life choices particularly to alleviate any fear of
a frightening, choking death:

C4 (respiratory specialist): So, yes, I do indicate that PEG tube feeding may
prolong life by that mechanism but make it very clear that again that’s not a cure
for motor neurone disease; ultimately it’s not going to change the outcome.

The palliative care clinicians acknowledged they were generally involved
late in the disease process so tended to reiterate rather than initiate such
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discussions. The palliative care clinicians made the point that end-of-life
discussions when the patient was first introduced to palliative care may not be
an acceptable initial conversation to have, and that, while discussions were
patient-led, they did prompt the discussions as the person physically declined
(C3, C2, C1, and C19). Despite the NICE (2016) guidelines and the European
guidelines on the clinical management of amyotrophic lateral sclerosis
(Andersen et al., 2012) recommending various trigger points for end-of-life
communication to occur, one clinician did not see NIV initiation as one of those
trigger points (C18). Instead, the clinician felt it was a stage a person with MND
had to go through, and not a trigger for considering the end of life:
C18 (rehabilitation specialist): I don’t actually see that as end of life. I just see
that as a stage in their illness that they all seem to go through. So, I’ve never
actually considered non-invasive ventilatory support as a trigger for end of life
[discussions].
In addition to being asked if there were any trigger points in MND that
would initiate end-of-life communication, the clinicians were asked by the
interviewer if end-of-life choices of care were initiated when NIV was offered:
C19 (palliative care consultant): It’s a good question. I may not necessarily
bring the two together. I think at the beginning with the NIV I’m mainly focusing
on the fact that, “I’m concerned about your breathing” – sorry, “concerned about
your respiratory function. You’re having the NIV and I want to see how you’re
feeling with that.” I may not necessarily at that time, right at the beginning,
embark on a conversation about what might happen if – I guess if the future
were to be that there was a discussion about withdrawing from NIV. So, I may
not have that right at the beginning.
One of the nurses suggested that clinicians avoid the difficult end-of-life
communication, fearing the effect the conversation may have on their patients
and families:
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C8 (palliative care nurse): I think health professionals’ fear addressing those
issues [end-of-life choices], and the response that they might get from the
clients and the caregivers raising those issues.

In summary, the communication guideline recommendations are
generally adopted by clinicians in a manner which supports their patients and
are considered the best by the individual delivering the communication, but not
necessarily as the guidelines recommend (NICE, 2016). Some of the clinician
participants in this research focussed on the positives surrounding symptom
control rather than any prolonged suffering that may occur. The palliative care
specialists stated that they often had to clearly point out, and belatedly discuss,
end-of-life options which had not been triggered earlier in the disease process.
4.6.3. Communicating prognosis
Within the NICE MND Assessment and Recommendation Guidelines
(NICE, 2016) it is proposed that the person with MND can expect to understand
their prognosis from early diagnosis. The clinician participants were asked if
they included the prognosis within early communication with the person with
MND and their family. All the clinicians considered that giving the prognosis as
length of survival was difficult; all said that if asked for a prognosis by the
person with MND, their answer was not reflective of the course of the disease
but rather an attempt to ascribe a survival time factor:
C19 (palliative care specialist): I do say – and I couple that with the fact that,
“We don’t know how long you’ll have to live; that a prognosis is difficult to know,
and that we will do our very best to support you and keep you comfortable
through this whole process.”
There appears to be an unchecked assumption about what patients and
a family want to know when asking for a prognosis; for example, they may have
requested a description of the course of the disease rather than merely an
estimate of time until death. Family member participants F1, F2, F4 and F5
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described having been unclear of the specifics of MND when interviewed, or of
which symptoms to look out for that may have been responsive to intervention,
despite using the Internet for information.

All the clinician participants made the point that with the Internet so readily
available, people with MND and their caregivers either had already researched
or could have obtained information prior to their (clinician) involvement:

C1 (palliative care consultant): Some are [well informed]. Some are very
much ahead. Some may have read a lot on the Internet. Some may have read
some awful things on the internet.
C18 (rehabilitation specialist): And, you know, in the days of – living in the
days of Google and Internet they’re not restricted to doctors’ opinions and – you
know, these people have all been on the Net before they come to us. And I
think they’ve formed a pretty strong opinion about where they’re heading.
Table 4.3 indicates the types of communication family participants had
with clinicians prior to the offer or commencement of NIV. Specifically, the
benefits and burdens, end-of-life options, PEG insertion and at what stage of
the disease palliative care referral was recommended. The table also shows
whether the family participants interviewed had AHDs in place and whether
these had been formalised with their clinicians.

This research questioned whether the clinician participants discussed
prognosis with their patients. All the clinicians stated that they did but could not
give definitive timelines. Prognosis was not discussed in terms of how the
disease may progress or what the person with MND could expect to experience.
Throughout the course of the disease, only two families stated that they fully
understood the end-of-life care options (F3, F6).
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Table 4. 4. Family Communication with Clinician Pre-Commencement of NIV
Family
Participant

AHDs
formalised

Benefits
and
Burdens of
NIV
discussed

Increased
use of
NIV
discussed

End-of-life
options
discussed

F 1/2

Discussed
between
family
members.

Yes,
although
some
confusion

Not fully
understood
until
palliative
care
involved

F3

Yes, and
discussed
within
family
No, but
wishes
known by
husband

Not
physical
problems;
some
mechanical
issues
discussed
Yes, and
researched
on internet

Yes

Very late
and then
NIV
refused by
person with
MND

F4

F5

F6

P1

No, but
wishes
known by
family.
Yes, with
GP

Family
discussed
and
organised

Palliative
care
referral
and
options
discussed
Late in
disease
trajectory

PEG
insertion:
timing and
discussions

Yes

Yes

Yes, prerespiratory
problems

N/A

Too late;
patient
already in
palliative
care

Late in
disease
trajectory

No

No

No

patient
and wife
in denial

Yes: but
emphasis
on machine
mechanics
and sorting
out costs
No

Yes

Yes

Yes

Yes

Late in
disease

Late in
disease

Recommen
ded by GP;
patient
pulled PEG
out;
hospital
reinserted
Yes; prior
to
respiratory
distress
Initially
refused but
agreed RIG
later when
swallow
affected
Yes, but
unsure
when?

Pushed by
clinicians
but refused
by person
with MND

4.6.4. Delivering the diagnosis
Research participants were not directly asked how the MND diagnosis
was delivered to the family, however, several of the family participants
volunteered this information. One of the main causes of distress was the way
the MND diagnosis was delivered by the specialists (F1, F3, F5 and F6). F1
describes the situation where various tests had been performed on her family
member and the specialist phoned F1 to arrange an appointment for the
following day. F1 asked whether they now had a diagnosis and was told that
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they had, but the specialist told F1 that he would not discuss it over the phone
but would “deliver the news face-to-face tomorrow”. This caused much anxiety,
as F1 felt that had she known the diagnosis of MND she could have prepared
herself and prepared relevant questions:

F1 (family): Yes, I was quite frustrated when I was talking to him on the phone,
because I was – I knew I was going to get bad news. I just wanted to have that
so that I could research it before I spoke to Mum and Dad.

This point was confirmed when the family received the news, but it did not really
register on them until some 15 minutes later. Apparently, the person with MND
was only able to write on a white board at that time, and wrote:
F1 (family): “Is there a cure?” And he [doctor] said, “I’m afraid there’s not.” And
she said, “How long do I have to live?”

Unlike the experience of F3, the unexpected diagnosis of MND for the partner of
F5 was delivered by phone. F5 and the family member receiving the diagnosis
of MND stated they had little idea of what MND was:
F5 (family): No. [person with MND] did, because he – after we got rung up on
the phone, he did, you know, Dr Google.

The experience of F3 when receiving the diagnosis of her family member was
equally confusing:
F3 (family): Oh, yeah, initial diagnosis discussions. That was horrendous. …
So we were referred to a neurologist who will remain nameless. The first
appointment we had with him was in early July of 2011. He told us at that
meeting, “Well, either it’s bad, and I can help you, or it’s very bad and I can’t.”
And our immediate reaction is panic. You know, “Please tell us more.” “Oh, no, I
don’t want to worry you.”
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F4 described how his family member had become progressively
emotional (crying often) and developed slurred speech. Eventually, and after
the affected person had seen a neurologist, the family was referred to an ear,
nose and throat specialist for a speech impediment and it was he who
recognised fasciculation (quivering) of the tongue and diagnosed MND.

The family participant involved with F6 described how her family member
had various investigations including an MRI (Magnetic Resonance Imaging) the
results of which apparently showed no abnormality. At a later date the MRI was
reviewed by another specialist who found reportable changes. That the changes
had not been recognised earlier was quite distressing for the person concerned
and the family. F6 went on to say that the diagnosis was then confirmed many
times by various means which to the family seemed “ridiculous”:
F6 (family): So, you know, there was about a consultant and three neurologists
that they’d seen, and they all had a reconfirmation of diagnosis. So, it got a bit
beyond a joke, for want of some other words, to be told this.
The person with MND interviewed for this study (P1) described how he
was referred to a neurologist who, despite fasciculation being present in his
lower legs, did not perform an MRI. Instead the neurologist believed that the
fact that P1 had Type 2 diabetes explained the clinical manifestations. Ten
years later the fasciculations were in P1’s upper legs so he sought a further
neurological opinion. Again, he was told the issue was not MND. The partner of
P1 explained to the neurologist that P1 was often “quite violent in bed” with
uncontrolled movements:

P1 (person with MND): Uncontrolled movement. So, his suggestion was that
we sleep in separate beds. That didn’t go down very well with either [partner] or
myself. [Partner didn’t ask to go in. He [doctor] invited her in, and he was really
quite rude to her [partner].
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Inappropriate communication by doctors as illustrated by the dialogue
above (P1) was raised again by F6. This encounter involved a doctor who had
stood beside her family member’s bed and, because the number of bed days
allocated in an acute setting depends on a person’s condition, proceeded to
discuss aged care facilities:
F6 (family): … doctor, was very inappropriate about discussions over Mum’s
bed, like it’s that not including the client as such, to say that “she would need to
be out of here in a nursing home.” And that was particularly upsetting for Mum
and Dad.

Given that there is no specific diagnostic test for MND, diagnosis can be
arduous and protracted. However, frustration was voiced by families that MND
was not considered earlier in the illness as a potential diagnosis and the person
affected was not sent to see a neurologist. For example, F1 and F2 describe
how their family member had post anaesthetic respiratory difficulties relating to
an operation followed by heavy mucous secretions. Apparently, the person with
MND went to see at least three specialists (unsure which specialties) over
approximately 12 months who all stated there was nothing wrong. Finally, their
family member, already at the stage of losing her voice, saw a sleep specialist
who referred the person to a neurologist. As the consequences are so
devastating, it is understandable that clinicians want to undertake various tests
to ensure the correct diagnosis. However, this research has found that the way
the diagnosis has been given to the family participants caused considerable
distress and had implications for patient and family readiness to discuss end-oflife symptom control.
4.6.5. Communicating end-of-life options into NIV initiation
discussions
Many of the clinicians in this study, despite their years of experience,
found it extremely difficult to uphold the recommendation that discussion of the
potential for withdrawal of NIV occurs at the time of the offer or prior to the
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initiation of NIV (NICE, 2016). The priorities for symptom control and end-of-life
care in a person with MND may not be consistent with the clinician’s care aims
and preferences, so clear dialogue between health professional and patient is
essential. Whilst MND is a disease that progresses relentlessly, some symptom
relieving therapies may offer a short extension of life; NIV is one of those
therapies. However, prolonging life may not be the ultimate aim of people with
MND and any prolongation may be considered by them as an extension of their
suffering:
F2 (family): They talked about the end of life, but they [specialists] didn’t talk
about the fact that, you know, they [person with MND] might … be getting
confused and not be able to make the decision in the end.

Therefore, early understanding of and an agreement about end-of-life care
priorities and preferences is recommended to occur soon after diagnosis, and
especially when there is a deterioration of symptoms (Andersen et al., 2012;
Borasio, Voltz, et al., 2001; NICE, 2016).
4.6.6. Withdrawal of NIV communication: ethical and legal concerns

Most of the clinicians interviewed reported controlled experiences with
the withdrawal of NIV, generally undertaken within the comfort and security of
the family home with the full support of family members (C8, C9, C1, C2, C4,
and C19). However, there were some experiences that were not so controlled
and which, because of this, caused distress both to the clinicians and the
families. One of the nurses detailed an experience of when she had been
requested to remove NIV by a doctor without any discussion or contextual
information. Although she was in a hospital situation she felt unsupported and
unprepared for the outcome (C10). The nurse concerned refused to comply with
the request to remove the NIV, believing that this was outside her scope of
practice. The doctor making the request eventually came to sedate the patient
and remove the NIV. A concern expressed by one of the palliative care
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specialists was the ethical side of withdrawing NIV, and that communication had
to be very clear to prevent the person’s family misunderstanding and
experiencing the process as euthanasia rather than a person declining further
treatment (C1, C17):
C1 (palliative care consultant): It’s talking about end of life, which no-one
wants to do. Often people don’t want to hear. It’s talking about these quite
complicated ethical decisions, and certainly [in the U.K.] ethical education is
pretty minimal in medical, I think, and in nursing. So, people haven’t got a
background.

The importance of all members of a family understanding their family
member’s end-of-life choice in refusing ongoing symptom treatment was
emphasised by many of the clinician participants.

C2 (palliative care specialist): I guess the other difficulty that I worry about is
conflict within the family and if someone comes back later and says, “What were
you doing?” And support for the team, you know? Clearly this is a big deal for
any palliative care team to undertake at home.

C11 (respiratory specialist): I suspect it’s enormously difficult from the family’s
point of view unless the conversations leading up to it [NIV withdrawal] have
been really good and really clear.

As well as the ethical considerations, C5 highlighted the importance of
understanding the legalities and policies concerned with NIV withdrawal to
prevent emotional and lasting psychological issues particularly for the health
professionals and family members. The fear that unclear communication may
lead a bereaved family member to carry the scars of perceiving NIV withdrawal
as killing was expressed by one experienced MND nurse (C14), who had in fact
experienced this situation.
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Ideally the explanation that NIV can be stopped at any time, and that
medications can be used to alleviate any symptoms that may occur, should be
part of the initial NIV communication. Questions that may continue to worry a
person with MND can be answered and reiterated as the disease progresses,
hopefully reducing psychological stress. One of the palliative care specialists
(C13) made the point that it is difficult to know what amount of information is
sufficient regarding the removal of NIV, as it depends so much on the stage of
disease acceptance of the diagnosed person. Uncertainty around how or when
death may occur for each individual poses an additional barrier for the clinician
considering when to initiate such conversations (C13, C4):

C13 (social worker): The barrier is where they have enough information about
“if I take it [NIV mask] off” and where they’re at, at what stage they’re at, “Am I
going to die straight away and how is that going to be, and what symptoms am I
going to have, and will I be able to cope with them,” and so forth.

The concern of providing symptom relief with NIV and later in the same
conversation discussing the option of taking the NIV mask off when it was no
longer useful was dreaded by some clinicians (C4, C1).

The idea of killing, or being perceived to kill, with the withdrawal of NIV
was mentioned as a barrier (Table 4.4) to communicating withdrawal (C14).
C11 thought that the death-defying culture in which we live was a
communication barrier to discussing the end of life at the time of NIV initiation.
This was reinforced by C11 who, whilst acknowledging that the clinical
guidelines were a good idea in theory, felt that the real world frequently forced
their hand. C12 stated that some people who were symptomatically ready to
commence NIV were psychologically unprepared for the recommended
communication surrounding NIV withdrawal and the end of life. Such patients
would halt conversations relating to the end of life which were upsetting for
them (C6, C7, C8, C10, C4, and C12). One palliative care specialist (C3)
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confirmed that the potential of withdrawal of NIV and end-of-life choices are not
discussed often enough at the point when NIV is started. The specialist added
that this meant decisions relating to treatment choices were sometimes too late
to be useful.
4.6.7. PEGs as a symptom control measure
The discussions surrounding the potential usefulness of a PEG tube and
the explanation of the need for insertion prior to respiratory failure is a
recommendation of current MND guidelines (Andersen et al., 2012; NICE,
2016). It is recommended that communication about this occurs soon after
diagnosis and certainly when symptom control measures including NIV are first
offered. However, some of the clinicians felt that communicating the benefits
and burdens of PEG tubes and whether they had the potential to prolong life
was inadequately explained (C2, C3, and C5):

C3 (palliative care specialist): Just touching on PEG tubes again, I think
they’re often sold to people as more of a solution than they are, and I don’t think
the difficulties of PEG tubes are adequately communicated: the risks of leakage,
the risk of infection and the risk of aspiration. So, I think, you know, they’re kind
of seen as an easy option when someone can’t swallow, and the reality of
dealing with the other side of it isn’t always discussed as well.
C12 suggested that some people with MND and their families were
unsure why they had been sent to a respiratory specialist prior to insertion of a
PEG. They were also unsure if they wanted one and concerned they were being
“pushed” in that direction by well-meaning clinicians. In a discussion about PEG
insertion, one gastroenterologist stated:

C15 (gastroenterologist): [Clinicians are] always tempted, too tempted, to
make value judgments about quality [of life] on behalf of other people and we
really don’t have the right to.
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Further, PEG use appeared to be commonly described by clinicians to
patients and families in the context of potential increased survival, but the
potential of increased suffering appears to be less well addressed, if at all (C8,
C16). C19 and C17 did say that in some circumstances they would describe
survival in the context of suffering, particularly if the person had MND with
frontotemporal involvement (in which case C19 did not mention PEGs at all) or
older onset of MND.
C19 (palliative care consultant): The group that I don’t go down the PEG line
at all is – and I don’t know whether this is just me, but I don’t do it with the
frontotemporal group. I just avoid that now. Sometimes that can be an open
question, “Why aren’t you speaking about it?” But I guess I’m just concerned –
two things, one if the dementia – if the behavioural story becomes more difficult
and the person’s now pulling at their PEG or RIG, and second is really is this
the appropriate thing to be doing that may extend someone’s life?

The benefits and burdens of PEG tubes are often inadequately
discussed by clinicians leading to misunderstanding by the families. This
research could not clearly ascertain if this was confusion on behalf of some of
the clinicians who then passed on misinformation to the patients, or as C2
proposes:

C2 (palliative care specialist): I think that the discussions around PEG tubes
are done poorly, and the number of well-meaning people who think that they
can prevent aspiration, whereas clearly that’s not true, whereas if you ask
nearly all of my patients why their PEG tube was inserted they tell me it was to
prevent aspiration pneumonia, which is clearly not true, but it’s the myth that’s
out there.

The understanding that a PEG tube will not alleviate the risk of aspiration
was a point brought up by respiratory clinicians (RS1 and RS2) and the
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gastroenterologist (RS5) interviewed for this study. All these clinicians said that
this was frequently misunderstood by patients. Some of the families of people
with MND were confused about the timing of PEG being offered, particularly as
PEGs were encouraged prior to the appearance of symptoms that they might
relieve (swallowing difficulties and inadequate nutrition), or symptoms which
may prevent insertion of the PEG (respiratory insufficiency as an increased
anaesthetic risk). According to (F5):
F5 (family): I’m pretty sure we were never told to make a decision about
wanting to have a PEG, because the symptoms weren’t even slight at the
beginning.

The respiratory clinician C12 made the point that some families and people with
MND may not understand the potential of PEG tubes and may feel pressured by
clinicians, particularly if they were asymptomatic:
C12 (physiotherapist): “Gee, everybody’s been at them at the PEG, and we’ve
blundered in and said exactly the same thing, and, you know, making them feel
as though, you know, maybe they’re being pushed down a pathway that they
don’t want to go.” I think that’s really – you know, that’s not fair on them.

Whilst the insertion of a PEG tube is recommended prior to the
respiratory muscles decreasing in efficiency and the time at which NIV is
offered, communication of the benefits and burdens of both symptom control
methods are recommended early in the course of the disease. The aim was
generally to get a PEG inserted prior to weakening of the respiratory muscles,
at which point an anaesthetic would be too dangerous:
F5 (family): Yeah, but I only learnt by reading myself, I’m pretty sure, that the
PEG would have had to go in.
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F1 and F2 stated that their family member with MND was offered a PEG but it
was apparently too much of an anaesthetic risk by that time. Neither F1 nor F2
were sure if a PEG had been mentioned before then. None of the family
participants or the person with MND interviewed recall being told of the risks of
aspiration with a PEG or the possibility of infection. The dialogue below
indicates that one family, despite their good health literacy, thought (incorrectly)
the insertion of a PEG would improve the risk of aspiration:

F6 (family): She did, yeah, so in February, because of the distress caused by
choking on food and fluids. And because Dad was her main carer – Mum’s main
carer – he, I feel, probably more strongly advocated for it, because of the
distress on him as well in managing the choking with the aspiration.

Both C3 and C15 brought up the point that patient and family
understanding of medical complexities relating to NIV and PEG tubes need a
degree of health literacy. For example, the understanding that a PEG tube may
be offered and need to be inserted prior to any obvious swallowing difficulties in
a person with MND because of the risk that respiratory decline can make the
PEG insertion a significant anaesthetic risk:
C15 (gastroenterologist): And perhaps that’s health literacy, perhaps that’s my
fault for not explaining it clearly enough. But, yeah, I mean, I guess it’s a barrier
in terms of understanding the complexities of why they might need it earlier than
the need to use it; that is, if their respiratory involvement, or their respiratory
disease, is mild, but definitely present, but they’re swallowing beautifully at the
moment, the idea of putting in a PEG now for the future – even though you don’t
need to use it now – can be difficult to get across.
Family member F5 indicated that their understanding of PEG tubes was
due to their own investigation and that not one health professional indicated that
it would have to be fitted prior to respiratory muscle loss. Conversely,
participants F6 and F3 and their family members were very aware of the course
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of MND and had investigated symptom control options extensively. The health
literacy of F6 and F3 enabled them to ask pertinent questions of the clinicians
and make more informed decisions.

In summary, this research has found that there remains considerable
misunderstanding between clinicians and families about the benefits and
burdens of having a PEG in people with MND. The risk of aspiration is not
improved with a PEG in situ. The understanding by families that a person with
MND can develop swallowing difficulties as the disease progresses seems not
to have been well communicated. This research also identified that the
tardiness of referral for a PEG (described by some of the respiratory clinicians),
is often too late for the person with MND.

4.7. Time Allocated for Communicating and Discussing End-of-Life
Choices
Sufficient time to have detailed, emotional and difficult communication
relating to end-of-life choices with a person with MND and their caregivers was
considered a huge communication barrier (Table 4.4) and was mentioned by
the majority of the clinicians interviewed:
C2 (palliative care specialist): Time, you know. We’re all very time
poor, and these conversations take time, need to be re-visited, the patient’s
cognitive ability, family issues. You know, conflict within a family. All sorts of
things come into play. Like I say, when it’s easy it’s easy, and when it’s hard it’s
nearly impossible.

Adequate time is needed to explain possibilities such as risk of aspiration
infection if a PEG is inserted, whether to be treated by oral or intravenous
antibiotics or whether to be treated at all under such circumstances (C3). C3
made the point that allowing 10 minutes for such discussions, particularly when
a person with MND is already fatigued, is completely inadequate. The
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expectation that the person with MND will be able to meet with the necessary
clinicians in a short amount of time and be able to fully comprehend all that was
said to them is another issue:

C12 (physiotherapist): One of the things, you know, when we see the patients,
I’d like to spend a lot more time with some of them but some of them are just –
by the time they’ve seen the speech therapist and the dietician that morning,
and maybe spoken to [the nurse], and then they’re going to see us in the
afternoon to do some lung function, they’re just exhausted. …
So they’re fairly long conversations for a lot of people … the worst patients to
see is when you feel like you’re being rushed and you’re trying to introduce a
new therapy plus manage all the back end, knowing that you’re not going to see
them again, and knowing that they may be going to an area where there’s very
limited multi-disciplinary or specialist care to manage some of these more
difficult issues.
Adjusting communication to a person’s cognitive ability and health
literacy and ascertaining any family conflict was reported to require a great deal
of time. Clinicians spoke of the necessity to re-visit the same conversations to
ensure understanding but again, they find this very time consuming and not
always possible for people returning to the country (C11, C1, C2, and C3):

C11 (respiratory specialist): There are some people that are willing to engage
in this, and then there are other people where you can’t get them to engage in
discussions about end-of-life care. And so, my goal is to do it early and to do it
often until I feel like the patient and I, and family and I, are on the same page.
But it’s sometimes, in the real practical world, more difficult than that.
C2 (palliative care specialist): If it’s not in your routine practice, and you look
after an MND patient once every decade, then I think that’s really hard, you
know? So, yeah, I think that’s a barrier, lack of experience, yeah. And I think
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time. I mean, that’s – you know, if we think about – I mean, I think it would take
two to three visits of an hour each, you know?
C11 (respiratory specialist): I can imagine that in trying to teach people how
to do something that’s complicated there is a great temptation to focus on the
functional at the expense of the emotional, because the emotional is difficult,
and the conversations are difficult, and you have to talk about death and dying
and uncertainty and difficulty and what’s going to happen when this brand new
shiny machine that I’m just introducing you to doesn’t work anymore.

The family participants interviewed made the point that unless they were
assertive and asked the right questions, they could miss the relevant
information at the specialist appointments:
F5 (family): Because in these appointments you – particularly with a
neurologist who gives you an overall reading on how the whole thing’s going, if
you don’t ask questions, and you’re not an assertive sort of person, sometimes I
think you could walk out missing a lot, do you know what I mean?

Family participant F6 suggested that the communication recommendations
within the MND guidelines may not be relevant to all cases of MND. F6 went on
to suggest clinicians involved with communicating end-of-life choices make time
to listen to the person with MND and their family members:
F6 (person with MND): So, you know, some health professionals – I think
periods of silence to listen to the client are needed without the health
professional thinking, “I’ve got to tell them X, Y, Z, you know, because this is
what the evidence-based guidelines say.”

To summarise, both the clinician and family participants made the point
that significant time was required at specialist appointments to deliver the
necessary information and understand the broad spectrum of emotional and
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practical issues involved with MND. Having time to listen to the person with
MND and their family was considered particularly important.
4.7.1. Influence of frontotemporal changes in people with MND
The need for time for communicating end-of-life choices has been
identified in this research, but time and ability to recognise FTD in people with
MND is a further challenge. The clinicians were asked if, in their experience,
frontotemporal changes in a person with MND caused difficulties in decisionmaking regarding their treatment choices and end-of-life care. The clinicians
generally had little experience of poor decision-making that could be directly
attributed to frontotemporal cognitive changes, however, C1 did make one
observation relating to FTD:

C1 (palliative care consultant): It does feel like an iceberg really. There is an
awful lot under the water of how we do the communication. We’re not very good
at basic communication anyway, and then we’ve got this huge great mass that
we can’t quite see yet and we’re getting inklings of.

One of the respiratory clinicians observed that there may be increased
impact on the caregivers of a person with MND if frontotemporal changes were
affecting their understanding of symptom-relieving options:

C13 (social worker): What concerns me sometimes with that [frontotemporal
dementia] is that they [person with MND] don’t have a deeper understanding of
the situation [as they would] if they didn’t have the FT [frontotemporal]
happening, and it impacts on the carers, and that’s my concern.

Potentially prolonging the life and suffering of a person with MND by
making choices for options which may ultimately be detrimental for them was a
concern of C19 a palliative care consultant (4.6.7).
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4.8. Early Involvement with Palliative Care and Family Understanding
The majority of respiratory clinicians suggested that some end-of-life
communication should have been attempted with people with MND from early
diagnosis, prior to respiratory issues arising and their involvement in the
patient’s care (C11, C17, and C4). The involvement of a palliative care team
was identified as helpful in ensuring end-of-life communication occurred. C5
(respiratory physician), for example, stated that in his experience, end-of-life
communication commenced at or shortly after diagnosis and that the palliative
care team was involved from diagnosis:
C5 (respiratory specialist): From the very beginning. Palliative care team can
provide vital support before the end stage of the disease arrives. Their
involvement should not only revolve around end of life care.
The palliative care and respiratory clinicians interviewed for this study
were asked at what stage of the disease progression they became involved,
and their opinion as to whether the timing to palliative care was appropriate.
The clinicians responsible for offering NIV for symptom relief were also asked
when they involved or referred the person with MND to a specialist palliative
care service:

C4 (respiratory specialist): I mean, ideally all patients very early on, close to
the time of diagnosis. For various reasons some patients don’t want that, and
that’s okay, and it depends upon the support structure they have in place
already.
Despite guidance for early referral, there was a perception amongst
some of the clinicians that, at the time data for this research was collected,
some doctors involved at diagnosis or early in the MND trajectory believed that
palliative care was for the terminal stage or last few weeks of life only (C18,
C19):
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C19 (palliative care consultant): … or has inadvertently forgotten that we
[palliative care service] exist, or some other - or perhaps holds an old-fashioned
view that palliative care is simply for the dying - now, of course, motor neurone
disease is an incurable disease from day one, so it ought to involve us.

The palliative care specialist participants reported that people with MND
were frequently referred to them when already extremely ill and nearing the
terminal stage, often underprepared and lacking the ability to communicate
clearly their wishes for end of life (C1, C2 and C19):

C2 (palliative care consultant): To be honest, most of my [MND] patients are
referred very late, and we look after them for their end-of-life care.

This was reflected by most palliative care clinician participants who at times felt
frustrated that the referral to palliative care was made later than it should be to
optimise the benefits of palliative care for the person with MND and their
caregivers (C8, C2, C14, C18 and C19):

C19 (palliative care consultant): It does happen, where the person is referred
very late, and we think that’s disappointing because that patient has been
known to have MND in our area for some time.

Some respiratory clinicians report that occasionally difficulties in
communicating with the community palliative care teams regarding assistance
with NIV patient issues was an obstruction to adequate patient respiratory care
(C12). Frustration was apparent amongst respiratory clinicians that their
involvement was too late to adequately assist people with MND with developed
respiratory failure (C11, C12 and C17). The safest option for insertion of a PEG
tube is prior to failure of the respiratory system. Late referral meant that this
may not be possible, according to the gastroenterologist and the respiratory
specialists interviewed (C15, C4, C11, and C12):
173

C11 (respiratory specialist): If that [PEG] hasn’t been discussed by the time
the patient gets to me as a respiratory physician, I almost see it as a failure of
the system.

C15 (gastroenterologist): Understanding the medical complexities of PEG
tube insertion needs a fair degree of health literacy and that can sometimes be
a barrier. For example, the appreciation that respiratory involvement increases
your anaesthetic risk of the procedure and hence for me the need to put PEG
tubes in before significant respiratory involvement and that medical need for
that to happen can sometimes not be 100% understood.
Whilst all the clinician participants thought early palliative care
involvement for people with MND was a good idea, a referral to palliative care
did not always occur close to diagnosis (C8, C1, C2, C3, C13 and C19). The
reasons for this non-referral, or non-inclusion within an MDT (where available)
from diagnosis were unclear from the clinician responses, although a desire not
to undermine any hope that the person with MND may have, and patient denial,
were given (C4). The information gathered for this study indicates this may be
due to financial constraints, organisational policies of the local palliative care
service, or non-referral by neurologists and respiratory specialists. Respiratory
clinicians reported that palliative care services were often stretched and
understood that in their area of patient responsibility, it was not always possible
to keep people for ongoing specialist palliative care for protracted periods
(C11):
C11 (respiratory specialist): Now, I also know that, you know, there are a
variety of workforce issues that mean that palliative care teams struggle to
continue to see patients that are “on their books” for a long period of time.

In some areas resource constraints and funding rules require the
limitation of access to palliative care services, for example, a pre-requisite of
having a life expectancy of 3-6 months as an entry requirement:
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C16 (MND nurse consultant): Because I’ve had a palliative care specialist
from central **** ring me up, and he goes, “Well, you’ve made this referral to a
patient. Has he got less than three months to live?”
As the course and timing of MND is so difficult to predict, life expectancy and,
therefore, suitability for access to a palliative care specialist becomes virtually
impossible to forecast (C9, C13, C16, and C8):
C13 (social worker): Oh. Well, that’s a – well, you see the definition of
“palliative” – here at **** it’s about six months of life left approximately, right.

C16 (MND nurse consultant): But some pall. care teams are quite open to that
[early intervention], but some pall. care teams have this weird definition period
that they will not accept the patient until they have three months or less to live.
Recommended referral times, both to palliative care and to respiratory
specialists, is discussed more fully in Chapter 5. The use of specialist palliative
care too early in the diagnosis was questioned by one respiratory specialist,
who said that other organisations or the GP should be able to manage the
person with MND at least until symptoms became more complex (C4):

C4 (respiratory specialist): If they have good support otherwise from partner,
general practitioner, allied health staff, myself, then there may not be – from my
point of view and the neurology nurses, there may not be a great need for the
specific palliative care services to be involved.
The clinician (C4) suggested that when more complex end-of-life
treatment was required would be the time to involve palliative care specialists
and nurses. Several palliative care clinician participants, whilst acknowledging
early referral to the palliative care team to be important, thought that specialist
palliative care involvement could remain intermittent until the person with MND
became more symptomatic (C3, C16, C19, C8). This represents a departure
from the recommendation in the current guidelines. The few specific MND
clinics involved in this study were able to involve palliative care from diagnosis,
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and then have sporadic involvement until respiratory or swallowing became
problematic. However, the point was made that this presented a difficulty in
knowing exactly at what stage those symptoms were occurring, and whether at
times they were being missed (C1):

C1 (palliative care consultant): Now, that sounds very clear in some ways but
how do we know those stages are happening? And that’s why I think probably
we need to be in most – a lot of the time, so we [palliative care team] can
actually pick up some of those changes.

Of the seven participants interviewed within the category of the bereaved
families and people with MND, three were offered palliative care referral late in
the course of the disease (F1/2, F4, and P1). Two families (F3, F6) considered
the timing of their referral to palliative care appropriate (although it did not occur
at the time of diagnosis). When early palliative care was mentioned to family F5,
the benefits of what the service could provide were not adequately
communicated to the family to alleviate their fear of what palliative care meant:
F5 (family): That word “palliative” over-shone whatever they were saying to us.

The concept of palliative care was confronting to people with MND in this
research. From a symbolic interactionist perspective, the public understanding
of palliative care is of death and dying and is perpetuated by clinicians who
remain reluctant to discuss or refer to palliative care. Early palliative care
involvement for some people with MND and their families was confusing,
particularly if they were minimally symptomatic at the time of palliative care
discussions. From the clinician perspective, the way in which language is used
was pointed out by C19 as important:
C19 (palliative care consultant): I’m particularly conscious about technical
language, how difficult, intimidating and troubling technical language can be,
and it just is not a good communication style. So, it’s really clarity of language.
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The confusion within families about the role of palliative care was apparent in
the data. For example, participants F5 and F3 said:
F5 (family): She’s a specialist. And she said, “Now, I’ve got a letter here from
your GP saying that you’re in denial about all this.” And we said, “We’re
definitely not in denial about what’s happening to us. We’re just in denial that we
need to see a palliative care team so early.”

F3 (family): It was discussed, and because sort of our initial – you know, sort of
we now know that palliative care is really the only thing that you can do with
motor neurone disease. To us at that stage we were thinking “end of life” and
we’re getting a bit paranoid.

The provision of a holistic approach incorporating palliative care for
people with MND and their families is still dreaded by some patients and
families and adopted reluctantly by clinicians involved with diagnosis and early
involvement with MND (Oliver et al., 2016). MNDA recommendations are
generally accepted as a good thing by clinicians, but they are not always
reflected in practice (C8, C1, C2, C3, C16 and C19). Early palliative care or, as
recommended, palliative care referral from the time of diagnosis, is discussed
further in Chapter 5.

A point raised by C12 as a reason for early palliative care involvement
and referral from respiratory clinicians to palliative care specialists was a
practical one: the cost of prescription medications. An example given was the
high cost of glycopyrrolate (a medication used to assist in alleviating excessive
secretions) if prescribed by a respiratory doctor compared to prescription
through palliative care. This same prescribing issue exists in New South Wales
and Western Australia.
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In summary, there is broad agreement with the guidelines on early
referral to palliative care, but this does not necessarily translate into practice.
Barriers from the clinician’s perspective include the difficulty in estimating the
unpredictable course of the disease, reluctance to take further hope away from
the patient and family and the availability of the palliative care service to accept
the patient. From the perspective of the person with MND and their family, this
research identified a reluctance to be referred largely due to misunderstanding
what palliative care could provide and the support that could be offered.

4.9. Communication within a Multidisciplinary Team
The information already given to people with MND and their caregivers
was not always known by a subsequent healthcare professional, causing
confusion between healthcare providers from various organisations involved
with the same patient. One community nurse (C8) mentioned that the
organisation she worked for did not give out much information on symptom
control for people with MND, leaving it up to other organisations to provide this.
Below, C16 describes the frustration with working within the private healthcare
system and trying to access information from the public allied health system:
C16 (MND clinical nurse consultant): . . . look, I know it’s public and private,
or whatever it is, but there has to be some way that if, you know – and I can get
that it’s probably maybe because the community allied healthcare team is busy,
or whatever it is. But even having – knowing who the person has been referred
to from an OT [Occupational Therapist] point of view, so I don’t have to ring, you
know, three aged care teams to work out where the OT is, or even just having
assessors, if I ring My Aged Care to tell me, “Okay, well, this OT has seen your
patient,” so then I can follow up with that OT, I think would make it a bit easier
for me so I’m not constantly chasing my tail.
The neurological and palliative care nurses working and supporting
people with MND and their families within the community were described by the
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family participants as an informative and wonderfully knowledgeable resource.
However, the nurse participants in this study reported that they often had to
initiate communication and referrals relating to symptom control including
breathlessness and the potential for NIV even though they didn’t necessarily
perceive that to be part of their role or professional remit. These issues had
apparently not been broached by doctors:

C6 (neurological nurse): A recent example was a client who I could see was
noticeably becoming breathless and hadn’t at that stage been followed up by
anyone about it. So, I initiated the discussion about respiratory issues and got
them information about NIV so that they could be prepared when they saw the
respiratory physician for talks about NIV.

In order to ensure the person with MND and their family receive all
aspects of necessary care from diagnosis to death, an MDT approach to care
has been considered the most beneficial (Miller et al., 2009). A coordinated
team of specialists assists with advice on symptom control and identifying the
individual requirements of each person with MND and their caregivers. The
communication includes discussion about the introduction of NIV and the
potential for the withdrawal and consequences of withdrawal. However, this
research found that communication between health professionals within an
MDT was sometimes poor, particularly if the team was fragmented between
organisations, or split between metropolitan and country:

C1 (palliative care consultant): I think my other fear is you can get so many
teams of people involved. You’ve got specialist palliative care, GP and primary
care, respiratory care, gastroenterologist who’s been involved with the PEG, the
rehabilitation team, a neurologist who’s saying – you know, and the possibilities
of confusion and misinformation are enormous. And the inter-team – I was
going to say warfare.
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Within metropolitan areas the MND MDTs were generally coordinated teams
attached to a single area of healthcare. However, this was certainly not always
the case:

C19 (palliative care consultant): Now, the interesting thing in the city is that
not everywhere has a multi-disciplinary team. So, it’s a bit of a patchwork quilt,
and indeed would be the whole of Australia a patchwork quilt.
This perspective was found within urban and rural areas. Where
structured and coordinated MDTs did not exist this sometimes led to multiple
appointments in different facilities, and confusion as to which professional was
attending to what clinical problem. Certainly, there was comment from some of
the family participants that there was a lack of coordinated care, confusion with
who was who and who did what, and that they felt they were repeating
symptoms and issues many times to many different people (F1, F2). There was
also some confusion even between family members as to who was coordinating
their family member’s care and when asked if there was a specific team
involved, as the following exchange illustrates:
F1 (family): No … odd … they were very odd.
F2 (family): But “K” was coordinating everyone, wasn’t she?
F1 (family): No, no, she was just helping me – she’s the motor neurone group
lady.

F1 and F2 agreed that the amount of different appointments with different
organisations caused their family member with MND and her husband much
confusion, fatigue and wasted much precious time:
F1 (family): We’d been to a few speechies [speech therapist] and dietitians,
which Dad was getting confused about. So, I sort of explained to them that the
dietitian was about the nutrients that she was getting; the speechy was about …

180

how to swallow, and the muscles in the neck. And Dad said, “We’re saying the
same things to the same people.”
P1 (person with MND): So, he [doctor] made some comment about, “If you
haven’t heard in two- or three-weeks’ time, ring me and up and I’ll see what’s
going on.” So, we didn’t hear anything from anybody else. So, for three weeks
we were absolutely left in limbo, which was quite traumatic.

The speed of disease progression and the inability to find assistance with
immediate requirements was a recurring theme, and concurred with the findings
of McConigley, et al. (2014), who found that whilst clinicians should try to preempt the requirements of people with MND as their disease could progress
rapidly, this was not necessarily occurring. Families and people with MND felt,
for instance, that equipment needs from NIV to prosthesis requirements were
too slow to materialise once a need for the particular item had been identified by
health professionals (P1, F1, and F2). F5 acknowledged that their family
member was provided with all the technology they may require and seemingly
prior to their actual needs, which were well anticipated by their hospital and
MDT providers. This is in stark contrast to P1 who felt the provision of
necessary equipment was far too slow due, it was suggested, to poor
communication between healthcare professionals:
P1 (person with MND): So by the time that we went - the private contractor had

all the measurements done and the prosthesis was made - I’d gone too far to
use them. So, I think that’s probably an area where, particularly with MND, we
felt that things were happening and deteriorating faster than what … we could
get assistance with.’
The provision of technology, services, an MDT and specific MND
information and care seems to depend on where a person with MND lives or
who they are able to access. Communication about and monitoring of changes
in a patient’s health status and needs did not always occur within an MDT,
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leading to confusion and emergency hospital admissions. The one participant
(P1) with MND interviewed recalled how, following an overnight sleep study to
ascertain health difficulties affecting sleep such as respiratory insufficiency,
nothing was heard for several weeks and during which time P1’s breathing
became more difficult. The situation was only addressed when a friend calling at
P1’s home, finding P1 in respiratory distress, made a call to the MND specialist
and was advised to take P1 to hospital straight away. The specialist clinicians
interviewed for this study admitted that emergency presentations to hospital
with respiratory distress occurred in people with MND, and at worst this led to
tracheostomy insertion (C19). It was unclear from the data whether this was
because of MDT confusion but certainly mixed messages from members of the
MDT led to people with MND becoming confused about their care options:

C1 (palliative care consultant): There was one person who was told it [MND]
would – he’d known patients where it had burnt out after a few years and not
progressed. So those patients – you know, it can be difficult because they may
get mixed messages – different messages when they see a neurologist in a
clinic who says, “Oh, you shouldn’t be thinking about a gastrostomy” when
we’re already starting to talk about gastrostomy.

Some of the specialist teams discussed and prepared their patients for
emergency MND presentations to hospitals by giving cards or information with
their palliative care specialist contact details. This enabled the emergency
department doctors to contact them for guidance on a disease they may have
had little experience with (C14, C19 and C7).

The clinician participants within this study recognised that for some
people with MND, travelling between health professionals within an MDT whose
members were not co-located caused practical problems, particularly as the
disease became more advanced. The point was made that fragmentation of the
MDT also caused difficulties communicating between team members with
repercussions for continuity of appropriate care for the patient (C12).
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C1 (palliative care consultant): I feel it might be better if there was more of us
in the clinic together. And I know in many clinics you see the doctor, and then
they see the nurse, and then they see the OT, and then they see the physio,
and then they see the speech and language therapist, and then they see the
psychologist, and then – you know. And I can see the positives of that, but I
also feel it would be exhausting.
C11(respiratory specialist): That’s often in the practical world really quite
difficult with people who are, you know, poorly mobile, whose prognosis is very
limited, and who you just want to maximise, you know, the time that they have,
and you don’t want to waste their time by getting them in for lots of
appointments.

The communication between organisations, particularly if there was no
structured MDT incorporating palliative care or palliative care nurses with an
understanding of MND, caused issues around patient “ownership” and
perceived interference (C11, C12, and C1):
C4 (respiratory specialist): Look, I don’t think it’s [communication between
healthcare professionals] particularly ideal at all. The communication we have is
by letter, very occasionally a phone call. I don’t get a lot of – I mean, I write
letters, and I think I’m communicating, but I don’t feel I get a lot of feedback,
unless there’s a big problem.

C16 (MND clinical nurse consultant): Even though I might have requested
certain things on referral be done, the person who picks up that referral –
without even knowing the patient, and completely sometimes disregarding my
clinical judgment – might just say to a patient, “Well, this person just needs a
physio review, or an OT review,” forgetting all the other allied healthcare that
might be needed.

183

Lack of co-ordinated care and communication between organisations
within the same city was a concern of several clinicians, and there appeared to
be a varying level of regard for the quality and approach of some services (C11,
C16, and C1, C19). This is exemplified by C16:
C16 (MND clinical nurse consultant): It’s like a hotchpotch. Like with
anything, you know some palliative care teams we work really closely with;
some palliative care teams don’t want to know about it … Some pall. care
teams have this weird definition period that they will not accept the patient until
they have three months or less to live.

Further, there were times when test result reports between health
professionals appeared to be lost within a system and not available at specialist
consultations (P1, C16). Families expressed concern and frustration that
diagnostic reports did not ever reach their GP or specialists involved locally
(F6). Delay in hearing from specialists was an issue for both health providers
and families. This was raised as a concern by a person with MND who felt the
delay in receiving results from a sleep test meant delay in getting the correct
symptom relief measures:
P1 (person with MND): I didn’t get – this is one of the things that sort of upset
us a little bit. We didn’t get any feedback, you know, from the overnight [sleep
study] stay. And I felt afterwards that I could have been on the machine two or
three months before, because of the deterioration.
Inappropriate direction to other services was another concern voiced by
one of the bereaved caregivers (F4). The example they gave was of a health
professional who had felt a mobility device could ease an issue that the person
with MND and their caregiver were experiencing, but it wasn’t practical and
caused more worry:
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F4 (family): Then he started relating to the fact that, “Oh, we got all sorts of
devices. You know, we got these lifts and we got this, and we put them on
there,”. But, you know, the nurses have to have two people to operate it, but,
you know, you’re expected to operate it by yourself, you know?

Other family members wondered whether it was wise of healthcare
professionals to suggest additional aids or other services knowing delays to
getting them were likely, as typified by F6’s comment below:

F6 (family): Oh, yeah, she, you know, had all the speech, dietitian. But I think at
times, to be honest, people – the professionals – I think professionals should
feel it’s okay to – they need to – if you can’t do anything. Or that the client has
chosen they don’t want any more help as well, because it’s another person that
Dad’s dealing with making appointments, receiving phone calls. So it’s almost
taking the time out of the precious bit of time you’ve got left.
This research found that the clinician participants agreed that
communication between clinicians involved with the care of a person with MND
could be improved and was at times confusing. The family participants made
the point that time became increasingly valuable as the person with MND
became more unwell. Having to repeat issues or symptoms to many people
involved with the care of the person with MND took away valued time.
4.9.1. Advance care directives or care plan to be in place prior to
NIV
Planning for the end of life and discussing and preparing an AHD is a
recommendation of the current MND guidelines (Andersen et al., 2012; NICE,
2016). The AHD should detail what is to happen in the event of a concurrent
infection such as aspiration pneumonia, where the person may wish to die,
whether or when NIV should be removed or nutrition via PEG ceased. Being
able to communicate or be understood when the ability to talk has gone, was a
point illustrated by C6:
185

C6 (neurological nurse): His wife wanted a definite sign of when she would
stop the PEG feeds, if he was no longer able to communicate. I haven’t seen
the advance health directive, but she did say there was a special sign that they
would have.

This example illustrates a problem that may exist more widely; although
there was understanding between the couple about the cessation of treatment,
it was unclear if this was an arrangement that had been documented or was
known by healthcare professionals. C1 illustrated the challenge of ascertaining
exactly what a person with MND may want, by describing a situation where he
discussed when NIV was to be withdrawn with a patient if he can’t
communicate. However, the issue then becomes what exactly does
“communicate” mean? Clarity in documenting exactly what type of
communication is acceptable to all and understood by clinicians and the person
with MND (being able to talk, blink or by some special sign) in relation to ending
NIV or nutrition via a PEG is vital, particularly if a concise AHD has not been
documented. Some clinicians stated that to have a precise document
expressing a person’s end-of-life wishes took more experience and time than
they could provide (C8, C10); this further reinforces time poverty as an issue.

The clinician participants were asked at what point of the disease they
discussed AHDs with people with MND and whether their families were involved
with the decisions made. Clinicians appear to make the decision on when to
initiate discussions about end-of-life care and document outcomes of these
discussions in an AHD on an ad hoc basis:

C13 (social worker): We go pretty much according to what the patients can
cope with and what they seek, and if we feel they can deal with the information
then, yes, we – we can do it even from the first visit if it comes up.
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C7 (neurological nurse): The wife was quite happy with those choices, but one
of his daughters, who was a nurse, was not. So, there was a lot of conflict about
this daughter not - you know, wanting all interventions: PEG feeds, etc. So,
there was a lot of conflict making it distressful for the client and for the spouse.

Many of the clinicians discussed the importance of developing a rapport
with their patient before discussing AHDs (C13, C14, C19), but as some
clinicians only saw their country patients for one or two visits, this was not
always possible (C11, C12).
The clinicians were asked whether the AHDs were reviewed when a
person with MND had interventions such as a PEG or NIV. Whilst believing the
AHD should probably be discussed further at such times, few actually
incorporated any possible issues associated with symptom control measures
into the document:
C2 (palliative care specialist): Not routinely. They should be, but I don’t think
they are in clinical practice. And I think although we would assume that all of
these patients do [revisit their AHDs], I think it would be very interesting to know
how many actually did, because I’m not at all convinced that they do.
C18 (rehabilitation consultant): Look, we haven’t [reviewed AHDs] a lot. We
should have. xx [the palliative care consultant] does them all when they are –
when they do need to be done, but, no, I think that’s a hole in our service.
The clinicians were also all asked whether they found that the AHDs
were sufficiently detailed in order to be useful when clarity regarding treatment
was required:
C2 (palliative care specialist): Lots of people’s AHDs are very vague. They
give you a – I think they give you a general direction, though, as to whether
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someone wants aggressive or limited treatment. But they’re often not much
more help than that.
C3 agreed with C2’s comment about the vagueness of some AHDs and
gave the example of a recent document they received which had read pain
relief only, but on further discussion, the person concerned actually wanted
comfort measures such as medications for nausea and respiratory secretions.
Apparently, the person had not been offered guidance from any healthcare
professional or legal representative, so completed the document to the best of
their ability. This was then signed by the GP and dated the day before the
person had signed and dated it, making the document completely invalid. C11
suggested that perhaps structured AHDs were not the best option in clarifying
end-of-life choices, and that to prepare a person or proxy decision-maker who
had a good understanding of the likely decisions which may have to be made,
may be more effective than writing down every eventuality, which may not be
possible. C12 and C13 made the point that when AHDs are initially discussed,
the person with MND and their family may request all treatment possible, but as
time goes on, their approach to living longer may change. Conversely C16
shared the experience of caring for people with MND who initially stated they
did not want any interventions, but when faced with an inability to swallow or
breathe, requested PEG and NIV. C19 cited aspiration pneumonia as a good
example of potential lack of consistency between what is stated in an AHD and
actual patient and clinician behaviour at the pertinent time. The example he
gave is one in which a patient stated that no antibiotics were to be used, but
then presented to casualty with aspiration pneumonia and was given antibiotics:
C19 (palliative care consultant): It’s almost like pulling of the – like a scene
out of a western. One person’s pulling out an advance care [directive], the other
person’s giving the antibiotic [that has been declined in that advance care
directive], and you’re thinking, “Okay, well, everybody’s not harmed. Okay, it’s
happened. Okay, let’s now think about the future.”
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A few of the clinicians either stated that they lacked sufficient experience
to advise and assist with AHDs (C8, C10) or referred their patients back to the
GP (C4). Several of the clinicians, like C19 above, described that in their
experience, most AHDs lacked sufficient clarity to be useful (C7, C11, C15,
C16, C2), although all saw the value of having them. As participant C5 says:

C5 (gastroenterologist): The guidance surrounding [the] terminal stage of care
is poor and can lead to difficult decisions especially if AHD are not in place.

Despite understanding the importance of AHDs, family members F4 and
F5 had not managed to encourage their family member with MND to document
their end-of-life choices, and each expressed regret about this. On reflection
participant F5 thought this was probably a form of denial within the family,
although F4 stated it was because the person with MND simply did not want the
conversation as she “did not want to die” (F4).

Three of the families interviewed (Table 4.3) did appear to either have
had a formal AHD (F3) or have had an informal written agreement between the
person with MND and the family members (F1 and F2) about end-of-life care. In
all cases these family participants reinforced the clinicians’ perception of the
AHD as usually fairly ambiguous and not always known to all relevant persons.
F1, for example, stated that the person with MND had refused anything invasive
and that the document was unsigned by them. This document had apparently
not been shown to the doctors but was known to the community palliative care
team. Despite a formal AHD, F3 did admit that the person with MND
procrastinated in writing and signing the document as the person “did not want
to think about it too much” (F3). F3 reported that the document contained the
following:
F3 (family): If a sort of condition developed that was incapable of being sort of
effectively treated then he was palliative care only.
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Ambiguity and lack of clearly written AHDs was found in this research, with
much of a patient’s end-of-life wishes known to the families but not necessarily
to the attending clinicians. At times, this resulted in treatment that was perhaps
futile and not what the person with MND had wanted.
4.9.2. Family issues and suggestions
The country and outer metro families interviewed mentioned the
difficulties with travelling to appointments particularly as their family member’s
health deteriorated and increased fatigue and moving becoming increasingly
difficult (F1, F2, F6):
F1(family): She was exhausted by the time she got there and she just – we
couldn’t get from the car to the hospital to get a wheelchair to wheel her to the
doctor’s surgery.

One family from a rural area thought that the gap between specialist
appointments was too long. Initially at least, the appointments were every three
months and it felt a very long time for the family who accepted that they did not
necessarily hear and fully comprehend what the specialists had said to them
(F5). F5 went on to suggest that a mentoring system would be useful so that
information could be obtained from people with experience of MND, particularly
other caregivers. F5 observed that she would have appreciated more
involvement with people who had been through the MND experience:
F5: Yeah. I find that really difficult living in the country, because I don’t feel that
a lot of local nurses or medical people have had a lot to do with it. I know they
have, because we’ve had some people in our area with motor neurone. But it’s
talking to carers is the biggest communication need that I have really, because
they have the on-the-ground tips to give you, you know.

Family member F3 suggested that genetic testing should become more
available and included in MND communication. F3 related the experience of her
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family member with MND knowing that MND can be inherited and worrying
about their children and grandchildren. However, this comes with its own
problems as clearly outlined by a very experienced palliative care specialist:
C1 (palliative care consultant): The family can’t help because they’re just
terrified, and I think that’s the – the other issue, I think, is going to get worse – I
mean, we’ve had it with two families now with C9orf [genetic link]. One lady had
four daughters. So, while they were sitting there watching her die, two of them,
in theory, would be seeing how they would die. And so, you know, the impartial
family isn’t any more, because they’re even more involved than the patient, and
the patient, if they have some insight, is seeing, “I’m putting this on my children
who might be facing this as well.”

F6, who had much experience in negotiating the nuances of the health
system and had acquired excellent health literacy, suggested:

F6 (family): They’ve still got to be professionally responsible, but maybe they
need to start out differently by asking the question, “Do you want to eat, or do
you want to have this intervention?” And it’s okay for the person to say, “No,”
and the health professional has to accept that, and I suppose document … Not
that I’m thinking of, because maybe we as a family do ask the right questions,
and that’s a real key, is the health literacy, isn’t it, that people haven’t got.
F1 recommended greater GP awareness of MND particularly relating to
referral to a neurologist if there is no explanation for breathlessness or loss of
speech. F2 felt that the hard questions and hard decisions must be addressed
and not pushed to one side, by either families or clinicians. F4 was still affected
by how his family member with MND had suffered for so long, and despite not
liking to admit it, thought it would have been better if his family member had
been allowed to die:
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F4 (family): Yeah, basically, yes, yes … nine months to a year before she did
[died].

4.10. Patient and Family Communication and Understanding
The clinical participants were asked if, in their experience, people with
MND and their families were adequately aware of the prognosis and limitations
of the disease prior to their involvement. Denial and lack of understanding by
some people with MND and their families relating to how quickly the disease
can progress, was expressed as a communication barrier by some of the
clinician participants. However, it was apparent to clinician participants that
some people with MND and their families had experienced limited explanation
of the disease:
C2 (palliative care consultant): Some of them have clearly been told but don’t
necessarily want to hear, understand or acknowledge, and some clearly have
very limited explanation.
C13 (social worker): I don’t think they’ve always understood how quickly
things might be changing for them as an individual. And I don’t think they’ve
always fully understood the complications that can happen, you know, and the
interventions that may or may not be possible.

The majority (n=14) of the respiratory and palliative care specialists and
nurses interviewed talked of trying to ascertain the depth of knowledge of the
person with MND relating to their diagnosis and what they had previously
understood from other health professionals, prior to their own involvement. This
was attempted in several ways: repetitive discussions, asking for further
clarification on fragments of information from the person with MND, reflective
discussion and repetition of what the person with MND and their family had
understood. One clinician stated that trying to disentangle where people were in
their journey and in their understanding, would “contextualise” any advice that
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was then given to them (C11). An example of trying to ascertain what had been
understood about all that had been communicated to the person with MND and
their family is given by C11:

C11 (respiratory specialist): In a perfect world I use, you know, a lot of
communication skills like check back and cross-check, and things like that, to
see what they’ve understood. In the real world, I use some of that.

However, understanding how much a person understood and what they had
previously been told was frequently found to be difficult, both to assess and to
discuss, as C6 and C2 described:
C6 (neurological nurse): Sometimes you can see that they’re not processing
information. You can just see that look of confusion or terror, or blankness on
their face. Others, you think that they’ve understood and then you find out later
that they haven’t actually understood. They might be repetitive in a question or
just say something that makes you realise they haven’t understood’
C2 (palliative care specialist): We’re palliative care doctors. We like to think
that we’re good at communicating, but I think, I acknowledge, that often families
need to hear things multiple times.

The NICE Assessment and Management Guidelines recommend that clinicians
ask people with MND how much information they wish to receive and how much
they would like to have shared with their families (NICE, 2016). One of the
clinical nurse participants described how clinician communication can adversely
affect people with MND:
C16 (MND clinical nurse consultant): They’re kind of more psychologically
scarred about how diagnosis was given to them, and then how they’ve been
sent home to put their stuff in order, and, you know, wait for death to come.
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None of the six people with MND whose families were interviewed had
chosen withdrawal of NIV as a method of ending their life. The family member
of F3 with MND, a night time user of NIV only, chose instead to refuse food and
water to end his life. However, a discussion had taken place with the family,
although not documented within his AHD, that NIV could be withdrawn but it
would be when the person with MND was ready. However, F3 did state that
initially NIV had only been mentioned in passing as a treatment option for later
and that the detail of NIV had been communicated by two neurological nurses,
not specialists. F4 supposed that NIV may have been mentioned to his family
member, but neither the person with MND nor F4 pushed for more information
as F4 felt prolonging the illness or suffering was not their preferred option. F5
stated that the NIV was given to them with little alternative, whilst P1 had no
real idea or explanation of the implications of NIV:
F5 (family): It was definitely, “This is what you need because your lungs aren’t
working properly.”
P1 (person with MND): I think probably I wasn’t aware of the importance with
the breathing and I don’t think that that was probably adequately explained.
Now, they were saying, “Well, you go and have a sleepover; we’ll test to see
what – you know, how you’re sleeping, how you’re breathing,” all those sorts of
things. But there wasn’t any sort of gutsy type of verbiage about why … the
implications of it.

F1 and F2 said liquid morphine was suggested to assist their family
member to breath but nothing else was suggested until their family member was
entering the terminal stage at which point a syringe driver was offered. There
was confusion between the siblings in their understanding regarding a syringe
driver, as one had understood it to be intravenous delivery of medication (F2)
whilst the other had understood subcutaneous infusion (F1); both had attended
the same conversation with clinicians:
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F2 (family): I think the reason Mum didn’t want … the IV was because she just
didn’t want to accept that she was going to go, and that looked like another step
towards the end of life. And having someone in every day.

The candidate asked if the family member with MND was offered a
subcutaneous cannula just under the skin, which is the more normal option with
a syringe driver, rather than intravenous. The second family participant (F1)
responded that she understood that it was the subcutaneous option offered not
intravenous. Both F1 and F2 agreed that the partner of their family member with
MND was very hesitant about allowing liquid morphine to be used as he felt his
partner could become addicted to the morphine. This perhaps indicates a lack
of either communication reassuring the family, or a lack of understanding and
health literacy by the partner of the person with MND. Neither F1 nor F2 had
any recollection of the burdens of NIV being discussed until such a time when
their family member started to get pressure sores on her nose and mouth from
the NIV mask. At this point they were informed: “Oh, yes, that happens – that
has, you know, been known to happen before” (F1). Apparently, there had not
been any communication with F1 and F2 about the potential of withdrawal of
NIV when it was no longer effective or the person with MND had decided they
had suffered enough. F2 stated that the lack of ability of the person with MND to
communicate as the disease progressed was not discussed and that this led to
him feeling his family member may have made some ill-defined choices,
potentially resulting in increased suffering. F1 described a lack of recognition or
at least indication to the family by the clinicians, that the person with MND had
reached the terminal stage:
F1 (family): But still they didn’t think she was at end-of-life stage, but I think she
was at end-of-life stage at that stage, and we could have helped.

F4 was very determined to keep his family member with MND at home
and wondered if this may have been why end-of-life choices were not discussed
with him. F5 described that the communication surrounding NIV was well
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covered particularly by the respiratory technician; however, this was not the
case with communication relating to the PEG insertion, which was information
F5 found out via the Internet. F3 had no recollection of end-of-life
communication in the context of NIV and definitely none from the respiratory
clinician. F3 candidly acknowledged that the family had the “intellectual and
financial resources” to be able to look after their family member with MND at
home:

F3 (family): As I say, we were very lucky in the sense that we had the financial,
intellectual and emotional resources to be able to manage the situation with
assistance at home for most of the time.

As discussed earlier in this chapter, the clinicians interviewed for the
study described several reasons for not broaching the difficult conversations
surrounding NIV withdrawal and end-of-life choices. These reasons and the
barriers for end-of-life communication and the benefits and burdens of symptom
control measures offered, are discussed further in Section 4.11 of this chapter.
4.10.1. Differentiating between hydration and nutrition
One of the questions asked of the clinician and family participants related
to the hydration of the person with MND in the last few days of life, particularly if
they were refusing food and water and especially if they had a PEG inserted.
The clinicians were asked if, when detailing the consequences of stopping
nutrition as a means of ending life, they had described nutrition and hydration
separately. The clinicians were also asked if they had experience of people with
MND indicating that they were dehydrated or that there was a possibility that
they could be suffering as a consequence of dehydration if their fluid intake had
been ceased when nutrition was ceased:
C15 (gastroenterologist): Potentially, yes.
C19 (palliative care consultant): That’s a really good question, isn’t it,
hydration – differentiate hydration and nutrition.
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Some clinicians stated that they had experience with people with MND
apparently indicating symptoms of thirst or dehydration towards the end of life
after stopping fluids and nutrition (C7, C8). C11 was unsure if hydration was
related to the secretions (excessive or tenacious), and C18 felt nutrition was the
most important aspect to discuss and did not really distinguish between nutrition
and hydration. C14 stated that generally when the person with MND decided
that nutrition should stop, water was continued to prevent dehydration although
stopped if clinically indicated. C19 considered the symptoms of hunger and
thirst stating that:

C19 (palliative care consultant): They may well feel thirsty, and that needs to
be attended to, because that’s a terrible symptom if you’re to sit – if you’re lying
there and you can barely communicate. So, we need to – I agree, I agree. This
[small amount of water via a PEG] is not going to cause any harm to the patient,
and it’s not going to elongate life.

C15 said that on consideration of the point that whilst the person with MND may
want to stop nutrition, hydration may prevent the feelings of thirst. This was also
asked in the context of the AHD and whether the AHD was changed in
accordance with the patient’s wishes. The clinician participants were asked
whether the differentiation between hydration and nutrition was ever offered,
suggested or documented within an AHD:
C15 (gastroenterologist): I have to say I haven’t really pushed that
differentiation on advance care directives. But I think it is important, and
perhaps in future I will.
C1 and C3 stated they would continue with hydration and did differentiate
between nutrition and hydration for people with MND and their families. C4 and
C2 did not particularly differentiate between food and fluids when discussing
PEGs to people with MND but C4 acknowledged that for people using a mask
for NIV, thirst and a dry mouth were a potential problem anyway.
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The families of people with MND were asked whether those who chose
to refuse fluids as well as nutrition were comfortable or whether thirst and
dryness may have caused adverse symptoms. F3 was asked whether the oral
preparations they used were adequate to alleviate the feeling of dryness in the
person with MND following a decision to stop food and water via the PEG/RIG
by her family member with MND. F3 stated: “possibly not, you know”. Despite a
recommendation of hydration and using various oral rehydration products for
the symptoms of dryness for the person with MND, the family member F6 was
sure suffering occurred as a consequence:
F6: She was constantly, constantly, constantly trying to – yeah, absolutely she
did [feel thirsty]. You know, with – it was an overwhelming feeling.
F6 continued to explain how her family member had tenacious secretions and
was being inadequately suctioned by nurses in the hospital. F6 suggested that
suctioning is “not recommended by MNDA” and the health professionals were
reluctant to assist. Apparently, and after much negotiating with the hospital, the
partner of the person with MND was allowed to suction their family member. F6
readily admitted that the entire process of suctioning her family member was
distressing but did appear to improve her symptoms.

F2: So, you know, Mum and Dad got to the point where they were so exhausted
they couldn’t make decisions.

To summarise, this research has found that clinicians may not
differentiate between nutrition and hydration when communicating end-of-life
symptom control to people with MND and their families. Acknowledging that not
all people with MND have PEG tubes at the end of their lives, this research has
found that some people with MND were described by their families as appearing
to suffer from thirst in the terminal stage of their disease.
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4.11. Communication Barriers from Clinician and Family Perspective
Both clinician and family participants agreed there were barriers to
communicating end-of-life choices, documenting patient wishes (AHDs or clear
care plans/goals of care) and the implications of the withdrawal of NIV.

C11 (respiratory specialist): For some other people, you know, an extra
minute of life is unbelievably precious regardless of their state of health and
ability to interact. I think that that means we need to re-imagine the workforce
issues rather than we need to throw our hands in the air and say it can’t be
done.

One of the most noted barriers clinician participants was patient denial. When
asked how the clinicians dealt with denial:
C4 (respiratory specialist): “Oh, I just don’t want to think about it. I don’t want
to know.” So that can be a bit of a challenge that their defence mechanism,
their way of coping is one of, “That’s later on,” denial.

C16 (family): I let them be in denial.
Another barrier to communicating NIV withdrawal prior to
commencement mentioned by one of the more experienced clinicians (C19 and
reiterated by C18, C13, and C4) was the concern that having sensitive end-oflife discussions would upset the patient or the family:
C19 (palliative care consultant): I think one of the barriers is sensitivity or
worrying that that’s – even having that conversation is going to upset the patient
or the family.
C4 (respiratory specialist): I’ve got one particular lady now that those issues
are just too hard for her to discuss. And there’s a lot – even I feel
uncomfortable – I feel comfortable about discussing them.
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A further barrier to effective communication suggested by a neurological nurse,
was if the person with MND perceived themselves as a burden to their family.
This was communicated by C7:
C7 (neurological nurse): So mostly the reasons have been they don’t want
their life prolonged, because that’s how they see it maybe. They don’t want the
invasiveness. They don’t want even further carer burden. That seems to be
another big thing, the carer burden: “I don’t want to do that to my spouse.”

The information a person with MND and their family may have obtained
from the Internet may also pose a barrier to effective communication if not
adequately discussed:

C16 (respiratory nurse consultant): In many ways we find when patients first
come that’s a huge burden that they all have, because they’ve gone on the
Internet, they’ve read a lot of stuff about dying and how horrible it is, and, you
know – and most patients don’t want to die from that sense – you know, they’ll
have that fear of dying from suffocation and pain. And, I guess, you know,
having those early interventions – early conversations alleviate that sense.
The following summary (Table 4.5) shows some of the issues which may
present as a barrier to clear communication between clinician and people with
MND and their families identified by the participants in this study.
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Table 4. 5. Communication Barriers




















Many of the clinicians were reluctant to discuss the poor prognosis of
the person with MND too early but admitted that leaving those
conversations too late was not a good option for the person with MND
either (C6, C4).
Worrying that even the conversation will upset the family and person
with MND (C19, C6, C7, C14).
Sufficient time for detailed communication was a factor mentioned by
both clinicians (C2, C3, C4, C11, C12, C19, and C8) and the
bereaved family participants (F1, F2).
Languages other than English were potential problems with
communication, barriers to being able to communicate adequately
and misunderstanding, despite the use of interpreters (C12).
Communication with a family member because the person with MND
does not want to know (C7, C4).
Repetition of the end-of-life communication and readiness of the
person to want to hear; a person may be told the same thing several
times but must be ‘ready to hear it’ (C8, C9).
The stigma of MND as becoming a vegetative state or how alive they
are until the end (C14).
Clinician admitting that a barrier was the uncertainty of the disease
and admitting that clinicians did not want to face such uncertainty
(C11). Being able to say that not knowing how, when or what will
exactly happen and being honest from the beginning (C11) was a
barrier.
Patients ‘shutting down’ and not wanting to hear or stating they have
been told the same thing already (C12).
Denial or patient and family reluctance to engage in communicating
with their specialists was highlighted by several clinicians (C1, C4,
C12 and C16).
People with MND need to be ready to listen and hear end-of-life
options (C8).
Uncertainty to the ethical situation and the law can be a barrier for
clinicians to discuss withdrawal of NIV (C5).
Time (life) left as a barrier; communication should happen early
particularly as families are from all over the world, conflict may be
involved and planning for the whole family important (C3, C2).
People with MND delaying engaging in end-of-life symptom control
choices as they wish to try alternative medicinal cures (C18).
People with MND and their families who lack assertiveness and
confidence to ask questions (F5,F6, C3).
Clinicians just have a snapshot view of the disease and do not look at
a trend (F3).
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4.12. Chapter Summary
To answer the research questions, the candidate commenced by
undertaking an extensive literature review to ascertain what was already known
about the communication surrounding initiation and withdrawal of NIV (Chapter
2). The depth and extent of relevant knowledge determined the independent
variables and formulated the questions asked of the participants. The semistructured interviews with all participants were at least an hour in length and
comprehensively covered communication and topics relevant to NIV, MND and
the end of life.

Whilst the discussion (Chapter 5) that follows explores in greater depth
the areas of interest that have emerged from analysis of the data, a description
of the analysis has been provided within this chapter. The research questions
explored within this study include how clinicians explained the benefits and
burdens of NIV, the continuation of disease progression, referral to palliative
care and end-of-life care and choices including NIV withdrawal. The comments
and views of the family participants have been included and woven throughout
the chapter to add context and perspective to the clinicians’ descriptive
narrative. The presented data have been compared against the most recently
published recommendations for assessment and care of a person with MND,
the use of and potential withdrawal of NIV and, in addition, the understanding
and use of PEG tubes in MND. Some of the findings which relate to
recommendations from both the family and clinician participants, are included in
the recommendations and conclusion chapter, answering the last of the
research questions.

This research found that some of the difficult communication such as NIV
withdrawal and choices of end-of-life care were either assumed to have
occurred with other clinicians, were too difficult for a clinician to fully explain in
the time available or left too late for sufficient patient benefit and family
understanding. The time and repetition required for ongoing and lengthy
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communication relating to end-of-life choices and the removal of NIV was an
issue voiced by all the palliative care and respiratory specialists and some of
the nurses. Aspects of the most recent recommendations and assessment
guidelines (NICE, 2016) which have been referred to throughout this research,
have been questioned by both clinicians and family participants. The concept of
the need to preserve hope in relation to the difficult discussions and honest
communication about end-of-life choices and the potential of NIV withdrawal is
considered in the following discussion chapter. A comparison of the findings of
this study against recommendations in guidelines is also presented in Chapter
5.

It is hoped that by understanding both the participant clinician comments
and the actuality of the bereaved families, particularly the one person with MND
who so desired to have his opinions heard, that a greater understanding of
MND/NIV/PEG and end-of-life communication has been achieved. The potential
for the generation of practice knowledge is more fully discussed in Chapters 5
and 6.
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Chapter 5:
Discussion
5.1. Chapter Overview
This chapter integrates all that has been studied within this thesis, from
the introduction of the subject, the gap identified from the literature and the
findings of the participant interviews.

To undertake a detailed discussion of the findings of this research it is
important to highlight what is understood to be best practice and patient-centred
care in relation to the area under enquiry. The most recent MND
recommendations and guidelines have informed the participant questions.
Attention to the theoretical perspective, SI, which draws on the shared
experiences of the participants, is woven throughout the discussion to make
meaning of the findings. Using ID as the methodology to contextualise the
findings of this research, the knowledge gained is argued to be relevant and
applicable to clinical practice (Thorne, Reimer Kirkham, et al., 2004).

The contribution this research has made to the existing knowledge
concerning the communication and symptom control measures for people with
MND is explained. Understanding the communication difficulties encountered by
people with MND, their families and clinicians alike, formed the principal
component of this study. The Dreyfus Model of Skill Acquisition (Dreyfus &
Dreyfus, 1986) is used as a concept to understand clinician participant
communication in relation to experience.

Identifying where issues arose has provided the opportunity to propose
possible solutions and offer some suggestions for further research areas
(detailed in Chapter 6).
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The final five research questions (the first research question was answered by
the literature review) are considered in turn:
1) What is the evidence that the best practice communication content
(benefits and burdens of NIV, continued disease progression,
explanation and offer of a PEG, end-of-life discussions and
understanding potential NIV withdrawal prior to commencement of NIV)
is incorporated into the reported communication by clinicians to people
with MND and their families at the time of offering NIV?
2) What do MND families/significant others recall about the communication
(benefits and burdens, continued disease progression, PEG insertion,
potential NIV withdrawal and end-of-life discussions) provided by
clinicians at the time of respiratory failure and the offer of NIV?
3) To what degree do MND families/significant others feel that the NIV
communication provided by the clinicians at the time of the offer of NIV
prepared them for and helped them to understand the implications of
potential NIV withdrawal resulting in the death of their family member?
4) What, if any, unmet needs for information, support, palliative care, or
other services do the clinicians and the families/significant others (or
patients themselves) with experience of MND identify?
5) Following the literature review and clinician and family/significant other
interviews regarding NIV communication, what recommendations can be
identified that would improve end-of-life communication and process for
the patients, families and clinicians involved with the end-of-life care for
people with MND?
This chapter commences with a summary of the findings from this
research to provide context for the discussion that follows. The chapter is then
sub-divided under identified communication issues and discussed within the
framework of the research questions which are outlined above.
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5.2. Summary of the Key Findings from the Research
The following is a summary of the key findings from this research which will
be expanded upon in this chapter:
1) Some of the clinicians are unaware of the specifics of the
recommendations contained in the NICE MND Assessment and
Management Guidelines (2016).
2) These recommendations are open to clinician interpretation as far as
what, when, how and if to communicate end-of-life care options.
3) There is uncertainty around whether the clinicians with experience have
the capacity to communicate more clearly with people with MND
regarding symptom control and end-of-life choices, but they are known
not to follow guideline recommendations about the timing of
communication.
4) Communicating end-of-life options and the potential withdrawal of NIV
prior to the commencement of NIV is difficult for all involved regardless of
a clinician’s years of experience.
5) Clinicians experience limitations on the time available to talk to patients,
and so prioritise explaining the technicalities, maintenance and
mechanics of NIV to people with NIV and their families. Some of the
respiratory clinicians reported that they often feel it is not appropriate to
introduce NIV and its benefits and state its burdens and the potential of
withdrawal as an end-of-life choice when NIV is no longer of any benefit,
at the same time.
6) Many clinicians are reluctant to make an early referral for people with
MND to palliative care despite acknowledging this to be best practice.
7) Some palliative care clinicians feel that on referral, people with MND are
under-informed about the disease process, prognosis and symptom
control options.
8) Families are confused by the need for early involvement of palliative
care.
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9) Structured MND MDTs were rarely available particularly outside the
cities and often within cities. The benefits of an inclusive MND MDT for
people with MND are unavailable in many areas (Rooney et al., 2015).
10) NIV and PEGs are often encouraged by clinicians. Respiratory clinicians
see NIV as improving the quality of life, perhaps equating quality of life
with quantity, which may not be the priority of the people with MND and
their caregivers.
11) PEGs are commonly offered to people with MND to prevent or reduce
the incidence of aspiration.
12) Communication is often open to misinterpretation such as the word
“prognosis” and what the speciality of palliative care can do.
13) Families are confused about the roles and number of health
professionals involved with their family member with MND’s care; having
to repeat the same information is frustrating and exhausting for them.
14) There is confusion regarding who is involved with the patient’s ongoing

care decisions, among both clinicians and family and caregivers.
Between clinicians there appears to be confusion regarding which
clinician has overall responsibility for care and for communicating and
explaining the benefits and burdens of symptom control and end-of-life
options. If information relating to symptom control and end-of-life choices
is not clearly provided, the person with MND and their family have gaps
in their understanding and interpretation of the situation. The family may
be confused as to who they ask for clarity.

5.3. Research Question 2:
What is the evidence that the best practice communication content
(benefits and burdens of NIV, continued disease progression, explanation
and offer of a PEG, end-of-life discussions and understanding potential
NIV withdrawal prior to commencement of NIV) is incorporated into the
reported communication by clinicians to people with MND and their
families at the time of offering NIV?
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This research question, concerning clinicians’ communication practice,
was answered by asking clinicians rather than through an objective assessment
of what clinicians did. This sets the context and limitations of interpretation.
Clinicians were asked whether they were aware of aspects of the NICE MND
guidelines and if there were specific trigger points they used as an opening for
honest discussions including assessing how the person with MND and their
family had understood such communication. The clinicians were also asked
whether they discussed end-of-life options as recommended by the most recent
guidelines, or if they communicated the benefits, burdens and potential
withdrawal of NIV when initiating NIV. Their answers reflect their insights into
where they do not comply with current best practice as defined in the
guidelines, and the barriers they experience in implementing the communication
recommendations.

The NICE MND Assessment and Management Guidelines (2016) is an
extensive, detailed document easily obtainable online and available to
download. However, the lengthy document covers an enormous amount of
detail and time would be required to fully appreciate its recommendations.
Whilst many of the clinicians were aware of the most recent NICE MND
Assessment and Management Guidelines (2016) not all were aware of the
recommendations on timing and content of NIV related end-of-life
communication. Detailed end-of-life communication was assessed to be
necessary by the clinicians involved later in the disease, indicating that earlier
discussions delivering the diagnosis and general prognosis may not have
contained such communication. This research sought evidence for the
occurrence of best practice communication relating to the benefits and burdens
of NIV, end-of-life choices and potential of NIV withdrawal. This research has
found that communication recommended to occur soon after diagnosis and at
certain trigger points in the disease process, particularly at the commencement
of NIV, frequently does not happen.
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Understanding the communication experiences family participants have
with clinicians is an important aspect of answering this research question. The
family perspective is addressed within this question but covered more
comprehensively under the third research question (Section 5.5). This research
could not correlate the family participants’ experiences of communication with
those of the clinician participants.

The ability to initiate end-of-life communication on patient deterioration
and increased reliance on caregivers is extremely difficult for all concerned
(Aoun et al., 2012). This difficult judgement of timing appears to be complicated
by the clinician perspective of maintaining hope for the person with MND and
their family members. Preserving the feeling of hope by clinicians and,
therefore, not initiating these discussions was found to be a barrier and a strong
theme throughout this research. This finding is mirrored by the results of a study
which surveyed neurologists involved with the delivery of an MND diagnosis
and found the communication caused much stress for the clinicians for the
same reason (Aoun et al., 2016). Maintaining hope, however, may be
detrimental to the patient and family if referral to palliative care specialists is
delayed until well into the deteriorating phase of the disease. Despite many of
the clinicians identifying the barriers, having the confidence to know that the
communication is appropriate and the timing correct for the recipient is a
challenge. The respiratory clinicians in this research indicated that their priority
when initiating NIV was of a more practical nature: explaining the machine and
familiarising the family with its use. The respiratory clinicians acknowledged the
difficulty they had with introducing end-of-life discussions at the stage of
commencing NIV, although they understood it should happen.

When communicating the benefits and burdens of NIV and initiating
referral to palliative care, several of the clinicians stated they were reserved in
their communication. The time required at appointments to introduce and
reiterate the end-of-life options and potential withdrawal of NIV to ensure the
person with MND understood, was described as a significant barrier. Both
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communication and system barriers were identified in this research. These and
other barriers to the incorporation of best practice communication in the
management of MND are detailed further below. A table of communication
barriers identified by the clinician and family participants in this research is
included in Chapter 4 (Table 4.5). The issues found to have most influence on
clinicians’ communication with people and families coping with MND were the
availability of time and the wish to preserve hope.
5.3.1. System barrier: time allocated for significant communication
The MND Assessment and Management Guideline recommendations
(NICE, 2016) emphasise the importance of psychological and caregiver support
from the time of diagnosis. Proposed within the European Clinical MND
guidelines are two long appointments with a neurologist in order that the
diagnosis can be delivered in a sensitive, comprehensible and gentle manner
(Andersen et al., 2012). As the delivery of a diagnosis of MND is recognised as
requiring lengthy appointment times with the neurologist, so perhaps should the
appointment time for communication which incorporates end-of-life choices.
Many of the clinician participants within this study reported having insufficient
time for these discussions (C2, C3, C4, C8, C10, C11, C12 and C19). A
recently published journal article which addressed ethical considerations and
palliative care in people with MND, notes the variation in how people process
bad news (Danel-Brunaud et al., 2017). Danel-Brunaud et al. (2017, p. 301)
reaffirm the need for time to explain and discuss issues with people with MND
and their caregivers, suggesting several long interviews to make sure the
communication has been understood. A study into the importance of
compassion among health professionals from a cancer patient’s perspective
found that patients wish to be treated like a person, not the illness they have
(Sinclair et al., 2016). Family participants within the study recommended that
health professionals understand their patients more holistically. Again, this
ability to understand individual patients, their life, and their preferences of care
requires time. Building a relationship between patient and clinician by involving
palliative care services soon after diagnosis or by having a nurse case
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coordinator (neurological or palliative care) to build a trusting relationship may
enhance end-of-life communication.

This research has extended existing knowledge on whether the most
recent MND Assessment and Management (NICE, 2016) recommendations are
being followed and, if not, why not. The candid statements from the clinicians
explain the difficulty many find in judging the right time to introduce end-of-life
communication without causing the person with MND and their family excessive
distress. They also shed light on the time constraints within the medical system
which act as barriers to long and repetitive communication. In the Clinical
Practice Guidelines for communicating end-of-life issues with adults in the
advanced stages of a life limiting illness (Clayton, Tattersall, Currow, &
Hancock, 2007), uninterrupted time for such communication is considered
essential. Finding the right time and finding sufficient time are often inextricably
linked. The lack of time required for such involved, emotional and often
repetitive communication with people with MND was a concern voiced by many
of the clinician participants (C2, C11 and C12), and reiterated by the families
(F5, F6). The clinicians stated that they simply did not have time for the required
conversations which included choices of symptom relief end-of-life care and
hoped, and in many cases assumed, other health professionals did. As
admitted by many of the clinician participants, adequate time to have sensitive
discussions relating to the burdens of NIV and end-of-life choices became
secondary to addressing the technical aspects of care (C2, C11, C12). Several
of the respiratory clinicians explained that they only saw country people with
MND when they became symptomatic and required NIV and so explaining the
technicalities of the NIV machine took precedence and required explicit training
prior to a patients’ return to the country. Adequate time to have the more
sensitive communication was simply not factored into the appointments. This
research did not delve into the reasons why time could not be allocated for
longer specialist appointments to incorporate all aspects of communication
surrounding the benefits and burdens of NIV and end-of-life choices, and this
may be an area requiring further (political/financial) investigation.
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5.3.2. System barrier: delays and poor communication within the
health system
The timing of referral to a specialist (neurologist or respiratory specialist
particularly) of symptomatic but not necessarily diagnosed people with MND
was found to be slow. Families mentioned a delay or hesitancy in being referred
on to a specialist for symptoms that had been investigated but not easily
explained such as respiratory difficulties (F1, F6 and P1). Comments from some
of the bereaved family participants suggested that MND was not often
contemplated as a diagnosis by the more generalist doctors (F1, F6, and P1).
This may not have been because the diagnosis of MND was not contemplated
by clinicians but because they wanted to be sure of a diagnosis given the
gravity of the disease. However, the family participants had not understood the
delay in reacting to non-specific symptoms. Many and varied exploratory tests
proved negative for any specific disease but difficulty breathing continued
unexplained (F1, F2). All the family participants understood that there is not a
specific diagnostic test for MND and that diagnosis is more a process of
eliminating other diseases. However, even once the MND diagnosis had been
made one participant family described how their family member was subjected
to further uncomfortable and seemingly unnecessary tests to reconfirm the
diagnosis (F6). This again reflects the need for improved communication
between clinicians and people with MND, particularly relating to potential
respiratory issues.

Family participants volunteered information about how the diagnosis of
MND was given to their family member. Although this question was not
specifically asked, their comments exposed further communication issues. The
timing and delivery of the MND diagnosis in each of the participant families and
the one person with MND interviewed was poorly conveyed by the specialists.
This finding aligns with that of a recent national survey of neurologists
undertaken to establish how MND diagnoses are given (Aoun et al., 2016),
which found that once diagnosed there was frequently a delay in the results of
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tests reaching the person with MND and at times, also in reaching the clinician
most closely involved with the patient. By the time the results were made known
to the person with MND, an increase in severity of the symptoms had frequently
occurred. This finding was consistent with research conducted by McConigley
et al. (2014). Their research found that symptom relieving needs had often
changed by the time a person with MND had been assessed and subsequently
provided with devices to relieve their symptoms (McConigley et al., 2014).
Understandably, the difficulty was due to the progressive and often
unpredictable course of the disease which can differ according to the variants of
MND. The challenge for the clinician was to predict the course of the disease
and act on the symptoms without delay. The family participants in this research
acknowledged the work and advice given by MNDAust with the supply of
equipment, information and support for people with MND and their families. A
suggestion from one of the family participants (F5) living in a rural area was the
implementation of an online support and discussion forum for people who were
also traversing the MND journey so that others could benefit from shared
experiences. One family (F6) learnt much of their MND knowledge and gained
support from an online social site in the United States, having been unable to
find such a resource in Australia.

Practice that aligns with guidelines and recommendations may remain an
aspiration: indeed, good intentions to implement these have been demonstrated
by the sincere comments from clinician participants within this research (C1C19). The possibility of clinicians being guided by means other than formal
recommendations and MND guidelines was considered a possibility. For
example, early palliative care referral for people with MND is a guideline
recommendation acknowledged by many of the clinician participants to be
important but not necessarily reflected in practice. The clinicians involved prior
to palliative care found early communication relating to referral to palliative care
and end-of-life choices when these clinicians were offering symptom control
measures such as NIV and PEGS could take away hope. This corresponds with
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an article by O’Connor (2012) which highlights palliative care intervention
occurring too late to be effective. O’Connor suggested that in many instances
palliative care recommendations developed by experts were often regarded as
optional by clinicians (O'Connor, 2012). The palliative care clinicians
interviewed for this study said they were often involved late in the course of the
disease and at times stated an earlier referral would have been more beneficial
to the person with MND (C1, C2, C3 and C19). This was reiterated by some of
the respiratory specialists (C11, C12, and C16) who also felt their input at an
earlier stage of MND may improve adverse symptoms. This study found, as
other research studies have before, that referral to palliative care in MND often
occurs later than that recommended by the most recent guidelines (Bede et al.,
2011; Connolly et al., 2015). Referral to a palliative care service is discussed
further in Section 5.6.3. When asked how they communicated (i.e., verbal,
written document) end-of-life options, including the potential of NIV withdrawal,
the specialists involved suggested to patients that they look at the MNDA
website. Only in some cases had printed material from MNDA been prepared to
give to the people with MND. One family participant stated that following
diagnosis she was told not to contact MNDA, as they were described by the
clinician as being too negative (F3).

It was evident from the results of this research that when a structured
MDT existed, relevant information was provided to the patient when it was
considered appropriate after diagnosis, leading to clarity and choice in end-oflife care. A structured MDT also incorporated a palliative care specialist at an
earlier stage of the disease, which may have improved patient acceptability of
incorporating palliative care earlier into their care.
5.3.3. Communication barriers: clinician knowledge and experience
Within this research the European (Andersen et al., 2012) and U.K.
(NICE, 2016) guidelines in particular have been extensively quoted and referred
to as the most recently published recommendations for MND. This research into
communication surrounding NIV in MND and end-of-life choices sought expert
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and experienced clinicians for their views. In order to clarify what may be
understood to be an “expert” this research includes a reference to the Dreyfus
Model of Skill Acquisition (Dreyfus & Dreyfus, 1986) which has been widely
used in research on acquiring skills including the ability to communicate clearly.
The Dreyfus model researched how people attained skills and was based on
the study of chess players and members of the military, and subsequently used
as a model in nursing research (Benner, 1984). The model is based on five
levels of skill attainment from novice to expert, with experience and time as the
factors for acquiring skills. The skill components include perspective, ability to
make decisions and ability to decide relevance of a situation. The expert level
suggests a minimal reliance on rules and guidelines as the expert intuitively
knows what can be achieved (Dreyfus & Dreyfus, 1986). If the Dreyfus Model of
Skill Acquisition is considered in the context of this research then the expert is
the clinician (respiratory or palliative care) with experience of communicating
with people with MND and who is able to achieve excellence without much
difficulty (Benner, 1984). This excellence includes the ability to communicate
the difficult end-of-life choices people with MND and their families must make.
The findings in this research did not suggest that clinician experience in MND
increased the likelihood of following guideline recommended communication,
including end-of-life choices and NIV withdrawal, prior to the commencement of
NIV.

This research has identified that whilst the guidelines are generally
recognised by the clinicians, aspects of their content are not widely followed.
The length of time a clinician had been practising in their specialty did not
necessarily make the sensitive communication surrounding the end of life and
the potential of NIV withdrawal any easier and in some cases did not occur. The
idea of acquiring clinical and communication knowledge without necessarily
referring to guidelines was explored further in this research.

A study by Gabbay and May (2004) suggested that expertise in clinical
decision-making and care was achieved by unconscious assimilation of
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knowledge. This knowledge was communally strengthened by collegial
discussion and thought sharing (SI) rather than exploring specific clinical
guidelines. This concept, known as mindlines (Gabbay & May, 2004), revealed
that health professionals infrequently acquired guidance through clinical
guidelines and research articles; more often they gained their knowledge
through discussion with their peers and occasional readings. As identified in
Chapter 2, the recommendations in the current MND guidelines are largely
based on published studies and expert clinical opinion (Andersen et al., 2012;
NICE, 2016). The clinician participants in this research appeared to be basing
their communication decisions more on their own personal characteristics,
those of the patient and their family, their ability to interact and level of skill in
communication rather than reading and following the guideline
recommendations. The possibility exists that the further away the clinicians are
from their formal education and the more experienced they become, the less
likely they are to adhere to guideline recommendations. The personal clinical
experiences the participants had with NIV withdrawal in MND were found to
have some influence on their communication. The reasons and barriers behind
the clinician communication decisions are discussed in this chapter and the
implications of their decisions for the families are explored.
5.3.4. Communication barrier: preservation of hope
The most recent MND guidelines recommend sensitive communication
occurs when the person is ready to receive it and relies on an emotional
judgment and assessment of readiness of the patient and family by the clinician
(Andersen et al., 2012; NICE, 2016). However, if end-of-life choices have not
previously been discussed or understood this communication should occur
when the respiratory system fails and NIV/PEGs are offered (Andersen et al.,
2012; MNDA, 2014; NICE, 2016). Whilst the guideline recommendations
advocate a specific trigger or time for such communication, this research found
that sensitive end-of-life communication does not always occur when
recommended. The timing of end-of-life communication identified within this
research appears to be largely dependent on when a clinician is ready or feels
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the person with MND is ready to receive it, concurring with previously published
literature (Connolly et al., 2015; Smith, Disler, Jenkins, Ingham, & Davidson,
2017).

Clinicians assess patient and family readiness for end-of-life discussions
and respond to patient and family triggering behaviour or emotional indications
of wanting to have such communication (Clayton, Hancock, Butow, Tattersall, &
Currow, 2007). Clinician knowledge of the guidelines and other literature
relating to NIV was found to be variable and, understandably, appears to
depend on their clinical specialty and involvement with MND. Any previous
experience of NIV withdrawal in MND on the part of the clinician appeared to
have little effect in easing difficult early end-of-life communication, particularly in
relation to NIV withdrawal.

Coming to terms with the diagnosis and its implications is extremely
confronting and may be cloaked with the hope that “they got it wrong”. As this
study has found, Blackhall (2012) has suggested that clinicians with little
experience of people with MND wait for the patient or family to initiate the
discussions relating to the end of life to lessen the sense of hopelessness.

The preservation of hope and the concern that the conversation might
upset the family was a barrier for many clinicians to pursuing end-of-life
communication (C6, C7, C14 and C19). Clinicians also stated that in their
experience many people with MND and/or their families expressed the need to
live in the present as the future looked so bleak. However, if the clinicians wait
for the person with MND to initiate or ask relevant questions they may be
assuming that the person with MND has sufficient health literacy or
understanding to approach such difficult discussions. Studies that suggest
people with MND would like the clinicians to initiate sensitive communication
exist (Anderson et al., 2007; Blackhall, 2012). Commencing end-of-life
communication without waiting for the patient to instigate the discussions may
help to eliminate the possible difficulties encountered by those less able to ask
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pertinent questions. As some of the bereaved family participants acknowledged,
traversing the medical system and having the confidence and knowledge to ask
the relevant questions required a high level of health literacy (F3, F6). All the
bereaved family participants and the person with MND interviewed stated they
searched the Internet for information, particularly if they had not understood fully
what had been said by the health professionals. Potentially, the assumption that
people with MND will turn to the Internet to address their questions and fears
may lessen the urgency clinicians feel to initiate such sensitive communication.

If clinicians acknowledge that end-of-life discussions should happen
early, but also feel that it takes away hope, when should these discussions
occur? A recent German article (Löbbe, 2016) suggests that there are too many
guidelines in existence and that they do not always prove useful in complex
clinical situations. The article makes the point that evidence-based medicine
strives to provide the most advantageous care to patients, but that there are
other aspects of a clinician’s expertise which may equally provide the best care.
Löbbe (2016. p. 275) suggests that good communication technique, experience
and “willingness of the physician to make a decision contrary to the evidencebased guidelines” are important factors in best practice. Importantly, this
viewpoint may mean confusion regarding who should undertake the difficult
end-of-life discussions relating to NIV and its withdrawal, and when they should
or could occur. For the study reported in this research, 19 clinicians (eight of
whom were nurses) were interviewed, and the majority (seven out of eight)
nurse participants accepted the need to have these discussions and were
willing and felt able to do so despite sometimes being “hated” (C8) by the
patient for doing so. The nurses felt the person with MND and their family were
entitled to be able to plan in the full understanding of their disease potential.
This concurs with the findings of the study by Connolly, Galvin and Hardiman
(2015) which concluded that families were better able to make plans and
symptom-relieving treatment decisions early if given the options for care. The
feeling amongst the clinicians in this research who felt able to undertake these
discussions early in the diagnosis (C1, C16, C17) was that it alleviated the
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worry associated with the unknown course of the disease, particularly the issue
of choking to death which may concern them throughout the illness if not
tackled early (Borasio, Shaw, et al., 2001).
5.3.5. Communication barrier: frontotemporal dementia
Identifying FTD was difficult for health professionals particularly if they
only met the patient once or twice, which was often the case, particularly
between country patients and respiratory specialists (C1, C15, C19). The point
was made, however, that a person with MND with changes related to FTD may
not have a deep enough understanding of their health situation to make
decisions, which would affect their caregivers (C13). The family participants in
this research were largely unaware of FTD in MND as the condition had not
been discussed by their clinicians, although two families had found information
on the Internet (F3, F6).

A palliative care specialist (C1) stated concerns that FTD in MND was an
area requiring more research and understanding and often a condition going
unrecognised by clinicians and families. One of the specialist clinicians had
experience with people holding very strong beliefs against nutrition through the
insertion of PEGs (C15). Whilst this was certainly presented as a barrier for
PEG insertion in some people, the clinician wondered whether perhaps this
indicated involvement of FTD affecting decision making. One of the family
participants described a situation where their family member with MND was
taken shopping and despite not being able to swallow solid food herself, kept
collecting chocolate bars into the shopping basket (F1, F2). The family initially
thought this was “naughty” behaviour but described how the person with MND
was also insistent that her husband’s birthday was imminent and wanted to
send a card when the birthday had been some months prior. Despite the family
explaining correct dates, their family member with MND persisted. The family
concerned were vaguely aware of dementia being associated with MND but had
not associated this behaviour with FTD and had, therefore, not discussed it with
their palliative care specialists.
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The research question addressed in this section asked for evidence that
best practice communication is incorporated into communication for people with
MND at the time of offering NIV, as reported by clinicians. The clinician
participants involved at the stage of required symptom control intervention (NIV
and PEG) appeared not to follow the recommended best practice
communication and stated their barriers and reasons. In this research, time to
discuss and repeat sensitive end-of-life communication was found to be a major
barrier to commencing such communication in many instances. This research
found that communication is only as useful as the content is unambiguous, the
clarity with which it is delivered (in this research communicated by the
clinicians), and the willingness and ability to understand and remember by the
one who receives the communication. This is particularly relevant when
considering the often-subtle changes associated with FTD. The clinician
participants in this research admitted that recognising FTD in MND was difficult
especially if the family had not communicated personality changes in their
family member to the clinician. The often-subtle changes that may indicate FTD
could be an aspect of early support and coordination of care involving a case
manager soon after diagnosis. The suggestions to improve communication
difficulties made by participants in conjunction with the candidates own
suggestions are encompassed in Chapter 6.

5.4. Research Question 3:
What do MND families/significant others recall about the communication
(benefits and burdens, continued disease progression, PEG insertion,
potential NIV withdrawal and end-of-life discussions) provided by
clinicians at the time of respiratory failure and the offer of NIV?

This question was answered by the bereaved families of people with
MND through their recollections about the communication they had with
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clinicians relating to when NIV was discussed, the content of the discussions
and what they had understood about end-of-life care options. Their answers
show what they understood of their choices and what, in retrospect, they realise
they had not fully understood.

The guidelines advise that the benefits and burdens of NIV and PEGs,
and the option that NIV can be stopped at any time, should be communicated
prior to the commencement of NIV (NICE, 2016. The families were asked about
any alternatives to NIV and PEGs offered as symptom control methods. The
point of this line of questioning was to ascertain whether the benefits and
burdens of NIV and PEGs had been fully described, and then whether
pharmaceutical options which may mean a shorter life, were communicated to
the person with MND and their families. Of concern was that PEG insertion was
described to families as a way to minimise or prevent aspiration pneumonia, for
which the research literature shows there is no benefit (F1, F2, F6) (Potack &
Chokhavatia, 2008). The families confirmed that much of what they understood
about MND, NIV and PEGs was either found or clarified via the Internet.
Families also stated that being asked to think about the research questions had
made them realise the implications of aspects of NIV and end-of-life
communication they had not fully understood at the time; for example, the
withdrawal of NIV when a person with MND no longer benefited from it and the
option of pharmaceutical alternatives. The content of communication given to
the family and person with MND regarding treatment options was found to
greatly influence the decisions surrounding symptom intervention and care
choices.

It became evident that the family participants were presented with
overwhelming and confusing information particularly relating to NIV. This
research did not ask about family health literacy, however, many of the
participants (family and clinician) spoke about the need for a good
understanding of the health system and health literacy. Family participant
understanding for the potential of withdrawing NIV when it was no longer
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providing symptom relief or at the person’s request, was not clearly understood
by the families. Communicating the need to insert a PEG (if the person with
MND wants one) prior to any swallowing difficulty, has caused some confusion
for people with MND. Understanding that MND causes respiratory weakness
which in turn increases a person’s anaesthetic risk for inserting a PEG requires
a fair level of health literacy. Clinicians recommending inserting a PEG when
the person’s swallowing remains unaffected, the benefits and burdens of such a
measure, requires good communication skills and confidence, and patients and
families need the knowledge necessary to ask relevant questions. Many of the
family participants within this study were confused by the timing of PEG
insertion and were unaware of any risks of aspiration pneumonia (F1, F2, F3
and F6) (Potack & Chokhavatia, 2008). Despite guidelines recommending
communication of the benefits and burdens of NIV and PEG tubes prior to or, at
the latest, at the development of respiratory weakness, clinicians and families in
this research state that this did not necessarily occur (NICE, 2016).

Generally, the family participants and the one person interviewed with
MND agreed that they understood the workings of the NIV machine as
explained by the respiratory clinician. This corresponds with the respiratory
clinicians in this research stating that they focus on the workings and benefits of
NIV. The families also understood that the NIV did not provide any cessation of
the disease process and that they would become more dependent on NIV as
the disease progressed. However, the families did not fully appreciate the
difficulties they may then encounter such as any influence FTD may have on
their family member (not discussed with any of the family participants) and the
increase in caregiver involvement to ensure the NIV continued to work (F1, F2,
F3). The burdens of wearing and adjusting an NIV mask cannot be fully
understood until trialled, and the understanding that whilst the person with MND
may be able to initially adjust their own mask, as muscle weakness becomes
more pronounced their caregivers will by default become more involved.
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The family participants were asked if they were aware of the inevitable
disease progression despite NIV and PEG insertion and if this had been
communicated to them. The families all understood the severity of the diagnosis
but not the speed at which the disease could progress nor the limitations of the
interventions available. None of the bereaved families had anticipated how their
family member with MND would die even though they all understood respiratory
failure to be the main cause of death in MND. In this study one person with
MND starved himself to death (F3); another kept trying to pull off her NIV mask
for unknown reasons, possibly indicating “enough” (F1, F2); another pulled out
her PEG refusing further intervention (F4); and another died of respiratory
complications (F6). Of the six family participants interviewed, all but one had a
negative experience of the terminal stage of their family members’ life.

Within the sociological framework of SI, the way the family participants
interpreted the communication during the social interaction with their clinicians
affected the meaning they took from those interactions. The participants
identified barriers including being overwhelmed by the concept of an early
referral to palliative care. Family participant understanding of the burdens of NIV
and benefits of PEGs was unclear from the communication they had with
clinicians and was supplemented by their Internet sourced knowledge.
Suggestions to improve communication incorporating end-of-life issues and the
benefits and burdens of NIV/PEGS by the family participants are considered in
Chapter 6, when the final research question is answered.

5.5. Research Question 4:
To what degree do MND families/significant others feel that the NIV
communication provided by the clinicians at the time of the offer of NIV
prepared them for and helped them to understand the implications of
potential NIV withdrawal resulting in the death of their family member?
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The family participants in this research were questioned on many
aspects of their communication with clinicians and how their resultant
knowledge enabled them to adequately make choices. The ability to adequately
understand how to navigate an increasingly multifaceted health system requires
considerable health literacy. The lack of communication about how the health
systems worked and could be accessed, was voiced by the families who were
at times overwhelmed. As they endeavoured to navigate the care and services
required, the family participants described the difficulties they experienced in
understanding why they had to attend different appointments with different
clinicians in different locations. In an editorial by O’Connor (2012), discussing
palliative care recommendations in Europe, the point is made that some skill or
health literacy is required to traverse health systems.

The variability and accessibility of palliative care services for people with
MND is apparent within this research. The gap between rural and metropolitan
palliative care services and even within the same city appears to be mirrored in
some other countries (O'Connor, 2012). This variability makes provision for a
specific plan of care for people with MND, which incorporates an MDT difficult to
design. There is a need for a more patient-focused plan with emphasis on early
recognition of symptoms and information on who to contact locally. Such a plan
requires further development and research, but from discussion with
participants within this study, this was considered a useful ideal.

Apparent within this study were the emotional consequences for all
concerned, particularly the grieving families, when the end-of-life care options
had been misunderstood (F1, F2). Whether the option of NIV withdrawal was
inadequately communicated, undocumented or not communicated at all to
families by the time the person with MND had lost the ability to communicate
remains unclear from this relatively small participant group. Generally, the
clinicians could see some benefit of early communication about NIV withdrawal,
particularly in terms of ensuring transparency of information. However, the
majority felt the information was excessively confronting for the person with
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MND at the time of offering NIV. If end-of-life choices have not previously been
discussed or understood this communication should occur when the respiratory
system fails and NIV/PEGs are offered (Andersen et al., 2012; MNDAust, 2014;
NICE, 2016).

Previous studies have found that many people with MND and their
families would like clinicians to commence end-of-life communication early in
the diagnosis in order to organise their lives and make health care choices
(Anderson et al., 2007; Blackhall, 2012). Crisis decisions and presentations to
hospitals can occur if documented care plans relating to NIV in MND are not in
place and understood by families (Connolly et al., 2015). The family participants
(F3, F5) within this research, whilst acknowledging a degree of their own denial
in some instances, did suggest that in hindsight some of the decisions made
would have been different if they had fully understood the choices of symptom
control and end-of-life care.

The influences on communication and understanding have been
illustrated throughout this research and has demonstrated how denial and
health literacy have affected how the family participants communicated with the
clinicians (F3, F5, and F6). The perception among some of the clinicians that
the preservation of hope outweighs the requirement to fully communicate the
end-of-life choices suggests the clinician has assumed the dominant role within
the patient/health professional relationship.

From an SI perspective, the role of the clinician and the families and how
they interact and communicate can potentially be affected by stress and attitude
within the process of role interaction (Hochschild & Machung, 1989). The SI
focus on process and the influence of interacting personalities was proposed by
Burgess (1931) in relationship to family personalities and roles. Applying the
concept introduced by Burgess and identifying family in a broader sense to
include the clinicians, person with MND and the family, roles are developed and
defined by the interacting personalities (Burgess, 1931). This process may be
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fluid, however, values and attitudes are transmitted between all concerned in
communicating the prospects of MND, which may ultimately affect the way the
patient interprets their options for care.

Research into the dying process in MND in Australia and the United
Kingdom, found negative caregiver experiences were mainly due to the
unexpected death of their family member from co-morbidities, not respiratory
failure as originally anticipated (Ray et al., 2014). The study by Ray, French and
Street (2014) indicated that if families and people with MND were fully informed,
including about the progressive nature of the disease and how death may
eventuate, the family members were found to have had a more positive
experience of their family member’s end of life. This finding by Ray et al.
correlates with the results of this research where those experiencing ongoing
grieving and regrets in the way their family member died, or their symptom
control prior to death, were those who felt they either did not have or did not
understand the potential complexities of end-of-life choices (F1, F2 and F6). A
limitation to answering the fourth research question may be that those families
wishing to participate in this study are those who may have ongoing grieving
issues related to the way their family member had died.

The difficulties in communicating and encouraging planning in a disease
which offers no hope of a cure and only offers symptom control measures is an
area that requires further understanding. As some variants of MND may have a
life span of 10 years, the concept and treatment of the disease as chronic rather
than terminal may be more appropriate in some cases, particularly concerning
end-of-life communication (Lerum et al., 2016). None of the participant families
within this research experienced the variant of MND which can last for many
years. However, despite the length of their family member’s life from diagnosis
to death being less than three years, all felt palliative care involvement and endof-life communication at or soon after diagnosis was too premature. This
research found that the family participants had an image of palliative care as
terminal care and death-related. This concept may be perpetuated when
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clinicians want to preserve hope in people with MND and, therefore, avoid
referring to palliative care at a time they consider too early in the disease.
Perhaps if the person with MND and their families better understood the
significance of any symptoms they were experiencing they may feel more
inclined to seek specialist advice. From the time of diagnosis then, the
emphasis could be on explaining symptoms and who to contact in the event of
such symptoms occurring, instead of focussing on the end of the disease. The
timing of end-of-life communication and the involvement of a palliative care
service requires further exploration to alleviate the anguish of families planning
for their family member’s terminal stage.

The ethical and legal aspects of NIV withdrawal was raised as an issue
which could be confusing for families and health professionals alike. When
discussing the withdrawal of NIV, clinicians must be able to reassure families
that the withdrawal is not euthanasia nor an illegal or immoral act. This
communication should acknowledge the grief and sadness the family may
experience, but also reiterate that the disease itself will bring the person with
MND to their death. The importance of having conversations which include
disease progression despite any clinical intervention prior to the
commencement of NIV and that NIV withdrawal is a possibility at any time the
person with MND wishes is paramount to clear communication. Communication
ambiguity was illustrated by a family participant (F1) whose family member was
using NIV in her terminal stage and kept pulling the mask off. The family did not
know that their family member could have chosen much earlier on, or at that
stage, to cease using NIV and have pharmacological assistance for her
distressing symptoms (F1, F2). The bereaved participants involved stated that
in hindsight, the clinicians may have alluded to such a course of action, but the
family had not understood the communication or the implications. The clinicians
generally tried to assess how much the person with MND and their family had
understood of the communication incorporating end-of-life care by asking what
they already knew and repeating the information where necessary. However,
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this was often hampered by the level of health literacy of the person with MND
and family and where the person was in their disease trajectory.

The family participant component of this study was small, yet the results
did concur with the study by Anderson et al. (2007) which found clear
communication relating to end-of-life options was welcomed by most people
with MND and their families. Previously published literature found that most
people with MND and their families would like clinicians to initiate end-of-life
communication soon after diagnosis and to further discuss this as deterioration
of the disease occurs (Anderson et al., 2007; Astrow et al., 2008).
The “in hindsight” comments of some of the family participants within this
research described how, had they understood the course of MND more
completely, particularly the symptoms and speed of deterioration of the disease,
their end-of-life decisions on behalf of their family member (at the stage when
the person with MND was too ill to clearly communicate their wishes) may have
been different (F1, F2, P1). Potential withdrawal of NIV prior to the
commencement of the symptom relieving device was not clearly communicated
to any of the family participants within this study, although two families had
discovered this was a possibility from the Internet (F3 and F6). The
communication and emotional difficulties surrounding NIV withdrawal faced by
clinicians and families are encapsulated within studies (Faull & Oliver, 2016;
Faull, Phelps, Regen, Oliver, et al., 2014) and these difficulties were restated by
clinician participants within this study (C1, C4, C8, C10, C11 and C19). Some of
the complications expressed by the clinicians entailed ensuring the medications
were adequate to guarantee comfort on withdrawal of the NIV and coping with
the emotions of family members present. This was particularly evident if the
family of the person with MND had not fully understood or were not in
agreement with the wishes of their family member with MND.
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5.6. Research Question 5:
What, if any, unmet needs for information, support, palliative care, or
other services do the clinicians and the families/significant others (or
patients themselves) with experience of MND identify?
The family participants were asked how satisfied they were with the endof-life communication delivered by the clinicians, and how this communication
enabled them to make their care choices (Appendix E). The family participants
were also asked whether there were discussions which they would have liked to
occur, but which did not. The following sections are intended to highlight areas
as described by the families, which this research has identified as being
problematic for them. The communication and logistic issues are presented in
the context of areas recommended within the most recent MND Assessment
and Management Guidelines (2016) and other substantiating literature.

Faull, Rowe-Haynes et al. (2014) highlighted a need to support all
involved with NIV withdrawal in MND and for detailed communication between
all parties regarding symptom management and NIV withdrawal. Increased
palliative care nurse involvement from diagnosis, perhaps taking the role of a
case manager coordinating with an MDT where available, is a recommendation
of this study and further examined in Chapter 6. Specific published research
into a nurse as an MND coordinator of care could not be found, although this
research found two situations in New South Wales where the clinician
participants stated this was occurring very efficiently (C14, C16).
5.6.1. Communication identifying differences in the concept of
suffering
This research found, as Lemoignan and Ells (2010) have, that quality of
life and the concept of suffering (which may equate to living longer with
symptom control devices) was poorly understood by those with MND and the
families involved with their care. Several of the families (and confirmed by some
of the respiratory specialists interviewed) stated that the technical component of
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NIV information was prioritised by the clinicians over the understanding of
respiratory failure and quality of life. In this research it was queried whether the
often-stated clinician view that the suffering of a person with MND would be
improved by alleviating respiratory distress with NIV, potentially extending a
person’s life (by a few months), was actually increasing their suffering.
However, when family participants considered length of survival as a priority
over distressing symptoms such as agitation, mask discomfort, frustration and
increased caregiver burden it was apparent that an increase in longevity was
not a priority, particularly as the disease progressed.

The issues surrounding caregiver burden in MND were not specifically
explored within this research as previously noted and has been well researched
by others (Aoun et al., 2013). However, it was highlighted as a problem by
some families (F1, F4, and F6) and nurses. The interviews from this study
revealed that caregiver burden was exacerbated by prolonging their family
member’s life when all options for the end of life and symptom control had not
been clearly explained. The fatigue, confusion and desperation experienced by
the family members F1 and F2 in not understanding that their family member
with MND could have had the NIV withdrawn, was profound.
5.6.2. Where a person with MND lives influences communication
and care
This research interviewed clinicians from different areas of Australia and
found that even within cities it depended on whether a person with MND fell into
a certain catchment area as to whether they could access a specialised MND
MDT, particularly one incorporating specialist palliative care. People with MND
who fell under the umbrella of a city service with a specific MND team, living
close enough so that either they could access a comprehensive clinic, or the
palliative care specialist/nurse could easily visit appear to be at a huge
advantage. The comprehensive clinics are able to assist people with MND and
their families to understand their equipment (and back up provision), the
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services on offer (including support groups), and to navigate all aspects of allied
health (Rooney et al., 2015). Delays in people with MND accessing a specialist
MDT (incorporating palliative care), were partly due to the time diagnosis may
have taken (during which time the person could have become more
symptomatic), and partly due to patient and system barriers. This research
concurs with a retrospective study which followed patients from early
identification of MND symptoms to the time they were referred to an MDT
incorporating palliative care (Galvin et al., 2015). Galvin et al. (2015) found a
failure by some clinicians to refer patients to an MDT caused delay in patients
having the assistance they may have required.

At the commencement of this study, consideration was given to possible
differences in availability of palliative care services and specialists generally
between metropolitan and rural areas. A systematic review by Kirby et al.,
(2016) identified that diagnosis and treatment of people with a terminal illness
was less well managed in rural situations when compared to metropolitan
areas. The review focused on the caregiver needs of urban and rural patients
with a terminal illness and led the authors to suggest further research was
needed into how a lack of rural accessibility to palliative care shapes the needs
of the person with a terminal illness (Kirby et al., 2016). The difference in
availability of specialist palliative care services between rural and metropolitan
areas may have played a part in referral time for palliative care, however, this
research has also identified the variation of access to palliative care services
available within the same city.
5.6.3. Early incorporation of palliative care
Nearly 10 years ago the suggestion was made that in order to refer a
patient beneficially and appropriately to a palliative care service the referring
clinician could ask themselves a simple question: “Would I be surprised if the
patient died within the next twelve months?”, thereby ensuring the referring
clinician thought of probable rather than possible death (Moss et al., 2008). In a
more recent systematic review, the “surprise question” was found to be an
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inadequate prognostic tool particularly with non-cancer conditions (Downar,
Goldman, Pinto, Englesakis, & Adhikari, 2017). This has relevance to this
research and certainly to further research, as it is unknown how many clinicians
may have asked themselves this question and, therefore, not referred people
with MND to a palliative care service. This would likely apply more to respiratory
specialists than GPs (who may only encounter a few cases of MND in their
career) because respiratory clinicians see people with MND as the respiratory
muscles are adversely affected. Within the guidelines early referral to palliative
care, soon after diagnosis, is recommended for people with MND (Connolly et
al., 2015; MNDAust, 2014; NICE, 2016). The bereaved family participants,
person with MND and the clinicians all acknowledged that referral to specialists
for symptom control measures often happen too late during the disease to be
helpful. However, early referral to palliative care was viewed by the families and
person with MND and some clinicians (C1, C2, C3) rather differently.

The Australian Institute of Health and Welfare (2014) suggests that
specialist palliative care, end-of-life care and palliative care are all terms used
interchangeably. The institute suggests that end-of-life care is commonly
understood to mean caring for a person with the diagnosis of a life-limiting
illness, whilst palliative care is considered to be the approach to terminal care.
One of the key areas identified was the need for clarity in understanding
terminology among patients, their families and healthcare workers to avoid
miscommunication, particularly with terms such as palliative care and advance
care planning (Australian Institute of Health and Welfare, 2012). Given the
common misunderstanding of the term palliative care - found also within this
research (F5, F3) - to mean no hope and death rather than symptom control
and support, early referral to the specialist service can be confronting for
patients (Galvin et al., 2015). A European study focused on the early referral of
people with lung cancer to a palliative care service found that patients do not
like being referred to specialist palliative care services (despite available
specialist palliative care services) and were, therefore, frequently referred late in
the disease process (Charalambous, Pallis, Hasan, & O’Brien, 2014). Despite
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an early referral to specialist palliative care being a current recommendation for
people with lung cancer (Smith et al., 2012), the study by Charalambous, Pallis,
Hasan and O”Brien (2014) found this was not being translated into clinical
practice. In a study by Oliver et al. (2011) palliative care specialists have found
that people with MND are often referred late in the disease process. Several
studies have found clinicians like to preserve hope by not initiating early
communication surrounding the end of life (Aoun et al., 2016; Faull, RoweHaynes, et al., 2014) and this finding is confirmed and discussed
comprehensively within this chapter.

Whilst most of the palliative care clinicians felt they were generally
involved later in the course of MND than they would have liked, there was some
thought that contrary to the recommended guidelines, referral at diagnosis may
be too soon (C1, C2, C3). As MND could in some instances be considered a
life-limiting chronic disease, early palliative care may not always be appropriate.
This study concurred with the suggestion in an editorial by Burgess, Braunack
Mayer, Crawford and Beilby (2013) that people with a life-limiting chronic
disease, which may describe some variants of MND, be initiated on patient
symptoms and not solely on diagnosis. Most of the palliative care and
respiratory clinicians stated that referral at diagnosis of MND was
recommended but went on to qualify this by stating it did not often occur as it
was too confronting for the person with MND and their families in some
instances.

As none of the families with MND were referred to palliative care at
diagnosis, the acceptability of this cannot be determined from this study. Overall
the families thought that palliative care involvement was appropriate as their
family member deteriorated. Conversely, some of the clinicians argued that if
palliative care teams were not involved early, symptoms may be missed that
could have been ameliorated and prevent unwanted hospital admissions (C1,
C11, and C12). The finding in this research that if families (P1) were not fully
informed early of their choices of care it may lead to emergency hospital
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presentations agreed with Connolly, Galvin and Hardiman (2015). However, the
manner in which this communication occurs and whether it necessarily needs to
be given by palliative care specialists is highlighted within this study.

The symbolic association of palliative care with no hope emerged from
this research, both from the clinicians’ reluctance for early referral to the
specialist service, and from the families’ pre-conceived opinions. Certain
environments can create feelings of uncertainty and how the individual interacts
with that environment may change depending on previous experiences or
experiences of others which may have influenced the individual (Blumer, 1969).
Palliative care for many people is assumed to be solely involved with the end of
life. The individual interpretation and meaning of an environment such as
palliative care is not necessarily conforming to a social construct, but more to
experiences and individual analysis. This negative image of palliative care has
the potential of being reinforced by clinicians who hesitate to explain and
communicate the many aspects of the service in the belief any hope a person
with MND may have, will be eliminated.

There were also practical reasons mentioned by the clinical participants
as to why early referral to palliative care was not happening in their districts. In
particular, the unpredictability of the course of MND, the availability, funding
rules and budget of the local palliative care teams and in some instances the
preferences of those clinicians involved with the diagnosis of MND (C19, C1,
and C2). None of the family participants interviewed thought that palliative care
from diagnosis was appropriate and felt it to be too confronting.

All the family participants involved with this study were very prepared to
be referred and understood the value of referral to a respiratory or gastric
specialist as symptoms became evident or worsened. However, the concept of
early referral to a palliative care specialist for symptom relief seemed
unacceptable. If this is an “image problem” for palliative care, then perhaps
there needs to be a subset of the specialty which is called MND symptom
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control. The inconsistencies within health areas for the provision of palliative
care, particularly in the more urban areas in Australia, the varying levels of
palliative care offered and the mixed opinions of when palliative care should be
usefully offered, appear diverse from this study.
5.6.4. Multidisciplinary teams
The inclusion of palliative care within the MDT is a current
recommendation for the management of MND (NICE, 2016). There is evidence
that MDTs can offer health benefits to patients in most areas of disease
management (Marsilio, Torbica, & Villa, 2016; Rooney et al., 2015). In Europe,
there are MND guidelines which not only recommend referral to a recognised
MND Association on diagnosis but also referral to a specialist MND MDT
(Andersen et al., 2012). A recent study in Ireland found that people with MND
survived approximately seven months longer if under the supervision and care
of a MND specific MDT (Rooney et al., 2015). In the study by Rooney et al.
(2015) the benefits of a well-structured, centralised MDT were suggested to
have the ability to increase the life span of those diagnosed with MND. Rooney
et al. explored and compared whether centralised MDT services would have a
better survival outcome than community-based care which incorporated a care
coordinator. The study concluded that centralised MDT offered a holistic clinical
environment for the person with MND and their families, which improved their
clinical well-being and survival. The study proposed that this may be due in part
to the variation in perspectives and in communicating choices of care between
clinicians, patient and caregiver. Rooney et al. imply that this varied input into
decision-making can enable clearer understanding of clinical possibilities which
can then be incorporated into an AHD.
However, as found in this research, structured MDTs are not always
readily available in Australia. There was considerable variation found in the
geographical co-location of the health professionals that work together to form
an MDT. Ideally the MDT members offer their various skills to improve the
disease process of those they help and in doing so share their knowledge with
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those within their team. The involvement of multiple organisations; not just
those making up the MDT, but those involved as neurological, respiratory or
palliative care nurses plus those offering personal care were often
uncoordinated and disassociated.
There were comments from all the families regarding the number of
people involved with the care of their family member with MND, particularly for
those who remained at home. This related to involvement of multiple
organisations, even within the MDT, causing confusion for the family and
person with MND as to who was responsible for what, and who was organising
ongoing care. The MDTs described by family participants appeared, in many
instances, to be made up of independent health professionals rather than a
formal MDT within one organisation. It is possible that within the more
structured, centralised MND MDT this situation does not arise. However, within
the small number of family participants, and reiterated by the neurological
nurses, confusion does occur. For example, people with MND who lived in
country areas were sent home from city hospitals without organised battery
backup or contingency plans for power outages or technical problems. Other
difficulties voiced by the families included having to attend different specialty
appointments in different places, as the MDT was scattered within various
organisations. One of the MND nurse specialists involved with trying to
coordinate care for people with MND voiced frustration with the lack of feedback
she was receiving from within the organisations involved with multidisciplinary
care in her area. Another city specialist was frustrated by the lack of
cooperation of a country palliative care team post discharge home. It seems
that within Australia the level of community palliative care offered varies
enormously and depends on the preference of the state or territory health
service.
The role of breast cancer nurses has been briefly explored to see
whether their model of patient support could be utilised for MND (Jiwa et al.,
2013). In the study by Jiwa et al. (2013) the role and availability of the breast
cancer nurse negated the need for the person with breast cancer to personally
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attend the MDT meetings. The appropriately trained nurse, as case coordinator,
was fully cognisant of the health status of the person with breast cancer and
was able to report on their behalf to the MDT. The study also found that the
sharing of information between health disciplines was challenging, which
certainly concurs with the findings from this research (C1, C2, C16). Specialist
care nurses, in this case for MND, have been found to play a vital role in the
care of people with MND in Scotland (Ferrie, Robertson Rieck, & Watson,
2015). In the comprehensive report by Ferrie, Robertson-Rieck and Watson
(2015) into planning care for people living with MND, one of the findings was the
importance of the role the specialist care nurses played in coordinating
services, care provision and providing advocacy for the person with MND. The
nurses, where available, were able to advise availability of local services and
provide accurate information which enabled informed decision-making by the
person and family coping with MND. However, despite the vital role the
specialist nurses played, the report went on to say there were many instances
where no one person was identified as taking overall responsibility for
assessment and care of the person with MND and their family. Whilst the
specialist nurse service is to some extent emulated by the community
neurological nurses in Western Australia, their role can overlap with the
community palliative care nurses and support workers from MNDAWA. This
finding of multiple organisations causing confusion for people with MND was
also highlighted in the Scottish MND report by Ferrie et al. (2015) who
described the different care and funding systems as a “bewildering array of
services and people” (p. 182). Each available service in Australia is extremely
valuable but can become confusing for the people with MND and their families.
5.6.5. The usefulness of the advance health directive (AHD) or
documented care plan
A documented advance care plan is a recommendation of the most
recent MND Assessment and Management Guidelines (2016) and it is
suggested that it is discussed prior to the person with MND losing the ability to
clearly communicate. Detailed exploration of the content of an AHD was not a
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priority of this study; however, the participants were asked at what stage they
were discussed and whether they had proved useful. The palliative care
specialists generally initiated the AHD. Considering how late in the disease they
were involved, perhaps the contents of the AHD may not have assisted the
patient appropriately in enabling choices of care. Where the palliative care
clinicians had experience with following AHDs the documents were generally
vague and inadequate (C11, C15, C18). Conditions such as aspiration
pneumonia were not covered, despite recommendation in the current MND
guidelines to detail how concurrent infections should be treated (or not) (NICE,
2016). Rather than writing a formal documented care plan, the families seemed
to have informal inter-family agreements about what the person with MND
would have wanted as they entered the terminal stage of their disease. None of
the families interviewed were encouraged to write AHDs early in the disease,
but most admitted they probably would not have wanted to do so. The AHD
appeared to be as confrontational as the early referral to palliative care. This
made treatment choices difficult for clinicians having to rely on the family
making difficult decisions, such as to withhold feeding and hydration to enable
one person with MND to starve himself to death (C3). The clinician participants
were asked if they ever re-visited the AHDs with a patient when a symptom
control measure was initiated or if a decision to withdraw NIV under certain
circumstances (such as not being able to communicate) was made. Few
clinicians other than palliative care specialists involved themselves with AHDs
and fewer yet re-visited them to make relevant additions or adjustments,
although all thought this a good idea (C11, C15, C18). The American Academy
of Neurology (2012) recommends annual communication and documentation of
a patient’s preference for continuation and potential withdrawal of NIV and any
reasons for not having those discussions to also be clearly documented. Annual
discussions, and documentation of these discussion, with patients about
continuation of NIV and related symptom control preferences could be an
inclusion into an MND specific pathway, was one to be developed (further
discussed in Chapter 6).
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A recently published journal article which explored NIV in patients’ (with
varying diagnoses) perspectives on advance care planning or AHDs found
evidence that discussing advance care may increase hope rather than diminish
it in people with respiratory failure (Smith et al., 2017). As found in this
research, having end-of-life communication and clear understanding on the part
of the patient and family may have alleviated some of the concerns and distress
leading towards the terminal stage of life (F1, F2, F3, and C7).
5.6.6. Barriers to clinician and family communication
In summary, there were many barriers to effectively communicating
symptom control and end-of-life to people with MND and their families. The
points below encapsulate the barriers as described by the participants in this
research:


Many of the clinicians were reluctant to discuss the poor prognosis of the
person with MND too early but admitted that leaving those conversations
too late was not a good option for the person with MND either (C6, C4)



Clinicians worried that even the conversation will upset the family and
person with MND and take away hope (C19, C6, C7, C14)



Insufficient time available for detailed communication was mentioned by
clinicians (C2, C3, C4, C11, C12, C19, and C8) and family participants
(F1, F2)



Time (life) left - communication should happen early, particularly as
families are from all over the world, conflict may be involved and planning
for the whole family is important (C3, C2)



A person may be told the same thing several times but must be “ready to
hear it” (denial) (C8, C9)



The uncertainty of the disease and clinicians who did not want to face
such uncertainty (C11); clinicians reticent to say they do not know how,
when or what will exactly happen and not being honest from the
beginning (C11)
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Denial about the disease or patient and family reluctance to engage in
communicating with their specialists was highlighted by several clinicians
(C1, C4, C12 and C16)



Uncertainty around the ethical situation and the law can be a barrier for
clinicians to discuss withdrawal of NIV (C1, C5)



People with MND and their families who lack assertiveness, adequate
health literacy and the confidence to ask questions (F5, F6, C3).

5.7. Research question 6:
Following the literature review and clinician and family/significant other
interviews regarding NIV communication, what recommendations can be
identified that would improve end-of-life communication and process for
the patients, families and clinicians involved with the end-of-life care of
people with MND?
The final research question is answered in the final chapter of this thesis
and encapsulates the recommendations of all the participants in this research,
and those recommendations suggested by the candidate. Further areas for
research are identified, and improvements for the vision of care and
communication are suggested.

5.8. Chapter Summary
At the time of writing 50 years have passed (1967-2017) since the
founding of modern palliative and hospice care at St Christopher’s Hospice, and
in that time there has been much progress towards improving all aspects of
end-of-life care including communication. The importance of allowing time to
ensure clarity in communicating and documenting the patient’s end-of-life
choices irrespective of the diagnosis has been identified.

Within this research there have been three main perspectives to explore,
and these were identified by gaps in the literature reviewed (January 1990 to
240

July 2016). The most recent MND guidelines recommended communication
relating to NIV initiation, potential withdrawal and the end of life were compared
to the clinician participant interviews (NICE, 2016). The bereaved family
participants, who were also the caregivers for the person with MND, were asked
what they remembered being communicated to them and what they understood
about NIV and end-of-life. The comparison of all material derived from
participant interviews to the most recent guidelines has continued throughout
the results and the discussion chapters.

Complex processes are at play between those delivering and those
receiving communication encompassing end-of-life choices, yet in many
instances it is the clinician who decides whether the person with MND is ready
to hear such communication. The theoretical approach which underpins this
study reveals how varied people are in making sense of their own and others’
behaviours and communication. Symbolic Interactionism has identified how the
same experience can have different meanings for everyone. This aspect of the
study could be explored further to understand how communication can be
delivered in various ways to minimise misapprehension and confusion with endof-life choices.

The potential burdens of NIV and PEG tubes should be communicated
early in the disease process to prevent futile treatment which may prolong
suffering. Time to reinforce or repeat end-of-life choices to ensure patient and
family comprehension as well as patient and family willingness to participate in
such communication are all factors considered by clinicians before commencing
sensitive discussions. Patient initiation of sensitive communication and the
ability to ask relevant questions in a stressful situation may depend on the
health literacy and assertiveness of the person with MND and their family. This
was recognised to be the case by some of the family participants within this
study, who tended to turn to the Internet for their information. Again, insufficient
time is a factor in commencing sensitive discussions and was reiterated by
clinicians of all specialties interviewed in this research.
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Communication between people with MND, their families and health
professionals can be clouded by a mixture of technical jargon, insufficient time
to have insightful conversations, the barriers of patient denial and perceived
lack of empathy in the clinician. Whilst this is not unique to MND communication
(Humphris, 2015), clinician avoidance of difficult discussions has been identified
by Faull, Rowe-Haynes and Oliver (2014) in MND and seen again in this
research.

The clinicians may find clear direction for end-of-life care in well written
AHDs; however, the point has been made by participants within this study that
few directives are written down, sufficiently explicit or readily available. None of
the clinician or family participants re-visited their AHDs (or where there were no
written documents, re-discussed with family members) when situations
changed, or the disease progressed. Denial of the incurable nature of the
disease is a barrier to clear written treatment choices but even such a barrier
may only affect formality in documentation; this research has shown that the
preferred end-of-life patient choices often appear to be known by the clinicians
either by discussions with family members, or remarks made to the specialist
palliative care team at some stage of the disease.

Finally, the recommendations which all participants proposed and those
recommendations which the candidate has suggested based on the completed
research are encapsulated in the last chapter of this thesis, answering the last
research question.
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Chapter 6:
Recommendations and Conclusion
6.1. Chapter Overview
This study has explored the relevant literature extensively and involved
26 participants in detailed interviews exposing the experience and difficulties
encountered with communication surrounding the initiation and withdrawal of
NIV and end-of-life discussions in MND. The clinical participants have provided
insight into barriers to sensitive communication into end-of-life choices and the
benefits and burdens of NIV. Improving communication and managing end-oflife in MND and minimising undue prolonging of suffering are the objects of the
recommendations derived from this research. The bereaved family participants,
who have been involved with a family member with MND, have provided a
glimpse into their experiences and understandings of the options for symptom
relief as communicated to them. The family participants have also described the
health systems they learnt to navigate, any frustrations they encountered and
made some suggestions for other families negotiating the MND path.

This concluding chapter commences with the key issues and
recognition of what this research has contributed to the knowledge and
understanding of end-of-life choices and communication in people with MND.
The recommendations from all the participants who were involved in the study
cover aspects of MND which they felt could be improved upon. Whilst some of
the suggestions are not directly related to the original research topic, the
candidate felt these valuable comments should be included as they may
indicate areas of potential research and avenues for improvement in caring for
people with MND and their families.

The final chapter answers the last research question posed by the
candidate by providing recommendations for improvement in communicating
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the difficult, sensitive discussions surrounding the end of life. The final and sixth
research question is:

Following the literature review and clinician and family/significant other
interviews regarding NIV communication, what recommendations can be
identified that would improve end-of-life communication and process for
the patients, families and clinicians involved with the end-of-life care for
people with MND?

6.2. Key Issues Identified from this Study
The following findings were identified as issues within this study, and
recommendations regarding these are found in Section 6.5:

1. Communication is adversely affected by specialists having insufficient
time to ensure people with MND and their families are sufficiently well
informed about their end-of-life choices. Specialists, particularly
respiratory clinicians, have difficulty having the necessary sensitive
communication about treatment choices and the progressive nature of
the disease due to limited consultation time.

2. There appears to be some disparity between what the MND guidelines
recommend regarding early referral to a palliative care service and what
families stated was appropriate for them. From this study it is also
apparent that clinicians do not always refer newly diagnosed people with
MND to palliative care. This study has highlighted that the bereaved
families of people with MND have not understood the benefits and
capabilities of palliative care as explained to them and perceive palliative
care, with some fear, to mean death. Clinicians and families agree that
the optimal time to refer people with MND to a palliative care service is
challenging.
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3. Families reported that too many agencies/health professionals are

involved with general and specialist care for people with MND. Families
spoke of the need to repeat the same issues to several different people,
which consumed valuable time and effort. The families were very aware
that time was not on their side and resented the intrusion from so many
different services. This potentially affected end-of-life care and symptom
control as stated by one family (F1, F2).

4. Communication barriers exist for people with MND and their families
particularly when discussing end-of-life care and particularly when there
is no structured MDT or single individual responsible for patient care
involved. Families with little experience or knowledge of the health care
system and who have lower levels of health literacy often do not have the
skills to ask relevant questions related to symptom control and end-of-life
issues.

5. Complex communication barriers have been identified in this research
when clinicians initiate NIV in people with MND. Trigger points have been
suggested in the literature as a time when communication regarding endof-life choices be commenced; the offering of NIV is one such trigger
point. However, this research has found that in many instances,
insufficient time and a fear by clinicians of taking away hope often
prevents the necessary NIV and end-of-life conversations from taking
place.

6. The clinicians acknowledged that advance end-of-life care planning
was not as honest as it might be because doctors are reluctant to say
they do not know what will happen or how long until death. Most
clinicians did not re-visit AHDs once written despite changes in symptom
control such as a PEG use which might cause an adverse health
situation necessitating an instant decision for ongoing care.
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7. This study found that some of the families would have liked more
understanding of the disease trajectory and prognosis so they could
make plans and organise their lives. Whilst all the families acknowledged
the variability of the disease and its progression, comment was made
that when certain symptoms developed, a better idea of the remaining
duration of time might be given.
6.2.1. How this research contributes to knowledge
The issues identified from this research as listed above have provided a
platform for making improvements for people with MND and the communication
of their end-of-life choices particularly surrounding the initiation and withdrawal
of NIV. The communication surrounding death and palliative care remains
offensive to many, clinicians and patients alike. This research revealed the gap
between clinicians’ understandings of MND communication recommendations
and guidelines on the one hand, and the communication they consider
appropriate on the other. Valuable insights to the barriers preventing such
communication between clinicians and people with MND and their families have
been provided (Chapter 4; Table 4.5). Family participants stated that referral to
palliative care at or soon after diagnosis was confronting, despite it being a
guideline recommendation. This research suggests the possibility that the
further away from a clinician’s original formal medical education and, therefore,
the more experienced they are in their field, the less likely they may be to read
and comply with MND recommendations and guidelines.

This research provides a much-needed addition to the literature on the
experiences of caregivers and families who have had a family member die from
MND and had experience with, or refusal of, NIV as a palliation measure. The
research also adds valuable insight into the clinician’s perspective of what,
when and how communication is delivered and the barriers they encounter.
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6.3. Participant Recommendations for Improved Communication
The family participants were asked to “please comment on any discussions
which you would have liked to have taken place, with whom and how would you have
liked those discussions?” (Question 21; Appendix E).

Some of the families (F2, F5, and P1) within this research expressed a
lack of understanding of the distressing symptoms and available options for
care particularly at the terminal stage of the disease. Whilst all had some
knowledge of what could occur, and that death would very likely be from
respiratory distress, some of the families appeared unprepared for what
eventuated. There was general lack of understanding that the person with MND
would find increasing difficulty in communicating clearly and, therefore, a poor
comprehension as to why early discussions of end-of-life choices were
necessary. There was confusion about some clinical aspects of the end of life
which had not been discussed either by clinicians or between family members
during the disease.

The families made many valuable points and recommendations within
this study. First, the person with MND interviewed (P1) suggested that clinicians
be more proactive and able to anticipate potential issues instead of responding
to a situation. Two family members (F1 and F2) recommended that families
could be more in control of their situation by asking the difficult questions of the
clinicians to understand what could eventuate within the disease progression.
However, that involves a level of health literacy and confidence, plus the
emotional capacity to cope with the potentially confronting answers. Several
family participants made the point that in hindsight, they would have asked
different questions because now they knew what was important to ask. Some
families may have required guidance to ask the right questions, as levels of
health literacy varied. One family member (F4) stated that if he did not
understand what a clinician had said, he turned to the Internet to find answers,
whilst other families used the Internet for information as soon as their family
member had been diagnosed (F3, F5, F6). The families were asked whether it
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would have been useful to be provided with more written information on the
relevance of the progressive symptoms in relation to the relevant specialist
intervention. All suggested it would have been helpful as negotiating the health
system was confusing and very time consuming. The family participants (F3,
F4) and the person with MND (P1) said they would have liked an idea of the
progression timeline of the disease to plan their lives better. All acknowledged
specific prognostic timing was difficult with MND but suggested an indication of
where the disease was heading when a particular symptom occurred would
have helped them manage their lives.

The family participants recommended earlier referral to specialists once
a symptom was evident but not necessarily explained clinically. Importantly, the
more rural families felt they should have the same access to services as
metropolitan families, although the specifics of those comments were not
advanced further. For example, F5 stated that there was a lack of informed
MND caregivers in her rural area and it was the ability to talk to others in a
similar caring situation that she longed for. Mentoring at an early stage of MND
from others who have gone through the MND experience before was
recommended by F5.

One family (F3) would have liked information about genetic testing and
its availability communicated to them by the clinicians. The content of
communication which one person with MND and their family may require may,
however, be too confronting for another. Better communication between a
clinician and those involved with the person with MND, may mean that many of
these concerns could be explored and discussed.
In summary family participants recommended that:


There is better explanation from clinicians about the symptoms which
may occur in MND and the meaning of those symptoms in relation to the
progression of the disease.
248



Involvement of a palliative care specialist does not occur until symptoms
became more obvious and symptom control is required.



A mentoring (online or in person) system is established to enable regular
contact with others going through the MND experience for more rural
families.



There is a single agency (or care coordinator) appointed instead of
multiple agency involvement.

The clinician participants were asked two questions (Questions 35 and
36; Appendix D) which yielded recommendations for communication and care
for people with MND: “What are the barriers to discussion between clinician and
patient, significant others and caregivers about commencement and
subsequent withdrawal of NIV?” and “Anything else you think I should know
about your experience in communicating about the MND experience for
patients?”

Various themes emerged from the clinician participant interviews and
one of the most common was the need to be able to allocate sufficient time for
communicating all aspects of symptom relief and end-of-life choices. Informed
communication, developing a rapport and establishing trust with the person with
MND and their family were considered important, but these involve a
considerable amount of time spread over several occasions. The frustration
voiced by the clinicians was the difficulty in allocating the amount of time
required to ensure understanding and being able to repeat the communication.
As stated by C2 (palliative care specialist) doctors don’t know where they can
find this time. None of the clinicians could give a satisfactory answer as to how
to solve this issue, only that they had to try to make time for those discussions.
Many of the specialists felt that they were rushed and probably inadequately
communicating end-of-life care options. People with MND from the country, who
only came to see the MND MDT for symptom management interventions such
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as NIV, had informative discussions about NIV but without follow up to address
the more sensitive issues. This was frustrating for the clinicians and
unsatisfactory for the person with MND and their family (C13).

Some of the clinicians admitted difficulties with having end-of-life
discussions when initiating NIV: although they felt they were offering something
which may help the patient they did not want to remove hope by discussing
potential withdrawal. The point was made that some people with MND and their
families do not want to have those discussions, despite the clinician trying to do
so. Denial, the understanding held by the person with MND and/or their family
plus variable levels of health literacy were barriers to end-of-life communication
occurring at the time the current guidelines recommend (NICE, 2016).
Frontotemporal dementia was found in this research to be a symptom of MND
which some clinicians are not fully conversant with or is not easily recognised.
Frontotemporal dementia could be affecting decisions made by some people
with MND but, again, time is required for the clinicians to be able to listen to and
understand the individual to recognise the FD behavioural nuances.

The sharing of relevant information between clinicians and closer
collaboration within MDTs and with their patients was found to be an area which
can be improved, concurring with previous studies (Danel-Brunaud et al., 2017).
In areas where the palliative care specialist, respiratory specialist and allied
health professionals were not part of a formalised MND MDT, communication
between all the clinicians involved was described as particularly poor at times.
Differing opinions can exist within clinical teams which could confuse a person
with MND and their family, or communication may be assumed to have
occurred with the patient when it hasn’t. These problems may well be eliminated
if there was a person coordinating and responsible for the care of the person
with MND and their family.
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In summary clinician participants recommended that:


There is better explanation for people with MND and their families about
the emotional end-of-life issues and not just the practical symptom
control issues such as the workings of NIV.



More appointment time is allocated to enable a rapport to develop with
the patient and to ensure clear communication.



Improved communication between health care providers, and even within
the MDT.

6.4. Recommendations for Further Research and Suggestions for Policy
and Funding Reform
There is a need for further research to assist people with MND and their
families to understand the implications of the course of this devastating disease.
In light of the research findings, the following section considers how changes to
policy and funding may be achieved.
6.4.1. Coordination of care incorporating sensitive end-of-life
communication
Specialist clinician time needs to be allocated for sensitive
communication so that people with MND and their families better understand
the benefits and burdens of symptom control measures and end-of-life choices.
Communication may be improved if there was an overall coordinator
responsible for the needs of the person with MND and their family. As
discussed in Chapter 5 (Section 5.6.4), other health disciplines incorporate a
specialist nurse to guide a person through the complexities of decision-making
at diagnosis, and onwards with symptom control and either disease progression
or cure. MND is different from most other diseases in that there is no hope of a
cure and such hope that there is remains within the realms of symptom control
and the assurance of a comfortable death.
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Throughout Chapter 5 barriers have been identified relating to clear
delivery of information from clinicians, and the understanding of important
issues by people with MND and their families. Also revealed was an apparent
lack of overall responsibility for the person with MND, unless in a highly
specialised MND MDT. Allocating a health professional to take overall
responsibility within the MDT is not always practical if the MDT is fractured and
disparately located. However, ensuring one health professional is responsible
for coordinating the care and changing requirements for the person with MND
and their family is needed. The recommendation that sensitive end-of-life
choices and potential NIV withdrawal is communicated to the person with MND
prior to its commencement suggest that a case manager, possibly an MDT
member, is allocated at the time of diagnosis. Allocating responsibility for
planning ongoing care with the family of a person with MND and taking the lead
in communication with them is a recommendation of this study and is in line with
current MND recommendations (Faull, de Caestecker, Nicholson, & Black,
2012; NICE, 2016). One of the recommendations of this research is for a
multidiscipline (trained in palliative care and neurological diseases) nurse case
manager to be appointed from diagnosis, and preferably to be one of several
nurses in the role. The case manager would be involved from diagnosis until
either hospital admission or death at home. To avoid coordinator nurse “burn
out”, it may be preferable to have a small team who can organise the early
requirements and support for the person with MND and their family. The case
manager would assist people with MND to navigate their local specialists for
symptom control, allied health services and general entitlements to community
care. The case manager/team would also ensure that the patient’s GP was kept
informed with all the specialist interventions and recommendations. Many of the
long and sensitive discussions relating to end-of-life choices can be undertaken
or reiterated by the nurse, thereby alleviating the need for patients (and
specialists) to have repetitive time-consuming communication. This would
facilitate continuity of care and trust and may avoid duplication of services in
some areas.
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An area for further research is to develop and trial the recommended
model of allocating a palliative care/neurological nurse case manager from the
diagnosis of MND. Of interest would be exploring the communication with the
patient’s GP and how well the GP is kept informed of their patient’s progress
and any interventions. This research found that GPs remain involved with the
day-to-day wellbeing and support of people with MND and their families. An
individualised care plan could be developed to assist sharing of information
between GPs and local specialists, (such as when symptoms begin), and
specialists who are willing to bulk-bill (direct billing to Medicare). The case
manager would also report back to the MDT for ongoing advice and support,
eliminating the need for the person with MND to be present and thereby
reserving precious personal time for the person with MND and their family.

This model allows for continuity of care, development of trust and,
therefore, the ability to engage in sensitive communication relating to end-of-life
choices and the useful aspects of early palliative care. An audit of the efficacy of
a case manager can measure the savings made in terms of specialist time,
multiple lengthy appointments, and associated financial costs. The case
manager would attend the first specialist appointment and then be able to
reiterate and clarify communication involving all aspects of MND care to the
person with MND and their family. The possibility for funding a case manager
might be investigated under the National Disability Insurance Scheme in
conjunction with state health departments.
6.4.2. Reducing the number of people involved with patient care
This research recommends trying to minimise the number of agencies
involved with long-term people with MND under palliative care. The possibility of
coordinating home care within one organisation, may alleviate some of the
issues of too many people being involved, as identified by the families within
this study. This may require further research into policy and funding to
determine the feasibility of allocating one agency to provide community
palliative care (including all aspects of nursing requirements such as dressings,
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urinary catheters and equipment), personal and home care. An issue only
touched upon in the current study was the variability in funding in relation to
accessing long-term specialist palliative care. This was identified as a significant
barrier for people living with MND and other potentially long-term neurological
diseases.
6.4.3. Addressing the communication barriers for people with MND,
their families and clinicians
This research did not study how health literacy affects communication
and choices of symptom control in people with MND. However, during the
interviews the family and clinician participants recognised that inadequate
health literacy may affect how some families understand health issues and their
ability or confidence to communicate concerns. Ideally health literacy can be
assessed by the clinician, so they can ensure end-of-life choices have been
understood. However, the subtle changes which can be associated with FTD
can mask patient choices for care which could ultimately adversely affect
caregivers (caregiver burden). A trial of an online discussion group or mentoring
facility is recommended to investigate the value or providing the opportunity for
caregivers and people with MND talk to others who are also going through
complex MND experiences and decisions. Such a mentoring facility may also
inform and encourage people with MND and their families to have the courage
to ask questions of their clinicians and may assist in overcoming some of the
communication barriers.
Disease specific guidelines have a very detailed purpose in providing
evidence of certain treatments and ongoing care advice for a person with that
specific disease. Most diagnosed illnesses offer an element of hope of cure
and, therefore, the guidelines relating to that illness assist clinicians to offer
current best practice for finding a cure. However, in many of the neurological
diseases, MND in particular, there is neither a specific diagnostic test nor any
hope of a cure. Therefore, the present guidelines offer recommendations for
symptom control, general management and support which, whilst generally
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known by clinicians, are not always followed. Whilst communication
recommendations are incorporated into the most recent MND guidelines, there
is little specific guidance on best practice communication for the clinicians to
follow. This research has highlighted the area of recommended communication
surrounding the initiation of NIV and PEG tube insertion and found the
comprehensive recommended end-of-life communication infrequently occurs. A
further recommendation of this study is for research involving families and
people with MND so that they can give their views on when the sensitive
communication relating to the end of life should occur, and with whom they may
prefer those conversations. This would lead to greater involvement of bereaved
MND families in the writing of recommendations.

A palliative care nurse (or a case manager) who liaises with the
respiratory clinician at commencement of NIV (if the person with MND has not
previously been involved with a palliative care team), would be advantageous
for rural patients particularly, who have not had the benefits of a structured
MDT. This would facilitate continuation and elaboration by the nurse of any
communication tentatively commenced by the respiratory clinician. The
palliative care nurse also offers a conduit between the deteriorating patient,
symptom control via NIV and PEGs and the palliative care specialist team
(which includes all members of the MDT). This would be the equivalent of a
breast care/cancer nurse being included in the specialist appointments to
support and coordinate ongoing care for people with breast cancer. This role
could be either a neurological nurse upskilled to palliation or a palliative care
nurse trained more comprehensively in neurological conditions, as previously
recommended in this section.
6.4.5. Establishing a progressive timeline of information
The development of a written and/or an electronic instrument which
describes the various symptoms people with MND may experience (rather than
describing what is happening within the disease process), who to question
(which health professional) about any symptom and some of the alternative
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symptom-relieving choices available (including their benefits and burdens) is
recommended. This would also incorporate a timeline which gives families and
people with MND an idea whether they need to act fast. For example, if the
patient is experiencing headaches on waking or generally feeling breathless, it
is time to speak to a doctor about a referral to a respiratory specialist. Symptom
relieving options offered by a respiratory specialist would be identified, and
some relevant questions listed to assist the person with MND know what to ask
the specialist. The timeline would include a list of the specialists in the patient’s
area (linked into Google Maps) and which specialists will bulk-bill (Medicare
fund) for appointments.

An instrument such as this may prove useful for people with MND to preempt their needs, understand their choices and be more proactive with
implementing their symptom relieving requirements. This could be developed as
an interactive app for smart phones, and/or as a written hand-held document for
people with MND. The instrument would include instructions, comments and
recommendations inserted by specialists (or case manager) at the time of their
appointment. This tool may assist people with MND and their families to
remember, understand and revisit sensitive communication. It would also
incorporate advice on when to consider writing an AHD and outline the
advantages for optimising care when patient preferences are clearly known and
documented. This would be suggested to occur at trigger points identified in the
literature (NICE, 2016; Rafiq et al., 2012). An electronic timeline would enable
up-to-date care wishes concerning end-of-life care to be identified and changed
as required by the person with MND. The instrument would also incorporate the
ability to SKYPE (or similar) with specialists at an allocated appointment time,
so any updated information would be shared between clinicians, patient and
family plus the case manager. This would minimise the need for the person to
travel which becomes difficult as the disease progresses.
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6.4.6. Study the timing of preferred referral to a specialist palliative
care service
The recommendation in the NICE MND Assessment and Management
Guidelines (2016) for early referral to palliative care, whilst known by clinicians,
does not translate into clinical practice. The barriers and clinician concerns for
early palliative care referral have been identified throughout this research.
However, it is the family participants who clearly stated their reluctance for early
referral and were shocked by the suggestion of palliative care when their family
member with MND was relatively asymptomatic. The clinicians have identified
that family members may not be ready for this discussion early on. This
research recommends that palliative care is introduced and described to people
with MND after they have identified a symptom requiring treatment or control,
using the symptom as a reason to explain the benefits of palliative care
involvement. Greater involvement of MND families regarding explanation, timing
and level of involvement of palliative care, timing of end-of-life communication
would be provided by the case manager as proposed in Section 6.4.1.
6.4.7. Funding of palliative care services as a barrier to ongoing
care
This study has encountered several clinicians who have described
access to a specialist palliative care service (in their area) for people with MND
to be limited to their last three months of life. Others described the palliative
care service not being able to keep people with MND on their books long-term
due to the palliative care funding in their area. This finding neither complies with
the MND guideline recommendation of referral to palliative care at or soon after
diagnosis, nor makes the time of referral any easier to determine for clinicians.
The recommendation of this research is intermittent referral to a palliative care
service which would provide advice on symptom control, without a specific
prerequisite for survival time or diagnosis for admission to the service. This
model of intermittent palliative care, which has been discussed in Chapter 5
(Section 5.6.3), may encourage recognition of symptoms and provide ongoing
high-level care. An intermittent palliative care service is recommended in
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conjunction with an MND case manager. The cost of an intermittent palliative
care service may be offset by fewer emergency admissions to hospital which
occur particularly when people with MND have symptom complications.

6.6. Limitations
This study has covered many aspects of communicating end-of-life
choices focusing particularly on the stage of MND when the respiratory muscles
weaken, and the effects of respiratory difficulty become apparent to the person
with MND. Several limitations are identified within this study. Importantly and
unfortunately there were no neurologists available or willing to participate in this
study. The neurologist view-point would have added greater depth of
understanding of both communication content and responsibility for overall care
of the person with MND. The lack of neurologists may also have influenced the
recruitment strategy of family participants. As GPs are involved with the ongoing
general health care of people with MND, it may have been relevant to have
included their perspective and this may be considered a limitation of the study.
However, the focus of the research questions was on those participants with
considerable clinical experience of MND, and GPs may not have such
experience.
The clinician participants have given examples of how they communicate
and candid examples of when they found it difficult. As this study could not link
the family participants with any clinicians interviewed, the study was limited in
being able to verify how clearly each clinician communicated end-of-life options.
However, the bereaved family participants were clearly confused on many
aspects of the terminal stage of their family member’s MND, although this
confusion may have been a symptom of their grief. Unfortunately, a relatively
small number of bereaved families applied to participate (six) and this is
recognised as a limitation of the study. This may be due to participant fatigue as
there have been various MND research projects in Western Australia involving
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bereaved families undertaken recently, or simply that as MND is a rare disease
there were few families available.

A further limitation identified is the interview process which involves
retrospective recall as well as aspects of life which impact on memory, which in
turn may affect how their reality is recalled. In considering the methodology,
research questions and participant semi-structured questions, the research
method was developed to obtain the most accurate and dependable
information. There were some disadvantages to using semi-structured
questions to interview all the participants. The main disadvantage was the
extended time of the interviews which meant that the analysis of the data was
also time consuming. In analysing the data from the in-depth interviews,
generalisation of the information was not always obvious and at times, difficult.
The possibility exists that the data collected for this study may have been
different if a method other than the one chosen was selected. The candidate
did, however, take trustworthiness measures to ensure objectivity was
maintained as much as possible (Chapter 3, Section 3.13.1).

6.7. Conclusion
Whilst acknowledging that MND offers no hope of a cure and early endof-life communication is often laden with emotional difficulties, it nonetheless
remains vital for the person with MND and their family to be provided with the
information they need to be able to make informed choices. The research
questions within this study aimed to determine whether the international and
national guideline recommendations into NIV communication which included the
benefits and burdens of NIV, end-of-life choices and the potential of being able
to withdraw NIV were being integrated into clinical practice. The significance of
whether this sensitive communication was occurring had implications for the
management of how people with MND planned their end of life and the choices
they could make for their care. The questions sought to determine whether the
guideline recommendations were being followed, and if the people with MND
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and their family members understood their care options. The research also
explored the clinician and family view of the timing of referral to a palliative care
service, and the barriers to implementing the recommendations for
communication.

Despite the bereaved family participant cohort of this study being small
(six participants of which two were siblings interviewed together), their
experiences provided valuable information. Of particular interest was the family
perspective on the value of early referral to specialist palliative care. The most
recent guidelines and recommendations advise referral to palliative care soon
after diagnosis (NICE, 2016). However, none of the family participants nor the
one person with MND interviewed, stated that palliative care was a service they
required soon after diagnosis when they had so much to come to terms with in
their lives already. Their reluctance could be due to the influence of a
community-wide view of palliative care as a service associated with death, or
that the services that palliative care provides were not adequately explained. In
this research, those who were referred early felt it too confronting to
contemplate at that time (F3, F5), particularly as the person with MND had
minimal symptoms. The person interviewed with MND and three other families
experienced late palliative care referrals when the symptoms had significantly
worsened. Whilst beneficial to them for symptom control at that point, it was too
late to adequately commence end-of-life care communication, fully understand
the potential of NIV withdrawal and be able to plan for what was left of their
lives. The understanding amongst the family participants of what palliative care
could offer and how it can improve the experience for people with MND and
their families appears to not be communicated by some clinicians. This finding
was readily admitted to by many of the clinicians, particularly those involved
early in the disease trajectory. The rationale for not referring or discussing
specialist palliative care was stated to be a combination of the time required to
have adequate end-of-life communication and the sense of taking away any
hope the person with MND may have. There was also the barrier of the access
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to palliative care services which differed geographically, in many instances
determined according to a patient’s time left to live (in months).

A nurse case manager involved soon after diagnosis of MND would offer
continuity of service, facilitate collaboration between specialties and act as a
conduit between clinicians, patient and their family. Rather than clinical
speciality boundaries for care and communication, collaboration and sharing the
cost of a nurse coordinator would not only save the specialists time (and
money) but improve the experience for the person with MND and their family.
The idea of a progressive timeline document for the patient, either hardcopy or
an electronic app, that provides clear information about symptom description
and significance, was informally discussed with the family participants and
person with MND and was welcomed as a helpful idea to improve
understanding and planning. However, further research into the design and
structure of such an instrument is required.

The opposition by families for multiple organisation involvement with
patient care and the complaint of valuable time being taken by repetition of
issues and perceived personal intrusion was a valuable finding of this thesis.
However, it is a difficult issue to solve. Presently, Australia is very variable in
how MDTs and community services are structured and offered to patients and
families. Even within cities it depends on which area a person with MND lives as
to how the services are structured and how accessible they are. This study
recommends one single local organisation being charged with providing
community nursing, palliative care, personal care, home help as well as a
structured MDT to optimise patient care, efficiency and cost. Within this
structure a nurse case manager would manage the patient requirements, assist
with appointments and communicate between all health professionals involved.
Such a model of care ought to be trialled and evaluated.

As more research is undertaken into MND, hopefully all aspects of
communication will be improved. In a very recent systematic review of
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evidence-based studies into all aspects of multidisciplinary care in MND/ALS,
timely symptom management and end-of-life communication are highlighted as
areas needing improvement (Hogden, Foley, Henderson, James, & Aoun,
2017). The review incorporates many of the published research articles which
broadly make up the most recent MND management recommendations
(Andersen et al., 2012; National Institute for Health and Care Excellence, 2016).
Hogden et al. (2017) discuss optimal management of palliative care as well as
the effectiveness of MDTs for people with MND. Hogden et al. recommend the
development of further guidelines to improve communication between clinicians
to provide coordinated care for people with MND and their families. The
research reported in this thesis echoes the findings and suggested further work
by Hogden et al. (2017) and offers additional recommendations which may help
to provide solutions to the barriers encountered in communicating end-of-life
options in MND.

Communication surrounding the initiation and withdrawal of NIV was the
principle issue for this research. The experiences of the families and person
with MND showed that despite the guidelines recommending communication of
potential NIV withdrawal prior to initiation, this seldom occurred. This was
reiterated by the health professionals responsible for NIV initiation and verified
by the palliative care clinicians who in many cases felt they were the first to
suggest this option. The reluctance to communicate NIV withdrawal and by
default, end-of-life options prior to the terminal stage, had emotional
consequences for the families and clinicians alike. This study established that
whilst many of the clinicians involved with the early symptoms of MND vaguely
knew the content of the most recent MND guidelines regarding communicating
NIV withdrawal and end-of-life options, few followed the recommended timing of
such communication. Some of the clinicians were not fully aware of the
recommendations, and some decided to do what they considered best practice
rather than follow the recommendation. The incorporation of an appropriately
trained nurse case manager from diagnosis, in cooperation with the specialist
clinicians, would help develop rapport with the patient and family, encouraging
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such communication. In conjunction with either an electronic or hand-held
progressive timeline instrument, end-of-life and symptom control options and
communication would be documented for the family and patient to revisit and
reacquaint themselves with their choices. By exploring family, patient and health
professional perspectives on NIV and end-of-life communication, opportunities
for further research have been identified from this study.

This research adds valuable information and expands on the most recent
literature with insights into family and patient preferred timing of palliative care
and why communication between organisations and between clinicians and
people with MND and their families is frequently difficult. MND is a progressively
debilitating disease with some appalling symptoms and complex tangential
dimensions such as FD. MND is also a complex disease, varied in its course
and timing of symptoms and its rarity makes clinician experience in coping with
those involved difficult. This research has taken a distinctive in-depth approach,
covered many areas of importance and taken the time to extensively interview
and listen to clinicians and families involved with MND.

Whilst understanding that recall and retrospective memories can be
confusing and influenced by situational variables, this thesis has provided
insightful and valuable descriptive information which, it is hoped, may improve
how people with MND are helped to understand and communicate their end-oflife care.

The epilogue which follows explores the personal growth the candidate
experienced whilst undertaking this study and the candidate’s appreciation of
the enormity of receiving a diagnosis of MND for the person and family involved.
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Epilogue
Thesis Reflections
Exploring the communication surrounding the initiation and potential
withdrawal of NIV in people with MND has provided the candidate with a
profound understanding not just of the people with MND but their families,
caregivers and clinicians. The participants spoke with sincerity and reflection
which provided insightful information both for this study and to enable the
candidate to improve her nursing and communication skills.

All the participants involved in this study were English-speaking as a first
language. However, communication between clinicians and those with MND
was often reported as confused, unclear and sometimes involved avoidance of
the inevitable outcome of MND. The emotional impact and difficulty of delivering
such devastating news to people with MND and their caregivers created
communication barriers. This was clearly stated by C3: “So, I think it’s all about
the quality of the communication leading up to that process (symptom relief, NIV
withdrawal and end-of-life communication) and investing the time in the
process.”

Despite the English language being understood by all concerned, what
was reported to be said and what was understood often appeared at odds.
Perhaps the English language itself is partly to blame, with many words having
different meaning to different people. An example of this was the word
“prognosis” whose dictionary definition is “A medical prediction of the future
course of a disease and the chance for recovery. Note: Prognosis is often used
as a general term for predicting the unfolding of events”
(www.dictionary.com/browse/prognosis). This term was most frequently used by
clinicians to mean a prediction of length of time a person had left to live.
However, in their conversations with clinicians many caregivers and people with
MND appeared to understand the term to mean ”what to expect; symptoms and
control methods, benefits and burdens of NIV and gastrostomy tubes”
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Therefore, conversations appeared to disengage at that point unless the person
with MND or their caregiver had the confidence or sufficient health literacy to
ask further questions about symptom control or other aspects of prognosis. It
would be unreasonable for a clinician to ensure that those involved with MND
had the same literal meaning to every word used, but it might be an indication
that verbal communication maybe insufficient to ensure understanding of the
vital aspects of MND.

By the completion of data collection, no participant had had to cease the
interview or request emotional support, and all sent affirming post-interview
emails to the researcher. Most offered to answer more questions or be reinterviewed should further information be required. All the bereaved participants
stated that the interview was a cathartic experience for them and hoped the
information they provided might enhance communication for those people with
MND and their families in the future. The enthusiasm, insight and thought with
which the family participants and the one participant with MND spoke meant the
experience was as enlightening and profound for the candidate as it was a
therapeutic for the participants.
As an investigator into understanding clinician’s delivery of end-of-life
and symptom control communication and having listened to the experiences of
the bereaved families, the candidate is left with an overwhelming feeling that
clinicians are communicating as time dictates. There are too many variable
influences at play to completely remove ambiguity and guarantee that crucial
information is always fully understood by the recipient via verbal communication
alone. It is hoped that some of the recommendations of this study will lead to
further research and improved communication between clinicians and people
with MND. Some of the clinical participants provided feedback either during or
after the interviews which may indicate potential change, and these comments
have been included within this thesis and epilogue. Time for professional
reflection whilst answering the study questions appeared to be appreciated by
all the clinicians interviewed:
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C19: I think that set of questions is an excellent set of – if I may say so, Lottie,
because you’ve covered so much there, and very astringently. You know,
you’ve gone into depth with each of those areas. So, I think that that’s
excellent. No, that’s really good. Yeah, yeah, I think that that’s good.
C18: No, no, look, this is very important. You’re doing great work.
C15: That’s a very good question, Lottie, and I have to say I haven’t really
pushed that differentiation on advance care directives. But I think it is
important, and perhaps in future I will.

I am immensely grateful for the opportunity to have undertaken this study
and to have enhanced my own comprehension of the importance of clear
communication not only with those involved with MND but generally in palliative
care. It is my sincere desire that this study will lead to further investigation into
the delivery of end-of-life communication and the understanding of the
measures required by people with MND to ensure choices of symptom control
are explained and understood.
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study.
*Researchers
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Emphasis’s needs of the caregivers.
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providing care for patients
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complexity of patient
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when providing patients
with information relating to
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* Follow-up data was
limited particularly
relating to patients
refusing NIV. Decision
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PEG grouped
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Highlights the need for
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and the complex
communication issues.
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small number of
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Fast deterioration phase,
impairing communication
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Marconi, A., Fossati, F.,
Molinari, E. (2012).

Respiratory function of
people with amyotrophic
lateral sclerosis and caregiver
distress level: a correlation
study using questionnaires.

Correlations between a
caregiver’s level of distress
and a patient’s respiratory
function; shows importance
of caregiver’s function.

Phelps, K, Regen, E, Oliver,
D, McDermott, C, & Faull, C.
(2015).

Withdrawal of ventilation at
the patient's request in MND:
a retrospective exploration of
the ethical and legal issues
that have arisen for doctors in
the UK. Qualitative research:
24 interviews with doctors.

Ethical and legal advice
and guidance required to
support clinicians in NIV
withdrawal in MND.

States the importance of
communicating the benefits and risks
associated with NIV to people with
MND prior to initiation. Recommends
further research on impact of
withdrawal on families.
If a caregiver has the potential to
influence the person with MND’s
respiratory function, then the
relevance of complete understanding
of the benefits and burdens of NIV
may influence not only the patient
choices but quality of the remaining
life as well as the quality of life of
their caregivers.
The ethical and moral dimensions for
communication surrounding the
initiation and withdrawal of NIV are
discussed with doctors. Study
suggests greater integration of
neurology and palliative care
specialties.

Oliver, D, & Faull, C. (2013).

*No contributory
inferences can be
made as this is a
cross-sectional study
*small study
sample.
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Author and year

Research design:
sample, size and sites

Phukan, J., & Hardiman, O.
(2009). Journal of Neurology,
256, 176-186.

The management of
amyotrophic lateral sclerosis;
a review of current practice.

Phukan, J, Elamin, M, Bede,
P, Jordan, N, Gallagher, L,
Byrne, S, . . . Hardiman, O.
(2012).

The syndrome of cognitive
impairment in amyotrophic
lateral sclerosis: A
prospective population-based
study in 160 ALS patients
and 110 control patients.
The preferred priorities for
care document in motor
neurone disease: Views of 11
bereaved relatives and
caregivers; semi-structured
interviews.

Preston, H., Fineberg, I.,
Callagher, P., & Mitchell, D.
(2011).

Rafiq, M., Proctor, A.,
McDermott, C., & Shaw, P.
(2012).

Respiratory management of
motor neurone disease: a
review of the current literature
and discussion paper.

Comments and key
findings
Recognises strategies in
cognitive management,
caregiver burden and
depression guided by the
American Academy
Practice Parameter.
Co-morbid dementia found
to occur in 14% of newly
diagnosed ALS patients
and some cognitive
impairment in 40 % of ALS.
Discusses the use of a
document which describes
a patient’s priority of care
(PPC). Document seen as
a good prompt for difficult
decisions between
clinicians and patients.
The impact of the use of
NIV for treating respiratory
weakness. Palliative care
needs and stopping NIV
support /end-of-life issues
should be regularly
discussed with people with
MND.

Limitations

Implications of findings for
thesis research and questions
Symptom relief and slight increase in
survival, caregiver burden should be
discussed early in diagnosis, and
discussions relating to the withdrawal
of NIV should be included.

*Study limited to
analysis of cognitive
dementia; subtle
behavioral changes
did not fulfill study
criteria.
*Due to limited
resources, a small
study the findings of
which cannot be
generalized.
*Possible
unintentional male
gender bias.

Cognitive impairment may occur in
40% of ALS patients; the implications
of cognitive impairment may affect
communication and understanding
skills?
Used as a communication aide;
A document of this type may help to
improve or offer triggers to clinicians
to initiate end-of-life discussions.
Participants felt the document had
little impact on actual end-of-life care.

Outlines the problems which can be
associated with NIV plus the benefits
if patients are able to tolerate it.
Discusses palliative care strategies
as alternatives to NIV and reiterates
the importance of ascertaining the
patient’s wishes regarding their endof-life care at the time of or soon after
the initiation of NIV.

291

Author and year

Radunovic, A., Annane, D.,
Rafiq, M., & Mustfa, N.
(2013).

Ray, R., Brown, J., & Street,
A. (2014).

Virdun, C., Luckett, T.,
Davidson, P. M., & Phillips, J.
(2015).

Wood-Allum, C., & Shaw, P.
(2010).

Research design:
sample, size
Mechanical ventilation for
amyotrophic lateral sclerosis /
motor neurone disease.
Search and review of
Cochrane Neuromuscular
Disease Group literature
regarding NIV use.
Dying with motor neurone
disease, what can we learn
from family caregivers?
Secondary analysis from two
data sets employing similar
data collection and analysis.
Dying in the hospital setting:
A systematic review of
quantitative studies
identifying the elements of
end-of-life care patients and
their families rank important.
Motor neurone disease: a
practical update on diagnosis
and management based on a
lecture given by author.

Note: Symbols used within table:

Comments and key
findings

Limitations

Review suggests that NIV
can increase and improve
the life of people with ALS.

Recommends effective
planning for death;
normalise the dying
process in MND from
caregiver perspective.

Implications of findings for
thesis research and questions
Suggests further research to
understand the influences which
affect access to NIV, the cost
personally and economically for
patients and their families.

*Sample size limited
despite data from two
countries.

Identifies the need for strategies to
encourage and normalise end-of-life
discussions and AHDs.

This review reiterates the
domains of palliative care
most important to patients
and their families.

Effective communication and shared
decisions regarding treatment are
fundamentally important at the endof-life particularly relating to the
hospital environment.

A general update on MND
care, reinforcing the need
for discussions with
patients and families
relating to NIV ahead of
need.

Due to proven prolonged survival,
clear discussions must be held with
patients and families well ahead of
commencement of NIV.

* Authors identified limitation

+ Candidates suggested limitation
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Appendix A: 2) Summary of Additional Literature Relevant to Study: July 2016-July 2017
Author and year

Danel-Brunaud, V.,
Touzet, L., Chevalier, L.,
Moreau, C., Devos, D.,
Vandolaeghe, S., &
Defebvre, L. (2017b).
Smith, T., Disler, R.,
Jenkins, C., Ingham, J., &
Davidson, P. (2017).

Hogden, A., Foley, G.,
Henderson, R.James, N.,
& Aoun, S. (2017)

Research design

Comments and key
findings

A review.

Ethical considerations and
palliative care in patients
with amyotrophic lateral
sclerosis.

A good perspective of the ethical
issues to be considered in MND/ALS.

Perspectives on advance
care planning among
patients recently requiring
non-invasive ventilation for
acute respiratory failure.
Amyotrophic lateral
sclerosis: improving care
with a multidisciplinary
approach.

Explains the complexities and
perspective of NIV use in acute
respiratory failure illustrating similar
ethical and communication difficulties
as in MND.
Further exemplifies the desired care
for people with MND by improving the
MDT approach.

A qualitative study using
thematic analysis.

A review.

Limitations

Implications of findings for
thesis research and questions
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Appendix B: Ethics ECU Approval
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Appendix C: Ethics ECU Amendments.

Hi Lottie
Project: 12099 CHAPMAN
Project Name: A retrospective study into the communication surrounding
the initiation and withdrawal of non-invasive ventilation (NIV) in patients
with motor neurone disease
Thank you for your email requesting amendment to your ethics application. The
following amendment has been reviewed by members of the Human Research
Ethics Committee:


Inclusion of the stories of people with MND who spontaneously contacted
the researcher to participate in the project. The researcher will not be not
recruiting people with MND however has requested to include these
people as part of the project.
The Information Letter and Consent Form for family members (already
approved) will be used for people with MND to provide consent for
inclusion in the project.

Ethics approval has been granted for this amendment.
Kind Regards
Faye
Faye Walmsley
Ethics Support Officer
Office of Research & Innovation, Edith Cowan University,
270 Joondalup Drive, Joondalup, WA 6027
Tel: +61 08 6304 5032 | Fax: +61 08 6304 5044 | CRICOS IPC 00279B
Email: research.ethics@ecu.edu.au
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Hi Lottie
Project: 12099 CHAPMAN
Project Name: A retrospective study into the communication surrounding
the initiation and withdrawal of non-invasive ventilation (NIV) in patients
with motor neurone disease
Thank you for your email requesting an amendment to your ethics
application. The following amendment has been reviewed by members of the
Human Research Ethics Committee:


Advertise the project through interstate contacts via palliative, MNDA
(general) websites or word of mouth

Ethics approval has been granted for this amendment.
Kind Regards
Faye
Faye Walmsley
Ethics Support Officer
Office of Research & Innovation, Edith Cowan University,
270 Joondalup Drive, Joondalup, WA 6027
Tel: +61 08 6304 5032 | Fax: +61 08 6304 5044 | CRICOS IPC 00279B
Email: research.ethics@ecu.edu.au
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Appendix D: Clinician Participant Questions
Semi structured questions and prompts for clinicians
Target group Clinicians
Clinicians involved/experienced with patients with MND who are:
 At the stage of respiratory decline and NIV initiation, and /or
 Involved with the terminal stage of the disease process when the
withdrawal of the NIV is considered.
These may be general practitioners, respiratory physicians, neurologists,
palliative care specialists, palliative care nurses (Registered and Enrolled
Nurses) and allied health professionals.
Questions are prompts only and will not be asked if they have been
answered previously.
Introduction


Thank you for making the time to help with this research.
As you know my name is and my background is….



As you know from the information sheet, the aim of this research is to
understand the communication surrounding the initiation and withdrawal
of non-invasive ventilation in patients with MND, including the benefits,
burdens and limitations in order to optimise future health care provided.


Aim

Consent & control of the interview and support if required


Everything you tell me is confidential. I will not reveal your identity to
anyone and I will de-identify the information you give me by using
codes known only to me. If you give me permission I may use some of
your quotes but these comments will remain anonymous. I’d like to
thank you in advance for your contributions to this research, as it will
help improve care provided to people with MND and their families.



I would like to tape the interview so that I can concentrate on listening
to you rather than writing.









Is that okay?

YES

NO

It is up to you how much you want to say and if there’s a question you
would rather not answer, you can just say you don’t want to answer it.
If at any point you want to stop, pause for thought or reschedule the
interview, you simply have to say so.
(I would like to remind you of your employer assistance program (EAP)
should you feel you would like to discuss any issues that have
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adversely affected you, and the availability of a Lifeline Counsellor
(92614444) or Lifeline Crisis Line (131114)

I will turn the tape on now.
General introduction open-ended questions which may
negate the need for some of the question prompts
1. Before we start on the more structured questions, do you mind my asking
general questions relating to your area of expertise is and how long have
you been practicing in your specific area?
2. What is your ‘role’ here at [NAME OF CLINIC, HOSPITAL, GP
PRACTICE]?
3. Have you undertaken any ‘specialty’ training either related to or not
directly related to your own discipline? What/Where/When?
4. Can you provide an estimate of your current practice in terms of
percentage of people with MND (e.g., 80%)?
5. Understanding that MND is a rare disease, how much experience in
terms of years, have you had working with patients diagnosed with
MND?
6. Do you work within a multidisciplinary team? YES

NO

IF NO: Do you refer the MND patient at diagnosis to the
multidisciplinary team associated with you?
7. How involved are the MND patient’s general practitioners with ongoing,
day-to-day care?
Next I’d like to discuss what information you provide to people with MND
and their families:
8. The NICE MND NIV guidelines and much of the recent literature,
recommends various trigger points for ‘honest’ communication with
patients and families relating to end-of-life care and the benefits and
burdens of NIV. With that in mind;
 8.1 Please can you tell me when in the patient’s journey you usually
have these conversations?
 8.2 At which stage are end-of-life issues addressed by your team,
and is there standardised information offered to patients and families?
 8.3 Are there specific trigger points within the disease trajectory that
you use as an opening for these honest discussions?
 8.4 Is the patient’s prognosis included in these ‘honest’ discussions?
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 8.5 Is there anything else you would normally include in ‘honest’
communication?
 8.6 Is there usually only one “honest” communication session or are
there usually more than one, and do these conversations include
family members?
 8.6 How do you assess whether the MND patient and family have
fully comprehended the information regarding prognosis, end-of-life
and NIV implications communicated by you?
 8.7 In your experience are people with MND, families and significant
others adequately aware of the prognosis and limitations of treatment
options for the disease prior to your involvement with them?
 8.8 If the patient with MND declined to have family members present
at the time of sensitive discussions, how is medical and general
support information provided to the families/caregivers?
9. Thinking how you approach the discussion with patients with MND at the
start of NIV, what information do you usually give?
 9.1 Is end-of-life care discussed at this time?
 9.2 What are the specifics of the benefits, burdens (including carer
burden) and limitations of NIV that you always discuss with people with
MND?
 9.3 Is the potential of increased dependency on NIV discussed?
 9.4 Is hydration and nutrition mentioned i.e. PEG/RIG insertion?
 9.5 Do you usually include information about physical support i.e.
potential equipment needs, and psychological support for both patient
and family when NIV is commenced?
10. What, in your opinion, do people with MND need to know to be able to
make an informed decision regarding the use of NIV?
11. Do you feel that the communication between you and other healthcare
providers relating to MND patient treatment and/or medical care is
adequate to ensure patient and family understanding of:
 11.1 Symptom relief options i.e. PEG/NIV
 11.2 What to expect relating to disease progression and death
 11.3 Psychological support for patients
12. Do you consider NIV a palliating measure in people with MND, and if so,
do you describe it as such?
13. When in your opinion, should people with MND become involved with the
palliative care team?
14. Have you had experience of any people with MND declining the use of
NIV at the stage when the respiratory muscles and diaphragm start to fail
and if so what were the MND patient’s reasons and what alternatives did
you give (palliative care options?)
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15. When do you usually discuss the potential/eventual withdrawal of NIV
with the patient/family: is there a trigger point or indication that this
conversation should occur?
16. Were discussions relating to possible NIV withdrawal reiterated during
the course of the MND patient’s use of NIV?
17. How is the specific information given; verbal and written form? Who by?
Now I’d like to discuss the communication you may have with people
with MND and their families around the actual terminal phase of the
disease, or the end-of-life issues:
18. As the patient’s swallow is adversely affected (or prior to), is the use of
PEG/RIG tube discussed with the family and patient in relation to
prolonged survival? When would this be discussed?
19. Do you differentiate between nutrition and hydration in the context of
ongoing patient survival, particularly if the patient has
indicated/documented a desire not to be kept alive?
20. Do you mention hydration via a PEG/RIG for patient comfort of alleviating
feelings of dehydration?
21. Do you weigh your MND patient prior to the PEG insertion, in order to
monitor weight changes?
22. Have you ever had issues with people with MND in the end-of-life stage
indicating they were dry or dehydrated? YES/NO:
23. Do you think dehydration is a problem for some people with MND at the
end of life?
24. When NIV and PEG/RIG’s are initiated, what if any further directions are
incorporated into the AHD? (Are nutrition and hydration discussed in
relation to the end-of-life stage and as separate entities, and how are
these documented?)
25. When do you discuss Advance Health Directives with people with MND?
26. When an exacerbation of the disease occurs, are the Advance Health
Directives re discussed and clarified? If so by whom?
27. Understanding that dementia/personality changes can be subtle and can
affect people with MND decision making, have you had changes to the
patient’s wishes/AHD which have surprised you i.e. not as understood by
family and yourself to be the wishes of that patient or lack of
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understanding of the importance? (should AHD’s be discussed at
diagnosis and at revisited at various trigger points onwards?)
28. Are the family incorporated into discussions relating to the Advance
Heath Directives? If not, when are the patient’s wishes discussed with
families or significant others?
29. Generally, in your experience, are the Advance Care Directives clearly
detailed enough to ensure the wishes of the patient are upheld?
30. Are potential emergency presentations to hospital with shortness of
breath discussed in relation to tracheostomy (discussions which include
family/significant others?)?
31. Is the difference between NIV and tracheostomy (invasive ventilation)
explained?
32. Have you ever been involved with the withdrawal of NIV in an MND
patient and if so can you describe the situation(s)?
33. Do you have any other comments about the withdrawal of NIV?
34. Do you have any comments relating to the communication surrounding
NIV initiation or withdrawal?
 Anything about the issues relating to NIV use?
 Anything about the terminal stage of the disease?

35. What are the barriers to discussion between clinician and patient,
significant others and caregivers about commencement and subsequent
withdrawal of NIV?
36. Anything else you think I should know about your experience in
communicating about the MND experience for patients?
Thank you for participating in this research
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Appendix E: Family Participant Questions
The following questions and statements are considered prompts for
interviews with family members and significant others of people who have lived
with Motor Neurone Disease. Questions will not be asked if they have been
answered previously.
Introduction



Thank you for making the time to help with this research.
As you know my name is and my background is….

Aim


As you know from the information sheet, the aim of this research
is to understand the communication surrounding the initiation and
withdrawal of non-invasive ventilation in patients with MND,
including the benefits, burdens and limitations in order to optimise
future health care provided.

Consent & control of the interview and support if required








Everything you tell me is confidential. I will not reveal your
identity to anyone and I will de-identify the information you give
me by using codes known only to me. If you give me permission I
may use some of your quotes but these comments will remain
anonymous. I’d like to thank you in advance for your contributions
to this research, as it will help improve care provided to people
with MND and their families.
I would like to tape the interview so that I can concentrate on
listening to you rather than writing.
Is that okay?
YES
NO
It is up to you how much you want to say and if there’s a question
you would rather not answer, you can just say you don’t want to
answer it. If at any point you want to stop, pause for thought or
reschedule the interview, you simply have to say so.
Details of a free counselling service and the MNDAWA Care
Advisory team offering emotional support and advocacy (Motor
Neurone Disease Association of WA Inc Phone: 9346 7355) are
supplied to you should you wish to discuss any issues which may
arise from the research interview.

Individuals who may become upset may choose to cease the interview or
continue. I will provide information about support available through the Motor
Neurone Disease Association of Western Australia (MNDA [WA]) emotional
support program which they may choose to access soon after or at a later date.
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I will also offer a written handout with details on Lifeline Counsellor (92614444)
or Lifeline Crisis Line (131114). Individual participants may elect not to answer
any of the questions given as prompts.
I will turn the tape on now.
General introduction open ended questions which may negate the need
for some of the question prompts








If you feel comfortable with discussing your family member, (may I call
him/her by his/her Christian name?) perhaps you would like to tell me
something about his/her life prior to the diagnosis on MND?
Are you able to tell me about how the diagnosis was made and how you
both came to understand that he/she had MND?
When you heard the diagnosis, did you have any concept of MND and
the implications of the disease?
May I ask how or whether you searched for further information and if so
from where did you seek this information?
As time and the disease progressed, how did this affect you both and
those within your extended families and friends?
May I ask how long from the time of a definite diagnosis until your family
member died?
Do you mind my asking your family member’s age on diagnosis and in
which area were you living? This is just for general demographic
information and anonymity by using coding as previously described, is
assured.

Question prompts
1. Who initially discussed NIV with you and your family member with MND?
(prompt: GP, Respiratory specialist, Neurologist)

2.It is a recommendation of MND guidelines and some journal articles that
‘honest’ communication occurs between doctors and people with MND and their
families. Do you consider that your conversations with the doctors contained the
‘honest’ information you required?

3.Thinking back to when non-invasive ventilation (NIV) was first discussed, what
information was given to you at that time about it? (prompt:I will explain about
NIV if this is required). What information was provided about:




the benefits,
the burdens and
the limitations?
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4. When NIV was first discussed, was there information given about the
possible need of a feeding tube to be inserted into the abdomen? (prompt:
PEG/RIG)


Did you understand that your family member’s ability to swallow could
be affected by the disease?



Was there a discussion about nutrition and hydration via the feeding
tube?

5. What information was given to assist you and your family member make a
decision to start or decline NIV?


For example any paperwork relating to support groups in your
area, palliative care or equipment availability?



Were any alternatives offered such as general support and
palliating medications?

6. Do you recall mention of NIV eventually no longer being useful and having to
be withdrawn?



Please tell me what you understood then about what “withdrawal”
meant?
Did you understand that the disease would still progress even
with NIV?

7.Can you remember the clinician who initiated NIV having conversations with
you about the end-of-life of your family member with MND?




Can you recall how you understood what was discussed?
Can you remember when an Advance Health Directive (AHD)
was first discussed?
Do you recall what was included within the AHD?

8. Was positive invasive ventilation (tracheostomy) mentioned or explained?
(prompt: sometimes, patients have an emergency tracheostomy unless they
have made it very clear they do not want this kind of emergency treatment)
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9. Knowing what you know now:






Is there anything you did not understand about NIV?
Is there anything you wish you had known?
Is there anything that would have changed the decisions or
choices relating to NIV made by your family member with MND or
yourself?
Who would you like to have explained those choices to you?
When do you think would have been the best time to explain this?

10.What do you think are the important things to know in order to be able to
make an informed decision about using NIV?



In hindsight, how satisfied are you with the use of NIV and the
end-of-life process?
Did the communication prior to the commencement (or refusal) of
NIV cover the relevant information on the benefits, burdens and
limitations?

11.In the case of the person you knew who had MND:







How informed do you think their decision (commencement or
refusal) regarding the use of NIV was?
Was the withdrawal of NIV discussed and if so when and by
whom?
Were you present when this discussion took place?
Was the Advance Health Directive re discussed during the
progression of the illness?
At what stage was this discussed?
Did this AHD include the commencement and withdrawal of NIV?

12.If the patient with MND declined to have family members present at the time
of discussions about NIV, were you (as a family member or significant other)
able to obtain information relating to ongoing patient care?
13.During the last few days of your family member’s life, are you aware if they
experienced any feelings of dehydration or dryness?


If so was it felt that to offer water via the feeding tube (if they had
one) would prolong their life?



Was this potential issue discussed clearly with you by the
doctors?
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14.If the NIV was withdrawn can you describe what happened and whether you
were fully informed for the sequence of events before the withdrawal?

15.Who explained what was going to happen?

16.Was this the same as the explanation given before the NIV was
commenced?

17.Would you have liked more information before the NIV was withdrawn?



From whom?
When?

18) Do you recall if the person you knew who had MND had involvement with a
multidisciplinary team; specialists to cover all different areas of their care?











Speech Pathologist
Respiratory Physician
Social Worker
Palliative Care
Occupational Therapist
Physiotherapist
General Practitioner
Neurologist
18. B) of all the specialists involved, which of the health
professionals had overall responsibility for your family member’s
ongoing care?

19.If the MND patient you knew decided not to commence on NIV, what options
were suggested i.e. palliative involvement/symptom control and support?

20.How satisfied were you with your family member with MND end-of-life care
and the communication between the patient, family/significant other and the
clinicians?
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21.Please comment on any discussions which you would have liked to have
taken place, with whom and how would you have liked those discussions?

22.Please add any comments relating to your understanding of the person you
knew that had MND and their choices of treatment.

Thank you for participating in this research
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Appendix F: Participant Consent Form

A retrospective study into the communication surrounding the
initiation and withdrawal of non-invasive ventilation (NIV) in
patients with motor neurone disease
This study has been approved by the Edith Cowan University Human Research
Ethics Committee.
 I have been provided with a copy of the “Participant Information Letter”,
explaining the research project.


I have read and understood the information provided.



I have been given the opportunity to ask questions and have had any
questions answered to my satisfaction.



I am aware that if I have any additional questions I can contact the research
team.



I understand that participation in the research project will involve participating
in a face to face or telephone interview.



I understand that the information provided will be kept confidential; the
identity of participants will not be disclosed; and that all information will be
securely stored.



I understand the information provided will be used for the purposes of this
research and may be included in future research projects, and I understand
how the information is to be used.



I understand the research content will be presented for publication and I will
be given the opportunity to read the research prior to publication



I understand that my involvement is voluntary and I can withdraw at any time
without an explanation or penalty.



I understand that the content of this research may cause some possible
sadness and that professional counsellor information and contact details will
be offered to all participants

____________________
_______________
Signature

____________________
Print name

Date
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Appendix G: Clinician Participant Information
A retrospective study into the communication surrounding the initiation and withdrawal
of non-invasive ventilation (NIV) in patients with motor neurone disease
Dear ………(doctor or nurse)
My name is Lottie Chapman, a Registered Nurse, and Ph.D. candidate in the School of Nursing
and Midwifery, Edith Cowan University. I am writing to you to ask for your participation in the
research I am conducting for my Ph.D.
The aim of my research is to explore the communication process that occurs between
clinicians, patients and significant others regarding the initiation (or refusal) and withdrawal of
non-invasive ventilation (NIV) for people diagnosed with Motor Neurone Disease (MND).
Communication around NIV has been identified as an area needing further research (National
Institute for Health and Clinical Excellence, 2010). In this study, I am looking specifically at how
clinicians, patients and families make treatment decisions and how this decision-making can be
improved. This study has been approved by the Edith Cowan University Human Research
Ethics Committee as research for a PhD.
You are invited to discuss your experiences with MND and specifically NIV, contributing
to recommended research into NIV communication. Participation involves one face-to-face or
telephone interview with me, a nurse researcher, which will last 20-30 minutes and will occur at a
time and place most convenient for you. Your participation is entirely voluntary and you may cease
or withdraw from the interview at any time.
The interview will be audio taped for accuracy. All information will be kept private and
confidential, and no identifying information will be released to any source except where required
by law. A research identification number will be assigned to the interview and associated
transcripts and only I will know the identity of the respondent. All data will be stored on passwordprotected computers in the researcher’s office at ECU. Only authorised persons, who understand
that this information must be kept confidential, will have access to it. When the study has been
completed, all anonymous recordings and written documentation will be archived and stored in
securely locked files for a minimum period of five years, as required by law. Your answers will be
combined with the answers from other people for analysis and reporting purposes. Findings will
be reported in my dissertation and may be published in relevant health related peer-reviewed
journals. No personal or identifying information will be conveyed in any of the publications arising
from this research. By taking part in this study you agree not to restrict the use of any data, even
if you withdraw.
Although this study might not benefit you or your patients directly, this study should
contribute to a better understanding of the complex issues involved in treatment decision-making
for seriously ill patients. Should this research raise any emotional concerns or questions, and you
wish to have someone to talk with you, support information from your free employer counselling
scheme (EAP) is available or information for Lifeline counsellors will be supplied to you.
All clinical participants (respiratory, neurologists, palliative doctors and nurses) must have
experience with MND discussions particularly surrounding the initiation/refusal and/or withdrawal
of NIV or personal experience of being present at the initiation or withdrawal of NIV, and be able
to converse in English in order to be eligible to participate in this research.
To take part in the interview or obtain further information, please contact me: Phone:
0417960430 cschapma@our.ecu.edu.au. You may also speak to my Ph.D. Supervisor about
this study, Professor Anne Wilkinson at (08) 6304-3540 or
or email her at:
anne.wilkinson@ecu.edu.au.
If you have any concerns about the research project or wish to
talk to an independent person, you may contact the Research Ethics Officer at Edith Cowan
University, 270 Joondalup Drive, Joondalup WA 6027 Phone: 08 6304 2170 or email
research.ethics@ecu.edu.au.
Many thanks for your interest and assistance,
Sincerely,
Lottie Chapman, PhD Candidate, Edith Cowan University
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Appendix H: MNDA WA Newsletter Entry

Opportunity to participate in Research
A retrospective study into the communication
surrounding the initiation and withdrawal of noninvasive ventilation (NIV) in patients with motor neurone
disease
The aim of my research is to explore the communication process that occurs between
clinicians, patients and significant others regarding the initiation (or refusal) and
withdrawal of non-invasive ventilation (NIV) for people diagnosed with Motor Neurone
Disease (MND). Communication around NIV has been identified as an area needing
further research (National Institute for Health and Clinical Excellence, 2010). In this
study, I am looking specifically at how clinicians, patients and families make treatment
decisions and how this decision-making can be improved. This study has been approved
by the Edith Cowan University Human Research Ethics Committee as research for a
PhD, and has the support of MNDA WA/NSW.
You are invited to participate and discuss your experiences in this area,
contributing to much needed research into NIV communication. All family/significant
other participants must have been closely involved with the MND patient particularly if
the patient used or refused NIV.
Participation involves one face-to-face or telephone interview with me, a nurse
researcher, which will last only 30-40 minutes and will take place at a time and place
most convenient to you. Your participation is entirely voluntary and you may cease or
withdraw from the interview at any time.
Although this study might not benefit you or your family directly, this study
should contribute to a better understanding of the complex issues involved in treatment
decision-making for seriously ill patients.
To be included in this research, participants must speak English and be over
eighteen years, be a family member or significant other of a deceased MND patient, be
able to give informed consent, and will be assessed on these criteria if interested in
participating, by the researcher at the stage of the return of the consent form prior to
the interview commencing.
If you are interested in assisting this research, further information can be
obtained by contacting the researcher Lottie Chapman RN., M. Palliative Care at:
cschapma@our.ecu.edu.au. Or by phone
You may also speak to my Ph.D. Supervisor about this study, Professor Anne
Wilkinson at (08) 6304-3540 or
or email her at:
anne.wilkinson@ecu.edu.au.
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Appendix I: Silver Chain Notice of Research

Approved Research Project for Palliative Care,
Respiratory, Neurology Doctors and Nurses or Allied
Health professionals with experience with MND and NIV
A retrospective study into the communication
surrounding the initiation and withdrawal of non-invasive ventilation
(NIV) in patients with motor neurone disease
The aim of my research is to explore the communication process that
occurs between clinicians, patients and significant others regarding the initiation
(or refusal) and withdrawal of non-invasive ventilation (NIV) for people diagnosed
with Motor Neurone Disease (MND). Communication surrounding NIV has been
identified as an area causing some confusion and needing further research
(National Institute for Health and Clinical Excellence, 2010).
In this study, I am looking specifically at how clinicians, patients and
families make treatment decisions and how communication influencing decisionmaking can be enhanced. The PhD research also incorporates a small study
interviewing clinicians at a UK hospice as a comparison with Western Australia.
This project has been approved by the Edith Cowan University Human Research
Ethics Committee as research for a PhD and by the Silver Chain Human
Research Ethics Committee.
You are invited to discuss your experiences with MND, and specifically
NIV, contributing to recommended research into NIV communication.
Participation involves one face-to-face or telephone interview with me, a nurse
researcher,
which
will
last
20-30 minutes and will occur at a time and place most convenient for you. Your
participation is entirely voluntary and you may cease or withdraw from the
interview at any time.
To take part in the interview or obtain further information, please
contact me:
Lottie.Chapman,RN.,M.PalliativeCare:
cschapma@our.ecu.edu.au. Phone:
You may also speak to my Ph.D. Supervisor about this study, Professor Anne
Wilkinson at (08) 6304-3540 or
075 or email her at:
anne.wilkinson@ecu.edu.au
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Appendix J: Family Participant Information Letter
A retrospective study into the communication surrounding the initiation
and withdrawal of non-invasive ventilation (NIV) in patients with motor
neurone disease
Dear Family Member:
My name is Lottie Chapman, Registered Nurse and Ph.D. Candidate in
the School of Nursing and Midwifery, Edith Cowan University. I am writing to you
to ask for your participation in the research I am conducting for my Ph.D. The
aim of my research is to explore the communication process that occurs between
clinicians, patients and significant others regarding the initiation (or refusal) and
withdrawal of non-invasive ventilation (NIV) for people diagnosed with Motor
Neurone Disease (MND). Communication around NIV has been identified as an
area needing further research (National Institute for Health and Clinical
Excellence, 2010)(National Institute for Health and Care Excellence, 2016).
In this study, I am looking specifically at how clinicians, patients and
families make treatment decisions and how this decision-making can be
improved. This study has been approved by the Edith Cowan University Human
Research Ethics Committee as research for a PhD.
You are invited to discuss your experiences in this area and contributing
to much needed research into NIV communication. Participation involves one
face-to-face or telephone interview with me, a nurse researcher, which will last
only 30-40 minutes and will take place at a time and place most convenient to
you. Your participation is entirely voluntary and you may cease or withdraw from
the interview at any time.
The interview will be audio taped for accuracy. All information will be kept
private and confidential, and no identifying information will be released to any
source except where required by law. A research identification number will be
assigned to the interview and associated transcripts and only I will know the
identity of the respondent. All data will be stored on password-protected
computers in the researcher’s computer at ECU. Only authorised persons, who
understand that this information must be kept confidential, will have access to it.
When the study has been completed, all anonymous recordings and written
documentation will be archived and stored in securely locked files for a minimum
period of five years, as required by law. Your answers will be combined with the
answers of other people for analysis and reporting purposes. Findings will be
reported in the researcher’s dissertation and may be published in relevant health
related peer-reviewed journals. No personal or identifying information will be
conveyed in any of the publications arising from this research. By taking part in
this study you agree not to restrict the use of any data, even if you withdraw.
Although this study might not benefit you or your family directly, this
study should contribute to a better understanding of the complex issues
involved in treatment decision-making for seriously ill patients. Discussing
medical decision-making for your family member is not expected to create any
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emotional distress for you, the participant, but it may raise minor concerns for
some individuals. If you would like to have a support person present during the
interview that may be very helpful for your support. Details of a free counselling
service and the MNDA Care Advisory team offering emotional support and
advocacy (Motor Neurone Disease Association of WA Inc Phone: (08 9346
7355) and MND NSW (02 8877 0999) are supplied to you should you wish to
discuss any issues which may arise from the research interview.
If you have any questions raised about this survey or to have someone to talk
with you, support information and contact information for counsellors will be
supplied to you.
The following information provides the specifications required for
participation in this research:
Inclusion criteria:
1) All family/significant other participants, must have either been closely
involved with the MND patient particularly if the patient used or refused NIV
2)All participants must speak English and be over eighteen years, be able to
give informed consent, and will be assessed on these criteria if interested in
participating, by the researcher at the stage of the return of the consent form
which includes a description of these criteria.
Exclusion criteria:
1) Anyone under 18 years
2) Anyone unable to give consent
3) Anyone unable to communicate in English
4) Anyone with no connection to people with MND
5) Any family previously associated with the researcher as a nurse who cared
for their family member with MND
6) A person with MND (unless the person with MND specifically wishes to tell
their story)
To take part in the interview or obtain further information, please contact
me at: cschapma@our.ecu.edu.au. You may also speak to my Ph.D. Supervisor
about this study, Professor Anne Wilkinson at (08) 6304-3540 or
or
email her at: anne.wilkinson@ecu.edu.au.
If you have any concerns about the research project or wish to talk to an
independent person, you may contact the Research Ethics Officer at Edith
Cowan University, 270 Joondalup Drive, Joondalup WA 6027 : Phone: 08 6304
2170 or Email: research.ethics@ecu.edu.au
I really appreciate your interest and time in reading this letter,
Sincerely,
Charlotte (Lottie) Chapman, PhD Candidate, Edith Cowan University
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Appendix K: Nvivo10 Node Screen Shot

.
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Appendix L: Nvivo10 Information Screen Shot
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Appendix M: 1) Example of Initial Interview Coding
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Appendix M: 2) Secondary Random Participant Coding
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Appendix N: Silver Chain Ethics Approval
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Appendix O: St John of God Hospitals Ethics Approval
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Appendix P: Research Approval Neurological Council of WA
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Appendix Q: Transcription Confidentiality Agreement
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Appendix R: Ethics Approval Wisdom Hospice
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Appendix S: PRISMA Checklist
TITLE
Title 1 Identify the report as a systematic review, meta-analysis, or both.
ABSTRACT
Structured summary 2 Provide a structured summary including, as applicable: background;
objectives; data sources; study eligibility criteria,
participants, and interventions; study appraisal and synthesis methods; results; limitations;
conclusions and implications of key findings; systematic review registration number.
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known.
Objectives 4 Provide an explicit statement of questions being addressed with reference to
participants, interventions, comparisons, outcomes, and study design (PICOS).
METHODS
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed
(e.g., Web address), and, if available, provide registration information including registration
number.
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report
characteristics (e.g., years considered, language, publication status) used as criteria for
eligibility, giving rationale.
Information sources 7 Describe all information sources (e.g., databases with dates of coverage,
contact with study authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits
used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in
systematic review, and, if applicable, included in the meta-analysis).
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms,
independently, in duplicate) and any processes for obtaining and confirming data from
investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding
sources) and any assumptions and simplifications made.
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of
individual studies (including specification of whether this was
done at the study or outcome level), and how this information is to be used in any data
synthesis.
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in
means).
Synthesis of results 14 Describe the methods of handling data and combining results of studies,
if done, including measures of consistency (e.g., I2 ) for each meta-analysis.
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the
cumulative evidence (e.g., publication bias, selective reporting within studies).
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup
analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in
the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Study characteristics 18 For each study, present characteristics for which data were extracted
(e.g., study size, PICOS, follow-up period) and provide the citations.
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any
outcome level assessment (see item 12).
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Results of individual studies 20 For all outcomes considered (benefits or harms), present, for
each study: (a) simple summary data for each intervention group (b) effect estimates and
confidence intervals, ideally with a forest plot.
Synthesis of results 21 Present results of each meta-analysis done, including confidence
intervals and measures of consistency.
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies
(see Item 15).
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup
analyses, meta-regression [see Item 16]).
DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for
each main outcome; consider their relevance to key groups (e.g., healthcare providers, users,
and policy makers).
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at reviewlevel (e.g., incomplete retrieval of identified research, reporting bias).
Conclusions 26 Provide a general interpretation of the results in the context of other evidence,
and implications for future research.
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g.,
supply of data); role of funders for the systematic review.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS
Med 6(7): e1000097.
doi:10.1371/journal.pmed1000097
For more information, visit: www.prisma-statement.org.
Page 2 of 2
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Appendix: T: COREQ checklist Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist
No

Item

Guide questions/description

Domain 1:
Research team
and reflexivity
Personal
Characteristics
1.

Interviewer/facilitator Which author/s conducted the interview or focus group?

PhD Candidate

2.

Credentials

What were the researcher's credentials? E.g. PhD, MD

M. Palliative Care, RN, CFIAC, CT(ASC)

3.

Occupation

What was their occupation at the time of the study?

Clinical Nurse/Case co-ordinator

4.

Gender

Was the researcher male or female?

Female

5.

Experience and
training

What experience or training did the researcher have?

Previous research prior to attaining M. Palliative Care,
and Cytotechnologist Fellow International Academy of
Cytology
All family participants previously unknown to
candidate. Two of the nineteen clinician participants
were known to the candidate as worked in the same
area.

Relationship
with
participants
Was a relationship established prior to study
commencement?

A working relationship with the two clinicians known
to the candidate. No relationship established with the
other twenty-four participants.

6.

Relationship
established

7.

Participant knowledge What did the participants know about the researcher? e.g. A letter via email explaining the research was sent to
of the interviewer
personal goals, reasons for doing the research
each participant and this is attached as Appendices G
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No

Item

Guide questions/description
and J. Further verbal explanation if participants
enquired, at commencement of the interview.

8.

Interviewer
characteristics

What characteristics were reported about the
Trustworthiness is reported in Chapter 3 of this thesis.
interviewer/facilitator? e.g. Bias, assumptions, reasons and No issues reported by the candidates
interests in the research topic

Methodological
orientation and
Theory

What methodological orientation was stated to underpin
the study? e.g. grounded theory, discourse analysis,
ethnography, phenomenology, content analysis

Interpretive Description (framework) and Symbolic
Interactionism (theoretical perspective)

Sampling

How were participants selected? e.g. purposive,
convenience, consecutive, snowball

Purposive and snowball

Domain 2:
study design
Theoretical
framework
9.
Participant
selection
10.

11.

Method of approach

How were participants approached? e.g. face-to-face,
telephone, mail, email

Initially the family participants applied to partake in
the research having read an advertisement in the
MND Australia newsletter. The clinicians were
approached via their places of work who sent out an
email advertising the research, and interested
clinicians applied. This was snowballed by word of
mouth between clinicians.

12.

Sample size

How many participants were in the study?

Twenty-six

13.

Non-participation

How many people refused to participate or dropped out?
Reasons?

None
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No

Item

Guide questions/description

Setting
The family participants were interviewed at their place
of choices which in each case, was their home. The
clinicians were interviewed at their place of work

14.

Setting of data
collection

Where was the data collected? e.g. home, clinic,
workplace

15.

Presence of nonparticipants

Was anyone else present besides the participants and
researchers?

16.

Description of sample

What are the important characteristics of the sample? e.g. Experience of the participant of caring for a person
demographic data, date
with MND. Demographic data was collected

17.

Interview guide

Were questions, prompts, guides provided by the authors? Yes, and included in the Appendices (D and E)
Was it pilot tested?

18.

Repeat interviews

Were repeat interviews carried out? If yes, how many?

No

19.

Audio/visual
recording

Did the research use audio or visual recording to collect
the data?

Yes, each interview was recorded with two recorders
and were able to be transcribed verbatim.

20.

Field notes

Were field notes made during and/or after the interview or Minimally as everything was recorded to enable
focus group?
completed transparency.

21.

Duration

What was the duration of the interviews or focus group?

Between 60-90 mins

22.

Data saturation

Was data saturation discussed?

Yes, between candidate and supervisors

23.

Transcripts returned

Were transcripts returned to participants for comment
and/or correction?

Yes, each participant had their transcript returned.
Only one participant made a correction, and this was
grammatical.

No

Data
collection

Domain 3:
analysis and
findings
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No

Item

Guide questions/description

Data analysis
24.

Number of data
coders

How many data coders coded the data?

Primarily the candidate, but one of the supervisors
selected transcripts at random for coding

25.

Description of the
coding tree

Did authors provide a description of the coding tree?

Yes, and further described in Appendices K, L, M and
N.

26.

Derivation of themes

Were themes identified in advance or derived from the
data?

Derived from the data

27.

Software

What software, if applicable, was used to manage the
data?

Nvivo10

28.

Participant checking

Did participants provide feedback on the findings?

Some provided feedback at the time of the interview
and some of the clinicians sent positive feedback via
email when commenting on their transcribed
interviews. As yet, the full findings have not been
provided to the participants

Reporting
29.

Were participant quotations presented to illustrate the
Quotations presented themes / findings? Was each quotation identified? e.g.
participant number

Yes, the quotations are clearly attributed to the
participant and the themes identified.

30.

Data and findings
consistent

Was there consistency between the data presented and
the findings?

Yes

31.

Clarity of major
themes

Were major themes clearly presented in the findings?

32.

Clarity of minor
themes

Is there a description of diverse cases or discussion of
minor themes?

Yes
Yes
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